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ABSTRACT 
Enhanced bone resorption is a common pathology in destructive bone diseases.  
Many cytokines (e.g. IL-6 and TNF-α) and chemokines (e.g. CCL2, CCL3 and CCL5) 
elevated in patients exert pathological roles in leukocyte migration and 
inflammation, but their effect on direct bone destruction remained elusive.  
Published research into osteoclastogenesis was carried out in co-cultures, from 
which osteoclast differentiation, resorption and mediator secretion data was 
obtained.  The main objective of this thesis was to establish a working methodology 
for the in vitro differentiation of CD14+ve mononuclear cells into osteoclasts and to 
decipher the direct effects of IL-6 and CCL3 on osteoclastogenesis and bone 
resorption. 
IL-6 trans-signalling exerted an effect in both basal and pathological 
osteoclastogenesis, whereas its inhibition via sgp130-Fc significantly reduced 
osteoclast formation and bone resorption in vitro.  Although not examined in vivo, 
the translational use of sgp130-Fc as a therapeutic for destructive bone pathology 
was postulated from data showing a reduction in osteoclast differentiation and 
resorption after stimulation with HYPER-IL-6.   
Secondary to IL-6 trans-signalling, it was hypothesised that the neutralisation of 
CCL3 in vitro and in vivo would significantly reduce osteoclast differentiation and 
resorption.  Osteoclast number significantly reduced in the presence of anti-CCL3, 
but TRAP+ve cell count was unaltered, suggesting an early role of CCL3 in osteoclast 
multi-nucleation/fusion.  Additionally, in vivo data showed a protective effect of 
anti-CCL3 with significantly reduced bone erosive scores and osteoclast counts  
thereby presenting CCL3 as a novel biomarker of disease activity in destructive 
bone disease.  In contrast, TNF-α, CCL2, and CCL5 were shown to have no role in 
direct osteoclast differentiation in our monocultures.  
In conclusion, for the first time this work documents novel and important roles of 
IL-6 trans-signalling and CCL3 in increased osteoclast differentiation and bone 
resorption.  Our data highlights the importance of IL-6 trans-signalling and provides 
evidence for the use of CCL3 as a predictive biomarker in destructive bone diseases.  
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1 Chapter 1:General Introduction 
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1.1 Bone Homeostasis 
The human skeleton consists of an average of 206 bones and has many important 
functions; supporting body structure, mechanical levers for movement, protecting 
internal organs (including the central nervous system), maintaining an ionic 
environment (Ca2+), and in the generation and replenishment of haematopoietic 
cells.  Bone homeostasis and remodelling is therefore essential to many biological 
functions.  Bone remodelling is a tightly coupled and regulated process in which the 
rapid destruction of bone by osteoclasts occurs (taking 14-21 days), followed by the 
formation of osteoid and new bone matrix by osteoblasts (taking ≥3 months; Figure 
1.1); referred to as the basic multicellular unit (BMU; Raisz 1999, Jilka 
2003).Multiple factors play a role in the regulation of bone homeostasis, where the 
release of humoral factors including calcium, growth factors and degradation 
products induce osteoblastogenesis and bone formation (i.e. parathyroid hormone 
(PTH), vitamin D, TGF-β, prostaglandin E, osteocalcin and several pro-inflammatory 
cytokines; Chenu et al. 1988, Rodan et al. 1998,Neer et al. 2001, Kanazawa et al. 
2015). 
Differences in bone turnover kinetics can lead to several pathological outcomes 
related to enhanced osteoblast or osteoclast activity, where diseases such as 
osteopetrosis, rickets, osteomalacia, and osteophyte formation result due to 
increased osteoblastogenesis (Rogers et al. 1997, Stark & Savarirayan 2009, Elder & 
Bishop 2014) or alternatively diseases including osteitis fibrosa cystica, Paget’s 
disease and osteoporosis result due to elevated osteoclastogenesis (Sleiman et al. 
2004, Ralston et al. 2008, Jobke et al. 2014).  Under both pathological circumstance, 
changes in joint structure results.  Extensive research relating to synovial 
components in bone diseases was reported, but limited research of how arthritic 
diseases directly affect the homeostasis of osteoblasts and osteoclasts (i.e. the 
BMU) is currently available.  Due to the major implications of bone destruction in 
joint structure and overall patient health and well being, this thesis will focus upon 
the only cell capable of resorbing bone; the osteoclast.  A relationship between the 
osteoclast, synovial infiltrate and the cartilage in arthritic diseases must however be 
2 
 
kept in mind (Danks et al. 2002, Kinne & Burmester 2007, Schett 2007, Schett 
2007,Schett & Teitelbaum 2009, Hitchon & El-Gabalawy 2011, Knowles et al. 2012). 
 
1.1.1 An overview of osteoblasts and osteocytes 
Osteoblasts are mononuclear cells differentiated from mesenchymal stem cells in 
the presence of RUNX2 and its downstream signalling protein Osterix (Ducy et al. 
1997, Nakashima et al. 2002).  The association of osteoblasts via tight junctions at 
bone-forming sites facilitates the secretion of bone matrix, which after ~10 days 
becomes calcified (Nijweide et al. 1982).  In addition to bone matrix, osteoblasts 
secrete the major osteoclast-stimulating mediator RANKL (receptor activator 
nuclear factor κβ (RANK) ligand) which is essential for osteoclast differentiation, 
along with the main natural osteoclast inhibitor; Osteoprotegrin (OPG), RANKL 
decoy receptor.   
When an osteoblast becomes ensnared in bone lacunae, the secretion of bone 
matrix stops and terminal differentiation into osteocytes ensues.  Osteocytes are 
found in plentiful numbers and act as modulators in osteoblast and osteoclast 
stimulation due to their mechanosensory phenotypes (Caetano-Lopes et al. 2007).   
1.1.2 An overview of osteoclasts 
Osteoclasts are differentiated from a haematopoietic origin as originally performed 
and reported by Donald Walker in the 1970s, where osteopetrotic mice were cured 
through treatment with wild-type spleen cells (Walker 1975).  This finding was later 
translated into humans by Coccia et al. (1980) who treated an osteopetrotic 5 
month old girl with bone-marrow from her brother (HLA-MLC identical) resulting in 
active osteoclasts (containing Y chromosome) alongside her own osteoblasts, which 
in tandem reduced disease pathogenesis.  Osteoclast differentiation was 
subsequently well studied through the use of gene knock-out models in 
osteopetrosis which highlighted essential genes in osteoclastogenesis, and in 2006 
CD14+ve cells were identified as osteoclast precursor cells (Komano et al. 2006).  
Osteoclast differentiation relies on the essential presence of macrophage colony 
stimulating factor (m-CSF) and RANKL.  Terminally differentiated osteoclasts are 
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giant multinucleated, tartrate resistant acid-phosphatase+ve (TRAP+ve), cathepsin 
K+ve (CATK+ve), vitronectin receptor+ve cells (Davies et al. 1989, Simpson & Horton 
1989 Motyckova et al. 2001, Takayanagi et al. 2002).  Osteoclast polarisation 
facilitates adhesion to bone matrix and results in a ruffled membrane at the 
resorptive edge.  The secretion of acid, TRAP and enzymes (CATK and matrix 
metalloproteases; MMPs) at the ruffled membrane leads to bone resorption and 
cartilage destruction.  Bone degradation products (e.g. collagen fragments C-
terminal telopeptide of type-I collagen, CTX-1, or N-terminal telopeptide of type I 
collagen, NTX-1) and growth factors (e.g., TGF-β) are released from the matrix and 
thought to contribute in the stimulation of osteoblastogenesis; thus, a self-
regulatory loop for bone homeostasis is maintained (Boyle, Simonet & Lacey 2003).  
The process of osteoclastogenesis will be further introduced in Section 1.2. 
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 Figure 1. 1 - An illustration of cellular involvement in bone homeostasis.In the presence of osteoclast stimulating factors (m-CSF and RANKL) CD14+ve 
mononuclear cells differentiate into osteoclasts, classified by their giant multinuclear phenotype and expression of vitronectin, TRAP and CATK.  The 
expression and secretion of TRAP and degradative enzymes (CATK and MMPs) from the osteoclast results in bone resorption, leading to the dissolution of 
bone matrix (e.g. collagen fragments) and the secretion of growth factors (e.g. TGF-β).  Following bone resorption, bone formation is stimulated via the 
osteoblast where new osteoid is laid down and calcified. 
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1.2 Osteoclastogenesis 
Osteoclast precursors undergo six main steps in becoming mature osteoclasts.  
Firstly, CD14+vemonocytes migrate into local areas due to a concentration gradient 
of pro-inflammatory cytokines and chemokines; i.e. TNF-α, IL-1 and IL-6 (McInnes 
and Schett, 2007).The retention of these precursors in the joint occurs until a high 
cell density is obtained, priming the cells for fusion and differentiation.  In tandem 
to the secretion of pro-inflammatory cytokines and chemokines, m-CSF and RANKL 
are secreted from co-localised cells (stromal cells, osteoblasts, T cells) and are the 
main instigators of monocyte fusion and differentiation (Susa et al. 2004).  M-CSF 
stimulates cell proliferation through its receptor (c-fms) expression on precursor 
cells.  Ligand binding also enhances further secretion of chemotactic mediators 
which facilitate the initial migration of cells and increasing cell survival (Nemunaitis 
1993, Yang et al. 1996 ,Ross et al. 2006).The importance of m-CSF was shown in 
osteoclast differentiation where c-fms-/- mice lack terminally differentiated 
osteoclasts (Kikuta & Ishii 2013). 
RANKL originates either from proteolytic cleavage by matrix-metalloprotease-3 and 
-7 secreted from the osteoblast/osteoclast respectively, or is secreted directly from 
mesenchymal cells, osteoblasts and T cells (Jimi et al. 1999, Yu et al. 2004, Blair et 
al. 2005, Wada et al. 2006).RANKL binds to RANK on pre-osteoclasts and initiates its 
signalling pathway (Figure 1.2).  In brief, there-localisation of TNFR-associated 
cytoplasmic factor 6 (TRAF6) results from RANKL-RANK binding stimulating 
downstream signalling and leading to cell fusion.  Primarily this occurs through 
dendritic cell-specific trans-membrane protein (DC-STAMP), a protein found at 
significantly increased levels in arthritic joints (Han et al. 2001, Yagi et al. 2005, 
McInnes & Schett 2007, Mizutani et al. 2009, Kikuta & Ishii, 2013).  In addition to 
DC-STAMP, TRAF6 also stimulates the activation of NF-κβ and ERK signalling in 
addition to osteoclast-specific target genes; NFATc1, c-fos, CATK, TRAP, adhesion 
integrins, chemokine/cytokine secretions and calcitonin (CTR) receptor (Jimi et al. 
1999, Yu et al. 2004, Blair et al. 2005, Wada et al. 2006, McInnes and Schett, 2007).  
The importance of c-fos in osteoclast-macrophage lineage determination has been 
reported both in vitro and in vivo.  In vivo c-fos deficient mice develop osteopetrosis 
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which can be rescued through bone marrow transplantation, and in bone marrow 
macrophage cultures p38 inhibition resulted in attenuated c-fos and decreased 
osteoclast differentiation (Grigoriadis et al. 1994, Huang et al. 2006). 
The multinucleation of precursor cells is paramount to the transcription and 
expression of osteoclast-specific genes, and their subsequent resorptive 
capabilities.  A correlation between nuclei number and the resorptive potential of 
the osteoclast has previously been shown by Piper, Boyde & Jones (1992), 
highlighting the importance of multinucleation.  An association between osteoclast 
size due to Fra-2 (Fos associated protein) and bone destruction has also been made 
by Bozec et al. (2008) who reported increased size to link to destructive bone 
diseases.  Additional to multinucleated cells, the adhesion integrin αvβ3 is also 
paramount for attachment of differentiating osteoclasts to bone, whilst also playing 
a role in cytoskeletal reorganisation (Kikuta & Ishii 2013).  Of importance is the 
transition of αvβ5 integrin, which is present prior to multi-nucleation but reduced 
after differentiation, to αvβ3 integrin which presents with opposite expression 
patterns (Sago et al. 1999). 
Finally, a vital step for osteoclast adhesion to bone matrix is the polarisation of the 
cell body resulting in the formation of a ruffled membrane at the resorptive edge 
due to actin cytoskeleton rearranging.  This ruffled membrane facilitates the 
transportation of acidifying vesicles along microtubules to the plasma membrane 
where a tight junction has formed between bone and osteoclast.  A proton pump is 
relocated to the osteoclast-bone interface, and H+ are secreted which associate 
with Cl- (pumped out of the cell) forming HCl, leading to the acidification of bone 
mineral (pH4.5).  The secretion of MMPs and enzymes (CATK and TRAP which 
function at low pH) leads to the further destruction of bone and mineralised 
cartilage, leading to the formation of resorption pits/lacunae(Boyle, Simonet& 
Lacey 2003).  The degradation products (e.g. C-terminal telopeptide of type-I 
collagen, CTX-1, or N-terminal telopeptide of type I collagen, NTX-1) can be 
quantified in vitro to determine osteoclast resorptive activity. 
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Within bone homeostasis, a regulatory mediator of osteoclast differentiation and 
resorption is secreted from co-localised cells (osteoblasts and bone marrow stromal 
cells) in response to osteoclast-stimulating mediators.  This decoy receptor of 
RANKL is termed osteoprotegerin (OPG), and a close regulatory role between OPG 
and RANKL exists.  In destructive bone diseases, an unbalance between osteoclast 
inhibitory and stimulatory signals occurs often resulting in enhanced osteoclast 
formation and/or activity.  As a consequence substantial bone erosions develop and 
progressively get extenuated over time.  Although there are many pathogenic 
instigators leading to the uncoupling of bone homeostasis, many of these are 
hormones and inflammatory mediators.  Within this thesis the term destructive 
bone disease will be used to describe diseases of the joint or alveolar bone where 
substantial bone resorption has occurred; i.e. osteoporosis, periodontitis, 
rheumatoid arthritis. 
 
Figure 1. 2 - Signalling pathways activated by RANKL-RANK.The binding of RANKL to its 
receptor RANK activates TRAF6 stimulating downstream signalling pathways leading to the 
transcription and expression of osteoclast-specific genes (e.g. ATP, TRAP, CATK, DC-STAMP, 
Atp6V0d2 and integrins).  
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1.3 Stimulators of osteoclastogenesis 
Hormones, cytokines and chemokines are thought to play a major role in the 
destructive phenotype identified in many forms of inflammatory arthritis.  An 
overview of the main instigators of osteoclastogenesis follow, specifically those 
with direct links. 
1.3.1 Hormonal impact on osteoclastogenesis 
Many hormones are known to exert a role in osteoclastogenesis and are pivotal to 
pathological bone destruction. 
1.3.1.1 Oestrogen 
Oestrogen inhibits osteoclastogenesis and associated bone resorption in mammals, 
and is essential in bone development due to its role in epiphyses closing.  The 
precise means of how this occurs is still unclear, but it is likely to be associated with 
precursor cell differentiation, and pro-inflammatory cytokine secretions (i.e. IL-
6).The expression of oestrogen receptor (ERα) has been confirmed on osteoblasts, 
pre-osteoclasts and osteoclast; exerting a dual mechanism on osteoclast activity 
(Oreffo et al. 1999).  Firstly, direct binding of oestrogen to its receptor on the 
osteoclast induces the osteoclast to lose attachment to bone surfaces, and 
increases osteoclast apoptosis (Liu & Howard 1991, Kameda et al. 1997).  However, 
oestrogens effects on osteoclastogenesis are primarily induced by its impact on 
osteoblast activity.  After activation by oestrogen the osteoblast secretes OPG 
which acts as a decoy receptor to RANKL and thus prevents osteoclastogenesis(Bord 
et al. 2003).Oestrogen therefore exerts an effect on both mature (directly through 
receptors on the osteoclast) and differentiating (indirectly through the osteoblast) 
osteoclasts.  In females oestrogen is defined as an evolutionary advantage which 
allows the retention of calcium in the body for embryo development (Riggs, Khosla 
& Melton 2002).   
1.3.1.2 Testosterone 
Similar inhibiting effects of testosterone on osteoclastogenesis have been reported 
to oestrogen, but these may occur via two mechanisms; conversion of testosterone 
into oestrogen via aromatase, and direct effects mediated through androgen 
receptors (Chen et al. 2001, Michael et al. 2005).  These two mechanisms are 
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known to be independent of each other where inhibiting the ER or aromatase has 
no effect on the reduction of osteoclastogenesis as a result of 
testosterone/androgen receptors, and vice versa (Chen et al. 2001).  Testosterone 
also exerts an inhibiting effect on osteoclastogenesis in the presence of its 
stimulator PTH (see Section 1.3.1.5) in a concentration dependent manner, due to 
the expression of androgen receptors (Chen et al. 2001). In cultures containing 
CD14+ve cells only, and in co-cultures of mononuclear cells and osteoblasts, 
testosterone at physiological concentrations, and also over a dose-range, reduces 
osteoclast differentiation and resorptive activity, and in co-cultures leads to 
increased OPG secretions from osteoblasts (Michael et al. 2005).  
1.3.1.3 Calcitonin 
Calcitonin also plays an essential role in the regulation of osteoclast activity.  
Calcitonin hormone controls serum levels of calcium, firstly by enhancing calcium 
excretion from the kidneys, and secondly by directly inhibiting bone resorption 
through activating the calcitonin receptor on the osteoclast, leading to a reduction 
in cellular movement and secretion of resorptive enzymes (Copp et al. 1962, 
Warshawsky et al. 1980, Takahashi et al. 1988, Zheng et al. 1994).  
1.3.1.4 Prostaglandin 
Prostaglandin, specifically E2, is a pivotal mediator in bone homeostasis.  PGE2exerts 
a dose-dependent stimulatory effect on osteoclastogenesis and bone resorption, 
and this is mediated through its receptors EP2 and EP4 (Lader & Flanagan 1998).  
PGE2 exerts this effect through increasing RANKL signalling and facilitating cross-
signalling between downstream RANKL and EP2 and EP4 signalling pathways; an 
indirect effect mediated by the osteoblast (Kobayashi et al. 2006).  Through the 
inhibition of prostaglandin synthesis by addition of indomethacin, a significant 
decrease in osteoclast number and bone resorption results, identifying its 
importance (Kaji et al. 1996, Lader & Flanagan 1998). 
However, contradictory results are published for the direct effects of PGE2 on 
osteoclastogenesis, where PGE2 has been reported to reduce osteoclast number 
and resorption.  Kobayashi et al. (2005) concluded that this effect was due to a 
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changing expression of EP receptors, where mononuclear cells could auto-reduce 
their surface expression of EP2 and EP4 to evade the direct inhibiting action of PGE2 
in cultures. 
1.3.1.5 Parathyroid hormone (PTH) 
Parathyroid hormone regulates calcium by leading to its release or resorption in 
bone, the kidney and/or the intestine.  PTH release is increased due to low calcium 
or due to elevated levels of serum phosphate.  PTH then activates the osteoblast 
and causes an increase in RANKL and an attenuation in OPG secretion, leading to an 
indirect stimulation of osteoclast differentiation and subsequent resorptive activity.  
PTH is often increased in destructive diseases and causes an increased release of 
calcium from the bone due to enhanced osteoclast formation and resorption (Poole 
&Reeve 2005). 
Additional to PTH, growth hormone, thyroid hormone vitamin D and glucocorticoids 
are all also associated with increased bone resorption. 
 
1.3.2 Pro-inflammatory cytokines in destructive bone diseases 
In addition to the above hormones many cytokines are found elevated in 
inflammatory destructive bone diseases (i.e. RA), including IL-1, TNF-α and IL-6 
(Hopkins et al. 1988, Issekutz et al. 1994).  The secretion of these pro-inflammatory 
cytokines is likely to occur from infiltrating leukocytes (e.g. T cells, neutrophils), 
chondrocytes, stromal cells, osteoblasts or osteoclasts (Firestein et al. 1994, Braun 
et al. 1999, Raza et al. 2005, Joosten et al. 2009).  Although the direct mechanism of 
action of cytokines on osteoclast differentiation is still under investigation, these 
cytokines are involved in the migration of precursor cells and the secretion of 
RANKL which in tandem increases osteoclastogenesis. 
1.3.2.1 IL-1 and TNF-α 
Interleukin-1 (IL-1) is a stimulator of osteoclast differentiation and functional 
resorption in vitro and in vivo via three main ways; osteoclast stimulation, indirectly 
enhancing RANKL secretion from neighbouring cells (T cells), and increasing co-
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stimulating mediators i.e. prostaglandins (PGs; Klein& Raisz1970, Jimi et al. 1999).  
IL-1 has two main receptors (IL-1R type I and II) to which it binds, each of which has 
differing downstream signalling pathways with divergent effects.  IL-1R type I is the 
receptor of main interest in inflammatory arthritis due to its role in inflammation.  
Type II however, acts as an endogenous suppressor of IL-1 activity by competitive 
binding (Kuno & Matsushima 1994).Following IL-1 binding to IL-1R type I, TRAFs and 
NF-κβ signalling pathways (identical to RANKL signalling) are activated, amplifying 
both IL-1 and RANKL signals (Eder 1997).  Similarly to IL-1, tumour necrosis factor- 
alpha (TNF-α) stimulates the recruitment and differentiation of osteoclast 
precursors from bone marrow (Bertolini et al. 1986).TNF-α binds to TNF receptors 
(TNFR) found on cell membranes or as soluble forms (i.e. TNFR1).  An adaptor 
protein such as TRAF is again utilised and effects on inflammation, proliferation or 
cell survival are exerted (Gravestein & Borst 1998).Direct mechanisms of TNF-α on 
osteoclastogenesis are controversial, where the majority suggest a RANKL-
dependent mechanism of action due to co-localised cells increasing RANKL 
secretion in response to TNF-α.  However, a RANKL-independent mechanism was 
suggested by Kobayashi et al.(2000)but data was not reproducible questioning its 
validity.   
1.3.2.2 IL-6 
IL-6 is also significantly enhanced in destructive bone diseases and is secreted from 
stromal cells and osteoblasts in the joint (Ishimi et al. 1990, Srirangan & Choy 
2010).  Specifically, this cytokine enhances monocyte migration in the presence of 
its receptor IL-6R, and was linked to enhanced osteoclastogenesis due to increasing 
RANKL secretion (Hashizume et al. 2008).  IL-6R can be found in both membrane 
bound and soluble forms, facilitating two independent signalling pathways; classical 
and trans-signalling.  IL-6 classical signalling is known as the pathway resultant of IL-
6 binding to membrane bound IL-6R, which then associates and dimerizes with 
gp130.  Membrane bound IL-6R expression was reported on monocytes and 
macrophages and it is these cells which can respond to IL-6 classical signalling.  This 
classical pathway is thought of as the regulatory pathway for resolution of an 
immune response and cellular regeneration.  However, cells which do not express 
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membrane bound IL-6R or are not currently known to express it (i.e. the 
osteoclast), can still respond to IL-6 through their ubiquitous expression of gp130 
(Kishimoto et al. 1995, Kotake et al. 1996, Grivennikov et al. 2009, Miyamoto et al. 
2009, Jones, Scheller& Rose-John 2011). 
IL-6 trans-signalling occurs through the binding of IL-6 to a soluble form of its 
receptor (sIL-6R), which dimerizes with gp130 on the cell membrane, and activates 
JAK/STAT pathways. The secretion of sIL-6R was reported from cells of the joint (i.e. 
osteoblasts, stromal cells etc.) and occurs due to two mechanisms; proteolytic 
cleavage and alternative splicing (Ishimi et al. 1990, Tamura et al. 1993 and 
Srirangan and Choy 2010).  Proteolytic cleavage occurs through a disintegrin and 
metalloproteases domain-containing protein-10 and -17 (ADAM10 and 
ADAM17respectively), where IL-1 and TNF-α induced neutrophil apoptosis release 
sIL-6R (Schumacher et al. 2015).  Alternative splicing of mRNA coding for IL-6R also 
leads to loss of specific membrane domains, resulting in its soluble form (Galicia et 
al. 2004).  Evidence of IL-6 trans-signalling in osteoclast formation was first 
reported in 1993 by Tamura et al. where osteoclast number significantly increased 
after treatment of murine co-cultures (bone marrow and osteoblasts) with IL-6 
(200ng/mL) and sIL-6R (500ng/mL), and not in the presence of these mediators 
alone.  However, the direct effects of IL-6 trans-signalling on pure monocultures of 
osteoclastogenesis are still unknown.  However, it was postulated that any affect IL-
6 had on osteoclastogenesis was through sIL-6R and trans-signalling; it’s thus 
believed to be the pathogenic signalling pathway involved in inflammation 
associated with disease.   
In addition, the increased presence of IL-1, TNF-α and IL-8 in destructive bone 
disease synergistically increases IL-6 secretion (Pathak et al. 2015).Other mediators 
sharing gp130 are also postulated in osteoclastogenesis.  Interleukin-11 (IL-11) and 
leukaemia inhibitory factor (LIF) are both secreted by bone cells and reported to 
‘stimulate’ osteoclast differentiation, but reported data since has not been 
reproducible and remains controversial (Lorenzo et al. 1990, Reid et al. 1990,Hill et 
al. 1998, Lee & Lorenzo 2006).  Alternatively, the opposite effect was reported for 
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oncostatin M which inhibited osteoclast differentiation and resorption, and pushed 
cells down a macrophage lineage (Heymann et al. 1998). 
1.3.2.3 IL-7 
Controversial findings are presented for the role of interleukin-7 (IL-7) in bone 
homeostasis where both stimulatory and inhibitory roles were suggested.  In vitro 
supplementation of IL-7 into human osteoclast differentiation cultures increased T 
cell secretion of RANKL, indirectly increasing osteoclastogenesis but not directly 
(Weitzmann et al. 2000).  Supporting this, T cell-/- mice treated with IL-7 showed no 
change in osteoclastogenesis or bone destruction (Toraldo et al. 2003).  Opposing 
this, IL-7 supplemented in vitro was reported to decrease osteoclast numbers by 
Lee et al. (2003), and in vivo IL-7-/- mice were shown to have increased 
osteoclastogenesis (Lee et al. 2003).  Further work establishing the role of IL-7 in 
osteoclastogenesis is however needed. 
1.3.2.4 IFN-γ, IL-4, IL-13, IL-12 andIL-18 
Additional to the main osteoclast-stimulating mediators, inhibitors of 
osteoclastogenesis also exist; interferon-γ (IFN-γ), interleukin-4 (IL-4), interleukin-13 
(IL-13), interleukin-12 (IL-12) and interleukin-18 (IL-18) (Lee & Lorenzo 2006).  IFN-γ 
inhibits bone resorption through interfering with the RANK signalling pathway and 
degrading TRAF6, thus preventing pre-osteoclast differentiation (Takayanagi et al. 
2000).  IL-4 similarly affects RANKL signalling, but this time at the level of NFATc1, 
therefore disrupting differentiation (Cheng et al. 2011).  Alternatively, IL-13 inhibits 
osteoclastogenesis indirectly through reducing PGs, simultaneously increasing OPG 
and osteoblast migration (Lind et al. 1995,Palmqvist et al. 2006).  Similar indirect 
mechanisms are exerted by IL-12 and IL-18, which inhibit osteoclastogenesis 
through altering T cell behaviour and increasing the secretion of granulocyte 
macrophage colony-stimulating factor (GM-CSF; directs differentiation of 
precursors away from the osteoclast) respectively (Horwood et al. 2001).  In 
addition, IL-12 has also been linked to the enhanced apoptosis of pre-osteoclasts 
thus inhibiting osteoclast maturation and subsequent resorption (Kitaura et al. 
2002). 
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1.3.3 Pro-inflammatory Chemokines 
The reported activity of several inflammatory CXC- and CC-chemokines in 
inflammatory arthritis was documented over the past 15 years.  The main role of 
these chemokines is in the chemotaxis of neutrophils (CXC- chemokines primarily), 
monocytes and macrophages (CC-chemokines primarily) via concentration 
gradients, in addition to a role in angiogenesis.  Chemokines thus exert a dual effect 
in maintaining the diseased joint with nutrients and leukocytes via the new 
vasculature.CXCL1, CXCL6, CXCL7, CXCL8 (IL-8), CXCL9, CXCL10, CXCL12, CCL2 
(monocyte chemotactic protein-1), CCL3 (macrophage inflammatory protein 1-α), 
CCL5 (regulated upon activation of normal T-cell expressed and secreted) and 
CCL20 are all elevated in the synovial joint of RA patients due to their enhanced 
secretion from synovial macrophages and fibroblasts (Koch 2005, Boyce et al. 2006).  
However, only a few of these chemokines were linked to osteoclastogenesis or 
functional resorptive activity in inflammatory arthritis, where most were identified 
from co-culture methodologies, making the direct role of these chemokines on 
osteoclast differentiation elusive. 
1.3.3.1 CCL2 
CCL2 is elevated in inflammatory arthritis patients and is secreted from fibroblasts, 
synovial cells and infiltrating leukocytes causing monocyte migration (Kim et al. 
2005, Koch 2005, Vangsness et al. 2011).CCL2 signals through its membrane-bound 
receptors CCR2 and CCR4, found on monocytes, macrophages and some T cells 
(Vergunst et al. 2008).In addition, osteoclast and osteoblast secretion of CCL2 can 
occurs, but only in the presence of RANKL are functional osteoclasts produced (Kim 
et al. 2005). 
Direct effects of CCL2 on osteoclastogenesis are currently unknown, although 
previous studies suggest CCL2 is not pivotal to inflammatory pathogenesis 
presented in the arthritides; its neutralisation (anti-CCR2) had no effect on reducing 
inflammation in RA patients (Vergunst et al. 2008).However,CCL2 was shown to 
increase RANKL secretion and DC-STAMP expression, subsequently exerting an 
indirect role of CCL2 on destructive pathology associated with arthritis (Kim et al. 
2005).  Differential effects ofCCL2 in mouse and human disease were reported, 
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where CCL2 leads to increased mononuclear fusion in humans and therefore 
osteoclastogenesis (likely due to increased RANKL; Kim et al. 2005), but in mice 
both stimulatory and inhibitory effects are known (Quinones et al. 2006). 
1.3.3.2 CCL3 
CCL3 is secreted from T cells, fibroblasts, B cells and macrophages and is known to 
induce the migration of osteoclast precursors (monocytes), neutrophils, T cells and 
macrophages to high density areas (Wolpe et al. 1988, Trifilo et al. 2003, Narni-
Mancinelli et al. 2007, Enzerink et al. 2009,Zucchetto et al. 2009, Takahashi et al. 
2015).  CCL3 exerts its migratory effect after binding to its receptors CCR1 and 
CCR5.  CCR1 is found on leukocytes (including monocytes) and is expressed on 
osteoclasts (Yu et al. 2004).  In the process of osteoclastogenesis, CCR1 is thought 
to be the main receptor for CCL3 due to its elevated presence in destructive bone 
diseases.  A lack of signalling through CCR5 has suggested this receptor as 
inconsequential in osteoclast formation (Doodes et al. 2009, Lebre et al. 2011).  
CCR5 is therefore suggested as being important to cell migration into arthritic 
joints, but then CCR1 becomes the dominant receptor for mononuclear cell 
retention and osteoclastic differentiation.  
CCL3 is significantly increased in many destructive bone diseases including RA, OA, 
JIA and MM, where its concentration was significantly correlated to 
osteoclastogenesis (Koch et al. 1994, Choi et al. 2001, Oba et al. 2005, Pharoah et 
al. 2006, Szekanecz et al. 2010, Vallet et al. 2011, Vangsness et al. 2011).  Although 
co-cultures have mainly been used, CCL3 was shown as pivotal to the process of 
osteoclastogenesis, where its inhibition has resulted in decreased osteoclast 
number.  A clear role of this chemokine in osteoclast differentiation is therefore 
evident, but its mechanism is still elusive. Supporting a role of CCL3 in 
osteoclastogenesis is its stability at low pH (Ren et al. 2010), giving it a major 
advantage over other chemokines that get denatured in acidic environments; H+ 
ions secreted from actively resorbing osteoclasts. 
In addition, indirect effects of this chemokine are reported due to its ability of 
increasing the co-secretion of cytokines and chemokines into the inflammatory 
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milieu of the joint;IL-6, sIL-6R, CCL2 and CCL5 (Chintalacharuvu et al. 2005, Koch 
2005, Pharoah et al. 2006). 
1.3.3.3 CCL5 
Sharing the same receptors as CCL3, CCL5isalso significantly elevated in destructive 
bone diseases (Yano et al. 2005, Pharoah et al. 2006).CCL5 induces monocyte 
motility in the presence of RANKL in addition to stimulating osteoclast migration 
across growth substrates (Yu et al. 2004).  Although very few studies have 
investigated the effects of CCL5 on direct osteoclastogenesis, CCL5 has been found 
to enhance monocyte/macrophage migration (Keophiphath et al. 2010).The 
presence of lymphotoxin can lead to augmented CCL5 secretion, as can elevated 
Ca2+ (Yano et al. 2005, McInnes and Schett. 2007 and Calmon-Hamaty et al. 2011).  
However, such increases in CCL5 could be due to an autocrine regulation loop, 
where CCL5 in turn prevents further osteoclastogenesis due to the blockade of 
CCR1 and CCR5 thus preventing CCL3 signalling.  Further experiments in 
monocultures of osteoclast precursors are however needed to determine the role 
of this chemokine in osteoclastogenesis. 
 
1.3.4 Conclusion on the effects of inflammatory mediators on 
osteoclastogenesis 
The role of inflammatory mediators in osteoclastogenesis is vast, where many 
complex effects are exerted with causative links to the prevalence of destructive 
diseases (Yu et al. 2004, Kokkonen et al. 2010).  Substantial gaps in our knowledge 
of the direct effects of these hormones, cytokines and mediators in direct 
osteoclast differentiation are however apparent due to the substantial use of co-
culture methodologies. 
 
1.4 The hypothesised role of the osteoclast in pain 
A significant impact of the presence of pro-inflammatory mediators on 
osteoclastogenesis and the resultant pathology was introduced, but additionally a 
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modulatory role in hyperalgesia and nociception has been postulated.  The 
evidence for this notion is derived from published literature which is summarised in 
the sections that follow. 
1.4.1 Acid-Induced bone pain 
Pain is a common symptom associated with destructive bone diseases and in the 
last 20 years has been linked to the osteoclast. In 2006 Nagae et al. published data 
stating that the inhibition of osteoclastogenesis (bisphosphonates, OPG, 
alendronate and zoledronic acid) led to a significant reduction in bone resorption 
and hyperalgesia, compared to controls; a link between the osteoclast and pain 
perception.  Supporting their theory, an increase in mRNA for the acid-sensing ion 
channel (ASIC) in dorsal root ganglions provided a mechanism behind increased 
sensitivity under the acidic environment created by the actively resorbing 
osteoclast.  The protection of joint architecture and decreased hyperalgesia was 
later reported by Strassle et al. (2010).  Further evidence was reported by Abe et al. 
(2015)through the analysis of c-fos and transient receptor potential channel 
vanilloid subfamily member 1 (TRPV1) expression in the dorsal horn of spinal cord 
ovariectomized (OVX) mice.  Both c-fos and TRPV1 were significantly increased in 
OVX mice compared to matched controls, and this increase was susceptible to 
inhibition through alendronate treatment; thus linking hormones to pain. 
1.4.2 Pro-inflammatory mediator induced pain 
In addition, pro-inflammatory cytokines stimulating osteoclastogenesis are also 
hypothesised as having a role in pain.  The secretion of pro-inflammatory cytokines 
leads to altered nociceptor function effecting pain perception (Loeser and Melzack, 
1999).  One theory could be that the secretion of cytokines/pain mediators (IL-6, 
bradykinin, endothelin-1 and nerve growth factor; NGF, Besson 1999)could have 
come directly from the osteoclast simultaneously enhanced pain perception and 
osteoclastogenesis.  However, the direct secretion of these mediators from the 
osteoclast has not yet been proven, but their nociceptive role is known (Ren and 
Dubner 2010). 
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1.4.2.1 TNF-α 
The direct role of TNF-α in pain is still debated, but increased secretion from 
receptive cells is known to occur, which sequentially activates and prolongs 
hyperalgesia (Richter et al. 2010). 
1.4.2.2 IL-6 
IL-6 increases heat-induced and mechanical pain, which through its inhibition (IL-6 
neutralising antibody) can be attenuated (De Jongh et al. 2003).  Although the 
mechanism behind this increase is currently unclear, it is thought that the increased 
expression of gp130 on peripheral nerves in the presence of IL-6 encourages 
neurite growth and survival (De Jongh et al. 2002).  In addition, IL-6 is also linked to 
the secretion of nerve growth factor (NGF) which is commonly released from 
injured tissues, thus increasing nociceptor sensitivity whilst preparing the body for 
injury response (Anderson & Rao 2001). 
1.4.2.3 NGF 
NGF is associated with neurite growth and survival.  Previous publication has 
reported the enhanced secretion of NGF from T cells and mast cells in models of 
bone destruction, where enhanced pain perception was reported (Lambiase et al. 
1997).  The addition of NGF in animal models leads to heightened heat and 
mechanical sensitivity through increasing TRPV1 expression and bradykinin 
receptor binding.  Although research into NGF and arthritis is limited, the peptide 
bradykinin is elevated in rheumatoid arthritis (RA) patients (Hargreaves et al. 1988, 
Xie et al. 2014).  Additionally, in murine models a decrease in bradykinin receptor 
results in decreased arthritis severity.  Thus a tentative link between NGF and 
bradykinin increases in arthritic patients could be postulated.   
Our knowledge of the osteoclasts role in different types of pain linked to 
destructive bone diseases is therefore limited, where extensive further research is 
needed.  However data combined from these studies could be collated with those 
investigating the destructive pathology caused by the osteoclast (both in vitro and 
in vivo; using imaging methodology discussed in the next section), to create an in-
depth profile of pathogenicity associated with osteoclastogenesis. 
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 1.5 Imaging destructive bone diseases 
To establish the impact of the osteoclast on bone pathology, traditional in vivo 
techniques include ultrasound (US), radiography, computed tomography (CT) and 
magnetic resonance imaging (MRI), all of which provide an image of joint structure.  
US is based upon sound waves travelling through the body and being deflected back 
to the originating probe for detection once a tissue is reached that they cannot 
travel through.  The length of time it takes for the signal to be received depends 
upon the tissue they reached (Dǿhn et al. 2006).  The advantages of US are that it 
has a good sensitivity for bone erosions and is relatively cheap; however, the joint 
imaged has to be easily accessible and this is sometimes problematic. 
X-rays (traditional radiography composed of one ray, and CT scans composed of 
multiple rays), travel in one dimension and are passed through the area of interest 
before being detecting on the other side.  Highly calcified bone absorbs the energy 
and soft tissue does not (although still visible but hard to distinguish; Taouli et al. 
2004).  In CT scans a computerised 3-D image is composed following cross-sectional 
analysis (Dawson et al. 2001).  This technique offers an advantage over US and x-ray 
as it reconstructs a 3D image where cross-sectional erosions can be viewed; 
however, soft tissue is again difficult to distinguish. 
Thirdly, MRI utilises radio-waves of low-frequency to penetrate areas of interest 
and images are acquired from the time it takes for the reflected signal of 
magnetized spins from H+ in the object to be detected, defining tissue location, 
structure and composition (McQueen 2000).  Although this method yields the most 
integrated image of bone and soft tissue, it is not as sensitive as CT for calcified 
tissues, is prone to artefacts and is the most expensive imaging modality. 
1.5.1 Imaging methods for the diagnosis of destructive bone diseases 
The use of these above in vivo methods is highly important in diagnosing and 
monitoring physiological disease progression, in addition to furthering our 
knowledge of how these diseases affect the body.  In RA patients, during the first 
two years of disease duration substantial erosions and joint space narrowing are 
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common pathologies seen (Ved et al. 2002,Nogueira-Barbosa et al. 2010, Døhn et 
al. 2012).  However, by the time these imaging methods highlight such erosions, 
they are well-established and substantial bone destruction has normally occurred.  
The need for an early imaging system of disease progression is pivotal to diagnose 
and hinder osteoclast-associated disease progression.   
1.5.2 Possible imaging methods for the early identification of destructive bone 
disease 
For many years osteoclastogenesis and resorption research was carried out utilising 
many two dimensional (2D) in vitro methodologies; e.g. counting osteoclast 
numbers or area of resorption.  Imaging methods used for histological 
quantification of area resorbed commonly include light microscopy, scanning 
electron microscopy (SEM) and transmission electron microscopy (TEM).  Light 
microscopy is the most common, in which visible light is reflected of the surface of 
the substrate and magnification lenses facilitate its visualisation.  SEM directs a 
focussed beam of electrons onto the sample which interact and release signals back 
to the detector regarding surface topography (Sreeja et al. 2009).   Methods similar 
to SEM have also been used by Sasaki, Debari and Hasemi (1993) who studied 
Howship’s resorption lacunae through back-scattered electron microscopy (signals 
reflect off samples and travel back to detector at their source) and scanning probe 
microscopy (probes scan the surface of a sample and relay information back to a 
computer).  Thirdly, TEM uses electrons which travel through the sample and are 
detected on the opposite side, thus yielding data regarding internal structures.  
Although 2D imaging methods described previously were essential in assessing cell 
counts and resorption areas, their significant disadvantage is that they cannot 
quantify 3D processes; i.e. two resorption pits may have identical surface areas but 
their depths and volumes may be significantly different. In vivo imaging methods 
including CT and MRI would therefore be preferable as they facilitate 3D 
visualisation and subsequent quantification.  3D imaging methods are generally of 
higher resolution with increased sensitivity, but also have their disadvantages: 
they’re costly, need trained personnel and are challenging in method set up.  The 
benefits of using 3D imaging methods over 2D do outweigh these however, and are 
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essential when planning experiments to further our knowledge in both 
osteoclastogenesis and bone resorption; sequentially relating this back to 
destructive bone diseases.   
The use of 3D imaging to quantify osteoclast phenotype has in the last 5 years been 
reported, although many improvements are still needed.  Confocal laser scanning 
microscopy (CLSM/confocal microscopy) was utilised within in vitro studies where it 
utilises point illumination with a pin-hole to eliminate out-of-focus light, resulting in 
a high-resolution image with x, y and z dimensions.  Using this technique, living or 
fixed cells can be imaged and identified based on their subcellular structure and 3D 
parameters can be quantified i.e. resorption pits (Coxon 2012, Goldberg et al. 2012, 
Mediero et al. 2014).  Grevers et al. (2011) used confocal microscopy to highlight 
the F-actin structural rings in osteoclasts stimulated with S100A8 (RA alarmin 
responsible for enhanced inflammatory response) which were significantly elevated 
to those from control cultures.  Three years later, Mediero et al. (2014) showed 
intrinsic differences between pre-osteoclasts, differentiating osteoclasts, and 
mature osteoclasts by nuclei number and F-actin conformation.  Furthermore, 
Nevius et al. (2015)used two-photon microscopy to show the effects of EBI2 (a G 
protein coupled receptor involved in monocyte migration) on osteoclastic 
movement and giant nucleated cell differentiation.  From all of these studies the 
use of 3D imaging has therefore been proven effective and a  useful tool for cell 
identification and furthering osteoclast knowledge. 
In tandem, several researchers investigated the use of CSLM for the quantification 
of resorption.  The first studies investigating the 3D characteristics of resorption pits 
were reported in the 1990s, where Jones, Arora & Boyde (1995) used a 'video-rate, 
line confocal reflection light microscope' to identify bone mineral density as the 
rate-determining step in osteoclast resorption and pit volume.  In 1999 James et al 
commented on the advantages of using confocal microscopy for data relating to 
resorption pit number, area and volume.  It was concluded that all three 
parameters are necessary to fully understand the resorptive behaviour of the 
osteoclast as pit area may be comparable between two pits but their volume may 
alter significantly (James et al. 1999). 
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 This variation in pit volume was later found to correlate with soluble markers of 
bone resorption (CTX and NTX). Following this, 13 years passed before a second 
study investigating pit depth was published.  In 2012 Goldberg et al. used confocal 
microscopy paired with Sirius red staining (identifying resorptive edge) to show the 
role of Rac1 and Rac2 in osteoclast-mediated bone resorption.  In Rac1-/-cultures 
resorption pits had a reduced volume and area compared to wild-type cultures, but 
in Rac2-/- cultures although a reduction in resorption volume was found, pit area 
was unchanged.  However, Goldberg et al. (2012) did not further define why this 
change occurred (i.e. probable change in pit depth or anomaly) and therefore the 
osteoclasts true resorptive capability remained unanswered.   
Simultaneously, Jeon et al. (2012) also published a confocal microscopy 
methodology with the aim of producing 3D representations of resorption pits.  Jeon 
et al. (2012)reported that multiple pits of relatively small surface area and depth 
were present at the start of osteoclast differentiation, but that after 14 days of 
culture pit area increased, and by day 21 pit depth also increased.  Therefore pit 
area was apparently linked to osteoclast size, and pit depth to osteoclast resorptive 
potential (z dimension).   
An alternative method for determining pit characteristics, Super Depth Surface 
Profile Measurement Microscope (SDSPMM), was also reported by Soysa et al. 
(2009) after the limitations of 2D imaging where reported.  In SDSPMM a 3D image 
was obtained from which pit depth and volume could be calculated, from using 
data obtained from the z-dimension.  Soysa et al. (2009) concluded that osteoclasts 
cultured under stimulatory cytokine conditions yielded enhanced volumes and 
depths of resorption pits compared to un-stimulated cultures; supporting confocal 
data obtained by James et al. 1999 and Goldberg et al. 2012.  Taken together, all of 
these studies provide substantial support for the use of 3D imaging techniques in 
clarifying the role of the osteoclast in vitro.  Such methodologies are therefore 
imperative to further our knowledge of the differentiating osteoclast and its 
resorptive capabilities in both health and disease.   
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 1.6 Destructive Bone Diseases 
Through the utilisation of imaging methods described previously, and the 
combination of biological tests, many destructive bone diseases of the joint can 
now be identified in clinic. These diseases result due to an unbalanced increase in 
bone resorption versus osteoid formation, which leads to a multitude of 
pathological events associated with the bone and overall joint health.  The 
identification, classification and diagnosis of destructive bone diseases was well 
documented over the past decades (Table 1.1) and the pathological presentation 
commonly includes inflammation of soft tissues lining the joint, cartilage 
destruction, osteopenia and periosteal reaction, narrowing of joint spaces, fusion of 
joints and bone erosions (as shown in Figure 1.3).     
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Table 1. 1 - A descriptive table of destructive bone diseases in order of UK prevalence.
Destructive Bone 
Disease 
Description 
Periodontal 
disease 
A disease caused by excessive and highly pressurised oral activity which 
enhances osteoclastic resorption of alveolar bone.  Resulting inflammation 
may ensue with further trauma and possible infection (Repeke et al. 2010). 
Osteoarthritis 
(OA) 
A degenerative disease of joints with gradual destruction of cartilage 
exposing underlying bone surfaces heightening bone resorption leading to 
pain on movement. (Hayami et al. 2004). 
Osteoporosis 
A disease of low bone mass (often diagnosed after a fracture) thought to 
occur due to uncontrolled resorption and insufficient new bone formation.  
Common in post-menopausal women due to the link between oestrogen 
and osteoclast differentiation and resorption (Raisz 2005). 
Rheumatoid 
arthritis (RA) 
A chronic systemic inflammatory disease primarily of the extremities 
presenting with inflamed & tender joints and bone destruction visible from 
radiological assessment.  Affects 1% of the male population and 3% of the 
female population.  Prevalence >55 years old.  Autoimmunity is thought to 
play a major role (Ichikawa et al. 2016, Toma et al. 2007). 
Osteitis fibrosa 
cystica 
Destruction of the skeleton due to enhanced osteoclastogenesis results 
from hyperparathyroidism thus predisposing the patient to fractures.  
Brown tumours are commonly found on bone structures as they are 
resorbed (Maina & Kraus 2012). 
Paget’s disease 
A disease associated with pathological osteoclast and osteoblast activity.  
Enhanced osteoclast differentiation leads to substantially increased 
osteoclast size and resorption.  To compensate, osteoblasts rapidly lay 
down new bone matrix which is inadequately organized with poor 
structure, leading to enlarged and misshapen bones (Doyle, Banks& 
Pennock1980). 
Multiple 
myeloma 
Multiple myeloma is a hematologic malignancy coupled to significantly 
enhanced osteoclast resorption and bone destruction.  Pathogenic 
mechanisms behind enhanced destruction are currently thought to be due 
to excessive secretion of osteoclast stimulating and osteoblast inhibiting 
factors from tumours (Pearse et al. 2001). 
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 1 Inflammatory cell infiltrate (monocytes/macrophages/T 
cells/B cells) 
2 Increased pro-inflammatory cytokines 
3 Hyperplasia 
4 Cartilage destruction 
5 Bone destruction 
6 Pannus formation 
 
Figure 1. 3 - An illustration of the joint pathology associated with the arthritides.In 
arthritic joints 6 aspects of pathology are commonly seen.  Inflammatory cells 
(monocytes/macrophages/T cells/B cells) infiltrate into the joint due to elevated pro-
inflammatory cytokines and chemokines (IL-6 and CCL3).  Such elevated levels of 
inflammatory mediators results in both hyperplasia and pannus formation in the joint.  
Additionally, cartilage is slowly degraded by enzymes, revealing unprotected bone 
underneath which is subject to destruction. 
 
The inflammatory phenotype of a joint is common between destructive bone 
diseases.  The influx of inflammatory cells (monocytes/macrophages/B cells/T cells) 
into the synovial capsule precedes the localised secretion of several pro-
inflammatory cytokines (TNF-α, IL-6, IL-1 and IL-8; Schett 2007).  These pro-
inflammatory cytokines lead to several effects; enhanced fibroblastic proliferation, 
concurrent hyperplasia, co-secretion of inflammatory cytokines, enhanced cartilage 
damage and bone destruction.  In tandem, infiltrating inflammatory cells secrete 
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matrix metalloproteases (MMPs) which degrade cartilage and reveals underlying 
bone, enabling further bone resorption (Danks et al. 2002, Hirayama et al. 2002, 
Schett, 2007).  The invasion of the whole joint thus progresses, often resulting in 
pannus formation (Figure 1.3), and periosteal reaction (uncontrolled bone 
proliferation in psoriatic and reactive arthritis), further enhancing the pathogenesis 
of the disease (Schett 2007, Rana et al. 2009). 
Additional to the inflammatory changes, four common structural joint changes also 
occur.  Joint space narrowing, joint fusion (especially in spondyloarthritides patients 
where sacroiliac joints are remodelled), excessive bone formation resulting in 
osteophytes (thought to result from a lack of Dickkopf-1; Wnt inhibitor), and joint 
destruction (Uderhardt et al. 2010, Ichikawa et al. 2016).  Although several reasons 
exists for increased bone resorption (i.e. decreased osteoblast activity), in this 
thesis the main focus is upon the uncoupling due to inflammatory cytokines and 
chemokines which facilitate bone destruction as already discussed (Heymann et al. 
1998, Uderhardt et al. 2009, Kitaura et al. 2014).  As the osteoclast is the only cell 
capable of bone destruction, it is of paramount importance.  Understanding the 
role of the osteoclast in destructive bone diseases is therefore essential to fully 
explore the complex relationship between pain, inflammation and pathology in 
arthritis. 
 
1.7 In vivo models of arthritis 
To further our understanding as to how osteoclasts mediate a role in the 
inflammation, pathology and pain associated with destructive bone diseases, in vivo 
models of arthritis are needed.  The use of these models is pivotal in providing the 
most up-to-date translational research for both disease pathogenesis and novel 
treatment strategies (Bendele 2001).Many murine models for the arthritides are 
available and include the following; adjuvant induced arthritis, antigen induced 
arthritis, streptococcal cell wall arthritis, immune complex induced arthritis, 
surgically induced osteoarthritis and collagen induced arthritis(Brackertz, Mitchell& 
Mackay1977, Cromartie et al. 1977, Trentham et al. 1978, Holmdahl et al. 1992, 
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Van Lent et al. 1995, Bendele et al. 1999, Finnegan et al. 1999, Nandakumar et al. 
2003, Dinser 2008, van der Berg 2009). 
Adjuvant arthritis is the original model of arthritis commonly used to establish the 
effects of novel drugs.  This model is induced by injection of complete Freund’s 
adjuvant into the joint resulting in the presentation of a polyarticular disease after 
1-2 weeks, where inflammation and bone destruction present (Bendele et al. 
1999).Acute arthritis results when using this model as clinical symptoms last less 
than a month, presenting a major disadvantage for the relevance to human disease.  
A second model, antigen-induced arthritis, was developed over 40 years ago by 
Dumonde & Glynn(1961) and differs from adjuvant arthritis by the injection of a 
known antigen (fibrin or methylated bovine serum albumin) into the joint, which 
contains the arthritis to the injected joint (van den Berg et al. 2007).  Histological, 
inflammation, bone and cartilage destruction are presented, likening it human RA 
(van den Berg et al. 2007).  However due to the lack of penetrance its use to study 
human RA is questionable. 
A third model known as streptococcal cell wall induced arthritis can be induced 
through the injection of cell wall components from streptococcal cultures into the 
joint space. The resulting disease presents as a chronic polyarthritis with erosive 
phenotype, although a secondary ‘reactivation’ phase may be necessary; limiting its 
translation to human disease (Schimmer et al. 1998).  Alternatively, inflammatory 
arthritis could be induced through injection of anti-bovine serum albumin IgG 
antibodies followed by BSA, thus evoking an immune-complex.  This type of 
inflammatory arthritis results in enhanced infiltration of polymorphonuclear cells 
and joint pathology (Rocha, Andrade & Jancar 1996). 
Alternatively, a model of non-inflammatory arthritis could be used, known as 
surgically induced arthritis.  This model is commonly used to study human 
arthritides such as OA.  The model is induced through surgical trauma to the joint, 
mimicking that which would occur in the human disease.  In contrast to the human 
disease however, arthritis develops quickly, but this is advantageous for therapy 
testing (Bendele et al. 1999). 
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Lastly, the most utilised animal model for arthritis is collagen-induced arthritis (CIA) 
which was first reported by Trentham et al. (1978).  CIA presents with systemic 
immune system involvement and is a poly-articular erosive disease like human RA.   
Characteristic histology findings of synovial joints include; enhanced leukocyte 
infiltration, synovial hyperplasia, inflammatory pannus formation, cartilage 
destruction and bone erosions (Song et al. 2015).  Commonly, male DBA/1 mice are 
used to study CIA due to an average of 90% showing full disease penetrance, and 
successful presentation (Dinser 2008).  The high penetrance of this disease is a 
major advantage making this an ideal model for RA and potential therapeutics; 
increases reportable data, and decreases the need for high sample numbers and 
cost (Kannan et al. 2005).    In addition, it was reported that the same pro-
inflammatory cytokines are involved in both the pathogenesis of CIA and RA, 
including IL-1, IL-6, and TNF-α, where the development of pharmacological RA 
treatments have arisen from CIA animal studies (Goldring et al. 2000 &Kannan et al. 
2005).  Furthermore, auto-antibodies to type II collagen are also found in murine 
samples, presenting with similar immune involvement as human RA. 
Although the above models have all been used with varying degrees of success for 
the presentation, evaluation and treatment of human arthritis, the CIA model is the 
most commonly used due to its similarity in disease presentation to human RA.  
However, CIA only ensues after induction and therefore is not a natural progression 
as RA is.  Additionally, CIA shows greater penetrance in male mice, compared to RA 
showing increased penetrance in females. Although the reason behind this is still 
unknown, the difference is thought to be due to the involvement of the sex 
hormone testosterone, but this does raise an interesting question of sex bias.  
Despite this, procedural induction is relatively easy, produces high incidence and 
penetrance, and can be used to develop pharmacological target therapies (Bendele 
2001). Reproducible results are generally collated through this model, although 
intra-experiment differences do arise.  However, in human RA no two patient cases 
are the same, thus this model also provides insight into patient individuality 
(Kannan et al. 2005). 
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1.7.1 Collagen-induced arthritis (CIA) 
The basis for CIA use was first proposed in 1978 by Trentham et al. where the self-
recognition of type II collagen by auto-antibodies was described in joints after the 
induction of CIA (emulsion of complete Freund’s adjuvant (CFA) and type II 
collagen).  The importance of many cytokines, chemokines and growth factors in 
the arthritides and their therapeutic potential was illustrated and reported through 
the use of CIA over the past 40 years.  For example, Lubberts et al. (2004) defined 
the role of the novel cytokine IL-17 in osteoclast-mediated pathology.  In their 
study, the treatment of mice at first presentation of CIA with anti-IL-17 significantly 
decreased bone and cartilage degradation in hind limbs, coinciding with reduced 
inflammation; later reported to be due to significantly decreased systemic IL-6.  
Additionally, treating well-established CIA mice with anti-IL-17 (a later time-point) 
also yielded promising results in deliberating the progression of joint pathology 
(Lubberts et al. 2004).  The above reported use of CIA therefore highlights the utility 
of such an in vivo model in distinguishing the role of inflammatory mediators 
previously shown to exert a significant role on osteoclastogenesis in vitro, and to 
then postulate potential novel pharmacological targets in destructive bone 
diseases. 
 
1.7.2 Therapeutic drug development 
The importance of the above models was pivotal in the development of novel 
therapeutics targeting inflammatory arthritis and destructive bone diseases.  
Although past the scope of this project, it is important to appreciate the 
translational impact of potential therapies from in vitro to in vivo.  Several 
therapeutic drugs (biologic DMARDs) are currently available and used in the 
treatment of inflammatory arthritis and some of these are highlighted in Table 1.2.   
From the collated data it is evident that further research into pharmaceutical 
agents which will inhibit, block or reduce the formation or resorptive activity of the 
osteoclast is going to be crucial for developing treatments against destructive bone 
diseases, where pathogenic inflammatory components are already reduced. 
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Table 1. 2 - An overview of currently available biologics. 
Drug Mechanism of action Tested in 
Etanercept 
A TNFR fusion protein that binds to TNF-α and 
blocks its binding to membrane bound TNFR, 
thus inhibiting TNF activity (Anandarajah et al. 
2008) 
RA, JIA, psoriatic 
arthritis and 
ankylosing 
spondylitis 
Adalimumab 
A monoclonal antibody that binds to TNF-α and 
prevents its signalling through membrane bound 
TNFR (Kempeni 1999) 
RA, psoriatic 
arthritis, ankylosing 
spondylitis and 
Crohn’s disease 
Infliximab 
A monoclonal antibody which binds to TNF-α and 
again prevents its binding to membrane TNFR 
(Gengenbacher et al. 2007) 
RA, psoriatic 
arthritis, ulcerative 
colitis Behçet’s 
disease and Crohn’s 
disease 
Anakinra 
This receptor antagonist competitively inhibits IL-
1R preventing IL-1 from binding to its receptor 
(Fleischmann et al. 2006) 
RA and some 
inflammatory skin 
diseases 
Tocilizumab 
A monoclonal antibody which binds membrane 
bound and soluble forms of IL-6R, thus blocking 
IL-6 binding and cell signalling (Genovese et al. 
2008) 
RA, JIA, MM, 
Castleman’s disease 
Denosumab 
Inhibits RANKL by acting as its decoy receptor 
(modelled on OPG), thus reduces osteoclast 
formation and bone resorption, leading to 
increase bone mineral density (Andrews 2008 , 
Baron et al. 2011, Sims and Romas 2015) 
Osteoporosis, bone 
metastases, post-
menopausal women 
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1.8 Project Summary 
In destructive bone diseases many pro-inflammatory cytokines and chemokines are 
known to be involved in the enhanced erosive phenotype presented.  However, the 
direct role of these mediators on the differentiation of CD14+ve mononuclear cells 
into osteoclasts and their corresponding resorptive activity was still unknown.  
Monocultures were therefore preferred over co-culture methodologies to gain a 
greater understanding.  No current methodology existed for the automated 
counting of adhered cells, which presented itself as an issue when previously trying 
to count extensive numbers of osteoclasts due to their highly adherent phenotype.  
In addition to this, the quantification of resorptive activity is traditionally performed 
using 2D imaging modalities, but research publications have described the 
limitations and short-falls of these methods in masking the complete resorptive 
phenotype of the osteoclast.  For this reason, novel methodologies for both 
counting adherent cells (osteoclasts) and for the quantification of resorptive activity 
through 3D imaging will both be reported in this thesis.  Following this, an 
assessment of specific pro-inflammatory mediators highlighted from Chapter 3 was 
completed to determine their role on direct osteoclastogenesis and bone 
destruction using these novel methodologies, and the targeting of each as a 
therapeutic will be assessed. 
1.8.1 Project Aim and Hypothesis 
The overall aim of this thesis was to establish the role of pro-inflammatory 
mediators in the direct differentiation of human osteoclasts and their resorptive 
activity using novel imaging methodologies which will determine their impact on 
associated pain and pathology related to arthritis.  Data reported from this thesis 
would subsequently lead us to accept or reject our hypothesis that IL-6, TNF-α, 
CCL2, CCL3 and CCL5 significantly increase the differentiation of the osteoclast and 
its resorptive potential heightening bone destruction.  This hypothesis was 
addressed in the proceeding chapters through the following aims; 
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• Aim 1- to establish a reproducible monoculture method for human 
osteoclasts in vitro and to create a novel, high-throughput, automated 
computer algorithm for adherent total cell counts.   
• Aim 2- to define the direct role of IL-6 trans-signalling in osteoclast 
differentiation stimulated by m-CSF and RANKL through the use of sgp130-
Fc.   
• Aim 3- to decipher the role CCL3 plays in the differentiation and functional 
resorptive activity of the osteoclast in vitro. 
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2 Chapter 2:Materials and Methods 
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2.1 Materials 
 
All chemicals were purchased from Sigma-Aldrich (unless stated otherwise). 
Solvents were supplied by Fisher Scientific (unless stated otherwise). A Millipore 
Milli-Q system produced dH2O that was used to prepare buffers, reagents and 
stains. Phosphate Buffered Saline (PBS) pH7.2 was supplied by Life Technologies 
Ltd. All plastic-ware, sterile tissue culture plates and ELISA plates were obtained 
from Greiner Bio-One Ltd. Antibodies (Anti-human CD14-FITC and Isotype Control 
FITC) used for flow cytometry were purchased from eBiosciences. 
 
2.1.1 Human osteoclast assay culture media 
Reagent were supplied by Life Technologies unless specified otherwise. 
A basic medium containing Roswell Park Memorial Institute medium 1640 (RPMI-
1640) was supplemented with 10% heat-inactivated foetal calf serum (FCS, 
Biosera), 20mM L-glutamine, and penicillin (50 units/mL)/Streptomycin (50μg/mL).  
Human proliferation medium was prepared by adding 5ng/mL or 10ng/ml m-CSF 
(R&D systems) into basic medium.  
Human osteoclast differentiation medium was prepared from basic medium 
supplemented with 5ng/mL m-CSF, 5ng/mL RANKL and 2.5μg/mL polyHistidine (all 
from R&D systems).   
 
2.1.2 Treatment of in vitro human osteoclast differentiation cultures with either 
sgp130-Fc, HYPER-IL-6 or sgp130-Fc and HYPER-IL-6 
Human osteoclast differentiation medium from Section 2.1.1 was supplemented 
with soluble gp130-Fc (sgp130-Fc) at 500ng/mL and/or a fusion protein of IL-6 
linked to sIL-6R (HYPER-IL-6), both generous donations from Professor Rose-John, 
University of Kiel) over a concentration range of 0.5-10ng/mL. 
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2.1.3 Treatment of in vitro human osteoclast differentiation cultures with anti-
CCL3 
Human osteoclast differentiation medium from Section 2.1.1 was supplemented 
with human anti-CCL3 antibody reconstituted with sterile PBS over a range of 0-
8ng/mL (MAB270; mouse IgG1 source, R&D systems).  As a control, human 
osteoclast differentiation medium was supplemented with mouse IgG1 isotype at 
the same concentrations as anti-CCL3 in assays (MAB002, R&D systems).  Human 
osteoclast differentiation medium was also supplemented with recombinant human 
OPG reconstituted with sterile PBS containing 0.1% BSA at 8ng/mL and 100ng/mL 
(185-OS, R&D systems). 
 
2.1.4 Buffers, staining solutions and mountants 
The solutions used for this project are listed Table 2.1. 
Table 2. 1 - Buffers, staining solutions and mountants. 
• Tissue culture 70% alcohol spray 
350mL methanol was diluted with 150mL dH2O. 
• MACS CD14+vecell fraction isolation 
MACS buffer – 58mg EDTA and 500mg bovine serum albumin (BSA) were dissolved in 
100mL PBS prior to sterile filtration. 
• Flow Cytometry Reagents 
Flow cytometry buffer – 150µL FCS was diluted in 15mL PBS. 
4% Formaldehyde – 10.8mL formaldehyde (37%) in 89.2mL PBS. 
• Cellular fixation 
Glutaraldehyde solution (10%) – 400µL glutaraldehyde stock diluted with 600µL dH2O. 
• TRAP staining of ivory disks 
Sodium acetate solution 0.2M – 0.164g sodium acetate dissolved in 10mL dH2O. 
Acetic acid solution 0.2M – 115µL acetic acid diluted in 10mL dH2O. 
Sodium tartrate solution 0.35M – 0.69g sodium tartrate was dissolved in 10mL dH2O. 
Naphthol AS-MX phosphate disodium salt solution – 3mg naphthol AS-MX phosphate 
disodium salt was dissolved in 300µL dH2O. 
Acetate buffer 0.1M – 3.52mL sodium acetate solution (0.2M) and 1.48mL acetic acid 
solution (0.2M) were added into 5mL dH2O.  
TRAP buffer – 1mL sodium tartrate solution* (0.3M), 100µL naphthol AS-MX phosphate 
disodium salt solution and 10µL Triton X-100 were added to 5mL acetate buffer (0.1M).  
3.89mL dH2O was then added into the solution. 
TRAP staining solution – 3mg Fast red violet LB salt was dissolved in the TRAP buffer. 
*resulting in a final 30mM tartrate solution eliminating phosphatase sensitive to tartrate (Li 
et al. 1970). 
• Haematoxylin Stain 
Equal quantities of Harris’ Haematoxylin Stain and dH2O were mixed together. 
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• Resorption Pit Staining 
Bleaching solution (1%) – 333µL hydrogen peroxide (30%) was diluted in 10mL dH2O. 
Toluidine blue stain (0.5%) – 0.25g toluidine blue stain was dissolved in 50mL dH2O. 
Calcein staining solution – 5mg calcein was dissolved in 10mL dH2O. 
• Confocal microscopy disk mountant 
Harvested disks were mounted using CyGEL (a liquid between 2-6oC, a solid at ≥6oC). 
• ELISA Reagents 
Wash buffer (0.05% PBS-T) – 10 PBS tablets dissolved in 2L of dH2O, containing 1mL of 
Tween-20.  
Blocking buffer – 1g BSA dissolved in 100mL PBS. 
Citrate buffer pH 3.95 – 4.2g citric acid (0.2M) dissolved in 100mL dH2O (pH adjusted using 
sodium hydroxide solution). 
Sodium hydroxide solution – 2mg NaOH in 50mL dH2O. 
Tetramethylbenzidine (TMB) – 240mg (TMB) was dissolved in a solution containing 5mL 
dimethyl sulphoxide (DMSO) and 5mL of absolute ethanol. 
Development buffer – 10µL hydrogen peroxide (30%) and 100µL TMB were dispersed in 
10.5mL citrate buffer. 
Stop solution (12% sulphuric acid) – 60mL of 99.99% sulphuric acid in 440mL of dH2O. 
• Preparation of Complete Freund’s Adjuvant (CFA; an immuostimulator) 
100mg Tuberculosis (TB) was ground up into a fine powder.  Small amounts of incomplete 
Freund’s adjuvant (IFA) were added to create a suspension of TB, 20mL of IFA in total.  
Once at 5mg/mL the solution was aliquoted into 2.5mL vials and frozen (-80oC) 
• Preparation of collagen solution 
5mg of collagen from chicken sternal cartilage (C9301) was dissolved in 2.5mL 10mM acetic 
acid and placed at 4oC mixing overnight 
• Preparation of CFA + collagen (stimulates immune response to collagen) 
2.5mL CFA and 2.5mL collagen solution was mixed for 5 minutes until a thick emulsion 
which floated on water formed 
• Fixation of joints using 10% neutral buffered formalin solution 
10% neutral buffered formalin solution (200mL) was used to submerge joints 
• Storage buffer for murine joints – 70% alcohol  
700mL methanol was diluted with 300mL dH2O 
• EDTA decalcification solution (demineralisation of bone to allow for wax 
histology) 
5 PBS tablets were dissolved in 1L of dH2O 
70g EDTA was then added and the pH was adjusted to 7.1 using sodium hydroxide 
• Rehydration solutions (essential for staining as hydrophobic after embedding) 
Xylene (100%) – 500mL 
90% alcohol – 450mL industrial methylated spirit (IMS) diluted with 50mL dH2O 
100% alcohol – 500mL IMS 
• Dehydration solutions (minimizes cell damage and maintains sample integrity)   
100% alcohol – 500mL IMS 
90% alcohol – 450mL IMS diluted with 50mL dH2O 
Xylene (100%) – 500mL 
• TRAP preparation buffer for histological sections (shoulders/knees/ankles) 
0.82g of sodium acetate and 0.58g of tartaric acid dissolved in 50mL dH2O 
• TRAP stain for histological sections (shoulders/knees/ankles) 
0.5mg/mL naphtol AS-MX phosphate and 1.1mg/mL fast red TR salt dissolved in 50mL 
preparation buffer 
• Haematoxylin stain 
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Undiluted Harris’ Haematoxylin (50mL) 
• Scott’s tap water (blueing reagent for staining) 
1 part Scott’s tap water concentrate was dissolved in 9 parts of dH2O and stored for a 
month or until discolouration 
 
2.1.5 Murine CIA model 
Male DBA/1 mice (n=12) were obtained from Charles River and divided into two 
treatment groups.  6 mice received an antibody against mouse CCL3 which was 
reconstituted in sterile PBS (MAB450; monoclonal rat IgG source, R&D systems), 
and the remaining 6 received a monoclonal rat IgG isotype antibody reconstituted 
in sterile PBS (MAB006, R&D systems).  Delivery of both was by 100µL 
intraperitoneal injection (i.p.) at 5mg/kg. 
 
2.1.6 Hardware and Software 
Hardware and software used in this thesis are listed in Table 2.2. 
Table 2. 2 - Hardware and software used to observe, measure and quantify cells and or 
cell activity.
Equipment/Software Supplier Purpose 
BD Accuri C6 flow cytometer BD Biosciences Flow cytometry 
BD CFlow Plus software BD Biosciences Flow cytometry analysis 
Olympus BX41 Microscope Olympus Visualisation of cells 
Olympus Camedia C-3030 
Digital Camera 
Olympus Image acquisition  
Canon EOS 100D Digital Camera Canon Image acquisition 
Matrix Laboratory (MATLAB) Mathworks Image analysis for cell number 
and characteristics 
Corel Paint Shop Pro X5 Corel UK Ltd. Image analysis for cell number 
and characteristics 
Image J. Ink National Institute of 
Health (NIH) 
Resorption pit analysis for cell 
activity 
LaserSharp Bio-Rad Confocal image acquisition 
MetaMorph BioImaging Solutions 
Inc. 
Confocal image analysis for 2D 
and 3D characterisation of 
resorption pits 
Omega Control/ Omega Data 
Analysis 
BMG LabTech ELISA plate reader to  measure 
presence of soluble mediators for 
pain, inflammation and pathology 
GraphPad Prism 4 GraphPad Software 
Inc. 
Data analysis and presentation 
Microsoft Office 2013 Microsoft Data analysis and presentation 
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2.2 Methods 
A comprehensive account of the methods used to culture, count and characterise 
human osteoclast differentiation assays are detailed in this section.  For a more 
comprehensive list of methods used for osteoclast culture, resorption pit 
quantification, erosive pathology imaging, and in vivo techniques, the following 
reference can be used; Bone Research Protocols (specifically Chapters 11, 24, 25, 
26, 27, 29, 33 and 38). 
 
2.2.1 The acquisition and isolation of CD14+ve cells from peripheral blood of 
healthy human volunteers 
Consent from healthy human volunteers was taken under a project reviewed by the 
Research Ethics Committee for Wales (Reference No 12/WA/0045), for the 
acquisition of venous peripheral blood.  From each donor enrolled into the study, 
40mL whole blood was collected and immediately placed into a falcon tube 
containing heparin, preventing coagulation.  Blood (10mL) was then layered onto 
5mL histopaque-1077 (Sigma-Aldrich) and centrifuged at 400g for 30 minutes 
leading to the separation of blood components due to differing cell densities.  
Plasma was removed from all tubes allowing the interface layer of peripheral blood 
mononuclear cells (PBMCs) to be collected and transferred into separate sterile 
falcon tubes containing 10mL Hanks Buffered Saline Solution (HBSS) (Life 
Technologies), and were then centrifuged for 10 minutes at 300g. Post-
centrifugation, the HBSS was removed from all tubes and 10mL of fresh HBSS was 
added to each tube and the pellet of PBMCs was re-suspended.  The cells were 
washed three times in HBSS before being re-suspended in 5mL human basic 
medium and placed on ice.  A sample of the PBMC population was diluted 1:10 with 
human basic medium and a cell count was performed using a haemocytometer 
(Section 2.2.2).  After this initial cell count 2 x 105 cells were removed and placed on 
ice ready for further preparation and analysis using flow cytometry (Section 2.2.3). 
The PBMC suspension was centrifuged for a further 10 minutes at 300g and all 
medium was carefully removed from the tube.  The pellet was then re-suspended in 
a solution of anti-human CD14 MACS microbeads (20µL per 107 cells) and MACS 
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buffer (80µL per 107 cells), which was then incubated on ice for 15 minutes.  
Following this the cell suspension was put through a pre-separation filter (pre-
rinsed with 500µL MACS buffer) over the MS column.  CD14-ve cells were collected 
in a waste falcon tube and disposed of, and CD14+ve cells were maintained within 
the magnetic column.  The column was washed through three times using 500µL 
MACS buffer prior to the removal of the column from its magnet to a new, sterile 
falcon tube.  The CD14+ve cells were flushed out of the column into the sterile tube 
using 1mL MACS buffer and 1mL human basic medium.  A second cell count with a 
1 in 5 dilution was performed on the CD14+ve cell population (Section 2.2.2).  After 
this second cell count, 2 x 105 cells were removed and placed on ice ready for 
further preparation and analysis using flow cytometry (Section 2.2.3). Finally, cells 
were spun at 300g for 10 minutes prior to be re-suspended in human basic medium 
to a concentration of 3.2 x 106 cells/mL.  This cell suspension was then used to seed 
the ivory disks used in the human osteoclast assay (Figure 2.1, Section 2.2.4). 
 
2.2.2 Manual cell counting using a haemocytometer 
Cell counts during the human CD14+ve cell isolation stages were performed using a 
haemocytometer.  The cell suspension was diluted either 1 in 5, or 1 in 10 using 
human basic medium and then applied to a haemocytometer.  Cells within the four 
corner sections of the haemocytometer were counted and total number of cells/mL 
were calculated using the formula in Figure 2.2. 
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Figure 2. 1 - The acquisition and isolation of CD14+ve mononuclear cells from human whole blood.Whole blood (10mL) was layered on top of histopaque 
(5mL) and spun at 400g for 30 minutes.  PBMCs were isolated and transferred into a sterile tube prior to washing 3x in HBSS (10mL).  Cell counts were 
carried out to calculate MACS buffer and bead volumes for CD14+ve mononuclear cell isolation.  After magnetic separation, these cells were counted, and 
seeded on ivory disks at 3.2 x 106 cells/mL. 
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𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑇𝑇𝑜𝑜 𝑐𝑐𝑛𝑛𝑇𝑇𝑇𝑇𝑐𝑐 𝑝𝑝𝑛𝑛𝑛𝑛 𝑛𝑛𝑚𝑚 =  𝑇𝑇𝑎𝑎𝑛𝑛𝑛𝑛𝑇𝑇𝑎𝑎𝑛𝑛 𝑇𝑇𝑜𝑜 𝑇𝑇ℎ𝑛𝑛 4 𝑞𝑞𝑛𝑛𝑇𝑇𝑞𝑞𝑛𝑛𝑇𝑇𝑛𝑛𝑇𝑇𝑐𝑐 𝑥𝑥 𝑞𝑞𝑑𝑑𝑇𝑇𝑛𝑛𝑇𝑇𝑑𝑑𝑇𝑇𝑛𝑛 𝑜𝑜𝑇𝑇𝑐𝑐𝑇𝑇𝑇𝑇𝑛𝑛 𝑥𝑥 104 
 
Figure 2. 2 - Example view of a haemocytometer.Cell counts were obtained from the top 
left, top right, bottom left and bottom right quadrants (1mm2 in total).  An average from 
these four quadrants was taken, multiplied by the dilution factor, and then multiplied by 
104 to yield a cell count/mL. 
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2.2.3 Analysis of human CD14+ve mononuclear cell purity using flow cytometry 
Flow cytometry was used to determine the percentage of CD14+ve cells within the 
PBMC population initially isolated using histopaque, and within the final 
mononuclear cell population used to seed the ivory disks.  Samples containing 2 
x105 cells from each of these populations were taken and spun at 800g for 2 
minutes.  The pellet was then re-suspended in FACS buffer (400μL), and each 
suspension was divided into two tubes.  A monoclonal anti-CD14 FITC antibody or 
its corresponding isotype (both eBiosciences, San Diego, CA) was then 
supplemented into the sample vials and placed on ice for 30 minutes.  After this 
incubation cells were again spun at 800g for 2 minutes prior to being washed in 
FACS buffer.  This was repeated 3 times.  Following the final removal of the 
supernatant, cells were re-suspended in 200μL FACS buffer and 200μL 4% 
formaldehyde, fixing the cells.  Once fixed, cells were then run through a flow 
cytometer (Accuri C6, BD) at 40,000 events, and the data collected was analysed 
using the partner software CFlow Plus (BD).  To remove cell debris and doublets 
forward scatter area (FSC-A) against height (FSC-H) plots and side-scatter area (SSC-
A) against FSC-A plots were drawn.  CD14+ve cells were then gated from scatter 
plots, and samples were compared against those labelled with the isotype.  A 
percentage purity of CD14+ve cells was then acquired. 
2.2.4 The in vitro monoculture of human osteoclasts 
Ivory disks, which mimicked the physiological matrix of bone, were seeded with 3.2 
x 106 CD14+ve mononuclear cells of ≥90% purity.  These disks were initially 
incubated at 37oC for 2 hours to allow cellular adhesion to the ivory disks.  After 
two hours the disks were placed within a 48 well culture plate containing 500μL of 
proliferation medium for 7 days.  Culture supernatants were collected and stored at 
-80oC and wells were replenished with fresh medium every 3-4 days.  To ensure cell 
density was of a high enough value to facilitate osteoclast differentiation, two disks 
from each experiment were harvested at day 0.  These disks were fixed and stained 
using glutaraldehyde, haematoxylin and TRAP stains. Assays containing disks with 
adequate cell density (>500 cells/mm2) were further cultured in differentiation 
medium containing 5ng/mL m-CSF and 5ng/mL RANKL (Figure 2.3). 
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After initial analysis of total cell counts obtained from a previously established 
method (Dr F. L. Collins) using 5ng/mL m-CSF, a reduction in total count was noted 
(counts were quantified by two individual analysts and results reported in Chapter 
3).  The concentration of m-CSF in proliferation medium was therefore increased to 
10ng/mL.  All subsequent assays and the validation of the automated counting 
algorithm were cultured in 10ng/mL m-CSF proliferation medium prior to culture in 
differentiation medium for 14 days which contained 5ng/mL.  Control culture 
conditions containing only proliferation medium were run alongside disks cultured 
in differentiation medium to establish the effects of RANKL addition (Figure 2.4).  
From initial results a power calculation was carried out to reveal a total of 8 
individuals were needed to determine whether a significant effect could be seen in 
the osteoclast differentiation assay. 
2.2.5 The addition of sgp130-Fc and HYPER-IL-6 into osteoclast cultures 
Sgp130-Fc was supplemented into differentiation cultures at 500ng/mL across the 
14 day time-course, alongside its addition into m-CSF control cultures (n = 8).  
HYPER-IL-6 was initially supplemented into cultures at 10ng/mL (n=7) but after low 
cell counts a dose range of 0.5ng/mL to 5ng/mL was tested in differentiation 
medium (n=1).  Following this the optimal dose of 0.5ng/mL HYPER-IL-6 was added 
into differentiation medium (n=8) across the 14 day culture period.  Finally, the 
combination of sgp130-Fc (500ng/mL) and HYPER-IL-6 (0.5ng/mL) was 
supplemented into differentiation cultures across the time-point (n=6).  Medium 
was collected, refreshed and treated every 3-4 days, and at day 14 disks were 
harvested and stained with haematoxylin and TRAP. 
2.2.6 Treatment of in vitro human osteoclast differentiation cultures with anti-
CCL3 
Ivory disks were seeded and cultured as previously stated in Section 2.2.4.  At day 0 
anti-CCL3 was supplemented into differentiation cultures at 0, 2, 4 and 8ng/mL, 
alongside their addition into m-CSF control cultures (n=8).  Medium was collected, 
refreshed and treated every 3-4 days, and at day 14 disks were harvested and 
stained with haematoxylin and TRAP. 
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2.2.7 Treatment of in vitro human differentiation assays with recombinant 
human IgG1 
Seeded disks from Section 2.2.4 were cultured for seven days in proliferation 
medium prior to being treated with differentiation medium containing 8ng/mL 
recombinant human IgG1 antibody for 14 days (n=8).  Control cultures containing 
m-CSF (5ng/mL) and IgG1 isotype (8ng/mL) were run in parallel (n=4).  Medium was 
harvested and replenished every 3-4 days and assays were terminated on day 14, 
where disks were fixed and stained with haematoxylin and TRAP. 
2.2.8 Treatment of in vitro human osteoclast differentiation cultures with OPG 
Methodologies outlined in Section 2.2.4 were used to seed disks and culture them 
in proliferation medium for seven days.  At day 0 either 8ng/mL OPG or 100ng/mL 
OPG were supplemented into differentiation cultures.  Medium was harvested and 
replenished every 3-4 days.  At day 14 disks were harvested, fixed and stained for 
total, TRAP, osteoclast cell number and functional activity. 
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 Figure 2. 3 - The time-course for the culture of human CD14+ve mononuclear cells in the 
proliferation and differentiation phase of the osteoclast assay.Previously established 
proliferation medium containing 5ng/mL was used to culture CD14+ve cells for seven days 
prior to addition of differentiation medium (5ng/mL m-CSF and 5ng/mL RANKL).The 
optimisation of these conditions led to an increase to 10ng/mL m-CSF in proliferation 
medium for seven days prior to addition of differentiation medium at the same 
concentrations as used previously used.  Every 3-4 days medium was harvested, 
replenished, and sample disks were fixed and stained.  In later experiments supernatant 
was harvested and replenished on days 1 and 3 to assess the early secretion of mediators. 
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Figure 2. 4 - Example plate map from a human differentiation assay.A representative plate 
map from an osteoclast differentiation assay illustrates multiple disks per time-point were 
run under each condition, accounting for inter- and intra-donor variability; two control 
disks from m-CSF only cultures were run alongside four discs cultured in differentiation 
medium.  Time-points within assays varied and including the following days; 0, 1, 3, 7, 10, 
14 and 17. 
  
M-CSF only M-CSF and RANKL 
Day 7 
Day 10 
Day 14 
Day 17 
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2.2.9 Histological staining for the identification of nucleated and TRAP+ve cells 
Disks were harvested at days 0, day 1, day 3, day 7, day 10, day 14 and day 17 of the 
human osteoclast differentiation assay (Figure 2.3 and 2.4).  At these time-points 
disks were removed from culture and washed twice with PBS.  Cells adhered to the 
ivory disks were fixed with glutaraldehyde solution for 15 minutes at 37oC, prior to 
being washed twice in PBS and left to dry for 5 minutes.  To identify the presence of 
pre- and mature osteoclasts, disks were incubated with 300µL TRAP staining 
solution for 6 minutes at 37oC, prior to being washed twice in PBS to remove the 
stain.     Haematoxylin (300µL) was then used as a counter-stain for nuclear material 
within the cells and was applied to each disk for 10 seconds at room temperature, 
prior to its removal by two washes with dH2O.  
 
2.2.10 Image acquisition across the x and y dimension of the disks 
Every disk was visualised and imaged using either a 4x magnification taking 4 areas 
of interest (4.375mm2 each using a Canon EOS 100D camera) or a 10x magnification 
capturing 13 areas of interest/ROIs (1.375mm2 each using the Olympus Camedia C-
3030 Digital Camera), Figure 2.5.  Following this the image was then processed for 
either cell counts or area resorbed. 
 
2.2.11 Manual total cell counting of human osteoclast assays 
Preliminary total cell counts were obtained manually through counting and 
electronically marking every cell adhered to each disk (Figure 2.6).  This method 
was carried out for all sections of the disk, equating to a total cell count for 
17.5mm2.  Within each culture condition, a minimum of 3 replicate disks were used 
to reduce to intra-assay variability.  As a result, the time for total cell counts using a 
manual method was >130 hours. A novel, high-throughput and automated method 
for cell counting was then developed and validated. 
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Figure 2. 5 - Schematic diagram of disk area imaged.Two methods were used for the 
collection of images across the x and y dimensions of the disks, which resulted to a total of 
17.5mm2.   i.) 4 images at x4 magnification were acquired using the Canon EOS 100D 
camera.  ii.) 13 images at x10 magnification were acquired using the Olympus Camedia C-
3030 Digital Camera. 
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i.) 
 
ii.) 
 
 
 
 
Figure 2. 6 - Manual total cell counting method.i.) The original image. ii.) An image which 
was manually counted; each cell was marked with green documenting its inclusion and 
then the image was saved. Scale bar = 100µm. 
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2.2.12 Development of a novel, high-throughput, automated cell counting 
algorithm 
A computational algorithm which facilitated high-throughput, reproducible 
and accurate total cell counts was necessary due to the large number of 
cells seeded on each ivory disk.   MATLAB was used to develop this 
algorithm due to its functionality for manipulating images in the raw data 
format.  The process used within every step of this algorithm is described 
below where example pseudocode can be found along with illustrative 
figures of the commands.  At each step of the algorithm figures could be 
produced and saved for comparison with the manual counting method.  The 
full code for the final development of this algorithm can be found in 
Appendix 1. 
 
 
2.2.12.1 The selected image was loaded into the workspace 
All axes were cleared and the sample image loaded into the workspace; 
known as (I).  (I) was then presented in an axis as shown in Figure 2.7, using 
the command imagesc(I). 
 
 
Figure 2. 7 - Loading an image into the workspace.An example image from day 0 of the 
differentiation assay was loaded into the workspace and displayed within a new figure.  
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2.2.12.2 Conversion into a binary image and application of a 
threshold 
The selected image was converted into a binary image through the 
command ‘im2bw’ which utilised a default threshold determined using the 
command ‘graythresh(I)’.  This binary image consisted of ‘0’ or ‘1’ only, 
indicating either the presence or absence of a signal; i.e. the binary number 
system (Kerman, 2002).  A second binary image was then produced which 
utilised a threshold manually set at 50 and defined by the function 
‘P.noise_thresh’, to remove all objects below this threshold (considered 
noise due to their small size). A second parameter of pixel connectedness 
was also set, ‘P.conn=4’ which allowed only ‘0’ pixels with 4 other ‘0’ pixels 
located directly next to them to be defined as an object.  Total number of 
objects within the binary and denoised binary images was then expressed 
underneath each image when shown as a figure using the ‘imagesc’ 
command (Figure 2.8). 
 
 
 
Figure 2. 8 - Conversion into a binary image and background noise reduction.A default 
threshold was set from the original binary image, where any objects falling below this 
threshold were removed (see dotted red circles), resulting in the reduction of total object 
count (stated under the image).    
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2.2.12.3 The selected image was normalised to ensure a constant 
background illumination across the disks 
The conversion of the image into a de-noised binary image led to clear areas 
of the original image being extensively covered with ‘0’ signal due to an 
uneven background illumination.  Initially it was thought that these disks 
could have undulations on their surface from disk preparation procedures.  
However, after maximising the effectiveness of the high-speed saw, no 
differences in the uneven background illuminations were seen, and areas of 
‘0’ signal still remained (Figure 2.9).  It was concluded that the areas of 
uneven background were inherent and natural within the disks, and would 
therefore be unavoidable. 
 
To overcome the inconsistent background illumination, a piece of code used 
within facial recognition software was used.  In theory this code was able to 
reduce alterations in facial illumination; i.e. ‘shadowing’(Haritha et al., 
2012andStruc, 2009).  It was this principle that was used to remove the 
uneven illumination from the images of the disks and facilitate the accurate 
visualisation of the objects ‘hidden’ under the large areas of '0' signal.  First, 
the original image was converted from the red-green-blue colour model 
(RGB model) into greyscale using the ‘rgb2gray’ command, and then the 
‘DCT_normalisation’ function was applied which led to the normalisation of 
the image; (Struc, 2009 andHaritha et al., 2012).  The normalised image was 
then denoised, presented in the figure, and the number of objects within 
the image were shown beneath (Figure 2.9). 
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i.) 
 
ii.) 
 
iii.) 
 
Figure 2. 9 - Accurate visualisation of total cells was achieved through image 
normalisation.When compared back to the original image (i), the denoised image (ii) 
showed several areas of high ‘0’ values in the image, which were known as areas of 
inconsistent background illumination(red boxes).  Through utilising the ‘DCT_normalisation’ 
code, a constant background illumination was maintained (iii) and total cell number 
obtained.   
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2.2.12.4 Objects counted within the image were segmented for 
clarification 
In order to confirm the algorithm’s definition of an object, all objects within 
the image were 'segmented' using the MATLAB command ‘bwperim’, 
resulting in an aqua-coloured perimeter appeared around each counted 
object.  Using ‘imagesc’ a subsequent figure demonstrated those counted, 
Figure 2.10.   
 
 
 
Figure 2. 10 - Segmentation of objects included in automated counts.The counted objects 
within the image were marked with an aqua perimeter allowing the comparison between 
the previous manual cell counts and the automated object counts.   
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2.2.12.5 Histogram of total object count 
After visualisation each counted object was placed into a histogram bar 
depending upon its size in pixels.  A histogram was coded for through 
defining the x and y dimensions, along with setting up the histogram bin 
sizes.  There were 21 histogram bins which were defined as follows;  bin 1- 
objects of size 0-100 pixels, bin 2- objects of size 101-200 pixels, and so forth 
up to bin 20 which contained objects of 1,901- 2,000 pixels, and bin 21 with 
objects >2,000 pixels, ensuring all larger objects were accounted for.  A loop 
was then set up to ensure that all objects within the denoised normalised 
image would be ‘selected’ and ‘placed’ into one of the bins defined.  Objects 
in the top left of the image were ‘selected’ first, and objects in the bottom 
right of the image were of the last to be ‘selected’.   
 
This histogram was then shown within a new figure using the command 
‘bar’ and the number of objects within each bin were displayed on top of 
the histogram bars (Figure 2.11).  Along with the visual representation of the 
histogram, a separate figure containing a subplot, ‘subplot’, was used to 
show the individual histogram bins as separate axes, and reveal which, and 
how many objects were in each bin, along with their physical distribution 
within the denoised, normalised image.  The total object counts from within 
each histogram bar was then exported out of MATLAB and into an excel 
spreadsheet using the command ‘xlswrite’, which was then saved and 
analysed further (Figure 2.11).   
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i.) 
 
ii.) 
 
 
Figure 2. 11 - A histogram illustrating cell size distribution and frequency.(i) A histogram 
illustrating cell size and distribution from automated cell counts shows the highest cell 
frequencies at the lower cell sizes (day 0 image).  (ii)  Through further analysis a subplot of 
the histogram highlights that the majority of cells were present within the first 7 histogram 
bins, after which the number of objects decreases in subsequent bins. 
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2.2.13 Development of a semi-automated method for total object count using a 
graphical user interface (GUI) 
In order to reduce the user input needed to carry out the above algorithm, a 
graphical user interface (GUI) was designed, with the basic principle of 'one click, 
one figure'; i.e. the automatically runs.  The GUI for total object counts, shown in 
Figure 2.12, was initiated through selecting ‘Load Image’, which would run the code 
described in Section 2.2.12.1 and result in the original image being uploaded into 
the GUI.  The second button ‘Threshold Image’ (section 2.2.12.2 code) would result 
in the images being displayed within the ‘Original Binary Image’ and ‘Denoised 
Binary Image’ axes. The ‘Normalise Image’ button (section 2.2.12.3 code), shows 
the normalised image within the Normalised Binary Image axes.  The ‘Segment 
Cells’ button (section 2.2.12.4 code) shows all objects within the image highlighted 
through an aqua-coloured perimeter.  The final two steps ‘Make Histogram’ and 
‘Save Results’ (section 2.2.12.5 code) together resulted in a histogram plot of object 
count, size and distribution, and also allowed the total object count data to be 
exported out of MATLAB and saved as an excel spreadsheet.  Two examples are 
shown in Figure 2.13; one illustrating smaller mononuclear cells, and the other 
showing a more diverse range of adhered cells. 
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i.) 
 
 
Figure 2. 12 - GUI example for automated cell counts.i.) The user inputs the image through 
the command buttons found within the ‘Panel’ which then facilitates the following; image 
thresholding, normalisation, segmentation, and the formation of a histogram of cell size, 
frequency and distribution to be created.  
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i.) 
 
ii.) 
 
 
Figure 2. 13 - Two examples from the GUI illustrating the diverse cell populations adhered 
to the ivory disks. (i) Image from an m-CSF only culture showing peak cell distribution on 
the left hand side of the histogram, being indicative of small objects.  (ii) Image acquired 
after 10 days of culture in m-CSF and RANKL. The main distribution of cells has shifted to 
the right, and a peak in histogram bar 21 can be seen, indicative of larger objects, most 
likely to be osteoclasts.  
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2.2.14 A fully automated, high-throughput algorithm for total object count 
was coded 
The pre-described GUI for total object counts provided a semi-automated 
method for cellular counting which was found to be 7.5-fold faster than the 
manual counting methods previously used.  However, user-input was still 
needed which slowed the process down and still took the analyst 13.5 hours 
of user input to analyse one experiment.  To fully automate the algorithm, 
the previously described code was modified which allowed it to loop 
through all images in a folder, processing and saving the results with just 
one click, thereby enabling it to be run overnight.  The computational code 
previously described was transformed into a function named 
‘Count_Cells_fxn’, which when then used in a new script.   
  
61 
 
2.2.15 Analysis of TRAP+ve and osteoclast counts in human osteoclast assays 
The automated algorithm provides a count for total cells but could not provide an 
accurate count for TRAP+ve and osteoclast number.  For this reason, TRAP+ve and 
osteoclast count from disks harvested were obtained manually.  The TRAP stain 
allows cells expressing TRAP to be distinguished from TRAP-ve cells, which were 
stained with haematoxylin only.  Within this thesis, TRAP+ve cell count corresponds 
to the total number of cells stained with TRAP.  The presence of osteoclasts was 
assessed through TRAP and haematoxylin staining by the following definition; an 
osteoclast was a multinucleated (≥3 nuclei) TRAP+ve cell of ≥30μm diameter in the 
smallest dimension of the cell.   TRAP+ve cells (green circles)and osteoclasts (blue 
circles)were counted manually and marked within each image using PaintShop Pro, 
thus allowing an electronic copy of each count to be maintained (Figure 2.14).  
These parameters were then exported into excel and saved alongside the 
automated total cell count data.  The percentage of osteoclastogenesis was then 
calculated using the automated total cell count and manual osteoclast count  (both 
at day 14), facilitating comparisons between donors. 
i.)                                                       ii.) 
 
 
Figure 2. 14 - The identification of TRAP+ve mononuclear and TRAP+ve multinucleated cells 
within osteoclast differentiation cultures.The presence of only TRAP-ve cells can be seen 
within (i) where cultures have only been supplemented with m-CSF.  TRAP+ve mononuclear 
cells were evident within (ii) and are circled in green, whereas TRAP+ve multinucleated cells 
are circled in blue.  Both images are stained with TRAP and haematoxylin; scale bar = 
100µm. 
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2.2.16 Assessment of osteoclast functional activity through resorption pit analysis 
A traditional method for the calculation of area resorbed through osteoclast activity 
was utilised and compared to a novel method of analysis for images acquired 
through confocal microscopy.  
 2.2.16.1 Identification of resorption pits using toluidine blue staining and 
light microscopy 
Once cells adhered to ivory disks were imaged, disks were scraped with 70% alcohol 
and incubated overnight in 300µL 1% H2O2 with mechanical shaking.  This method 
removed attached cells and bleached the disks of TRAP and haematoxylin stain 
prior to further staining.  The H2O2 was removed and disks were washed twice with 
dH2O.  300µL of toluidine blue stain (0.5%) was applied to the disks and incubated 
for 1 minute at room temperature.  The stain was removed and disks were washed 
twice with dH2O prior to imaging and analysis (Figure 2.15).  Mimicking the images 
obtained for cell counts, sections of each disk were obtained, resulting in a total 
area of 17.5mm2 imaged. Analysis of area resorbed was carried out within ImageJ, 
where pits outlined by the toluidine blue stain were circled and the area within 
them calculated based upon the known parameters of the image; 2064 pixels = 1 
mm.  Where tracks of resorption or conjoining pits were visible, one continuous 
area was analysed.  All areas of resorbed bone within each image were analysed 
creating a total area of resorption per 17.5mm2, along with data yielded regarding 
the number of resorption events and the range of resorption pit size. 
2.2.16.2 Identification of resorption pits using calcein staining and confocal 
microscopy 
To decipher whether confocal microscopy produced a more detailed and sensitive 
method of calculating total area resorbed per 17.5mm2, results were compared 
back to toluidine blue staining.  Disks for confocal microscopy were scraped within 
70% alcohol and left overnight in H2O2 prior to being washed twice in dH2O.  Disks 
were incubated in calcein stain (300µL) overnight on a mechanical shaker at room 
temperature.  Following this, the calcein was removed and disks washed twice in 
dH2O.  Disks were then mounted in 24 well glass-bottomed plates at <4oC using 
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CyGEL.  Once the disks were in place, the plate was removed and placed at room 
temperature enabling the solidification of CyGEL ensuring a firm mount reducing 
sample movement when imaging.  This thermoreversible property allowed the disks 
to be retained after imaging.  Once disks were mounted, laser scanning confocal 
images were acquired using a x20 objective lens and Nikon Eclipse TE300 linked to 
the LaserSharp 2000 software.  Through this software the orientation and location 
of the field of view could be controlled, along with the precise parameters of the 
confocal set-up.  Along with an Argon laser, two photon multiplier tubes (PMT) 
were active to detect signals at 480-490nm (PMT1 = scattered light) and >520nm 
(PMT2 = calcein signal output), and a transmission detector was active in collecting 
transmitted signals through the sample.  Specific data collection parameters were 
recorded for each disk and kept constant to ensure continuity across the data 
collection process. For each data collection the following parameters were never 
changed; zoom: 1.5, pixels-by-lines: 512 x 512, step: 0.2µm, xy pixel: 0.8µm, 
objective: 20X.  Using the x20 objective lens, images were acquired and then saved, 
exported and analysed using ImageJ as before in Section 2.2.16.1 for total area 
resorbed (Figure 2.16).  The results from these two methods for calculating total 
area resorbed were then compared (Chapter 3). 
To determine pit depth, laser scanning confocal images were also acquired at x60, 
using PMT set to detect signals at 480-490nm (PMT1 = scattered light) and >520nm 
(PMT2 = calcein signal output).  Transmitted light was also detected.  Set 
parameters remained constant in data collection to ensure reproducibility and 
accuracy in sample analysis; zoom: 1.5, pixels-by-lines: 512 x 512, step: 0.2µm, xy 
pixel: 0.27µm, objective: 60X.  Data sets could then be saved and exported ready 
for analysis in MetaMorph. 
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i.) 
 
ii.) 
 
iii.) 
 
Figure 2. 15 - Representative images of toluidine blue staining acquired via light 
microscopy. To assess area resorbed in human osteoclast differentiation assays toluidine 
blue staining was utilised.  Representative images (i, ii and iii) above illustrate areas of 
resorption through concentrated areas of toluidine blue stain.  Images were taken at x4 
magnification and are from 3 individual donors. 
 
i) 
 
ii.) 
 
iii.) 
 
Figure 2. 16 - Representative images of calcein stained disks acquired via confocal 
microscopy.  Areas of resorption can be identified through distinct regions of no signal 
(black pits) from confocal images obtained after calcein staining.  Individual pits were seen 
along with ‘tracking’ and areas of slight erosion (i, ii and iii).  Calcein stained disks were 
compared to previously acquired toluidine blue stained disks to assess the benefit of using 
novel imaging methods for calculating area resorbed.  Images were acquired using x20 Oil 
lens, with the following parameters; zoom: 1.5, xy pixel: 0.8µm, pixels x lines: 512 x 512.  
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2.2.17 The three dimensional characterisation of resorptive pits 
Data sets known as stacks were loaded into Metamorph (Molecular Devices Corp., 
CA).  Region measurements were used to calculate the average intensity of pits in 
each image, thereby defining the presence of a pit.  An inclusive threshold 
equivalent to this average intensity was applied to the stack thus identifying pits, 
and through the application of a median filter (3-by-3 pixels) a reduction of noise 
ensued.  This median filtered stack was then transformed into a binary image, 
allowing the creation of a single intensity image from the summation of all the data 
sets.  The background signal in this image was then equalised and subtracted from 
the original, leaving only intensity signals from the eroded pits.  Each pit was then 
analysed as a collective, and data regarding the following were documented; total 
area, total intensity, maximum intensity, perimeter, centroid X and centroid Y.  
Appendix 1 demonstrates this process using visual guides as does Figure 2.17.  
Additional to these, from total intensity the volume of a pit could be calculated 
using a correction factor (necessary due to differences in refractive index of the lens 
and mountant) and by determining the size of a 1-by-1 pixel;  1 𝑝𝑝𝑑𝑑𝑥𝑥𝑛𝑛𝑇𝑇 𝑛𝑛𝑏𝑏 1 𝑝𝑝𝑑𝑑𝑥𝑥𝑛𝑛𝑇𝑇 =  0.27 𝑥𝑥 0.27 𝑥𝑥 (0.2 𝑥𝑥 0.8) =  0.011664µ𝑛𝑛3 
𝑥𝑥𝑏𝑏 𝑝𝑝𝑑𝑑𝑥𝑥𝑛𝑛𝑇𝑇 = 0.27 
𝑆𝑆𝑇𝑇𝑛𝑛𝑝𝑝 𝑑𝑑𝑛𝑛 𝑧𝑧 𝑞𝑞𝑑𝑑𝑛𝑛𝑛𝑛𝑛𝑛𝑐𝑐𝑑𝑑𝑇𝑇𝑛𝑛 = 0.2 
𝐶𝐶𝑇𝑇𝑛𝑛𝑛𝑛𝑛𝑛𝑐𝑐𝑇𝑇𝑑𝑑𝑇𝑇𝑛𝑛 𝑜𝑜𝑇𝑇𝑐𝑐𝑇𝑇𝑇𝑇𝑛𝑛 = 0.8 
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Figure 2. 17 - Flow diagram for the calculation of depth and volume of pits from 3D 
confocal stacks.Data collected at x60 was loaded into metamorph and the average 
intensity of a pit was defined. Through the application of an inclusive threshold and a 
median filter, both background noise and data slices below the base of the pit were 
removed.  A binary image was then produced which could be summed to allow the removal 
of background signal and facilitate the creation of an intensity profile for each pit.0.27µm = 
pixel. 
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2.2.18 Analysis of soluble mediators linked to osteoclast differentiation and 
function by ELISA 
Supernatants collected from osteoclast assays were analysed within ELISAs (R&D 
Systems) for chemokines and cytokines implicated in destructive bone diseases; 
CCL2, CCL3, CCL5, IL-6, and TNF-α.   The specific dilutions and concentrations of the 
ELISAs used are contained within Table 2.3.  Additional ELISAs were run assessing 
the presence of soluble NGF (R&D systems), CTX-1 and TRAP5b (Immunodiagnostic 
Systems).   
The following standard protocol was used for the ELISAs; 100μL of capture antibody 
diluted in PBS was coated onto 96 well plates and incubated overnight at room 
temperature.  The next day each plate was washed 3 times using wash buffer 
(0.05% PBS-T) and dried prior to the addition of 300μL of blocking buffer (1% BSA in 
PBS) for 2 hours at room temperature with mechanical shaking.  During this 
incubation step samples were diluted if needed and standards were prepared in 
reagent diluent (1% BSA in PBS).  After blocking, plates were washed 3 times in 
wash buffer, and 100μL of samples and standards were applied to representative 
wells, where standards were run in duplicate.  The samples were incubated on the 
plates for 2 hours with shaking, prior to being washed 3 times with wash buffer.  
Following this, 100μL of detection antibody (specific for each ELISA) was added to 
each well and incubated on the plate shaker for 2 hours again.   Plates were washed 
3 times in wash buffer, dried, and streptavidin-HRP was added to each well (100μL).  
Plates were incubated for 20 minutes at room temperature away from direct 
sunlight, prior to being washed 3 times with wash buffer.  Finally, the addition of 
the substrate reagent which facilitated a colour change (100μL), and once 
developed the reaction was stopped through the addition of 50μL sulphuric acid 
(12%).  Plates were then read at 450nm using a plate reader. 
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 Table 2. 3 - ELISAs utilised throughout the project.. 
ELISA Capture Ab Detection Ab Standard 
Human CCL2 1.0µg/mL 50ng/mL 1000pg/mL – 15.6pg/mL 
Human CCL3 0.4µg/mL 200ng/mL 500pg/mL – 7.8pg/mL 
Human CCL5 1.0µg/mL 20ng/mL 1000pg/mL – 15.6pg/mL 
Human IL-6 2.0µg/mL 50ng/mL 600pg/mL – 9.375pg/mL 
Human TNF-α 4.0µg/mL 350ng/mL 1000pg/mL – 15.6pg/mL 
NGF 2.0µg/mL 50ng/mL 31.20 – 2,000pg/mL 
CTX-1 Kit specific 0 – 3.38ng/mL 
TRAP5b Kit specific 0.5 – 10U/L 
 
2.2.19 Collagen-Induced Arthritis (CIA) 
All animal experiments were conducted in line with ARRIVE guidelines and ethical 
permissions were granted under Home Office project licence 30/2928.  DBA-1 male 
mice aged 8 weeks (12 in total) were ear tagged and divided into two groups 
(control group and an experimental group; 6 in each) with equal weight 
distributions prior to being immunized at day 0 with 2 x 50µL of CFA containing 
2mg/mL collagen by intradermal (i.d.) injection.  Animals were observed every 
other day for sores and scabs located on their hind-quarters and were treated with 
iodinated povidone when necessary.  At day 21, each animal received 2 x 50µL i.d. 
of CFA and collagen, injected on the opposite side to previous injections, and were 
divided into two equal groups (n=6 in each).  One group were given 100µL 
intraperitoneal injection of isotype control IgG antibody (5mg/kg), and the other 
anti-CCL3 antibody (5mg/kg).  Animals received an additional 5 doses every other 
day prior to being culled by schedule 1 procedures.    
Callipers were used to measure paw diameter. Arthritis severity (by clinical score) 
was assessed in each mouse by scoring each paw on a scale from 1 to 4; 0= no 
evidence of swelling or erythema, 1= swelling of the tarsals or ankle joint along with 
erythema, 2= swelling of the tarsals and ankle joint along with erythema, 3= 
reasonable swelling of the tarsals and ankle joint along with erythema, 4 = 
substantial swelling of the entire foot and the presence of erythema.  An observed  
maximum clinical score 14 or loss of 20% of body weight (from baseline on Day 21) 
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necessitated humane killing of the animal in accordance with the severity limits of 
our Project Licence issued under  Home Office regulations.    The physical 
appearance, clinical signs, and the natural behaviour of the mouse were also 
monitored daily and any changes noted.  A schematic of CIA induction in mouse is 
presented in Figure 2.18. 
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Figure 2. 18 - The induction of CIA.Mice aged 8 weeks were weighed and injected at day 0 
with 2 x 50µL CFA containing 2mg/mL collagen by i.d. on the right hand side of their lower 
hindquarter.  Every other day mice were checked for clinical and physical signs of arthritis.  
If scabs formed they were treated with iodinate povidone.  At day 21, mice were again 
weighed and divided equally into two groups of n=6.  All mice received a booster of 2 x 
50µL again by i.d. on the left hand side of their lower hindquarter.  One group received an 
i.p. injection of 100µL anti-CCL3 (5mg/kg), and the other an i.p. of 100µL isotype control 
antibody (5mg/kg) every other day.    Every day mice were weighed, assessed for clinical 
signs of arthritis (scored from 0-4) and the diameters of their paws measured using 
callipers.  Mice were culled and joints harvested on day 29.   
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2.2.20 Fixation of murine CIA joints 
Mice were culled on day 29 and joint tissues from both fore- and hind-limbs were 
harvested.  All fur/skin was removed from the joints ahead of fixation.  Shoulder 
joints obtained were fixed in 10% neutral buffered formalin solution for 24 hours at 
room temperature and then placed into 70% alcohol for 2 weeks.  Knee and ankle 
joints were fixed and stored in 70% alcohol immediately after the animal was culled 
until they were decalcified (section 2.2.23).  Radiological images of hind- and 
forepaws were acquired prior to processing through to paraffin wax blocks for 
histological evaluation. 
 2.2.21 Radiological imaging and analysis of erosions in murine paw joints 
Hind- and forepaws were imaged using a KODAK-pro and were assessed for 
erosions by a rheumatology clinical research fellow and an orthopaedic surgeon.  In 
total 12 joints of the forepaw were assessed for erosions including; 2nd Distal 
Carpal - Radiale and Intermedium, Fused 4th-5th Distal Carpals – Ulnare, 1st to 5th 
MCP – Carpal and the 1st to 5th PIP – MCP (Figure 2.19).  Hind paw assessment 
criteria consisted of the following; Centrale – Intermedium, 4th-5th Distal Tarpals – 
Fibulare, 1st to 5th MTP – Tarsal and the 1st to 5th PIP to MTP (Figure 2.19). 
 2.2.22 3D reconstructions of murine joints using micro-computed 
tomography (µ-CT) 
Murine hind paws were sent to a collaborator at Gothenburg University (Professor 
Maria Bokarewa) where they were imaged using the µCT Skyscan1176 and 
reconstructed using the partner Bruker software.  Once the data was collected, 
reconstructed images of the hind paw, MTPs, talus and calcaneus were created. 
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Figure 2. 19 - Radiological assessment of erosions present within the fore- and hind 
paws.After joints were harvested from CIA mice, fore- and hind- paws were fixed prior to 
acquiring x-rays.  12 areas of interest were assessed within x-rays.  Forepaw joint of interest 
are circled in red; 2nd Distal Carpal - Radiale and Intermedium, Fused 4th-5th Distal Carpals 
– Ulnare, 1st to 5th MCP – Carpal and the 1st to 5th PIP – MCP.  Hind paw joints of interest are 
circled in blue; Centrale – Intermedium, 4th-5th Distal Tarpals – Fibulare, 1st to 5th MTP – 
Tarsal and the 1st to 5th PIP to MTP.  Images taken from Cook 1965. 
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2.2.23 Decalcification and processing of murine joints 
After fixation and imaging, shoulder, knee and ankle joints were decalcified in EDTA 
solution for a total of 3 weeks at room temperature.  Every 3 days the EDTA 
solution was replenished.  Joints were then x-rayed to confirm successful 
decalcification, and left in dH2O for 48 hours (refreshing after 24 hours) at room 
temperature.  Joints were then processed and embedded in paraffin prior to 
sectioning. 
 2.2.24 Histochemical staining 
Sections of 7µm thickness were cut from paraffin-embedded knee and ankle joints.  
All sections were taken through the same rehydration and dehydration processes 
irrespective of the staining process they were subjected to.  Rehydration was 
achieved through samples going a set of incubation periods in varying percentages 
of xylene and alcohol to gradually increase their solubility (described in Table 2.4).  
Following this rehydration, the stain was applied to the section and incubated for 
the specified amount of time.  After this, the section was rinsed in running water 
then distilled water or Scott’s tap water, prior to completion of the dehydration 
steps; a series of varying percentage alcohols followed by immersion in xylene for 
set incubation times.  Sections were then mounted using DPX (Sigma) and left to 
dry overnight prior to analysis and enabling long-term storage. 
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 Table 2. 4 - Rehydration and dehydration procedures used throughout the 
immunohistochemical staining of murine sections. 
Process Incubation Purpose 
Xylene 1 (100%) 5 minutes 
Rehydration allowing water soluble stains to penetrate 
sample 
Xylene 2 (100%) 5 minutes 
Xylene 3 (100%) 5 minutes 
100% IMS 1 3 minutes 
100% IMS 2 3 minutes 
90% IMS 1 3 minutes 
dH2O 2 minutes  
Staining procedure (e.g. TRAP or haematoxylin) 
dH2O 5 minutes 
Dehydration of specimens allowing long-term storage of 
samples mounted in xylene based DPX 
90% IMS 2 3 minutes 
100% IMS 3 3 minutes 
100% IMS 4 3 minutes 
Xylene 4 (100%) 5 minutes 
Xylene 5 (100%) 5 minutes 
Xylene 6 (100%) 5 minutes 
DPX mountant - Mounts slides enabling long-term storage 
 2.2.25 Haematoxylin staining 
Following rehydration, slides were immersed in Harris’ haematoxylin stain for 3 
minutes prior to being rinsed in running tap water.  Once the tap water ran clear, 
slides were placed in Scott’s tap water for 1 minute to develop and fix the ‘blue’ 
stain.  Slides were then dehydrated (Table 2.4) prior to imaging (Canon EOS 100D) 
and analysis. 
 2.2.26 TRAP staining in tissue sections 
Osteoclasts were observed in murine joints using TRAP stain.  The TRAP solution 
and TRAP preparation buffer were prepared as described in Table 2.2.  After 
rehydration, slides were placed in TRAP preparation buffer overnight at room 
temperature.  pH5 for the preparation buffer was maintained, and the next 
morning slides were placed in a moist incubation chamber where specimens were 
immersed in TRAP stain for 6 hours at 37oC.  After 6 hours, slides were washed for 5 
minutes in dH2O and ready for haematoxylin staining as in Section 2.2.25.  If no 
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haematoxylin staining was carried out, slides were then taken through the 
dehydration procedure as described in Section 2.2.24.  Once mounted, sections 
were visualised and imaged (Canon EOS 100D) prior to analysis. 
 2.2.27 Histological analysis: calculating the arthritis index, inflammatory 
index score, erosive score and osteoclast count 
All stained sections were analysed using an established method (arthritis index; 
Coppieters et al. 2006, Seeuws et al. 2010 and Yang et al. 2013).  Scoring 
inflammatory infiltration of synovial tissue, joint exudate, synovial hyperplasia and 
bone erosion. The assessment of the arthritis index was carried out as described in 
Table 2.5 and Figure 2.20.  Osteoclast-associated TRAP staining was counted 
manually and analysed using image analysis software (PhotoShop).  An area of 
interest was created and the total number of pixels per area reported.  A pre-set 
colour identifier (red) was then placed on top of the selected area where all pixels 
relating to that colour were identified and counted automatically, yielding the total 
TRAP pixels per unit area.  This number was then converted into a percentage for 
comparison between joints.  Finally, a manual count was completed identifying the 
number of TRAP+ve osteoclasts located in every joint. 
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 Table 2. 5 - Arthritis Index Scoring. 
Ar
th
rit
is 
In
de
x 
In
fla
m
m
at
or
y 
Sc
or
e 
Synovial 
inflammation 
0-Normal 
1-Some inflammatory infiltrate but adiposity hardly 
affected (10% inflammatory, 90% adipose) 
2-Similar amounts of inflammatory infiltrate to adipose 
tissue (50% inflammatory, 50% adipose) 
3-Inflammatory cells dominate tissue with small amount 
of adipose tissue (70% inflammatory, 30% adipose) 
4-Majority inflammatory cells with minimal adipose 
tissue (90% inflammatory, 10% adipose) 
5-No adipose tissue, all inflammatory infiltrate (100% 
inflammatory, 0% adipose) 
Exudate 
0-Normal 
1-Inflammatory cells in exudate 
2-High proportion of inflammatory cells in exudate with 
some fibrin deposits 
3-High proportion of inflammatory cells in exudate with 
substantial fibrin deposits 
Hyperplasia 
and pannus 
formation 
0-Normal 
1-Synovial layer showing signs of thickening 
2- Synovial layer creeping over the bone surface and 
invading the joint space 
3- Synovial layer creeping over the bone surface and 
invading the joint space with visible signs of cartilage 
loss 
De
ge
ne
ra
tiv
e 
Sc
or
e Bone 
erosions 
0-Normal 
1-Early stages of bone erosion including bone thinning 
2-Detectable erosion of bone by pannus formation 
3-Large area of bone eroded due to pannus 
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Figure 2. 20 - Arthritic Index Scoring.  Each joint was assessed for visible signs of the four following categories; synovial inflammation, exudate, hyperplasia 
with pannus formation and bone erosions.  In the shoulder joint only the head of the humerus was assessed, in the elbow joint the base of the humerus and 
radius were both assessed, and in the wrist joint the radius and carpals were assessed. The above example shows defined areas where these four 
parameters are met as indicated by the arrows. 
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 2.2.28 Statistical Analysis 
Data obtained in this thesis was processed using Microsoft Excel and GraphPad 
Prism, facilitating the graphical representation of the data.  All results were 
reported as the mean ± standard error of the mean (SEM) unless otherwise stated.  
Prior to statistical analysis, significant outliers (p≤0.05) were identified through the 
Grubb’s outlier test (GraphPad Quick Calcs) and removed from data sets.  Multiple 
statistical tests were carried out in this thesis including a two-tailed Student's t-test 
(used for a comparison of two normally distributed individual data sets), one-way 
and two-way analysis of variance (ANOVA; for comparing time-courses or dose 
responses of multiple data sets) which utilised a Bonferroni post-test to highlight 
groups with significant differences, and finally Spearman’s rank coefficient tests (to 
show correlational relationships between data sets) were reported.  Where 
statistical significance was reported, a minimum p value of ≤0.05 was considered 
significant.   
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3 Chapter 3:Creating an automated 
computational algorithm for counting cells in 
human osteoclast differentiation assays 
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 3.1 Introduction 
Over the past 20 years, the study of in vitro human osteoclast differentiation has 
become common practice.  In the 1980's the differentiation of the osteoclast from 
monocytes was discovered, where their distinct haematopoietic lineage from 
CD14+ve mononuclear cells was demonstrated providing definitive evidence (Massey 
& Flanagan. 1999).  Several research groups supported the haematopoietic origin 
of the osteoclast and identified macrophage colony stimulating factor (m-CSF) and 
receptor activator of nuclear factor κβ ligand (RANKL) as critical soluble factors 
necessary for the differentiation and maturation of osteoclasts (Nicholson et al. 
2000). 
The culture of osteoclasts was reported via two main techniques; monocultures and 
co-cultures.  In monocultures m-CSF and RANKL are exogenously supplemented 
into the medium, whereas in co-cultures these soluble factors are endogenously 
secreted from bone marrow cells, osteoblasts or T cells (Lacey et al. 1998, 
Takahashi et al. 1988, Nicholson et al. 2000, Boyle, Simonet & Lacey 2003, Lutter et 
al. 2010).  m-CSF is used across a broad concentration range (5-25ng/mL) in the 
literature to facilitate the proliferation and survival of CD14+ve mononuclear cells in 
culture (Massey & Flanagan, 1999, Nicholson et al. 2000, Kim et al. 2005, Hodge et 
al. 2011).  RANKL, at concentrations from 3 to 100ng/mL, is reported to induce 
mononuclear cell differentiation into osteoclasts (Quinn et al. 1998, Udagawa et al. 
2000, Nicholson et al. 2000, Han et al. 2001).  The range of RANKL concentration 
can be applied to cultures due to differences in precursor cell purity, number, 
source, cell subset, culture medium and substrate/adherent surface supporting cell 
culture.  m-CSF and RANKL concentrations are generally lower in co-culture 
methods using CD14+ve cells cultured with T cells due to their ability to secrete 
RANKL.  Furthermore, concentration may alter depending on the length of the assay 
and pre-defined primary outcomes; RANKL concentrations are generally lower for 
extended time-courses measuring osteoclast function versus shorter experiments 
studying osteoclast differentiation (Nicholson et al. 2000, Lutter et al. 2010). 
The interpretation of osteoclast differentiation assays is usually a result of several 
assessment criteria including; total cell count, osteoclast count, osteoclastogenesis 
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 (as a percentage of total cells) and area of bone substrate resorbed.  Substantial 
variability in the published literature with regard to each parameter due to their 
dependence on culture methodologies does exist; [m-CSF and RANKL], length of 
culture, seeding density, total area seeded, intra-assay reproducibility and inter-
donor variability. To acquire such data, the methodologies used required 
consideration.  Counting methods generally apply to cells in suspension 
(haemocytometer, fluorescent activated cell sorting, a spectrophotometer, 
electrical gating, medical imaging and manual counts) and cannot be utilised during 
the course of the osteoclastogenesis assays which rely upon cells adhering to matrix 
(Tzur et al. 2011, Bonetta et al. 2005).  Adherent cells would therefore need to be 
counted manually using a slow, laborious, time consuming microscopic method.   
The first aim of the project, was therefore to create a novel, automated computer 
algorithm to count adhered cells that was accurate, reduced analysis time and 
minimised inter-analyst errors in counting. It was considered an essential first step 
for delivery of data from the multiple osteoclast assays planned for this thesis. 
Additional to total cells, TRAP+ve cell data is also important when interpreting 
osteoclast assay data (Nicholson et al. 2000, Boyle, Simonet& Lacey 2003). In 
addition to this cell specific marker for osteoclasts, secondary soluble factors (e.g. 
TRAP5b and CTX-1) are frequently measured (sample/tissue culture supernatants, 
blood and synovial fluid) as surrogate markers of osteoclast activation and bone 
resorption (Halleen et al. 2000, Chailurkit et al. 2001, Shidara et al. 2008, Chubb et 
al. 2012).  Resorption of bone matrix/bone substrate is identified in vitro with 
toluidine blue staining of areas resulting in a blue perimeter around the resorbed 
area (Keller et al. 2012). Osteoclastogenesis cultures are also suggested to secrete 
several pro-inflammatory cytokines (IL-6, IL-1, TNF-α) and chemokines (CXCL8, 
CCL3, CCL2 and CCL5), which have all been implicated in the indirect differentiation 
and function of the osteoclast (Scheven et al. 1999, Kobayashi et al. 2000, Wintges 
et al. 2003, Kim et al. 2005, Yoshitake et al. 2008, Dapunt et al. 2014). The direct 
link between these cytokines/chemokines, the differentiation of CD14+ve 
mononuclear cells into osteoclasts and their subsequent resorption has not yet 
been fully determined in a monoculture system. 
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 The aim of this chapter was to establish a reproducible monoculture method for 
human osteoclasts in vitro to assist in the creation and validation of a novel, high-
throughput, automated computer algorithm for acquiring total cell counts in 
adherent cell cultures.  Characterisation of adhered cells, resorption pit analysis and 
the quantification of cytokines and chemokines in culture supernatants were also 
performed.  Osteoclast-associated soluble factors with potential importance for 
modulating pain, inflammation and bone pathology during inflammatory arthritis 
could therefore be postulated.  This chapter details methodology, results and 
discussion points under the following objectives: 
• To validate a reproducible and reliable method of osteoclast differentiation 
from CD14+ve monocultures over a 17-day time course in differentiation 
medium. 
• To create and validate a novel, automated, high-throughput and sensitive 
method for counting total number of cells on a plate. 
• To identify and measure potential early surrogate soluble markers of 
osteoclast differentiation from CD14+ve monocultures exposed to m-CSF and 
RANKL. 
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 3.2 Essential Methodology 
The below diagrams highlight the essential methods used throughout this chapter.  
Full detail of all these methods can be found in their respective sections in Chapter 
2 as stated. 
• Osteoclast assay set up (Chapter 2 Sections 2.2.1 - 2.2.4) 
Condition Number of Donors 
Number of Replicate 
Disks per donor Comments 
m-CSF only 8 3 Used within Sections 3.3.2 to 
3.3.5. Mean of replicates plotted 
for each time-point m-CSF and 
RANKL 
8 3 
m-CSF only 8 3 Used within Sections 3.3.7 to 3.3.9 and Section 3.2.11. Mean of 
replicates plotted for each time-
point. 
m-CSF and 
RANKL 8 3 
 
-PBMCs isolated from healthy human whole blood via density centrifugation went 
through magnetic activated cell sorting to yield a pure suspension of CD14+ve 
monocytes (as illustrated below). 
- Disks were seeded with 3.2 x 106 cells and cultured with m-CSF alone (5ng/mL) or 
in combination with RANKL (5ng/mL).  Culture supernatants collected and 
replenished every 3-4 days.  Disks harvested at each time-point. 
Caption 1 - Isolation of human CD14+ve monocytes from peripheral blood. Human blood 
layered onto hisotpaque is centrifuged yielding peripheral blood mononuclear cells.  
CD14+ve monocytes isolated by magnetic activated cell sorting and  3.2 x 106 cells/mL are 
seeded onto ivory disks prior to culture in osteoclast proliferation/differentiation medium.
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 • Quantitative parameter assessment of the osteoclast assay  
-Disks harvested at days 0, 7, 10, 14 and 17 were fixed with glutaraldehyde prior to 
staining with TRAP and haematoxylin to identify total cells and osteoclasts; 
quantified through MATLAB and manual counts.  Following cell counts adhered cells 
were removed and disks stained with toluidine blue or calcein to facilitate 
quantification of resorbed area.  Harvested supernatants were analysed by ELISA. 
 
Caption 2 - The osteoclast assay and functional analyses. Disks seeded with CD14+ve 
monocytes are cultured up to day 17 in the presence of M-CSF and RANKL.  Every 3-4 days 
disks and their supernatants were harvested and used for one of the following analyses; 
cell staining (TRAP and haematoxylin), area of resorption quantification (toluidine blue or 
calcein) and ELISA. 
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 3.3 Results 
3.3.1 Proliferation medium supplemented with 10ng/mL m-CSF resulted in 
increased mononuclear cell number 
Human osteoclast assays established by a previous PhD student utilized m-
CSF concentrations of 5ng/mL which yielded approximately 518 ± 56 
cells/mm2at day 0.  In the initial assays conducted for this thesis, at day 0 
cell numbers were substantially lower at 311 ± 15 cells/mm2, when using 
the same reagents and culture conditions.  These low cell numbers were 
found to be insufficient for the completion of osteoclast differentiation 
assays. 
 
Altering the concentration of m-CSF to 10ng/mL increased the total cell 
count to 565 ± 31cells/mm2 at day 0 (Figure 3.1), and restored the cell 
density to a level that was comparable to previously established assays. All 
subsequent assays used m-CSF at 10ng/mL for the proliferation phase.  
Assays where <500 cells/mm2 were recorded at day 0 were terminated due 
to insufficient cell number.  Assays with >500 cells/mm2 were then 
supplemented with differentiation medium (5ng/mL m-CSF and 5ng/mL 
RANKL) inducing osteoclast differentiation. 
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Figure 3. 1 - Supplementation of proliferation medium with 10ng/mL m-CSF led to an 
increase in total cell count at day 0. Previously established assays using 5ng/mL m-CSF 
(completed by previous PhD student) yielded a significantly higher number of total cells 
(dashed line) when compared to those initially ran in this project (presented as crosses).  
Optimisation to 10ng/mL m-CSF in proliferation medium led to comparable total cell counts 
to previously reported, and showed a concentration dependent effect of m-CSF (presented 
as filled diamonds).  Statistical analysis using a Student's t-test was performed between 
values obtained at both 5ng/mL and 10ng/mL m-CSF compared to previously established 
values, and mean ± SEM data values are shown; Significance * refers to p≤0.05. (Data 
plotted refers to 4 disks from 1 donor). 
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 3.3.2 Visualising the differentiation of human osteoclasts across a 17 day time-
course 
Human CD14+ve mononuclear cells were cultured in differentiation medium for a 
total of 17 days resulting in the formation of osteoclasts.  Throughout the time-
course of the assay disks were harvested, fixed and stained with haematoxylin and 
TRAP.    Representative images across the time-course illustrate cell phenotypes 
adhered to disks; mononuclear cells, TRAP+ve nucleated cells (up to, and including, 2 
nuclei) and TRAP+ve multinucleated osteoclasts (Figure3.2).  At day 0, cells present 
were small (32μm in diameter), mononucleated cells stained only with 
haematoxylin and were found within close vicinity to each other.  Seven days later, 
the presence of larger TRAP+ve multinucleated cells were evident, reaching around 
37μm in diameter, where a reduction in total cell coverage of the disk was noted.  
Along with these larger cells, a small number of TRAP+ve mononuclear cells were 
also present.  After a further 3 days (day 10), the presence of TRAP+ve 
multinucleated osteoclasts was seen, along with a further reduction in cell density.  
The diameter of these large TRAP+ve osteoclasts ranged from 61μm to >100µmwith 
no pattern in shape or surface area occupied.  At day 14, TRAP+ve osteoclasts and 
TRAP+ve multinucleated cells were still present, although fewer total cells were 
visualised adhered to the disks, possibly due to multinucleation. At the final time-
point of day 17, TRAP+ve multinucleated cells were present but cells expressed 
unusual phenotypes, possibly characteristic of cell death. 
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Figure 3. 2 - Representative images across the time-course of the osteoclast 
differentiation assay.At day 0, 7, 10, and 14 of the osteoclast assay, disks were harvested, 
fixed and stained using haematoxylin and TRAP.  Multiple TRAP+ve mononuclear cells (green 
circles)and multinucleated osteoclasts (red circles)were visualised in cultures 
supplemented with RANKL across the time-course.  In m-CSF only cultures only 
haematoxylin stained cells were visible.  Scale bar = 100µm. 
Day 0 
Day 10 
Day 7 
Day 14 
m-CSF  m-CSF and RANKL 
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 3.3.3. Total cell counts were highly labour intensive but did show a decrease 
across a 17-day time-course 
The number of total cells adhered to the ivory disks was counted manually.  At day 
0, 15,288 ± 2,296 cells/disk were reported which substantially reduced to 4,713 ± 
1,494 cells/disk at day 17 (no statistics carried out as disks arose from n=1 donor, 3 
disks per time-point; Figure 3.3).  The manual counting process used took >100 
hours to complete due to the necessity of replicates from just one donor.  This 
manual cell counting was also prone to analyst variability (two analysts) due to the 
high number of cells to be counted. 
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Figure 3. 3 - Total cell count from one donor reduces over a 17-day time-course.Total cell 
count was obtained through manual counts of cells adhered to each disk.  Data was 
obtained from three replicate disks seeded with CD14+ve cells and cultured over the time-
course of the assay.  Total cell count reduced in equal decline from day 0 to day 17 where a 
minimum total count was obtained.  Mean ± SEM is shown, statistical analysis was not 
done due to donor number=1; 3 replicate disks per donor. 
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 3.3.4 The automated cell counting method was successfully validated 
To ensure the accuracy and validity of the data yielded from the automated 
algorithm, 8 random images from the completed osteoclast assays were selected 
and run through manual and automated cell counts.  From the initial comparison, a 
large degree of error was shown between these two methods reaching a maximum 
of 78% difference.  From the automated method, each histogram bin obtained was 
analysed to determine whether its contents were objects (i.e. cells) or noise.  
Analysis showed that there were a vast number of objects always located within 
histogram bin 1 which was set at 0-100 pixels.  From the analysis of the subplots, 
this bin was shown to be selecting noise (individual or small groups of pixels which 
were not cells) as objects, and recording these.  Subsequently, total cell count 
increased and the percentage difference between manual counts and automated 
counts was 11.7% to 78.1%, an unacceptable value (Table 3.1). 
Histogram bar 1 was thus removed from total cell counts, and a further comparison 
between manual cell count and automated cell count minus histogram bin 1 was 
conducted.  A total percentage difference of 12.8% was found, which when 
compared to the total percentage difference of two manual counts (25.7%) showed 
no significant difference (Table 3.1).  Automated total counts (minus histogram bar 
1) were therefore obtained using this automated method and used for the 
remaining experiments within this thesis. For additional quality control, after every 
40 images a manual cell count was performed (~10 images per experiment), where 
results had to fall within the acceptable percentage difference criteria. 
 
 
  
92 
 
 Table 3. 1 - A comparison between manual and automated total cell counts.8 randomly 
selected images were counted manually and using the automated algorithm (Disk 1-8) and 
total counts were compared.  A comparison between two manual counts from two different 
analysts was also performed across five different randomly selected disks to give a baseline 
error percentage  (Disks A-E). 
Disk Total Cell Count 
(Manual) 
Total Cell Count 
(Automated) 
% Difference 
1 3128 3819 -22.1 
2 541 926 -71.2 
3 1687 3004 -78.1 
4 759 1038 -36.8 
5 989 1147 -16.0 
6 129 214 -65.9 
7 48 77 -60.4 
8 145 162 -11.7 
 
 
Disk Total Cell Count 
(Manual) 
Total Cell Count 
(Automated: minus 
histogram bin 1) 
% Difference 
1 3128 2978 4.8 
2 541 546 -0.9 
3 1687 1639 2.8 
4 759 679 10.5 
5 989 936 5.4 
6 129 132 -2.3 
7 48 45 6.3 
8 145 132 9.0 
 
Disk Total Cell Count 
(Manual 1) 
Total Cell Count 
(Manual 2) 
% Difference 
A 655 674 -2.9 
B 448 399 10.9 
C 297 341 -14.8 
D 290 283 2.4 
E 417 389 6.7 
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 3.3.5 A significant reduction in total cell count occurred after seven days culture 
in differentiation medium 
Total cell count at day 0 was 14,043 ± 1,576 cells/disk, which after seven days 
culture in differentiation medium significantly reduced to 8,187 ± 5,671 cells/disk 
(p≤0.01).  A further reduction from day 7 to day 10, and day 10 to day 14 was 
noted; 5,671 ± 817 cells/disk and 2,789 ± 413 cells/disk respectively, which 
corresponded with the decrease in cell density presented in the images.  A 
reduction in total cell count was seen from day 14 to day 17 (1,716 ± 377 cells/disk) 
was believed to be due to cell senescence and death.  For this reason all 
subsequent assays were only performed up until day 14 (Figure 3.4).  
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Figure 3. 4 - Total cell count over a 17-day time-course..  A significant reduction in total 
cell count was seen over the 17-day time-course after culture in differentiation medium.  A 
substantial decrease was seen 7 days after supplementation with m-CSF and RANKL.  At day 
17, low cell counts were obtained suggesting cell senescence, therefore future assays 
terminated at day 14.  Values were obtained from n=8 donors (3 disks per donor at each 
time-point) and mean ± SEM is shown.  Statistical analysis was performed using a one-way 
ANOVA with a Bonferroni post-test. Significance *** refers to p<0.001. 
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 3.3.6 The creation of an automated total counting algorithm substantially 
reduced analysis time and increased total cell count accuracy 
Analysis time was reduced 10-fold from 100 to 9 hours per donor (n=1) when using 
the automated counting algorithm opposed to manual counts.  The accuracy and 
reproducibility of results obtained also improved due to a lack of inter-analyst 
variability.  However, the automated method did contain a major limitation by not 
deciphering TRAP+ve from TRAP-ve cells.  This analysis of TRAP+ve cells and osteoclasts 
was therefore completed manually. 
 
3.3.7 TRAP+ve cell counts significantly increased after seven days of culture in 
RANKL medium 
After the addition of RANKL, TRAP+ve cell number was monitored across the time-
course of the differentiation assay (Figure 3.5).  A significant increase in TRAP+ve cell 
number from 0 ± 0 TRAP+ve cells/disk at day 0, to 2,266 ± 481 at day 7 (p<0.0001) 
was seen.  After a further 4 days in culture (day 10), TRAP+ve+ cell number increased 
to 4,982 ± 1162 cells/disk, supporting the presence of TRAP+ve cells in 
representative images in Figure 3.2.  From day 10 a significant reduction occurred 
to day 14, resulting in 2,450 ± 424 cells/disk where cells had fused into larger multi-
nucleated cells i.e. osteoclasts. 
 
3.3.8 Osteoclast numbers peaked after 10 days of culture in differentiation 
medium 
Osteoclasts form from the fusion of TRAP+ve mononuclear cells in the presence of 
m-CSF and RANKL.  Osteoclasts significantly increased from day 0 to day 7 in m-CSF 
and RANKL cultures; 0 ± 0 osteoclasts/disk to 120 ± 80 osteoclasts/disk (p<0.01, 
Figure 3.6).  A peak in osteoclast numbers was shown after ten days where 
osteoclast numbers reached 325 ± 71 osteoclasts/disk.  After a further 4 days 
osteoclast number slightly decreased to 85 ± 43 osteoclasts/disk, but this was not 
significant, suggesting that at day 14 either TRAP+ve cells were fusing to form giant 
multinucleated cells, or were being lost through cellular senescence, reducing 
TRAP+ve cells.   
96 
 
  
3.3.9 Percentage osteoclastogenesis significantly increased in the presence of 
RANKL to a peak at day 10 
The percentage of osteoclastogenesis at day 0 was 0% due to the absence of RANKL 
(Figure 3.7).  In the presence of RANKL a significant increase in osteoclastogenesis 
across the 14-day time-course was found (p<0.0001).  Reported here, the 
percentage of osteoclastogenesis was shown to increase to 0.8 ± 0.5% at day 7, to a 
peak of 2.3 ± 0.8% at day 10, after which it reduced to 2.0 ± 0.9%.  This data 
confirmed the successful differentiation of the osteoclast but revealed no 
information regarding functional resorptive activity.   
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Figure 3. 5 - TRAP+ve cell count significantly increased after seven days of culture in RANKL 
medium.. From Day 0, differentiation cultures were supplemented with m-CSF and RANKL.  
After 7 days of culture TRAP+ve cells significantly increased and were shown to reach a peak 
number at day 10. A significant reduction in TRAP+ve count then followed to day 14.  Values 
were obtained from 8 donors (3 disks per donor per time-point, mean plotted) and the 
mean ± SEM is shown.  Statistical analysis was performed using a one-way ANOVA with a 
Bonferroni post-test(between day 10 and 14) and a Student's t-test (between day 0 and 7 
due to different culture medium).  Significance * and *** refers to p<0.05 and p<0.001 
respectively. 
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Figure 3. 6 - Osteoclast count significantly increased after seven days of culture in 
differentiation medium.Through the addition of RANKL, an increase in osteoclast count 
from day 0 to day 7 was seen.  A significant increase in osteoclast number was found after 
day 10, following which a decline was noted.  Values were obtained from n=8 donors (3 
replicate disks per donor per time-point, mean plotted) and mean ± SEM shown.  Statistical 
analysis was performed using a Student's t-test.  Significance *** refers to p<0.001. 
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Figure 3. 7 - Percentage osteoclastogenesis significantly increased due to the addition of 
RANKL.After seven days of culture in differentiation medium a significant increase in 
percentage osteoclastogenesis was seen compared to day 0.  This increase continued to 
day 10, where peak osteoclastogenesis was seen, further supporting previously reported 
increases in TRAP+ve and osteoclast counts.  Following this a reduction in percentage 
osteoclastogenesis was noted at day 14.   Values were obtained from n=8 donors (3 
replicate disks per donor per time-point, mean plotted) and mean ± SEM shown.  Statistical 
analysis was performed using a Student's t-test.  Significance ** refers to p<0.01. 
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 3.3.10 Novel analysis of 2D resorptive parameters by confocal microscopy 
showed no significant improvement in sensitivity or accuracy 
A novel method of analysis was tested in this chapter with the aim to improve the 
sensitivity and accuracy of calculating total area resorbed (Figure 3.8).  The 
traditional toluidine blue staining method was used to show an average of 3.3 ± 
1.4% resorption from 12 individual images.  Alongside this, confocal microscopy 
images of the same 12 disks were collected using a x20 lens. A slight increase in 
area resorbed was found using this confocal methodology due to increased 
resolution; 4.4 ± 1.0%, however no significant increase was found.  Due to the 
highly labour-intensive and costly method of confocal microscopy, the traditional 
toluidine blue method was used to determine surface area eroded within 
subsequent chapters.  
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Figure 3. 8 - A novel analysis method for calculating percentage area resorbed.A 
comparison between traditional toluidine blue staining of disks (i) and x20 confocal data 
yielded from calcein stained disks (ii) harvested from human osteoclast differentiation 
assays at day 14.  No significant increase in sensitivity for percentage area resorbed was 
shown using the x20 confocal analysis method when compared to traditional toluidine blue 
methodology (iii) (p= 0.5236).  Values were obtained from 12 disks (duplicate disks from 
n=6 donors) and mean ± SEM is shown.  Statistical analysis was performed using a Student's 
t-test. (for toluidine blue images 1 pixel = 0.48µm, for confocal images 1 pixel= 0.8µm). 
i 
ii 
iii 
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 3.3.11 Establishing the importance of CCL2, CCL3, CCL5, IL-6 and TNF-α inhuman 
osteoclast differentiation in vitro 
To identify which cytokines and chemokines were expressed and secreted during 
the time-course of the osteoclast assay, supernatants were harvested and stored at 
-80oC upon collection.  Supernatants were then analysed via ELISA (R&D systems) 
for the presence of specific pro-inflammatory cytokines and chemokines.  The 
cytokines IL-6 and TNF-α were measured due to their relationship and role in 
inflammatory arthritis and destructive bone diseases.  The chemokines CCL3, CCL2 
and CCL5 were also measured due to their significantly elevated concentrations in 
inflammatory and destructive bone diseases.   
3.3.11.1 IL-6 was present in culture supernatants across the 14-day time-course 
of human osteoclast differentiation 
IL-6 was identified in all supernatants across the time-course.  Within m-CSF only 
cultures, 151.9 ± 56.31 pg/mL IL-6 was found at day 0, which decreased to 96.28 ± 
39.63 pg/mL at day 3 and continued to decrease until day 14 where 52.16 ± 36.36 
pg/mL IL-6 was found, (but not significantly; p=0.5949, Figure 3.9).  In comparison, 
m-CSF and RANKL cultures showed a decrease from 61.24 ± 25.23 pg/mL at day 3 to 
52.93 ± 14.76 pg/mL at day 7, followed by a slight increase in IL-6 concentration to 
81.86 ± 30.36 pg/mL at day 10.  A final decrease to 60.95 ± 24.24 pg/mL was then 
seen at day 14 (Figure 3.9).   
Secondary to this, the amount of IL-6 secreted per cell was next assessed.  A 
significant reduction in IL-6 secretion was shown across the time-course in m-CSF 
only cultures from 0.95 ± 0.37pg/mL at day 0 to 0.14 ± 0.11pg/mL at day 14 
(p<0.05).  In m-CSF and RANKL cultures IL-6 increased across the time-course (0.48 
± 0.17pg/mL at day 7 to 1.09 ± 0.58pg/mL at day 14) but not significantly.  Peak IL-6 
secretion per cell was shown around day 10 in m-CSF and RANKL cultures, which 
was simultaneous with peak osteoclast numbers.   
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Figure 3. 9 - IL-6 secretion/cell increased in the presence of RANKL in osteoclast 
cultures.i.) IL-6in m-CSF only cultures reduced over the 14 day time-course but this was not 
significant (p=0.5949).  ii.) After culture in m-CSF and RANKL, no significant increase in IL-6 
concentration was quantified, but concentration levels were maintained across the time-
course from day 3 to day 14. iii.) The secretion of IL-6 per cell was shown to significantly 
decrease over the 14 day time-course in m-CSF only supplemented cultures.  iv.) In the 
presence of m-CSF and RANKL a slight increase of IL-6 secretion/cell at day 10 was seen, 
occurring at a comparable time to peak osteoclast number.  Values plotted from n=8 
donors (the mean from 3 disk replicates per donor per time-point is reported) and mean ± 
SEM is shown.  Samples below the lower limit of quantification had no value recorded, 
explaining why some time-points do not have 8 replicates.  Statistical analysis was 
performed using a ANOVA with a Bonferroni post-test. Significance * refers to p<0.05.  
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 3.3.11.2 TNF-α was not secreted directly from the osteoclast 
In cultures supplemented with m-CSF only, and m-CSF and RANKL, TNF-α was not 
detectable as results were found to be below the lower limit of quantification 
(15.6pg/mL). 
 
3.3.11.3 Levels of CCL5 were undetectable within human osteoclast culture 
supernatants 
CCL5 was found to be below the lower level of quantification (15.6pg/mL) in 
supernatants tested from all donors (n=8). 
 
3.3.11.4 CCL2 concentration significantly reduced in osteoclast culture 
supernatants 
CCL2 significantly decreased in m-CSF only cultures from 21.9 ± 2.3 ng/mL at day 0, 
to 13.9 ± 2.3ng/mL at day 7, and finally to 8.0 ± 3.8 ng/mL at day 14 (p≤0.05, Figure 
3.10).  In m-CSF and RANKL cultures, a significant reduction in CCL2 was also seen, 
where similar levels of CCL2 were shown; 18.6 ± 5.4 ng/mL at day 7, and 7.6 ± 2.2 
ng/mL at day 14 (p≤0.05, Figure 3.10).  The concentration of CCL2/cell showed a 
significant decrease in m-CSF only cultures but not in m-CSF and RANKL cultures. 
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Figure 3. 10 - CCL2 was not directly secreted from the osteoclast in human in vitro 
osteoclast assays..  i.)CCL2 in m-CSF only cultures significantly reduced over the 14 day 
time-course. ii.) Through the supplementation of RANKL, a significant decrease in CCL2 
concentration resulted over the time-course from day 3 to day 14.  iii.) and iv.) CCL2 
secretion/cell showed a significant reduction in m-CSF only conditions but not in 
differentiation cultures.  Values plotted from n=8 donors (the mean from 3 disk replicates 
per donor per time-point is reported) and mean ± SEM is shown.  Samples below the lower 
limit of quantification had no value recorded, explaining why some time-points do not have 
8 replicates.  Statistical analysis was performed using a ANOVA with a Bonferroni post-test.  
Significance * refers to p<0.05. 
 
  
i.) 
iii.) 
ii.) 
iv.) 
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 3.3.11.5 CCL3 secretion per cell was shown to significantly increase after the 
addition of RANKL where a significant correlation between osteoclast 
number and CCL3 was shown 
m-CSF only cultures showed a concentration of CCL3 which was maintained across 
the 14-day time-course; at day 0 93.78 ± 23.03 pg/mL and at day 14 81.29 ± 25.73 
pg/mL (Figure 3.11).  Alternatively, CCL3 concentration in m-CSF and RANKL 
supplemented cultures at day 3 increased to 159.6 ± 21.22pg/mL from day 0, but 
this was not significant (p=0.0580) (Figure 3.11).The increase in CCL3 between day 0 
and day 3 was noted to occur prior to peak osteoclast numbers as shown in Figure 
3.6, and only occurred in m-CSF and RANKL cultures.  After 7 days in m-CSF and 
RANKL cultures, CCL3 concentration decreased to 109.3 ± 13.86 pg/mL, before 
falling to 102.5 ± 32.23 pg/mL at day 10 and 87.52 ± 11.99 pg/mL at day 14. 
The analysis of CCL3 secretion per cell showed no significant change in m-CSF only 
cultures; 0.76 ± 0.19pg/mL at day 0 and 0.51 ± 0.17pg/mL at day 14.In m-CSF and 
RANKL cultures a significant increase of CCL3 secretion per cell across the time-
course was quantified (p<0.05).  This coincided with increasing osteoclast numbers 
and thus a relationship between CCL3, RANKL and osteoclast number was 
postulated.  No significant correlation between total cell count and CCL3 
concentration was quantified, but a significant and positive relationship between 
osteoclast number and CCL3 concentration was present (p≤0.01, R=0.3221); thus 
suggesting a role for CCL3 in RANKL-induced osteoclast differentiation.  
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Figure 3. 11 - CCL3 secretion/cell significantly increased across 14 days in the presence of 
RANKL and was significantly correlated to osteoclast count..i.) CCL3 unchanged in m-CSF 
only medium.  ii.) In m-CSF and RANKL cultures an increase in CCL3 occurred at day 3 (not 
significant),which declined to day 14.  iii.) No significant changes in CCL3 concentration/cell 
were seen in m-CSF only cultures.  iv.) In m-CSF and RANKL cultures a significant increase in 
CCL3 concentration/cell was seen.  v.) and vi.) No correlation was found between total cell 
count and CCL3 concentration, but a significant, positive correlation was shown between 
osteoclast count/disk and CCL3 concentration (p<0.01, R=0.3221). Values plotted from n=8 
donors (mean from 3 disks per donor per time-point reported).  Mean ± SEM shown.  
Samples below quantification not shown.  Statistical analysis; Student's t-test (day 0 and 
14), one-way ANOVA (day 7 and 14) and Spearman’s rank coefficient, * refers to p<0.05.   
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 3.4 Discussion 
A monoculture method was used to study the differentiation and activity of human 
osteoclasts in vitro.  The monoculture method for studying human osteoclasts in 
vitro was already established in the Rheumatology Laboratory, but in this chapter 
was adapted to include a 7 day proliferation phase using 10ng/mL m-CSF. 
Supplementation of media with m-CSF enhanced osteoclast precursor proliferation 
in line with published methodologies that reported a range of 5-25ng/mL m-CSF in 
human osteoclast differentiation assays (Hodge et al. 2011, Nicholson et al. 2000).  
Following this proliferation period, the differentiation phase was initiated (day 0) by 
supplementing cultures with RANKL containing medium (5ng/mL).  In this chapter 
5ng/mL RANKL led to quantifiable osteoclast numbers, which were sufficient for 
functional analyses.  Approximately 2% of cells differentiated into osteoclasts at the 
termination of each assay (day 14).  This yield was comparable, all-be-it higher, than 
levels (<1%) published by Nicholson et al. (2000), and that reported by Quinn et al. 
1998, Udagawa et al. 2000 and Han et al. 2000 where a broad range of 5 to 
50ng/mL RANKL has been used. 
The culture conditions chosen in this chapter supported an optimal 14 day 
differentiation period, which generated a reproducible and reliable method of 
osteoclast differentiation from CD14+ve monocultures.  Day 14 was chosen as the 
end-point of the study due to a significant reduction in total cell count observed 
between day 14 and 17, which was attributed to osteoclast senescence and/or 
apoptosis. Although this observation was not further investigated, it does support 
the notion that the life-span of a differentiating osteoclast is limited to 2 weeks, 
where, after successful resorption, the cell becomes apoptotic, loses its adherence 
to bone, and is ingested by phagocytes (Manolagas, 2000).  To confirm whether this 
also occurs in culture, markers of cellular apoptosis (e.g. Fas ligand and its receptor) 
could be assessed during the assay via flow cytometry (Wu et al. 2005). 
Histological staining of ivory discs (used as the bone substrate) with haematoxylin 
and TRAP identified adherent osteoclast lineage and mature multi-nucleated 
osteoclasts on day 14 (Oddie et al. 2000).  The limitations of this method resulted in 
the development of novel methodologies, where confocal microscopy paired with 
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 fluorescence-based TRAP stains (i.e. ELF97) quantified osteoclasts and monitored 
their movement (Filgueira. 2004). However, the prohibitive cost of this novel 
method and limited accessibility to confocal microscopes dictated that light 
microscopy was sufficient to detect TRAP+ve cells in line with the objectives of the 
chapter. 
Following the use of traditional histological stains, total cell counts were performed 
manually.  Cell counts for each assay took >130 hours to complete which protracted 
the time frame for obtaining results and limited the total number of assays 
processed at any time.  Several cell counting methodologies were used for the 
quantification of cells in suspension (a haemocytometer, electrical gating and flow 
cytometry), but very few existed for counting cells fixed to the matrix on which they 
were grown (Tzuret al. 2011, Bonetta 2005).  The main published methodology for 
counting adhered cells was recently described by Ravi et al. (2014) where stained 
cells were counted manually using a tag function in image processing software; 
ImagePro Plus.  Such methodology matches that outlined in Chapter 2 Section 
2.2.11.  However, this method was time-consuming and prompted the creation of a 
novel, high-throughput automated algorithm for counting total adhered cells.  
Implementation of this automated method substantially reduced analysis time to 9 
hours whilst maintaining the accuracy of manual counts. 
During the creation of this algorithm, code for DCT-normalisation from previous 
illumination invariant facial recognition software was employed to overcome issues 
with inconsistent background lighting.  The use of this innovative illumination 
invariant recognition algorithm was tested by Leszczyński (2010) where its inclusion 
significantly benefitted the verification of tested facial features.  Using the same 
theory, the use of GUIs for high-throughput database searching was utilised by 
Ciancanelli et al. (2015) to find the binding sites of the transcription factor IRF7.  It 
was therefore evident that such an application was pivotal to developing not only 
businesses involving security or surveillance, but also within a wide range of 
applications as far afield as in biology; one example being shown in this chapter. 
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 Through the addition of the DCT-normalisation code, the automated, high-
throughput counting algorithm was created and modified into a GUI.  As described 
in this chapter this novel ‘6-click’ process, took a maximum of 5 minutes to count 
adhered cells, before being turned into a completely automated script.  This 
method was validated as it showed a comparable degree of accuracy in cell counts 
when compared to manual counts from two individual analysts.  For this reason the 
method was taken forward as an accurate cell counting algorithm.  The 
translational application of this automated method also meant that it could be used 
for object counting in many biological disciplines; leukocyte quantification in 
arthritic joints, nuclei counting in single cells, vacuole analysis etc. 
After total counts were obtained, a RANKL dependent increase in TRAP+ve and 
osteoclast number was observed, confirming data previously reported and 
reviewed by Quinn et al. (1998).  The next task was to accurately determine and 
quantify the resorptive activity of the osteoclast.  Traditionally toluidine blue was 
chosen over other methods such as scanning electron microscopy for the 
calculation of area resorbed, where it has long been documented that the addition 
of RANKL has a causative effect on an increase in osteoclastic resorption (Sarma & 
Flanagan. 1996, Keller et al. 2012).  In this chapter a novel method for the analysis 
of confocal images showed no significant benefit in sensitivity over the traditional 
toluidine blue method.  However, confocal images with higher resolution distinctly 
showed the presence of multiple erosions, but due to the following it was decieded 
the costs did not outweigh the benefits; lengthy acquisition times, sample mounting 
and equipment cost.  Although this direct comparison between toluidine blue and 
confocal had not previously been published, the results for the quantification of 
area resorbed using confocal microscopy supports those of Jeon et al. (2012).  Jeon 
and colleagues (2012) used confocal microscopy to identify area of resorption pits 
over the time-course of a standard osteoclast assay.  It was concluded that 
osteoclasts formed multiple smaller single pits at day 7, but by day 14 the fusion of 
multiple osteoclasts caused the appearance of larger areas of resorption.   
Following on from this, culture supernatants were analysed to obtain surrogate 
soluble mediators of osteoclast differentiation. Several pro-inflammatory cytokines 
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 were documented to play a role in destructive bone diseases including IL-1, IL-11, 
IL-15, IL-8, IL-17, TNF-α and IL-6 (Roodman. 1999, Azuma et al. 2000, Goldring et al. 
2002, Durand et al. 2013).  All of these cytokines were shown to increase pre-
osteoclast cell migration and fusion into mature osteoclasts, along with further 
effects on osteoclast resorptive ability, either in co-cultures or in vivo.  Recently, the 
increased presence of one of these cytokines, IL-6, in erosive bone diseases has 
become a main area of interest.  IL-6 is secreted from T cells, B cells and monocytes, 
and is significantly increased in RA patients where it correlates with bone 
destruction in arthritic joints and animal models (Robak et al. 1998, Nowell et al. 
2003, Mihara et al. 2012, Rose-John 2012).   Additionally, IL-6 was shown to 
increase in the presence of IL-1 and TNF-α, but its effects in vitro were variable and 
dependent upon culture methodology.  The direct secretion of IL-6 from osteoclast 
differentiation cultures was assessed in this chapter where results showed IL-6 to 
slowly decrease across a 14 day time-course.  A significant decrease in IL-6 
concentration per cell in control cultures confirmed that the secretion was driven 
by a RANKL-mediated effect from TRAP+ve cells.  The data in this chapter therefore 
indicated a role for IL-6 in osteoclast formation in monocultures, but a role in 
osteoclast-mediated resorption was not investigated.    
The indirect effects of IL-6 on bone resorption have previously been reported as the 
autocrine/paracrine secretion of IL-6 was shown to enhanced bone resorption in 
bone marrow co-cultures from patients with Paget’s disease (Roodman et al, 1992).  
More recently, an in vivo role of IL-6 trans-signalling was postulated from data 
published by Tanaka et al. 2013 where treatment of murine arthritis with an anti-
mouse IL-6R antibody led to attenuated osteoclast number and bone loss.  To 
investigate this further, the paracrine and autocrine involvement of IL-6 trans-
signalling in osteoclast differentiation, resorption and secretion of soluble 
mediators in monocultures will be assessed in Chapter 4. 
In addition to IL-6, TNF-α was tested for but found at negligible levels in the 
supernatants from the osteoclast differentiation assays, suggesting no role in the 
direct differentiation of the osteoclast.  This was a controversial finding due to 
previously published material that showed increases in osteoclastogenesis from the 
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 secretion of TNF-α in co-cultures of human marrow cells and from TNF-α secreted 
from osteoblastic cells (Roodman et al. 1999, Azuma et al. 2000).  The lack of 
detectable TNF-α described in this chapter was of particular note, as it provided 
evidence for the lack of TNF-α secretion direct from the osteoclast, possibly 
implying its redundancy in healthy osteoclastogenesis.  This was important as TNF-α 
is known to be significantly elevated and partly responsible for detrimental 
pathology in bone destructive diseases (Matsuno et al. 2002). 
In addition to these cytokines, a relationship between osteoclast formation and the 
inflammatory chemokines CCL9, CXCL12, CCL5, CCL2 and CCL3 has also been 
suggested where their increased presence has correlated to enhanced 
osteoclastogenesis and resorption (Koch et al. 1992, Choi et al. 2000, Han et al. 
2001, Yano et al. 2005, Pharoah et al. 2006, Iwamoto et al. 2008, Szekanecz et al. 
2010, Vallet et al. 2011, Wintges et al. 2013).  These chemokines stimulate the 
migration of pre-osteoclasts and facilitate their fusion into osteoclasts.  CCL5 was 
found at significantly elevated levels in erosive bone diseases such as JIA and RA 
(Patel et al. 2001, Pharoah et al. 2006, Wintges et al. 2013).  This chapter indicated 
that CCL5 was not detected within osteoclast supernatants obtained from either 
monocultures or control assays.  This concurs with data obtained in an in vivo 
model, whereby increased osteoclastogenesis and decreased bone formation was 
observed in CCL5 deficient mice (Wintges et al. 2013).  Such data suggests a 
possible role for CCL5 in the inhibition of osteoclast differentiation, and thus, could 
explain the lack of CCL5 in our cultures. 
In contrast to CCL5, CCL2 was detectable in supernatants harvested from m-CSF and 
RANKL cultures. Furthermore, a significant reduction in CCL2 was observed across 
the time-course.  This supported previous data that showed a requirement for a 
minimal level of CCL2 for the expression of DC-STAMP, but that CCL2 levels did not 
significantly increase thereafter, indicating CCL2 was not secreted from the 
osteoclast (Miyamoto et al. 2009).  The CCL2 level quantified in this chapter may 
have originated from mononuclear cells present at day 0, and as these 
differentiated into TRAP+ve cells a corresponding reduction in CCL2 levels was 
observed.  Alternatively, CCL2 may have been secreted from the osteoclast, but due 
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 to the increasing acidic conditions caused by the active osteoclast, this acid 
sensitive chemokine could have reduced over-time due to its short half-life (Zhang 
et al. 2009, Fan et al. 2011).  In the future, real time qPCR measuring the gene 
expression of CCL2, and CCL5, prior to their acidic degradation could confirm 
whether they are secreted. 
Finally, a third chemokine CCL3 is found at elevated levels in arthritic diseases.  No 
significant increase in CCL3 across the time-course of m-CSF and RANKL cultures 
was detected, but a significant increase in CCL3 concentration/cell was found, along 
with a significant, positive relationship with osteoclast count.  This supports 
previous data obtained from co-cultures where CCL3 was concluded to be an 
osteoclastogenic differentiation factor (Choi et al. 2000).  Along with this, the 
theory of CCL3 being able to withstand a low pH and maintain its functionality 
provides evidence for a role in the pathology of destructive bone diseases (Choi et 
al. 2000 and Han et al. 2001).  The concentration of CCL3 in this chapter was 
substantially lower than found in erosive bone diseases; RA-29ng/mL (synovial 
fluid), OA- 0.7ng/mL (synovial fluid), MM-1000pg/mL (bone marrow plasma) (Choi 
et al. 2000, Komano et al. 2006, Pharoah et al. 2006, Vallet et al. 2011, Vangsness 
et al. 2011).  This suggests that the production of CCL3 from the osteoclast is either 
capable of being increased due to the inflammatory milieu of the joint, and/or 
secondary sources of this chemokine exist; macrophages, monocytes and 
fibroblasts. 
Additional to the in vitro role of CCL3, in the last 20 years the in vivo role of CCL3 
was investigated.  The presence of significant quantities of CCL3 within the RA 
synovium was shown to induce the migration of CD14+ve and CD16-ve monocytes, 
thus linking CCL3 and bone erosions in arthritic diseases; RA, JIA, and OA (Koch et 
al. 1994, Komano et al. 2006, Pharoah et al, 2006, Vangsness et al. 2011).  
Furthermore, elevated levels of CCL3 were shown in another bone destructive 
disease, multiple myeloma (MM).  In MM, Choi et al. (2000) and Han et al. (2001), 
showed the presence of CCL3 in myeloma patients, where serum was collected and 
supplemented into bone marrow cultures, which resulted in a significant increase in 
osteoclastogenesis.  Furthermore, when these cultures where supplemented with a 
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 neutralizing antibody to CCL3, osteoclast formation was significantly inhibited (Choi 
et al. 2000, Han et al. 2001).  Alongside the effects of CCL3 on osteoclast 
differentiation, Vallet et al. (2011) proposed a dual mechanism of CCL3 in inhibiting 
osteoblast activity, which would therefore have led to the uncoupling of the 
osteoblast/osteoclast relationship further enhancing the pathology seen.  In order 
to fully understand the role CCL3 directly exerts on osteoclast formation and 
resorption, further in vitro and in vivo experiments will be presented in Chapter 5. 
As discussed above several studies have postulated a role for both IL-6 and CCL3 in 
erosive bone disorders both in vitro and in vivo, but there is a lack of research 
directly linking these mediators with the process of mononuclear differentiation 
into osteoclasts.  For this reason the further investigation of IL-6 and CCL3 in direct 
osteoclast differentiation and in the functional resorptive ability of these cells will 
be continued in Chapter 4 and 5 respectively. 
  
115 
 
 3.5 Conclusion 
During the course of this chapter a reproducible and effective method for the 
differentiation of human osteoclasts from CD14+ve mononuclear cells was reported, 
which facilitated an accurate and improved assessment of mediators involved in 
direct osteoclastogenesis compared to co-cultures.  In tandem, the creation of a 
novel, high-throughput automated algorithm for counting total cells was reported, 
alongside its validation for use in the established osteoclast assays.  Its use in 
osteoclast assays provided a significant advantage over manual total counts due to 
the following reasons; robustness, lack of inter-analyst variability and high-
throughput nature.  As such multiple disks could be run per donor increasing 
experimental validity.  In addition to total cell counts, the algorithm could also be 
used as a guide for counting osteoclast numbers manually, and provide a quick and 
easy method for calculating percentage osteoclastogenesis.  Finally, through the 
analysis of harvested osteoclast assay culture supernatants, TNF-α and CCL5 were 
shown to have no role on osteoclast differentiation.  CCL2, although present in 
supernatants, was not significantly altered in the presence of RANKL, suggesting 
limited effect on osteoclastogenesis. However, both IL-6 and CCL3 were increased 
in the presence of RANKL, suggesting an autocrine role of these two pro-
inflammatory mediators in the differentiation and maturation of the human 
osteoclast.  It was therefore concluded that IL-6 and CCL3 could be novel surrogate 
biomarkers of osteoclast differentiation, where further research distinguishing their 
impact on osteoclastogenesis and bone destructive diseases would be necessary. 
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4 Chapter 4:Assessing the importance of IL-
6/sIL-6R signalling in RANKL-mediated human 
osteoclast differentiation and functional 
resorption in vitro  
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 4.1 Introduction 
Levels of IL-6 (60.95 ± 24.24 pg/mL) detected in supernatants from osteoclast 
differentiations assays in Chapter 3 indicate that IL-6 and/or the combination of IL-6 
and sIL-6R (from here on termed IL-6/sIL-6R) have the capacity to regulate the 
biological responses in one or all of the following cell types; osteoclast precursor 
cells (e.g. monocytes and macrophages), TRAP+ve mononuclear cells and 
osteoclasts.  A role of IL-6 in bone formation is well documented from early 
osteoblastogenesis and maturation through to osteocyte formation (Johnson et al. 
2014).  Comparatively, less is known about its role in osteoclastogenesis and bone 
destruction.  Monocytes (osteoclast precursors) and macrophages express IL-6R 
and respond to direct stimulation by IL-6 via the classical signalling pathway; a 
regulatory/physiological pathway involved in resolution of immune response and 
cellular regeneration.  Limited evidence of IL-6R expression on the osteoclast is 
available (Chapter 1 Section 1.3.2.2), therefore it is not clear whether the osteoclast 
can respond directly to IL-6 via classical signalling, or whether it relies on trans-
signalling as described next (Kotake et al. 1996, Grivennikov et al. 2009, Miyamoto 
et al. 2009, Jones, Scheller & Rose-John 2011). 
A soluble form of IL-6R (sIL-6R) enables non-IL-6R expressing cells to respond to IL-6 
by forming an IL-6/sIL-6R complex, thus allowing IL-6 cell signalling in the presence 
of gp130; trans-signalling (Figure 4.1).  sIL-6R has a similar affinity for IL-6 as IL-6R, 
and also prolongs IL-6 plasma half-life (Oh, Revel& Chebath1996, Peters et al. 1996, 
Müller-Newenet al. 1998). sIL-6R is formed by proteolytic cleavage of cell 
membrane bound IL-6R (primarily from neutrophils) by ADAM10 and ADAM17 
(Garbers et al. 2011).  An increase in ADAM17 is commonly found in an 
inflammatory state (IL-1 and TNF-α) in concordance with an increase in sIL-6R 
(resultant of elevated neutrophil apoptosis; Garberset al. 2011).  The elevated 
presence IL-6 and sIL-6R, in addition to ADAMs leads to the expansion and 
recruitment of monocytes to areas of high concentration, therefore increasing the 
pool of osteoclast precursors, whilst also diverting the immune response away from 
a neutrophilic phenotype (apoptosis).  Additionally, sIL-6R can be formed by 
differential mRNA splicing. A polymorphism in the IL-6R gene at the coding site for 
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 proteolytic cleavage can change aspartic acid to alanine, and in 2013 this 
polymorphism was found to correlate with higher sIL-6R expression (Kim et al. 
2003).  However, the importance of the mechanism by which sIL-6R is generated is 
likely to alter within different diseases; i.e. reduced alternative splicing of sIL-6R is 
associated with RA (Marinou et al. 2007). 
Evidence supporting a role of IL-6 trans-signalling in osteoclast formation was first 
reported in 1993 by Tamura et al. who showed a significant increase of osteoclast 
number in murine co-cultures containing bone marrow cells and osteoblasts, when 
stimulated with IL-6 (200ng/mL) and sIL-6R (500ng/mL).  Furthermore, IL-6 and sIL-
6R were unable to trigger a comparable agonistic response when applied to the co-
culture system individually (Tamura et al. 1993).  These data show that osteoclasts 
respond preferentially to IL-6/sIL-6R stimulation versus IL-6.  However the co-
culture method did not provide insight to the direct actions of IL-6 trans-signalling 
on osteoclast differentiation, but highlighted its indirect effects through a RANKL-
dependent mechanism (Chapter 1).  For example, in co-cultures IL-6 stimulates 
RANKL secretion from synovial T cells and stimulates STAT3 signalling in osteoblasts 
leading to RANKL secretion (O’Brien et al. 1999, Hashizume et al. 2008).  
Contestable data was however published in 2003 by Kudo et al. who concluded IL-6 
trans-signalling exerted a RANKL-independent effect on osteoclast formation.  In 
their study, a significant increase in multinucleated cells and resorption pits were 
found in cultures supplemented with m-CSF and IL-6/sIL-6R, compared to m-CSF 
and IL-6 alone (Kudo et al. 2003).  Such data therefore suggested that IL-6 trans-
signalling played a role in osteoclastogenesis and that RANKL was not essential for 
this differentiation.  However, the use of RANKL-/- mice confirms the critical 
presence of RANKL for homeostatic osteoclastogenesis, where RANKL-/- mice 
develop severe osteopetrosis, decreased tooth eruption and defective leukocyte 
differentiation (Pettit et al. 2001).  The true physiological nature of multinucleated 
cells differentiated from cultures supplemented with m-CSF and IL-6/sIL-6R but not 
RANKL is therefore questionable, particularly as cell size and nucleus number were 
decreased (Kudo et al. 2003). 
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Figure 4. 1 - An illustration of extracellular IL-6 and sIL-6R activating IL-6 classical and IL-6 
trans-signalling IL-6 can signal through two signalling pathways depending on whether IL-
6R is expressed on the surface of the cell (i.e. monocytes/macrophages).  Classical signalling 
results from IL-6 binding to membrane bound IL-6R (top right pathway) which stimulates 
the dimerization of gp130, which is ubiquitously expressed on cells.  Cells which do not 
express IL-6R are still responsive to IL-6 though through the presence of  soluble IL-6R (sIL-
6R; released due to either proteolytic cleavage or alternative splicing) and cellular 
expression of gp130, termed trans-signalling (top left pathway).  IL-6 and sIL-6R form a 
complex in the extracellular space which can then activate gp130 on the cells membrane.  
Once bound gp130 dimerizes and activates the JAK/STAT pathway leading to downstream 
STAT3 signalling and activation of transcription factors and osteoclast differentiation target 
genes. 
 
Extensive literature was published supporting a role of IL-6 in osteoclast 
differentiation and bone erosions (as summarised in Hashizume & Mihara 2011).  
However the direct effect of the IL-6/sIL-6R complex upon monocyte differentiation 
into osteoclasts had not been established.  In addition, the specific effect of IL-6 
trans-signalling upon in vitro osteoclast formation and pathological bone resorption 
during inflammatory arthritis had not been evaluated.  For this reason, studies in 
the following chapter will utilise sgp130-Fc (a kind gift from Prof Rose-John) as a 
research tool to block IL-6 trans-signalling in an in vitro system of human 
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 osteoclastogenesis from CD14+ve mononuclear cells in the presence of RANKL.  
Sgp130-Fc is comprised of gp130’s extracellular region joined to the Fc region of 
human IgG1 and readily binds to IL-6/sIL-6R complex, with a 10-fold higher affinity 
than natural sgp130 (Jostock et al. 2001).  Additionally, sgp130-Fc specifically binds 
to the complex and thus only blocks trans-signalling, not classical signalling, where 
such a design was pivotal to the experiments in this chapter (Jostock et al. 2001).  
Sgp130-Fc will therefore be used to identify firstly any role IL-6 trans-signalling 
exerted in the direct differentiation of the osteoclast from CD14+ve mononuclear 
cells, and secondly, any role on mature osteoclast facilitated bone resorption, 
through the utilisation of both 2D and 3D methodology.  These two parameters will 
be measured in three different ‘models’ of osteoclastogenesis; i.) a physiological 
model utilising sgp130-Fc to inhibit autocrine IL-6 trans-signalling, ii.) a model 
simulating the inflammatory milieu of an arthritic joint (Nowell et al. 2003, Wong et 
al. 2006, Nowell et al. 2009), and iii.) a model to distinguish the therapeutic 
potential of inhibiting IL-6 trans-signalling in osteoclastogenesis.  Data collected will 
elucidate the importance of IL-6 trans- versus classical signalling in the pathological 
profile of bone destruction, and ultimately help understand signalling in destructive 
bone diseases, where the pathological inflammatory milieu of a joint is thought to 
be pivotal to resorption (both human: RA or MM, and murine: CIA or AIA; Kotake et 
al. 1996, Maslinski et al. 2003, Nowell et al. 2003, Nowell et al. 2009, Jones, Scheller 
& Rose-John 2011). 
The aim of this chapter was to define the direct role of IL-6 trans-signalling on the 
physiological differentiation of CD14+ve mononuclear cells into osteoclasts 
stimulated by m-CSF and RANKL through the use of sgp130-Fc.  HYPER-IL-6 was 
used to mimic the pathological inflammatory milieu of the joint and to establish the 
direct role of IL-6 trans-signalling on osteoclast formation and subsequent bone 
resorption.  Supernatants collected from across the time-course were used to 
measure the role of IL-6 trans-signalling in modulating the secretion of osteoclast-
associated chemokines (CCL2, CCL3, CCL5).  Specifically the aims of this chapter 
were; 
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 1. To determine the impact of basal IL-6 trans-signalling on the differentiation 
of human CD14+ve cells by measuring osteoclast formation, osteoclast-
dependent bone resorption and osteoclast-related chemokines using 
sgp130-Fc as a tool to specifically block the pathway. 
 
2. To simulate the pathological milieu of an arthritic joint using HYPER-IL-6 and 
monitor the resultant effects on osteoclast differentiation, resorption 
(overall &individually) and secretion of chemotactic proteins from CD14+ve 
mononuclear precursors and osteoclasts. 
 
3. To assess the therapeutic potential of sgp130-Fc inhibiting HYPER-IL-6 
induced osteoclastogenesis; thus evaluating its potential as a target for 
inhibiting enhanced osteoclast differentiation and resorption in vitro, 
highlighting potential translational applications. 
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 4.2 Essential Methodology 
The below diagrams highlight the essential methods used throughout this chapter.  
Full detail of all these methods can be found in their respective sections in Chapter 
2. 
• Osteoclast assay set up (Chapter 2 Sections 2.2.1 - 2.2.4) 
Condition Number of Donors 
Number of Replicate 
Disks per donor 
Chapter 
Sections Comments 
m-CSF only 5 4 
4.3.1 
Mean values 
from the 
replicate disks 
of each donor 
plotted 
m-CSF and sgp130-Fc 5 4 
m-CSF and RANKL 8 8 
m-CSF, RANKL and 
sgp130-FC 8 8 
m-CSF and RANKL 7 8 
4.3.2 m-CSF, RANKL and 
HYPER-IL-6 (10ng/mL) 7 8 
m-CSF and RANKL 1 4 
4.3.2.2  
m-CSF, RANKL and 
HYPER-IL-6 (0.5ng/mL) 1 4 
m-CSF, RANKL and 
HYPER-IL-6 (1ng/mL) 1 4 
m-CSF, RANKL and 
HYPER-IL-6 (2.5ng/mL) 1 4 
m-CSF, RANKL and 
HYPER-IL-6 (5ng/mL) 1 4 
m-CSF and RANKL 8 4 
4.3.2.3 m-CSF, RANKL and 
HYPER-IL-6 (0.5ng/mL) 8 4 
m-CSF and RANKL 6 4 
4.3.3 m-CSF, RANKL, HYPER-IL-
6 and sgp130-Fc 6 4 
 
-PBMCs isolated from healthy human whole blood via density centrifugation went 
through magnetic activated cell sorting to yield a pure suspension of CD14+ve 
monocytes (as illustrated). 
- Disks were seeded with 3.2 x 106 cells and cultured with m-CSF alone (5ng/mL) or 
in combination with RANKL (5ng/mL).  Culture supernatants collected and 
replenished every 3-4 days.  Disks harvested at day 14. 
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Caption 3 - Isolation of human CD14+ve monocytes from peripheral blood.  Human blood 
layered onto hisotpaque is centrifuged yielding peripheral blood mononuclear cells.  
CD14+ve monocytes isolated by magnetic activated cell sorting and  3.2 x 106 cells/mL are 
seeded onto ivory disks prior to culture in osteoclast proliferation/differentiation medium. 
 
 
• Quantitative parameter assessment of the osteoclast assay  
-Disks harvested at day 14 were fixed with glutaraldehyde prior to staining with 
TRAP and haematoxylin to identify total cells and osteoclasts; quantified through 
MATLAB and manual counts.  Following cell counts adhered cells were removed and 
disks stained with toluidine blue or calcein to facilitate quantification of resorbed 
area.  Harvested supernatants were analysed by ELISA. 
-In addition, individual pit parameters (area, perimeter, volume and depth) were 
imaged via confocal microscopy (x60) and quantified using MetaMorph.  All of 
these assessments can be found in the diagram which follows. 
  
124 
 
 Caption 4 - The osteoclast assay and functional analyses.  Disks seeded with CD14+ve 
monocytes are cultured up to day 14 in the presence or absence of sgp130-Fc and/or 
HYPER-IL-6.  Every 3-4 days disks and their supernatants were harvested and used for one 
of the following analyses; cell staining (TRAP and haematoxylin), area of resorption 
quantification (toluidine blue or calcein), confocal analysis of individual pit characteristics, 
and ELISA. 
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 4.3 Results 
In this section the impact IL-6 trans-signalling on osteoclastogenesis in the following 
models was assessed; a model of physiological osteoclast formation and functional 
resorption, a model simulating the inflammatory milieu of an arthritic joint, and a 
model to distinguish IL-6 trans-signalling as a therapeutic target.   
 
4.3.1 Determining the impact of IL-6 trans-signalling in a model of 
physiological osteoclast formation and functional resorption 
The potential impact of IL-6 trans-signalling upon the physiological process of bone 
resorption was studied in vitro by supplementing CD14+ve mononuclear cells with 
culture medium containing sgp130-Fc, m-CSF and RANKL.  Osteoclastogenesis 
assays finished after 14 days at which point osteoclast number (by TRAP staining) 
and the area of resorbed bone substrate (by toluidine blue staining) were 
quantified.  Markers of osteoclast differentiation (TRAP5b), resorption (CTX-1), pain 
and inflammation (NGF, CCL2, CCL3 and CCL5) were measured by ELISA over the 
time-course of each experiment. 
 
4.3.1.1 Sgp130-Fc significantly reduced TRAP+ve cell, osteoclast number and 
resorption of ivory disks 
TRAP+ve cell counts were significantly (p≤0.05) reduced by sgp130-Fc (donors: n =8, 
Figure 4.2 and Figure 4.3, i).  A significant 30% reduction in osteoclast count was 
observed in assays supplemented with sgp130-Fc versus control containing m-CSF 
and RANKL (donors: n=8, Figure 4.3, ii, p≤0.05).  Under non-differentiating 
conditions (m-CSF only) TRAP+ve cells and osteoclasts were absent or diminutive in 
number on the cultured disks (donors n=5, Figure 4.2 and Figure 4.3, iii and iv). 
The area of bone substrate resorbed was significantly reduced by sgp130-Fc 
(donors: n =8, 0.59 ± 0.16% of disk) compared to m-CSF + RANKL control cultures 
(donors: n =8, 1.09 ± 0.16%, Figure 4.4, p≤0.05).  No resorption was detected in 
cultures containing m-CSF ± sgp130-Fc (donors: n =5, Figure 4.4). The resorbed 
surface of the ivory disks was observed and analysed by traditional light microscopy 
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 and high resolution confocal microscopy.  Due to a lower frequency of resorption 
pits (Figure 4.3) and the high objective used for confocal microscopy, a 
representative image of multiple resorption pits on sgp130-Fc treated disks was 
hard to acquire.  However, fewer resorption pits were evident which were smaller 
in pit area, volume and depth as determined visually from x,y and z representation 
(Figure 4.5).  
 
4.3.1.2 CTX-1 and TRAP5b unaffected by sgp130-Fc treatment 
TRAP5b and CTX-1 were measured by ELISA on day 7 and 10.  TRAP5b levels were 
comparable in m-CSF + RANKL cultures and m-CSF + RANKL + sgp130-Fc on day 7 
(1.21 ± 0.90 and 1.26 ± 0.32 U/L) and day 10 (2.67 ± 0.85 and 1.22 ± 0.55 U/L; 
donors n=2, Figure 4.6, i).  The 2-fold reduction in TRAP5b by sgp130-Fc on day 10 
was not significant but supported the significant reduction in TRAP+ve cells and 
osteoclasts numbers observed (Figure 4.3). 
CTX-1 was not significantly affected by sgp130-Fc treatment of CD14+ve cell cultures 
also containing m-CSF + RANKL (day 7 and day 10), but a 4-fold decrease was noted 
on day 10 in the presence of sgp130-Fc, which was absent on day 7 (donors n=2, 
Figure 4.6, ii).   
 
4.3.1.3 NGF, CCL2, CCL3 or CCL5 secreted from osteoclast were unaffected by 
sgp130-Fc 
NGF was not detected in any of the supernatants tested (donors n=5, Figure 4.7).   
The level of CCL2 and CCL3 in cultures containing m-CSF and RANKL was unaffected 
by sgp130-Fc (donors: n =5, Figure 4.7).  The secretion of CCL5 by osteoclasts and 
TRAP+ve cells was low and variable (donors: n =5, Figure 4.7). 
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i.) 
 
ii.) 
 
iii.) 
 
iv.) 
 
Figure 4. 2 - Representative images of osteoclast differentiation cultures supplemented 
with sgp130-Fc.Disks were cultured for 14 days in differentiation medium (m-CSF and 
RANKL) either supplemented with or without sgp130-Fc (500ng/mL)from n=8 donors. i.) In 
differentiation medium only cultures many TRAP+ve mononuclear (green circle) and 
multinuclear cells(red circle)were seen adhered to disks.  Multiple resorption pits could also 
been seen across the disk.  ii.) Through the supplementation of sgp130-Fc a substantial 
reduction in both TRAP+ve mononuclear and multinuclear cells was seen, and cell size also 
appeared reduced.  Resorption pit number appeared reduced from differentiation cultures.  
iii.)  Control cultures containing only m-CSF lacked TRAP+ve cells.  iv.) Control cultures 
containing m-CSF and sgp130-Fc also lacked TRAP+ve cells. (Scale bar 100µm). 
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Figure 4. 3 - Sgp130-Fc significantly reduced TRAP+ve mononuclear and multinuclear cell 
formation.Across the time-course of the osteoclast assay sgp130-Fc (500ng/mL) was added 
into cultures.  After 14 days cells were still viable and disks were harvested and stained 
with haematoxylin and TRAP.  i.) A significant reduction in TRAP+ve cells resulted from 
sgp130-Fc supplementation(donors n=8; mean plotted from 8 disk replicates per donor).  
ii.)  Osteoclast count significantly reduced in the presence of sgp130-Fc(donors n=8; mean 
plotted from 8 disk replicates per donor).  iii.) and iv.) In m-CSF control cultures 
with/without the supplementation of sgp130-Fc, negligible TRAP+ve cells and osteoclasts 
were counted(donors n=5; mean plotted from 4 disk replicates per donor).  Mean ± S.E.M 
shown. Student's t-test was used to determine significance (* p≤0.05). 
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Figure 4. 4 - Sgp130-Fc significantly reduced total area resorbed in human osteoclast cultures.Following counts at day 14, disks were stained with toluidine 
blue.  i.) M-CSF and RANKL cultures had multiple resorption pits (yellow arrows), but treatment with sgp130-Fc (ii) substantially reduced their number.  iii.) 
and iv.) No resorption was found in m-CSF only cultures ± sgp130-Fc.  v.)  A significant reduction of total area resorbed in sgp130-Fc cultures was found 
compared to m-CSF and RANKL (donors n=8;mean plotted from 4 disks per donor,p≤0.05).  vi.)  No resorption was present in cultures lacking RANKL(donors 
n=5, mean plotted from 2 disks per donor).  Mean ± S.E.M. reported, statistical significance assessed using  Student's t-test (*p≤0.05). Scale bar = 250µm.  
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 i.) 
 
ii.) 
 
Figure 4. 5 - High resolution confocal microscopy revealed visually reduced resorption pit 
number and depth in sgp130-Fc supplemented human osteoclast cultures in 
vitro.Following toluidine blue staining and light microscopy, disks were bleached and 
stained in calcein prior to confocal imaging at x60.  i.) Multiple resorption pits were evident 
across the surface of disks cultured in m-CSF and RANKL.  ii.)  Supplementation of sgp130-
Fc into m-CSF and RANKL cultures yielded very few resorption pits (one pit visualised where 
lines intersect).  Where imaged, resorption pits were smaller in diameter and depth 
compared to m-CSF and RANKL cultures.0.27µm = 1 pixel. (Statistical analysis was not 
preformed due to donor number =1).  
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Figure 4. 6 - TRAP5b and CTX-1 levels decreased but not significantly in the supernatants 
of osteoclast differentiation cultures supplemented with sgp130-Fc.Soluble markers of 
resorption and osteoclast differentiation were assessed in the supernatants from 
osteoclast cultures(donors n=2; the mean of 8 replicate disks per donor was plotted).  i.)  A 
decrease in TRAP5b levels were found in cultures treated with sgp130-Fc compared to m-
CSF and RANKL cultures.  ii.) A similar decrease in CTX-1 levels were found in cultures 
treated with sgp130-Fc but this was not significant.  Mean ± S.E.M shown, statistical 
analysis carried out using a Student's t-test.  
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Figure 4. 7 - NGF, CCL2, CCL3 and CCL5 were not significantly altered by sgp130-Fc 
supplementation into osteoclast cultures.Harvested supernatants from osteoclast 
differentiation assays were analysed by ELISA for the presence of a pain mediator and 
inflammatory chemokines.  i.)  Negligible levels of NGF were reported in both m-CSF and 
RANKL cultures and those supplemented with sgp130-Fc (n=8 donors; mean plotted from 8 
replicates per donor).  ii.) and iii.) The secretion profiles of CCL2 and CCL3 from osteoclast 
cultures treated with sgp130-Fc matched that from m-CSF and RANKL cultures (n=8; mean 
plotted from 8 replicates per donor).  iv.)  The secretion of CCL5 was variable in cultures 
and although m-CSF and RANKL cultures showed elevated CCL5 levels compared to sgp130-
Fc treated, this was not significant (n=8; mean plotted from 8 replicates per donor).  Mean 
± S.E.M shown and statistical analysis was carried out using a one way ANOVA.  
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 4.3.2 Modelling IL-6/sIL-6 R joint inflammation to study osteoclastogenesis 
and bone resorption by IL-6 trans-signalling in vitro 
Human osteoclast differentiation cultures, grown under standard conditions were 
supplemented with the IL-6 trans-signalling agonist HYPER-IL-6. HYPER-IL-6 was 
used to mimic the inflammatory milieu of a diseased joint and to establish the 
direct impact of IL-6/sIL-6R upon osteoclastogenesis (TRAP), resorption of a bone 
substrate (CTX-1) and soluble mediators of pain, inflammation and osteoclast 
formation (NGF, CCL3, CCL5 and CCL2). 
 
4.3.2.1 HYPER-IL-6 (10ng/mL) reduced TRAP+ve cell and osteoclast number without 
affecting bone resorption 
Adherent cells on ivory disks were of a variable phenotype and surface coverage 
was reduced by HYPER-IL-6 (Figure 4.8). TRAP+ve cells were significantly decreased 
by HYPER-IL-6 compared with m-CSF + RANKL only cultures (141 ± 26 to 292 ± 51 
cells/disk; donors n=7,Figure 4.9, i, p≤0.05).  A 3-fold reduction in osteoclast 
number was also noted but this was not significant (donors n=7, Figure 4.9, ii).  
Although the number of bone resorbing osteoclasts were reduced, no significant 
change at day 14 to the area of bone resorbed by HYPER-IL-6 was found (donors 
n=5, Figures 4.9).   
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i.) 
 
ii.) 
 
 
Figure 4. 8 - The addition of HYPER-IL-6 (10ng/mL) to osteoclast cultures altered the 
cellular phenotype of cells adhered to disks.Disks were treated with 10ng/mL HYPER-IL-6 
for 14 days alongside those treated with m-CSF and RANKL.  i.) Representative images of 
adhered TRAP+ve mononuclear (green circle) and multinucleated osteoclasts (red circle) in 
differentiation cultures.  Resorption pits were also seen across the disks (orange circle).  ii.) 
Disks treated with 10ng/mL HYPER-IL-6 showed cells of altered phenotype, smaller size, 
and irregular shape, where fewer cells were found across the disk.  Many resorption pits 
were visible across the disk.  Scale bar equal to 50μm. 
 
  
135 
 
  
 
 
i.) 
0
200
400
600
m-CSF             (5ng/mL)
RANKL             (5ng/mL)
HYPER-IL-6   (10ng/mL)
n=7
+
+
-
+
+
+
*
TR
AP
+v
e  
ce
lls
/d
is
k
 
ii.)
0
50
100
150
m-CSF             (5ng/mL)
RANKL             (5ng/mL)
HYPER-IL-6   (10ng/mL)
n=7
+
+
-
+
+
+
n.s.
O
st
eo
cl
as
t c
ou
nt
/d
is
k
 
iii.) 
0.0
0.5
1.0
1.5
2.0
m-CSF             (5ng/mL)
RANKL             (5ng/mL)
HYPER-IL-6   (10ng/mL)
n=5
+
+
-
+
+
+
Ar
ea
 r
es
or
be
d 
(%
)
n.s.
 
Figure 4. 9 - TRAP+ve cells were significantly reduced in the presence of 10ng/mL HYPER-IL-6 but not osteoclast number.After 14 days of culture in an 
osteoclast assay ivory disks were harvested and stained for cell counts prior to cell removal enabling the quantification of area resorbed.  i.)   At 10ng/mL 
HYPER-IL-6 a significant decrease in TRAP+ve cells from m-CSF and RANKL cultures was found(donors n=7; mean plotted from 8 replicates per donor).  ii.)  
Osteoclast number remained unchanged with 10ng/mL HYPER-IL-6(donors n=7; mean plotted from 8 replicates per donor).  iii.)  Total area resorbed was 
comparable in m-CSF and RANKL cultures ± sgp130-Fc (data plotted from n=5 donors; mean represents 8 replicate disks).  Mean ± S.E.M shown and 
statistical analysis was carried out using the Student's t-test (*p≤0.05).  
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 4.3.2.2 Concentration dependent osteoclast differentiation and bone resorption by 
HYPER-IL-6 
The concentration dependent differentiation of CD14+ve cells by HYPER-IL-6 
(0.5ng/mL to 5ng/mL) in m-CSF + RANKL cultures was tested to further explain the 
lack of increase in osteoclast number in the presence of 10ng/mL HYPER-IL-6 
despite the significant increase in TRAP+ve cells (Figure 4.8 and 4.9).The 
concentration range was tested on cells harvested from n=1 donor, where 4 disks 
per concentration were assessed.  TRAP+ve cell numbers were highest on disks 
cultured in medium supplemented with 0.5ng/mL HYPER-IL-6 (1098 ± 346) versus 
m-CSF + RANKL cultures (380 ± 63, Figure 4.10 and 4.11).  Osteoclast number was 
increased 3-fold by supplementing differentiation medium containing m-CSF + 
RANKL with HYPER-IL-6 (0.5ng/mL); osteoclast/disk= 245 ± 58 versus 74 ± 18 (Figure 
4.11).  The area of bone resorbed by osteoclasts was increased by HYPER-IL-6 
(0.5ng/mL) in m-CSF + RANKL cultures; the percentage of the disk resorbed was 8.6 
± 2.3 versus 1.0 ± 0.2 (2 disks were assessed per concentration from n=1 donor, 
Figure 4.11).   
 
4.3.2.3 HYPER-IL-6 increased bone resorption without affecting TRAP+ve or 
osteoclast counts 
Subsequent assays (n=8 donors) were conducted in medium containing m-CSF + 
RANKL ± HYPER-IL-6 (0.5ng/mL) for a total of 14 days (Figure 4.12).  Total cell count 
was reduced by HYPER-IL-6, from 4172 ± 1187 to 2284 ± 484 cells/disk; but this was 
not significant (Figure 4.13).  TRAP+ve cell and osteoclast counts were reduced by 
HYPER-IL-6;although again not significantly (Figure 4.13).  Bone resorption was 
quantified as a functional measure for osteoclasts, where the area of each disk 
resorbed was significantly increased by HYPER-IL-6 (6.91 ± 1.77 versus 2.54 ± 0.70% 
for m-CSF + RANKL); see Figure 4.13 (p≤0.05). 
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 i.) 
 
ii.) 
 
iii.) 
 
iv.) 
 
v.) 
 
vi.) 
 
Figure 4. 10 - Representative day 14 images from osteoclast differentiation assays 
supplemented with HYPER-IL-6..  Over 14 days osteoclast assays were treated with   a 
range of HYPER-IL-6.  i.)  In m-CSF and RANKL cultures TRAP+ve mononuclear (green circles) 
and multinuclear cells (red circles) were adhered to ivory disks, in addition to multiple 
resorption pits.  ii.) At 0.5ng/mL HYPER-IL-6, TRAP+ve cells and resorption pits appeared 
increased compared to (i).  iii.)  In the presence of 1ng/mL HYPER-IL-6 TRAP+ve cells were 
reduced from (i) with fewer resorption pits.  iv.)  At 2.5ng/mL HYPER-IL-6 cell number 
appeared reduced but TRAP+ve cells and resorption pits were present compared to (i).  v.)  
In the presence of 5ng/mL HYPER-IL-6 TRAP+ve multinuclear cell number was reduced from 
(i).  vi.) In m-CSF only cultures no TRAP+ve cells were found.  (Scale bar 50µm). 
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Figure 4. 11 - HYPER-IL-6 at 0.5ng/mL increased TRAP+ve cell number, osteoclast count and 
total area resorbed.Harvested disks treated with a range of HYPER-IL-6 concentrations 
were stained and cell counts completed at day 14.  i.)  TRAP+ve cell count peaked at 
0.5ng/mL HYPER-IL-6 in osteoclast differentiation cultures.  HYPER-IL-6 at 1ng/mL to 
5ng/mL showed comparable TRAP+ve cell numbers to differentiation cultures.  ii.)  
Osteoclast number was found also to peak at 0.5ng/mL HYPER-IL-6, but osteoclastogenesis 
was still elevated in 1ng/mL-5ng/mL HYPER-IL-6 when compared to differentiation cultures.  
iii.)  A substantial increase in area resorbed was shown in the presence of 0.5ng/mL HYPER-
IL-6 when compared to differentiation cultures alone.  Resorption in 1ng/mL- 5ng/mL 
HYPER-IL-6 was comparable to differentiation cultures.  N=1 donor; 4 disks were assessed 
at each concentration from this one donor. No statistics carried out due to limited sample 
number.  Data was reported as mean ± S.E.M. 
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i.) 
 
ii.) 
 
 
Figure 4. 12 - Cultures treated with 0.5ng/mL HYPER-IL-6 showed reduced TRAP+ve cell 
numbers but increased bone resorption.The optimal dose of 0.5ng/mL HYPER-IL-6 was 
previously established and used over a 14 day culture period in the human osteoclast 
differentiation assay in n=8 donors (4 replicate disks were analysed for each donor at each 
time-point).  i.)  Many TRAP+ve mononuclear (green circles) and multinuclear cells (red 
circles) were found adhered to the ivory disks at day 14 in m-CSF and RANKL cultures.  ii.)  
Through the addition of 0.5ng/mL HYPER-IL-6, a reduction in TRAP+ve cells were noted but 
substantial resorption pit formation across the disk was evident.  (Scale bar 100um). 
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v.) 
 
vi.) 
 
Figure 4. 13 - HYPER-IL-6 cultures showed no significant change in total cells, TRAP+ve cells 
or osteoclast number, but area resorbed significantly increased at day 14.Cell counts and 
area resorbed were quantified from harvested disks.  i., ii. and iii.) No significant change in 
total cell number, TRAP+ve cell, or osteoclast number resulted from HYPER-IL-6 
supplementation(n=4 donors (total cell count) and n=8 donors (TRAP and osteoclast); mean 
of 4 replicate disks per donor plotted).  iv.)  A significant increase in area resorbed resulted 
fromHYPER-IL-6 supplementation in m-CSF and RANKL cultures(n=8 donors; mean of 4 
replicate disks plotted, p≤0.05).  v.) Resorption pits in m-CSF and RANKL cultures reduced 
compared to HYPER-IL-6 cultures (vi.) where extensive resorption was shown.  Mean ± 
S.E.M. shown and Student's t-test was performed (*p≤0.05).Scale bar 50μm.  
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 4.3.2.4 HYPER-IL-6 increased resorption pit depth but not pit area 
HYPER-IL-6 significantly enhanced bone resorption by osteoclasts. The impact of 
HYPER-IL-6 upon individual osteoclasts was next assessed by analysing individual pit 
parameters (area, depth and volume) using high resolution confocal microscopy. 
Disks from one representative assay were imaged (m-CSF + RANKL versus m-CSF + 
RANKL + HYPER-IL-6).  The surface area measurement for pits was comparable for 
m-CSF + RANKL (2518 ± 353.4 µm2) versus m-CSF + RANKL +HYPER-IL-6 cultures 
(2148 ± 370.2 µm2; Figure 4.14).  Pit volume was increased by HYPER-IL-6 (1196 ± 
257.4 versus 851.6 ± 212.6 µm3 for M-CSF + RANKL; Figure 4.14) but not 
significantly.  Pit depth was increased on disks from HYPER-IL-6 (12.32 ± 1.5 µm) 
versus m-CSF + RANKL cultures (6.304 ± 0.5µm; p≤0.001; Figure 4.14). 
 
4.3.2.5 TRAP5b levels unaffected by HYPER-IL-6 but CTX-1 levels increased 
TRAP5b was quantified on day 7 and 10 of the osteoclastogenesis assay.  There was 
no significant difference in TRAP5b levels when m-CSF + RANKL ± HYPER-IL-6 were 
compared.  CTX-1 was significantly increased by HYPER-IL-6 on day 7 (Figure 4.15, 
p≤0.05), but not on day 10 when compared to m-CSF and RANKL cultures. 
 
4.3.2.6 CCL2, CCL3 and CCL5 secretion was not altered by HYPER-IL-6 in vitro 
Supernatants from osteoclast cultures containing M-CSF + RANKL ± HYPER-IL-6 
were replenished every 3-4 days.  No NGF was detected in any of the supernatants 
collected over the 14 day time-course (data not presented).  CCL2 and CCL3 
production was unaffected by the inclusion of HYPER-IL-6 in the differentiation 
medium (Figure 4.16).  CCL5 levels were low and highly variable (Figure 4.16).   
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Figure 4. 14 - HYPER-IL-6 substantially increased resorption pit depth.  3-D data stacks were obtained using confocal microscopy for n=73 pits from 1 donor 
under m-CSF and RANKL cultures ± HYPER-IL-6.  i.)  m-CSF only cultures lacked resorption pits.  ii.)  In m-CSF and RANKL cultures multiple resorption pits 
with varying depths were seen compared to HYPER-IL-6 cultures (iii) with smaller pits and increased depth. iv. and v.)  Surface area and pit volume did not 
significantly change.vi.)  HYPER-IL-6 caused a significant increase in pit depth (p≤0.001).  0.27µm = 1 pixel.  Statistics were carried out using a Student's t-
test.  
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Figure 4. 15 - HYPER-IL-6 caused the significant early increase in CTX-1 levels at day 7..  
Supernatants harvested from osteoclast differentiation assays were assessed for the 
presence of TRAP5b and CTX-1.  i.)  TRAP5b levels at day 7 and day 10 were not significantly 
changed in the presence of HYPER-IL-6 when compared to m-CSF and RANKL cultures. ii.)  A 
significant early increase in CTX-1 levels was found at day 7 (p≤0.05), being indicative of the 
early activation of osteoclast resorptive activity in the presence of 0.5ng/mL HYPER-IL-6.  At 
the later time-point of day 10 this increase was no longer significant.  N=8 donors; mean 
plotted from 4 replicate disks per donor.  Mean ± S.E.M. shown and statistical analysis 
carried out using Student's t-test (*p≤0.05). 
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Figure 4. 16 - HYPER-IL-6 had no effect on the direct secretion of CCL2, CCL3 or CCL5 from 
the osteoclast..  The analysis of osteoclast assay supernatants by ELISA was carried out 
across the 14 day time-course.  i.) and ii.) Both CCL2 and CCL3 secretion profiles were 
comparable in cultures treated with 0.5ng/mL HYPER-IL-6 and differentiation medium 
alone(mean plotted from n=8 donors per time-point; 4 replicate disks per donor were 
cultured).  iii.)   CCL5 levels were increased across the time-course in HYPER-IL-6 treated 
cultures compared to differentiation medium only, but this increase was variable and not 
significant(mean plotted from n=8 donors per time-point; 4 replicate disks per donor were 
cultured).  Data reported at mean ± S.E.M. from n=8 donors per time-point (4 replicate 
disks per donor at each time-point).  Statistical analysis was completed using a one way 
ANOVA. 
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 4.3.3 Assessing the potential therapeutic benefit of blocking IL-6/sIL-6R 
signalling on bone in vitro 
The potential therapeutic benefit of specific blockade of IL-6 trans-signalling on 
bone resorption was measured in vitro. HYPER-IL-6 was used as an agonist of 
osteoclastogenesis whilst sgp130-Fc was used to block IL-6 trans-signalling. Soluble 
markers of osteoclast differentiation (TRAP5b), resorption (CTX-1), pain and 
inflammation (NGF, CCL2, CCL3 and CCL5) were measured by ELISA. 
 
4.3.3.1 The inhibition of HYPER-IL-6 induced bone resorption and soluble markers 
of osteoclast differentiation and resorption by sgp130-Fc 
HYPER-IL-6 (0.5ng/mL) containing osteoclast cultures were treated with sgp130-Fc 
(500ng/mL) and both consequential osteoclast differentiation and bone resorption 
data were quantified in vitro. The number of TRAP+ve cells and osteoclasts (per disk) 
were comparable on disks from m-CSF + RANKL ± sgp130-Fc + HYPER-IL-6 (n=6 
donors, Figures 4.17 and 4.18).  However significant reductions in HYPER-IL-6-
induced bone resorption by sgp130-Fc was noted (Figure 4.18, p≤0.05).   
Sgp130-Fc addition to m-CSF + RANKL + HYPER-IL-6 cultures had no effect on 
TRAP5b or CTX-1 levels being comparable to m-CSF + RANKL cultures at both day 7 
and day 10 (n=4 donors, Figure 4.19).  NGF was not present in m-CSF + RANKL ± 
HYPER-IL-6 + sgp130-Fc cultures (data not shown).  CCL2 was maintained at similar 
levels in all cultures until day 14, where a significant increase from 4.39 ± 0.76 to 
12.49 ± 0.38ng/mL was found in cultures supplemented with m-CSF + RANKL ± 
HYPER-IL-6 + sgp130-Fc (p≤0.001; n=4 donors, Figure 4.20).  CCL3 and CCL5 
remained unchanged by the addition of m-CSF + RANKL ± HYPER-IL-6 + sgp130-Fc 
compared to m-CSF + RANKL cultures (n=4 donors, Figure 4.20).       
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i.) 
 
ii.) 
 
Figure 4. 17 - Supplementation of sgp130-Fc and HYPER-IL-6 into osteoclast cultures 
yielded comparable osteoclast numbers to differentiation cultures..  The addition of both 
sgp130-Fc and HYPER-IL-6 into osteoclast differentiation assays was carried out throughout 
the 14-day time-course.  i.)  Multiple TRAP+ve multinucleated osteoclasts(red circles) were 
found in differentiation cultures alongside the formation of many resorption pits (orange 
circles).  ii.)  In the presence of sgp130-Fc and HYPER-IL-6, TRAP+ve multinucleated cells and 
resorption pit number were comparable to those of differentiation cultures. (Scale bar 
100um). 
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Figure 4. 18 - Sgp130-Fc and HYPER-IL-6 had no effect on TRAP+ve or osteoclast number, but do significantly reduce resorption area..  Cell counts 
completed at day 14alongside area resorbed quantification.  i.) and ii.) No significant change in TRAP+ve cell or osteoclast count was found between m-CSF 
and RANKL ± sgp130-Fc + HYPER-IL-6.  iii.) sgp130-Fc and HYPER-IL-6 supplemented cultures did however show a significant reduction in area resorbed 
(p≤0.05).  iv. and v.) Representative images of resorption pits from m-CSF and RANKL ± sgp130-Fc + HYPER-IL-6 cultures.  N=6 donors; 4 replicate disks per 
donor, mean plotted.  Mean ± S.E.M. shown.  Student's t-test performed (*p≤0.05).  Scale bar 50μm.  
i.) 
0
500
1000
1500
2000
m-CSF             (5ng/mL)
RANKL             (5ng/mL)
HYPER-IL-6   (0.5ng/mL)
n=6
+
+
+
+
+
-
+-sgp130-Fc    (500ng/mL)
n.s.
TR
AP
+v
e  c
el
ls
/d
is
k
 
ii.) 
0
200
400
600
800
1000
+
+
+
+
+
-
+-
n.s.
O
st
eo
cl
as
t c
ou
nt
/d
is
k
 
iii.) 
0.00
0.02
0.04
0.06
0.08
+
+
+
+
+
-
+-
*
Ar
ea
 re
so
rb
ed
 (%
)
 
iv.) 
 
v.) 
 
148 
 
  
 
i.) 
0
1
2
3
4
m-CSF             (5ng/mL)
RANKL             (5ng/mL)
HYPER-IL-6   (0.5ng/mL)
n=4
+
+
+
+
+
+
+
+
-
+
+
-
Day 7 Day 10
++- -sgp130-Fc    (500ng/mL)
n.s.
n.s.
TR
AP
5b
 (U
/L
)
 
ii.) 
0.0
0.1
0.2
0.3
0.4
m-CSF             (5ng/mL)
RANKL             (5ng/mL)
HYPER-IL-6   (0.5ng/mL)
n=4
+
+
+
+
+
+
+
+
-
+
+
-
Day 7 Day 10
++- -sgp130-Fc    (500ng/mL)
n.s.
n.s.
C
TX
-1
 (n
g/
m
L)
 
Figure 4. 19 - No significant changes in TRAP5b or CTX-1 were found in the supernatants 
of sgp130-Fc and HYPER-IL-6 supplemented cultures..  To help establish the effect of 
sgp130-FC and HYPER-IL-6 in combination on osteoclast differentiation and activity soluble 
levels of CTX-1 and TRAP5b were measured in harvested supernatants.  i.)  No significant 
change in TRAP5b levels over days 7 and 10 was noted either, suggested that osteoclast 
differentiation was not altered through the addition of sgp130-Fc and HYPER-IL-6.  ii.)  No 
significant change in CTX-1 levels were noted on day 7 or day 10, suggesting the degree of 
resorption in each of these cultures were comparable.  N=4 donors; mean plotted from 4 
replicate disks per donor.  Mean ± S.E.M. shown and statistics were carried out using the 
Student's t-test. 
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Figure 4. 20 - Supplementation of sgp13-Fc and HYPER-IL-6 into osteoclast differentiation 
cultures significantly increased CCL2 levels at day 14..  Following on from soluble markers 
of resorption and differentiation, the secretion of several chemokines were assessed in 
supernatants from n=6 donors where 4 replicate disks per donor were assessed.  i.)  
Overall, no significant change in the secretion of CCL2 across the time-course was noted, 
but a significant increase was noted at day 14 in sgp130-Fc and HYPER-IL-6 treated cultures 
compared to differentiation medium cultures (p≤0.001).  ii.) and iii.) The secretion profiles 
of CCL3 and CCL5 were comparable in sgp130-Fc and HYPER-IL-6 treated cultures when 
compared to differentiation cultures.  Results were reported as mean ± S.E.M., where the 
mean from n=4 donors per time-point was plotted.  Statistical analysis was performed 
using a one way ANOVA (all graphs) and a Student's t-test (concentrations at day 14 for 
CCL2; ***p≤0.001).  
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 4.4 Discussion 
An indirect relationship between IL-6 trans-signalling and increased 
osteoclastogenesis was first reported in 1993 by Tamura et al. but since has been 
reported in multiple cell systems through supplementation of IL-6 and sIL-6R into 
co-cultures of osteoblasts or bone marrow cells (Tamura et al. 1993, Heinrich et al. 
1998, Palmqvist et al. 2002).  The increased osteoclastogenesis resulted from IL-6 
stimulated osteoblasts and T cells which secreted RANKL, thus indirectly increasing 
osteoclast differentiation (Soysa et al. 2012).  The role of IL-6 trans-signalling in the 
process of osteoclastogenesis was further verified by the essential presence of both 
IL-6 and sIL-6R into cultures, and through the addition of anti-sIL-6R which reduced 
'osteoclast-like multinucleated cells' (Tamura et al. 1993).  Supporting this for the 
first time a direct link between IL-6 trans-signalling and osteoclastogenesis in m-CSF 
and RANKL supplemented CD14+vemonocultures was identified in this chapter. 
In our monocultures a basal level of IL-6 (Chapter 3, Section 3.3.11.1) was 
quantified in supernatants postulating a role of IL-6 signalling in osteoclastogenesis.  
Due to the clinical significance of increased IL-6 and its soluble receptor in 
destructive bone diseases (Houssiau et al. 1988, Kyrtsonis et al. 1996, Keul et al. 
1998), and the debated existence of membrane bound IL-6R on the osteoclast (Gao 
et al. 1998), IL-6 trans-signalling was focussed upon.  The inhibition of IL-6 trans-
signalling, via addition of sgp130-Fc, resulted in a significant decrease in TRAP+ve cell 
number, osteoclasts and area resorbed.  It was concluded that in our culture system 
IL-6 trans-signalling exerted a role in homeostatic osteoclastogenesis.  Following 
this, a pathological role of increased IL-6 trans-signalling in osteoclastogenesis was 
investigated, mimicking the clinical aetiology of elevated IL-6 and sIL-6R in 
destructive bone diseases.  The fusion protein HYPER-IL-6 was used initially at 
10ng/mL, which induced a significant reduction in TRAP+ve cells yet comparable 
levels of resorption were reported after 14 days of culture.  Such contradicting 
results suggested 10ng/mL HYPER-IL-6 stimulated the earlier differentiation of 
mononuclear cells into mature osteoclasts.  If this were the case then it is 
conceivable that by day 14 TRAP+ve cells had lost adherence to the bone substrate, 
and only the eroded bone surface remained.  This hypothesis may be tested by 
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 obtaining cell counts every 3 days to establish whether HYPER-IL-6 had a 
stimulatory effect on osteoclast differentiation at 10ng/mL.  Furthermore, to 
examine whether 10ng/ml HYPER-IL-6 was toxic to cultured cells, apoptotic cells 
could be quantified across the time-course using a TUNEL assay.  Alternatively, a 
dose response relationship for HYPER-IL-6 could be examined by supplementing 
varying lower concentrations of HYPER-IL-6 into assays to prolong the life span of 
the differentiating cells. This was next tested. 
A range of 0.5 - 5ng/mL HYPER-IL-6 was supplemented into disks cultured in m-CSF 
and RANKL (n=1 donor). This process provided preliminary data, which indicated 
0.5ng/mL HYPER-IL-6 as the optimal concentration to carry out analysis at day 14; 
increased TRAP+ve cells, osteoclasts and resorption at day 14.  Further supporting 
the selection of 0.5ng/mL HYPER-IL-6 the observed increased levels of TRAP5b and 
CTX-1 in harvested supernatants (day 7), suggested HYPER-IL-6 mediated an early 
increase in osteoclast differentiation. 
From such preliminary data, 0.5ng/mL HYPER-IL-6 was taken forward for the true 
assessment of HYPER-IL-6 on osteoclastogenesis on a larger sample size (n=8 
donors).  Total cell count at day 14 was substantially attenuated in HYPER-IL-6 
supplemented cultures when compared to m-CSF and RANKL alone, although this 
was not significant.  A comparable number of TRAP+ve cells and osteoclasts were 
also quantified in both HYPER-IL-6 supplemented cultures and m-CSF and RANKL.  
However, HYPER-IL-6 induced a significant increase in the area of bone surface 
resorbed compared to m-CSF and RANKL cultures.  Such data suggested an early 
role of HYPER-IL-6 in functional resorptive activity of the osteoclast.  The 
quantification of CTX-1 also supported this suggestion where significantly increased 
levels were found at day 7 in HYPER-IL-6 supplemented m-CSF and RANKL cultures 
compared to m-CSF and RANKL alone, but were comparable at day 10.  Collectively, 
the data described above indicates a role for HYPER-IL-6 in stimulating early 
osteoclast differentiation when compared to our control m-CSF and RANKL 
cultures.  
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 Although the direct mechanisms behind the early increase in osteoclastogenesis 
was not established, several theories can be postulated when in context with 
previous publications.  These theories span several stages of osteoclastogenesis 
including precursor cell proliferation, precursor cell migration, precursor cell fusion, 
TRAP+ve cell adherence, the secretion of degradative products, osteoclast motility 
and osteoclast survival, and will be discussed next (outlined in Figure 21). 
 
 
Figure 4. 21 - Postulated roles of IL-6 trans-signalling in early osteoclastogenesis.The 
combination of data presented in this thesis and that previously published has led to a 
number of postulated stages during osteoclast differentiation that IL-6/sIL-6R could 
influence.  The following stages could be effected by IL-6 trans-signalling and the effective 
mediator is hypothesised in italics in the diagram; Stage 1 - mononuclear cell proliferation, 
Stage 2- mononuclear migration due to chemotaxis, Stage 3 - TRAP+ve mononuclear cell 
fusion, Stage 4 - multinucleated TRAP+ve cell adherence to bone. 
 
The initial increase of osteoclastogenesis within our monocultures may have 
resulted from an increase in precursor cell proliferation and migration.  In a study 
by Jougasaki et al. 2010, monocytes treated with IL-6 and sIL-6R showed enhanced 
cell movement, thus directly linking IL-6 trans-signalling to precursor cell migration.  
Further supporting this theory, gp130 was identified to have a role in monocyte 
migration, therefore linking this receptor to osteoclast precursors (Johnson et al. 
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 2014).  IL-6 trans-signalling could therefore have enabled the migration of 
osteoclast precursors, aiding them in creating cell-cell contact needed for cell 
fusion.  Further experimental work assessing the migratory activity of the cells 
would be needed to distinguish whether IL-6 trans-signalling plays a role in 
osteoclast precursor proliferation and migration.  Such work could include 
fluorescently tagging phalloidin in the cell and tracking the re-organisation and 
polymerisation of F-actin via confocal microscopy; especially over the first 72 hours 
(methodology utilised by Campos et al. 2009).  Within this methodology an 
increased polymerisation would indicate enhanced cell migration, and therefore a 
greater chance of cell fusion. 
 
Following this, an early increased chance of cell fusion may also have resulted in the 
decreased TRAP+ve cell number seen at day 14.  The fusion proteins dendritic cell-
specific transmembrane protein (DC-STAMP), integrins and Atp6v0d2 are the most 
common in osteoclast differentiation (Kim et al. 2008, Miyamoto 2011, Oikawa et 
al. 2012, Soysa et al. 2012, Islam et al. 2014, Witwicka et al. 2015).  If IL-6 trans-
signalling stimulated the early increase of these proteins, an increase in precursor 
cell fusion may have occurred.  As illustrated in Section 4.2.2.3, there was no 
significant increase in TRAP+ve cell count, an early shift in peak TRAP+ve cell number 
could have been seen, which by day 14 had decreased to non-significant levels due 
to the limited precursor pool.  Although no current research has investigated a 
relationship between IL-6 trans-signalling and the expression of fusion proteins, 
there have been reports of the effect of IL-6 alone.  Sanecka et al. (2011) reported 
IL-6 secretion to be reduced from murine DC-STAMP-/- dendritic cells, therefore 
implying a role of DC-STAMP in IL-6 secretion.  The relevance of this relationship is 
however questionable in relation to the osteoclast as dendritic cells express IL-6Rα; 
therefore observed effects may have resulted from classical and not trans-signalling 
(Park et al. 2004).  Following this, IL-6 was reported to have no impact on DC-
STAMP or Atp6v0d2 expression in osteoclast precursor cultures (Teramachi et al. 
2014).  Again, such negligible effects could be a direct result of sIL-6R being absent, 
limiting signalling to the classical IL-6 pathway and not trans-signalling.  Overall, 
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 further experimental work is essential to identifying and understanding the role of 
IL-6 trans-signalling in the expression of fusion proteins. 
 
Subsequent to cell fusion resulting in multinucleated TRAP+ve cells, IL-6 trans-
signalling could have also exerted a stimulatory effect on cell adherence to the 
bone substrate.  This was highlighted by Gado and colleagues (2000) who reported 
a role of IL-6/sIL-6R in the elevated expression of adhesion proteins on the surface 
of bone marrow mononuclear cells in MM.  IL-6 trans-signalling could therefore 
have increased the number of precursor cells capable of adherence to the bone 
substrate, and thus, impacted on osteoclast differentiation and fusion.  Additional 
to this, IL-6 and sIL-6R secretions from apoptotic osteocytes are known to increase 
ICAM-1 resulting in increased osteoclast precursor recruitment, attachment and 
osteoclastogenesis (Cheung et al. 2012).  Furthermore, a link between IL-6 and 
αvβ3was also previously reported (Antonov et al. 2011), but it was thought that the 
αvβ3 stimulation caused NF-κβ signalling and which increased IL-6 secretion, and not 
vice versa.  To determine the effect of IL-6 trans-signalling on the expression of 
attachment proteins their gene or protein expression could be quantified between 
day 0-7 of osteoclast differentiation within m-CSF and RANKL cultures 
supplemented with and without HYPER-IL-6.   
The discussion points above yield speculation as to why the TRAP+ve cell count in 
sgp130-Fc supplemented cultures significantly reduced.  It is believed that the 
above points are more critical to IL-6/sIL-6R associated osteoclast differentiation, 
rather than mature osteoclast activity, due to representative images showing a 
significant lack of TRAP+ve osteoclasts in sgp130-Fc cultures, suggesting sgp130-Fc 
inhibited osteoclastogenesis early on, and conversely HYPER-IL-6 stimulated the 
early differentiation of osteoclasts.   
The significant increase in area resorbed could have resulted from two possible 
pathways.  Firstly, IL-6 trans-signalling could have increased the number of 
differentiating osteoclasts due to increased precursor cell proliferation, migration 
and fusion, as discussed above. Collectively, these changes would result in an 
increased resorption, and/or IL-6 trans-signalling stimulated motility and survival of 
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 mature osteoclasts, where a single osteoclast exerted a stronger resorptive 
phenotype.  In vivo data has previously suggested a role for IL-6 in mature 
osteoclast motility, where in IL-6-/- mice the osteoclast motility was significantly 
reduced in joints subjected to antigen-induced arthritis (Wong et al. 2006).  
However, a definition between IL-6 classical and IL-6 trans-signalling was not made. 
Following general osteoclast motility, a role of IL-6 trans-signalling on the secretion 
of resorptive enzymes from the osteoclast could also be postulated.  Supporting 
this hypothesis is our finding that HYPER-IL-6 caused a significant increase in pit 
depth (compared to m-CSF and RANKL cultures), but had no effect on pit surface 
area or volume.  As no increase in individual pit area was found, it is unlikely that IL-
6/sIL-6R caused an increase in osteoclast cell size, and therefore had no further role 
in precursor cell fusion for giant multinucleated cells.  The interpretation of pit 
depth data does exhibit one major limitation however; all data was obtained from 
one donor where multiple pits under each treatment condition were quantified.  
Increased sample number is therefore pivotal for reproducibility and reliability of 
this data to be proven and would need to be completed in future experiments (N.B. 
sample number was restricted due to time restraints).  Despite this, preliminary 
data shows for the first time that IL-6/sIL-6R is linked to a significant increase in pit 
depth.  Translationally, this data could have large diagnostic benefit, especially in 
patients with elevated IL-6 and/or sIL-6R, potentially allowing the classification of 
their disease phenotype (further discussed in Chapter 6).  Furthermore, IL-6 trans-
signalling has also been reported to attenuate new bone formation via a down-
regulation of osteoblast activity and a decrease in secretion of OPG thus 
heightening bone destruction (Gado et al. 2000). 
To our knowledge this is the first reported data of IL-6 trans-signalling significantly 
increasing resorption pit depth in a monoculture system, and suggests IL-6 trans-
signalling to stimulate the enhanced secretion of degradative enzymes.  In 
monocultures, no published data currently exists to identify IL-6 trans-signalling 
stimulating the secretion of resorptive enzymes (CATK, TRAP, MMP-2, -3, -9 and -
13etc.) from the osteoclast, therefore making this a distinct area of research for the 
future.  Interestingly, an association between CATK and IL-6 mRNA has been 
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 reported due to the discovery that a response sequence to IL-6 fell within the 5’-
untranslated region of CATK, and this was also true for TRAP, and once activated 
stimulates their secretion (Reddy et al. 1995, Rood et al. 1997, Li and Chen 1999, 
Podgorski et al. 2009).  However, a recent report indicated a significant decrease in 
IL-6 secretion due to CATK inhibition, therefore suggesting IL-6 was resultant of 
CATK expression, and not vice versa (Hussein et al. 2016).  Controversially, data 
reported from murine co-cultures showed unchanging CATK mRNA expression in 
the presence of IL-6, although cultures may have lacked sIL-6R preventing IL-6 
trans-signalling (Kamolmatyakul et al. 2001). 
IL-6 and sIL-6R have also been reported to induce the secretion of TRAP5b 
Hashizume et al. (2008) also reported IL-6 and sIL-6R to induce TRAP5b secretion, 
which could again have led to increased osteoclast differentiation.  A controversial 
role of IL-6 also exists for MMP secretion, where it’s been suggested to stimulate 
secretion of MMPs -1, -2, -3, -9 and -13 MMPs from synovial cells or murine 
calvarial cultures (Kusano et al. 1998, Hashizume and Mihara 2009, Suzuki et al. 
2010).  Such a mechanism could be explained by the individual actions of IL-6 
classical signalling versus trans-signalling, but this is not well characterised and 
needs further investigation.  As the specific pathway of IL-6 signalling was not 
confirmed in these experiments, inference of data is completed with caution.  
However, in murine calvarial cultures IL-6/sIL-6R complex enhanced MMP-2, -3, -9 
and -13 secretion, showing direct relation to IL-6 trans-signalling, but the origin of 
secretion was unknown due to the use of co-cultures (Kusano et al. 1998).  
Furthermore, IL-6 trans-signalling was reported to increase RANKL signalling and 
therefore enhance MMP9 secretion from osteoclasts, thus, providing a direct link to 
IL-6 trans-signalling and osteoclast activity (Sundaram et al. 2007).  To fully 
establish the effects of IL-6 trans-signalling on the resorptive enzyme secretion 
from the osteoclast an extensive amount of research needs to be completed 
including methodologies such as ELISAs (CTX-1), zymograms (MMPs), histological 
staining (of MMPs, TRAP) and protein quantification.  Following this, knock-out 
models of enzymes (both in vitro and in vivo) found to be associated with IL-6 trans-
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 signalling in osteoclast cultures could be used to further define its role in direct 
osteoclast-mediated bone destruction. 
An explanation for the observed increased in resorbed area can therefore be 
postulated from the results reported in this Chapter and from previous 
publications.  However, what is still unknown is why a general decrease in TRAP+ve 
cell number resulted.  It was reported that the downstream activation of 
phophoinositide-3 (PI3K) from IL-6 trans-signalling is an important anti-apoptotic 
mediator through phosphorylating B cell leukemia-2 (Bcl-2) and Bcl-2 associated 
death promoter (BAD), preventing their association  (Heinrich et al.  1998, Hirano et 
al. 2000).  Such a mechanism would therefore prolong cell survival, thus directly 
linking to IL-6 trans-signalling.  However, as the osteoclasts primary function is to 
resorb bone, once its purpose has been fulfilled cell death may occur.  For this 
reason it could be suggested that TRAP+ve cell number decreased at day 14 in 
HYPER-IL-6 cultures due to their extensive stimulation in the early stages of the 
osteoclast assay (day 1-7).  By day 14 osteoclasts have lost adherence and 
senescence associated secretory phenotype (SASP) may have been activated 
following STAT1/STAT3 and p53 interaction (downstream of IL-6 trans-signalling; 
Kojima et al. 2013), meaning only resorption sites remain.  Supporting this theory in 
our culture system supplemented with sgp130-Fc, the downstream activation of 
phophoinositide-3 (PI3K) from IL-6 trans-signalling would have been attenuated and 
cellular apoptosis would have increased.  To prove such a theory the quantification 
of anti-apoptotic protein secretion from the osteoclast (RT-PCR) or a TUNEL assay 
would identify the importance of IL-6/sIL-6R in osteoclast apoptosis.  TRAP+ve cell 
visualisation pre-day 14 (i.e. day 7) may reveal the optimal time-point of assay 
termination. 
Data reported from cultures supplemented with HYPER-IL-6 or sgp130-Fc 
highlighted the importance of IL-6 trans-signalling in osteoclast formation and 
osteoclast-mediated bone destruction.  Importantly, the supplementation of 
sgp130-Fc or HYPER-IL-6 into monocultures at day 0 was suggested as the rate-
determining step of osteoclastogenesis (Figure 4.22). 
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  Day 0 Day 1 Day 3 Day 7 Day 10 Day 14 m-CSF + RANKL Precursor proliferation & migration Precursor differentiation Osteoclast maturation and resorption m-CSF + RANKL + HYPER-IL-6 
Precursor proliferation & migration Precursor cell differentiation Osteoclast maturation and resorption 
Loss of substrate adherence 
Figure 4. 22 - An illustration of the postulated shift exerted by HYPER-IL-6.. The addition of HYPER-IL-6 is thought to have stimulated an increase in 
osteoclast precursor cell proliferation, migration and differentiation within the first days of culture in the presence of RANKL.  Subsequently peak osteoclast 
numbers were hypothesised to have occurred around day 7, where simultaneous increases in bone resorption and pit depth would have occurred (day 7 to 
10).  Following extensive resorption, mature osteoclasts are postulated to have lost adherence to the bone substrate, and therefore account for the 
decreased osteoclast number at day 14.    
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 4.4.1 The effect of IL-6 trans-signalling on the secretion of chemotactic 
proteins 
In addition to the proposed effects of IL-6 trans-signalling on osteoclastogenesis, it 
is thought that IL-6/sIL-6R may also affect the release of chemotactic proteins from 
differentiating cells and/or mature osteoclasts.  The release of such chemotactic 
factors could thus exert additional effects on osteoclast differentiation/resorption 
and co-localised cells.  Reported here, IL-6 concentration/cell increased over 14 
days and could therefore suggest self-amplification (Chapter 3, Section 3.3.11.1).  
Similarly, an increase in gp130 transcription and cellular expression was reported in 
smooth muscle cells when stimulated through IL-6 trans-signalling (Klouche et al. 
1999), and it could be postulated that the same occurs in osteoclastogenesis.  In 
vivo the hypothesised existence of an IL-6 trans-signalling induced amplification 
loop would result in severe bone destruction (i.e. the presence of such an 
amplification loop has been reported in smooth muscle cells by Klouche et al. 
1999).  In contrast, in vitro, the limited number of osteoclast pre-cursors  would 
mean a decrease in TRAP+ve cell count  would be observed despite the observed 
increase in bone area resorption, thus mimicking the results observed in this 
chapter. 
This chapter demonstrates that both CCL2 and CCL3 secretion in osteoclast 
differentiation cultures were independent of IL-6 trans-signalling.  This finding 
opposed that previously reported by Hu and colleagues (2008), who identified IL-
6enhanced CCL2 secretion and stimulated in vitro monocyte migration.  Similarly, 
and in contrast to the findings of this thesis, IL-6 and sIL-6R secretion from coronary 
obstructive pulmonary disease (COPD) patients was shown to significantly correlate 
to increased CCL3 (Ravi et al. 2014).  However, the use of co-cultures within the 
previously published studies and pure cultures in this thesis may account for the 
observed differences in IL-6 mediated CCL2 and CCL3 secretion.  Therefore, the data 
described within this chapter furthers knowledge in the field by showing elevated 
CCL2 and CCL3 secretion induced by IL-6 trans-signalling was not of osteoclast 
origin, and nor does it aid monocyte migration.  The effects reported from these 
previous studies are therefore independent of IL-6 trans-signalling in the osteoclast 
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 assay.  However, it is likely that they have synergistic relationships in inflammation 
and leukocyte recruitment in vivo.  Further experiments defining the role of CCL3 in 
osteoclastogenesis will be extensively reported in Chapter 5. 
 
4.4.2 IL-6 as a pain mediator in pathological bone destruction 
In addition to the postulated role of IL-6 trans-signalling in osteoclast differentiation 
and resorption pit formation, it has also been linked to bone associated pain.  
Crucially, IL-6 alone cannot sensitize nociceptors until sIL-6R is present, and mice 
lacking gp130 on nociceptors present with attenuated inflammatory algesia, thus 
further highlighting the role of IL-6 trans-signalling in nociception (Obreja et al. 
2002, Andratsch et al. 2009).  IL-6 trans-signalling in models of tissue inflammation 
and neuronal injury sensitizes transient receptor potential channel vanilloid (TRPV1) 
on DRG through gp130, leading to increased neuronal cell communication, 
induction of substance P, calcitonin gene-related peptide (CGRP) and galanin 
(Murphy et al. 1999, De Jongh et al. 2003, Oberja et al. 2005, Andratsch et al. 2009, 
Scheller et al. 2011, Miguel, Kraychete& Nascimento. 2014).  As pain assessment 
was not a primary outcome of the experimental methodology, this was however 
not directly assessed.  Despite this, a role of IL-6 trans-signalling in bone-associated 
pain will be discussed and put forward in relation to our findings. 
The supplementation of the osteoclast assay with HYPER-IL-6 resulted in an 
increase in the area resorbed implying significantly elevated osteoclast activity, an 
increase bone acidification and dissolution of bone mineral through  H+ secretion 
[carbonic anhydrase; H2O + CO2 → HCO3- + H+] (Gay & Mueller 1974, Lehenkari et al. 
1998).  Subsequently, increased bone pain could result from an enhanced activation 
of acid-sensing neurones (TRPV1) alongside the release of neuropeptides (i.e. CGRP) 
which potentiate and translate noxious stimuli into pain (Yoneda et al. 2011).  
Although pain cannot be measured in vitro, harvested supernatants from across the 
time-course could have been assessed for pH to yield data regarding the H+ content.  
Finally, any secondary effects of NGF, CCL2 and CCL3 as pain mediators were 
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 thought minimal due to their concentrations either being unquantifiable (NGF) or 
unchanging (CCL2 and CCL3) after stimulation with HYPER-IL-6. 
4.4.3 IL-6 trans-signalling as a potential therapeutic target in osteoclast-
mediated diseases 
In vivo IL-6 trans-signalling exerts a stimulatory role in bone destruction and 
associated pain, yet no direct evidence for its role on osteoclastogenesis has been 
reported, only from co-cultures.  For the first time data reported in this chapter 
proved IL-6 trans-signalling to directly and significantly increase the resorptive 
capability of the osteoclast and lead to substantial bone resorption.  Such data 
therefore presents IL-6 trans-signalling as a therapeutic target for the inhibition of 
bone destruction.  Sgp130-Fc was used to assess the efficacy of targeting IL-6 trans-
signalling to decrease bone destruction.  Sgp130-Fc was shown to significantly 
decrease osteoclastic resorption, through reducing levels of osteoclastogenesis, 
TRAP5b and CTX-1 to levels comparable to m-CSF and RANKL cultures.  Due to 
decreased osteoclast numbers in sgp130-Fc cultures an early role of IL-6 trans-
signalling in osteoclast differentiation is again suggested.  This further supports the 
hypothesised role of HYPER-IL-6.  If IL-6 trans-signalling exerted negligible effect on 
osteoclast differentiation and primarily affected the activity of the mature 
osteoclast, equal numbers of osteoclast would be found in sgp130-Fc treated to m-
CSF and RANKL only cultures. 
The results presented in this chapter support and further the knowledge of IL-6’s 
role in bone destruction, where previous data from IL-6-/- models have shown 
synergistic relationships between IL-6 and resorption.  For example, the synergistic 
relationship between IL-6 and estrogen in bone destruction (Poli et al. 1994), and 
the importance of IL-6 in mononuclear cell proliferation (Wong et al. 2006).  
However, the importance of IL-6 trans-signalling to classical signalling in osteoclast 
differentiation was still unknown.  IL-6 trans-signalling was first associated with 
osteoclastogenesis in a seminal in vivo study, whereby the treatment of murine CIA 
with sgp130-Fc resulted in significant reductions of arthritis severity (including 
inflammation, synovial hyperplasia, infiltration of leukocytes and joint destruction) 
and decreased disease progression (Nowell et al. 2009).  Additional work from the 
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 Rheumatology group at Cardiff University also suggested that the treatment of 
murine CIA with sgp130-Fc led to fewer TRAP+ve multinucleated cells in addition to 
reduced bone and cartilage erosions (Smale, unpublished).  The data of Nowell and 
colleagues (2009) is strongly supported by our in vitro data, which provided 
definitive evidence for a role of IL-6 trans-signalling on direct osteoclastogenesis, 
thus, highlighting IL-6 trans-signalling as a novel therapeutic target.  
The data presented here, in addition to the dual inhibitory functionality of sgp130-
Fc on inflammation and bone erosion (Nowell et al 2009), illustrate the direct and 
indirect effects of IL-6 trans-signalling on osteoclastogenesis.  Direct effects of 
attenuated IL-6 trans-signalling lead to reduced monocyte infiltration, migration 
and fusion resulting in decreased osteoclast pre-cursors.  In addition, data reported 
in this chapter also suggests that sgp130-Fc significantly attenuates the secretion of 
resorptive enzymes, reducing visible bone erosions both in vitro (area of disk 
resorbed) and in vivo (CIA joint histology).  Indirectly, sgp130-Fc prevents the 
secretion of osteoclast stimulating factors (i.e. RANKL) and chemotactic mediators 
(i.e. CCL2, CCL3 etc) from co-localised cells (T cells/stromal cells) further reducing 
osteoclast differentiation and favouring neutrophil differentiation and migration 
(Rabe et al. 2008).  Although further research is needed, the data presented within 
this thesis points to a possible role for sgp130-Fc in the treatment for pain (i.e. 
attenuated hyperalgesia and hypersensitivity), and for controlling bone resorption 
associated with hormone imbalances (i.e. menopausal women). Thus possibly 
identifying novel therapeutic areas for an IL-6 based therapy. 
The combined published data and that reported in this chapter therefore identifies 
the potential clinical use of sgp130-Fc.  In addition to the pre-discussed 
effectiveness of this treatment, its use also has a major advantage over currently 
used methods due to its specificity for inhibiting IL-6 trans-signalling.  Currently 
therapeutic strategies involve antibody antagonists to IL-6R (i.e. tocilizumab) which 
neutralise both membrane bound and soluble receptor, and have been clinically 
used in inflammatory diseases including RA where disease onset (i.e. decreased 
disease activity score) and pathology (i.e. C-reactive protein) are attenuated 
(Yoshizake et al. 1998, Choy et al. 2002).  However, the lack of specificity results in 
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 the global inhibition of IL-6 signalling, which could potentially exert negative side-
effects on homeostatic leukocyte migration and function (Mantovani, Kaplanski & 
Farnarier 2003, Weissenbach et al. 2004). 
The selective inhibition of IL-6 trans-signalling via sgp130-Fc shows increased 
efficacy and has increased potential for use as a therapeutic in the future treatment 
of destructive bone diseases.  Alternatively, in the future small interfering RNA 
(siRNA) could be used as a therapy for enhanced IL-6 trans-signalling (Whitehead et 
al. 2009).  sIL-6R gene expression could be targeted by siRNA thus preventing IL-6 
trans-signalling through proteolytic cleavage, while unaltering membrane 
expression of IL-6R, therefore maintaining classical signalling.  Precedence for this 
hypothesis was exhibited as siRNA targeting of IL-6 gene expression resulted in 
reduced signalling protein activation, cell expansion, interactions and survival 
(Bharadwaj et al. 2011).  However, prior to the use of either of these 
methodologies, definitive evidence of IL-6 trans-signalling in osteoclastogenesis is 
essential.  Therefore, further studies would include complete time-course 
concentration profiling of IL-6, sIL-6R and their complex to identify the time-points 
that IL-6 trans-signalling exerts its primary effects both in vitro and in vivo.  
Subsequently, effective concentration/dose ranges, dosage times and drug delivery 
routes would be distinguished, alongside a consideration of sgp130-Fc potency 
against alternative treatments of IL-6 inhibition. 
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 4.5 Conclusion 
The data presented within this chapter builds upon the published literature that 
suggested a role for IL-6 trans-signalling in co-cultures of osteoclasts (Tamura et al. 
1993, Heinrich et al. 1998 and Palmqvist et al. 2002).  Specifically, our data 
identifies a novel, direct link between IL-6 trans-signalling and osteoclastogenesis in 
m-CSF and RANKL supplemented CD14+ve monocultures.  Resorption pit 
characteristics were obtained from a confocal methodology developed in this 
thesis.  A novel pathological role of IL-6 trans-signalling (illustrated via HYPER-IL-6) 
in enhanced osteoclast resorption was reported alongside increased resorption pit 
depth (a novel pathological outcome).  Collectively, the data suggested that 
elevated IL-6 trans-signalling led to an early increase in osteoclast number, although 
this is yet to be proven.IL-6 trans-signalling was therefore presented as a 
therapeutic target in increased osteoclastogenesis in vitro, where supplementation 
with sgp130-Fc reduced osteoclast number and resorption to pre-established 
control levels.  In conclusion, this chapter presents preliminary data for IL-6 trans-
signalling as a therapeutic target in enhanced osteoclastogenesis, where further 
work investigating the translational impact of sgp130-Fc on in vivo 
osteoclastogenesis is key to its future pharmaceutical potential. 
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5 Chapter 5:Defining the role of C-C chemokine 
ligand 3 (CCL3) in osteoclast differentiation 
and functional resorptive activity in vitro and 
in vivo 
  
166 
 
 5.1 Introduction 
A novel role for CCL3 in osteoclast differentiation was postulated from the 
correlation of CCL3 and osteoclast number reported at the conclusion of Chapter 3.  
This chapter therefore aims to decipher the role CCL3 plays during the 
differentiation and functional resorptive activity of the osteoclast in vitro, and to 
elucidate whether this chemokine could be a therapeutic target in vivo for erosive 
bone diseases. 
M-CSF and RANKL signalling induces the characteristic gene expression of mediators 
pivotal to osteoclast differentiation and function; TRAP, CATK and calcitonin 
receptor (CTR)  (Boyle, Simonet& Lacey2003).  The third mediator OPG (natural 
decoy receptor of RANKL), inhibits osteoclast formation and maintains a healthy 
bone turnover system.  Disruption of this equilibrium results in a diseased state 
where cytokines and chemokines exert pathological roles leading to dysregulation 
of bone homeostasis.  In the last 15 years several inflammatory CXC- and CC- 
chemokines were reported to exert a role in osteoclastogenesis and functional 
resorption.  CXC chemokines are involved in the chemotaxis of neutrophils and the 
process of angiogenesis, both of which maintain the diseased joint with a constant 
supply of nutrients and leukocytes via the newly formed vasculature.  CXCL8, 
CXCL10, CXCL9 and CXCL12 are increased in synovial tissue (ST) and fluid (SF) of RA 
patients and are secreted from synovial macrophages and ST cells (Koch 2005).  
CXCL5, CXCL1, CXCL7, CXCL6 are also found at increased levels in RA SF and ST but 
are commonly secreted from ST fibroblasts (Koch 2005).  CC- chemokines CCL2, 
CCL3, CCL5, and CCL20 are all elevated and causative in monocyte recruitment to ST 
and SF in RA, and are secreted from ST fibroblasts and macrophages (Koch 2005).  
Several in vitro co-culture studies have monitored the effect of these chemokines 
on osteoclastogenesis.  However, the direct role of chemokines on mononuclear 
cell differentiation into osteoclasts is hard to distinguish due to their secondary 
effects on co-cultured cells.   
CCL3 is a chemokine of growing importance in destructive diseases (RA, OA, JIA and 
MM) where pathologically elevated osteoclastogenesis is reported (Koch et al. 
1994, Oba et al. 2005, Vangsness et al. 2011, Muller et al. 2015,).  Bone destruction 
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 results from the secretion of matrix degrading proteins and the secretion of H+ ions 
via proton pumps which together dissolve bone matrix.  Importantly, CCL3 is stable 
at low pH, as in an eroded joint, further implicating this chemokine in 
osteoclastogenesis and increased bone resorption.  The quantification of this 
increased bone resorption traditionally occurs through toluidine blue staining 
(Massey & Flanagan 1999).  Recent insight into two dimensional (2-D) analysis has 
yielded questions regarding its translocation to osteoclast activity, where 3D 
imaging is providing greater knowledge of the osteoclasts activity.  One pioneer in 
the field, Goldberg et al. (2012), published initial results of using 3-D imaging to 
quantify resorption, where it was concluded that area resorbed was deceptive due 
to altering volumes of pits dependent upon Rho GTPases in the osteoclast.  In order 
to further our knowledge of the effect CCL3 has on osteoclastogenesis and define 
the 3-D characteristics of resorption the novel analysis method using z-stacks from 
laser-scanning confocal microscopy used in Chapter 4 will similarly be used. 
A role of CCL3 has also been postulated in pain and inflammation due to 
significantly elevated levels in RA, OA, Arthus reaction, inflammatory bowel disease 
and chronic obstructive pulmonary disease (COPD), but the mechanistic action of 
this increase is still unknown (Ajuebor et al. 2004, Yanaba et al. 2004, Szekanecz et 
al. 2010, Vangsness et al. 2011, Ravi et al. 2014).  In these diseases, the significant 
increase in CCL3 was also found to be simultaneous with other pro-inflammatory 
cytokines and chemokines in the inflammatory milieu of the joint; IL-6, sIL-6R, CCL2 
and CCL5 (Chintalacharuvu et al. 2005, Koch 2005, Pharoah et al. 2006, Hashizume 
& Mihara 2011).  Published material states the effect of CCL3 on the co-expression 
of these mediators and significant enhancement on osteoclastogenesis in co-
cultures and in vivo models (Koch 2005, Oba et al. 2005, Nowell et al. 2009, 
Vangsness et al. 2011).  However, their direct effect on osteoclast differentiation 
and resorption remains elusive.   
Published material describes a clear indirect role for CCL3 in disease pathology, 
inflammation and possibly pain, but no direct evidence for its role on 
osteoclastogenesis was shown.  In this chapter, human in vitro monocultures will 
determine the role CCL3 exerts on osteoclast differentiation and on resorptive 
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 activity.  Additionally, through the use of in vivo methods, the effect of CCL3 on 
both 2D and 3D bone pathology and inflammation will be assessed.  The hypothesis 
for this chapter is that CCL3 enhances osteoclast differentiation and resorption in 
vitro and in vivo.  In order to address this hypothesis, the chapter proceeds with 
these following objectives:- 
1.) To measure CCL3 by ELISA from  cultures of human CD14+ve cells exposed to 
osteoclast-differentiation stimulating mediators, and to determine CCL3’s 
role in osteoclastogenesis and bone degeneration using a neutralising 
antibody in vitro 
 
2.) To investigate the presence of surrogate soluble markers of osteoclast 
differentiation (TRAP5B), resorption (CTX-1), pain and inflammation (NGF, 
CCL2, CCL3, CCL5, IL-6 and sIL-6R) by ELISA in osteoclast differentiation 
assays treated to anti-CCL3. 
 
3.) To study the effect of CCL3 inhibition on bone pathology in an in vivo model 
of murine inflammatory arthritis  
 
 
  
169 
 
 5.2 Essential Methodology 
The below diagrams highlight the essential methods used throughout this chapter 
to obtain the reported results.  Full detail of all these methods can be found in their 
respective sections as stated next to the diagrams. 
• Osteoclast assays (Chapter 2 Sections 2.2.1 - 2.2.4) 
Condition Number of Donors 
Number of 
Replicate Disks 
per donor 
Chapter 
Section Comments 
m-CSF only 4 4 
5.3.1 
Mean values 
from the 
replicate disks 
of each donor 
plotted  
m-CSF and OPG (100ng/mL) 4 4 
m-CSF and RANKL 8 4 
m-CSF, RANKL and OPG 
(100ng/mL) 5 4 
m-CSF and RANKL 1 4 
5.3.2.2 
m-CSF, RANKL and anti-CCL3 
(2ng/mL) 1 4 
m-CSF, RANKL and anti-CCL3 
(4ng/mL) 1 8 
m-CSF, RANKL and anti-CCL3 
(8ng/mL) 1 8 
m-CSF only 4 2 
5.3.2.3 to 
5.3.2.5 
m-CSF and anti-CCL3 (8ng/mL) 5 2 
m-CSF and IgG1 (8ng/mL) 4 2 
m-CSF and RANKL 9 4 
m-CSF, RANKL and anti-CCL3 
(8ng/mL) 9 4 
m-CSF, RANKL and IgG1 (8ng/mL) 4 4 
m-CSF only 9 2 
5.3.4 m-CSF and OPG (8ng/mL) 4 2 m-CSF and RANKL 8 4 
m-CSF, RANKL and OPG (8ng/mL) 5 4 
 
-PBMCs isolated from healthy human whole blood via density centrifugation went 
through magnetic activated cell sorting to yield a pure suspension of CD14+ve 
monocytes (as illustrated). 
- Disks were seeded with 3.2 x 106 cells and cultured with m-CSF alone (5ng/mL) or 
in combination with RANKL (5ng/mL).  Culture supernatants collected and 
replenished every 3-4 days.  Disks harvested at day 14. 
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 Caption 5 - Isolation of human CD14+ve monocytes from peripheral blood. Human blood 
layered onto hisotpaque is centrifuged yielding peripheral blood mononuclear cells.  
CD14+ve monocytes isolated by magnetic activated cell sorting and  3.2 x 106 cells/mL are 
seeded onto ivory disks prior to culture in osteoclast proliferation/differentiation medium 
 
 
-Disks harvested at day 14 were fixed with glutaraldehyde prior to staining with 
TRAP and haematoxylin to identify total cells and osteoclasts; quantified through 
MATLAB and manual counts.  Following cell counts adhered cells were removed and 
disks stained with toluidine blue or calcein to facilitate quantification of resorbed 
area.  Harvested supernatants were analysed by ELISA. 
-In addition, individual pit parameters (area, perimeter, volume and depth) were 
imaged via confocal microscopy (x60) and quantified using MetaMorph.  All of 
these assessments can be found in the diagram which follows. 
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 Caption 6 - The osteoclast assay and functional analyses. Disks seeded with CD14+ve 
monocytes are cultured up to day 14 in the presence or absence of anti-CCL3.  Every 3-4 
days disks and their supernatants were harvested and used for one of the following 
analyses; cell staining (TRAP and haematoxylin), area of resorption quantification (toluidine 
blue or calcein), confocal analysis of individual pit characteristics, and ELISA. 
 
 
• CIA (Chapter 2 Section 2.2.19) 
-Male DBA-1 mice (n=12) were equally divided into two groups; a control IgG1 
group (n=6) and an anti-CCL3 group (n=6). 
-Mice were injected i.d. at day 0 with 2 x 50µL CFA containing 2mg/mL collagen.  A 
booster i.d. injection of 2 x 50µL CFA + collagen was given at day 21.  At day 21 the 
IgG1 control group received 100µL i.p. injection of IgG1 antibody (5mg/kg), and the 
anti-CCL3 group received an i.p. injection of anti-CCL3 (5mg/kg). Mice received an 
additional 5 doses every other day prior to being culled on day 29.  Paw diameter 
was assessed every day alongside arthritis severity (clinical score); each paw was 
scored from 1 to 4 (see Chapter 2 Section 2.2.19 for details).An overview is 
presented below.   
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 Caption 7 - Murine CIA induction and treatment with anti-CCL3.  Mice were injected at 
day 0 with CFA + collagen, and were given a booster injection at day 21.  On day 21 mice 
were divided into two treatment groups, one receiving anti-CCL3 and one receiving control 
isotype IgG Ab.  Mice were monitored every day for paw swelling and arthritis severity.  An 
additional 5 doses were given to mice on alternate days, and on day 29 mice were culled. 
 
 
-Mice were culled on day 29 and joint tissues from both fore- and hind-limbs were 
harvested.  Shoulder joints were fixed in 10% neutral buffered formalin solution for 
24 hours at room temperature and then placed into 70% alcohol for 2 weeks.  Knee 
and ankle joints were fixed and stored in 70% alcohol. 
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 • Joint assessment (Chapter 2 Sections 2.2.20- 2.2.27) 
-Radiographs of forepaws and hind paws were acquired and assessed for erosions 
in 12 joints (Chapter 2 Section 2.2.21).  3D reconstructions of murine hind paws 
were obtained from µCT (Chapter 2 Section 2.2.22).  
-Post imaging murine forepaws were decalcified in EDTA over 3 weeks.  Joints were 
then embedded in paraffin wax ready for histological assessment.  Sections of 7µm 
thickness were cut and stained with TRAP and haematoxylin facilitating cell counts.  
Each section was assessed for arthritic index (inflammatory infiltration, joint 
exudate, synovial hyperplasia and bone erosion) and osteoclast numbers (n=6 for 
each treatment group; left and right forepaws assessed). A summary is presented 
below; 
Caption 8 - Methodologies for the analysis of bone destruction. Mice were culled on day 
29 and their hind paws and forepaws harvested.  All paws were examined by x-ray to yield 
a radiographic erosive score.  Hind paws were imaged by μCT for erosions and forepaws 
were embedded in wax and assessed histologically for TRAP+ve cells and an arthritic index. 
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 5.3 Results 
In this chapter the role of CCL3 in osteoclast formation and associated resorption 
was investigated both in vitro and in vivo.  Initial experiments using OPG, the decoy 
receptor of RANKL, at a previously published concentration of 100ng/mL, 
established whether our in vitro osteoclastogenesis assay was sensitive enough to 
show significant inhibition of osteoclast formation.  Following this, the osteoclast 
assay was used to determine the role of CCL3 in osteoclast differentiation and bone 
degradation both in m-CSF and RANKL cultures and in the presence of a neutralising 
antibody to CCL3 in vitro.  Supernatants were collected every 3-4 days and disks 
were harvested and fixed.  Haematoxylin and TRAP stains were used to visualise 
nuclei and differentiating osteoclasts.  Cell counts were reported as cells/disk 
(28mm2) and given as the mean ± S.E.M.  Secondary markers of osteoclast 
differentiation (TRAP5b) and bone resorption (CTX-1) were quantified.  TRAP 
concentrations were quantified on day 7 (the optimal time-point established in 
Chapter 3 Section 3.2.7 where a significant increase in TRAP cell number is first 
quantified) and CTX-1 concentrations were quantified on day 10 (the optimal time-
point established in Chapter 4 Section 4.3.1.2 due to negligible levels at day 7).  In 
addition, surrogate soluble mediators of pain (NGF, CCL2, CCL3, IL-6) and 
inflammation (CCL2, CCL3, CCL5, IL-6 and sIL-6R) were measured in human 
osteoclast differentiation cultures across the 14-day time-course in vitro.  Anti-CCL3 
was then tested as an experimental treatment for prevention of bone destruction in 
a murine in vivo model of collagen-induced arthritis (CIA) using radiological and 
histological analyses.  
 
5.3.1 OPG significantly inhibits osteoclastogenesis in m-CSF and RANKL 
supplemented cultures 
The supplementation of osteoclast differentiation cultures with 100ng/mL OPG 
significantly reduced TRAP+ve cells (87 ± 10) compared to m-CSF and RANKL cultures 
(536 ± 146; p≤0.05, Figure 5.1 and 5.2), with a similar profile of reduction for 
osteoclast number (OPG: 5 ± 2, m-CSF and RANKL: 299 ± 84; p≤0.05, Figure 5.1 and 
5.2).  The corresponding area of resorption was also significantly reduced in the 
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 presence of OPG (0.14 ± 0.01%) compared to m-CSF and RANKL cultures (1.98 ± 
0.56%; Figure 5.5 and 5.6, p≤0.05). 
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 - OPG (100ng/mL) 
M-CSF only 
  
   
M-CSF and RANKL 
  
   
 m-CSF and RANKL OPG (100ng/mL) 
Toluidine Blue 
  
 
Figure 5. 1 - Supplementation of OPG into m-CSF and RANKL cultures visually reduced 
TRAP+ve cell and osteoclast number.TRAP+ve cells (green circles)and osteoclasts(red circles) 
were visualised at high numbers in cultures supplemented with m-CSF and RANKL.  The 
addition of OPG resulted in a remarkable decrease in TRAP+ve cells and osteoclasts seen, 
along with a visual reduction in cell size.  In m-CSF control cultures no TRAP+ve cells or 
osteoclasts were seen.  Toluidine blue imaging showed the clear presentation of multiple 
resorption pits (yellow arrows)in m-CSF and RANKL cultures, but through the addition of 
OPG areas of resorption were negligible. Scale bar 50μm.  
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Figure 5. 2 - OPG supplementation significantly reduces osteoclast formation and 
functional resorptive activity..  After 14 days of culture in m-CSF and RANKL ± OPG 
(100ng/mL) cultured disks were harvested, fixed and stained to obtain TRAP+ve and 
osteoclast counts.  Post counts, cells were removed and disks were stained with toluidine 
blue for quantification of resorption. i. and ii.) m-CSF, RANKL + OPG showed significantly 
reduced TRAP+ve and osteoclast counts (both p≤0.05).  iii.) Supplementation of OPG caused 
a significant reduction in area resorbed compared to m-CSF and RANKL (p≤0.05).  N= 8 
donors for m-CSF and RANKL cultures; mean of 4 replicate disks plotted.  N=5 donors for m-
CSF, RANKL + OPG cultures; mean of 4 replicates per donor plotted.  Statistical analysis 
using a Student's t-test was performed. Mean ± SEM data values were reported.  
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 5.3.2 Determining the direct effect of CCL3 in human osteoclast 
differentiation and bone resorption in vitro 
The direct effect of CCL3 in osteoclast differentiation and bone resorption in vitro 
was investigated due to its significant correlation with osteoclastogenesis in 
Chapter 3.  Precursor cells were differentiated into osteoclasts in the presence of 
m-CSF and RANKL over 14 days where maximum osteoclast differentiation and 
resorption had occurred (Chapter 3.3.7 and 3.3.8).  In destructive bone diseases a 
complicated milieu of pro-inflammatory cytokines are present in the joint, 
potentially masking the direct role of CCL3 in osteoclastogenesis.  To understand 
the role of CCL3 in human osteoclast formation and resorption, a neutralising 
antibody to CCL3 was added to osteoclast cultures and its effect on osteoclast 
number (TRAP staining) and resorbed area (toluidine blue) measured at day 14.  3D 
confocal imaging of resorption pits was paired with novel analysis methodology to 
distinguish the direct effect of CCL3 in morphological pit characteristics including 
depth and volume.  
 
5.3.2.1 CCL3 secretion by osteoclasts significantly increases in the presence 
of RANKL in vitro 
CCL3 concentration at baseline (Day 0) was 93 ± 26pg/mL and after 24 hours 
remained unchanged in proliferation medium (89 ± 12pg/mL) but decreased in m-
CSF and RANKL cultures (56 ± 6pg/mL).  In m-CSF and RANKL cultures, a significant 
increase to 162 ± 24pg/mL was reported after 7 days (p≤0.05, Figure 5.3), which 
coincided with the significant increase in TRAP+ve cells (Chapter 3 Section 3.3.7).   
 
5.3.2.2 Concentration dependent decreases in TRAP+ve mononuclear and 
multinucleated cells results from anti-CCL3 treatment in vitro 
Osteoclast number significantly reduced in a concentration dependent-manner in 
the presence of 2-8ng/mL anti-CCL3 (p≤0.01), where comparative reductions were 
noted at both 4- and 8ng/mL.  Greater reproducibility was seen at 8ng/mL as there 
was a decreased data range.  A power calculation proved a 5-fold reduction in ‘n 
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 number’ using 8ng/mL anti-CCL3 compared to 4ng/mL anti-CCL3.  Total cell count 
was comparable between both concentrations highlighting unaffected precursor 
cell expansion; 10347 ± 501 versus 9167 ± 702 (Figure 5.4).  Subsequent 
differentiation assays with increased n number were therefore run with the 
supplementation of 8ng/mL anti-CCL3 to determine the impact of CCL3 in 
osteoclast formation and resorption.  No TRAP+ve osteoclasts were observed in m-
CSF cultures.  
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Figure 5. 3 - RANKL induces a significant early increase in CCL3 in monocultures..  
Proliferation cultures at day 0, were either supplemented with m-CSF only or m-CSF and 
RANKL. Control m-CSF cultures showed no difference in CCL3 concentration after 24 hours.  
Differentiation cultures however showed an initial reduction in CCL3 after 24 hours which 
was followed by a significant increase to day 7 (p≤0.05).  A gradual decline in CCL3 then 
followed from day 7 to day 14 when assays were terminated. N=7 donors (apart from day 1 
conditions where n=4 donors), means from 4 disks per time-point were plotted.  Statistical 
analysis using a One-Way ANOVA was performed between m-CSF and RANKL culture time-
points, and mean ± SEM data values are reported. 
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Figure 5. 4 - the addition of anti-CCL3 into human osteoclast differentiation cultures 
resulted in a significant dose-dependent reduction in osteoclast number.Osteoclast 
differentiation assays were treated with anti-CCL3 Ab from 0-8ng/mL from day 0.  Assays 
were terminated at day 14 when disks were harvested, fixed and stained with TRAP and 
haematoxylin. i.) A significant reduction in osteoclast count (p≤0.01) was seen across the 
concentration range of anti-CCL3 Ab.  In control cultures supplemented only with m-CSF, 
osteoclast number was negligible.   ii.)  Total cell number was shown at comparable levels 
in differentiation cultures and those supplemented with 8ng/mL anti-CCL3.  Data reported 
in this Figure was obtained from n=1 donor; minimum number of 4 replicate disks per 
treatment condition.  Statistical analysis using a one-way ANOVA was performed (** = 
p≤0.01), and mean ± SEM data values were reported.  
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 5.3.2.3 Supplementation of 8ng/mL anti-CCL3 into differentiation cultures 
significantly reduced osteoclast count at day 14 
TRAP+ve cell number was comparable in osteoclast cultures treated with m-CSF and 
RANKL in the absence and presence of anti-CCL3; 536 ± 146 and 555 ± 195 
respectively (Figure 5.5 and 5.6, i).  However, osteoclast number was independent 
to TRAP+ve cells and significantly reduced in the presence of anti-CCL3 compared to 
m-CSF and RANKL; 113 ± 41 opposed to 299 ± 84 respectively (p≤0.05, Figure 5.6, 
ii).   In m-CSF and RANKL cultures treated with an isotype control antibody, TRAP+ve 
cells and osteoclast counts were unchanged, thus proving the importance of CCL3 
specifically in osteoclast formation (n=4, Figure 5.6, iii and iv).  TRAP+ve cells and 
osteoclasts were absent m-CSF only cultures and m-CSF in combination with anti-
CCL3 or IgG (Figure 5.6, v and vi). 
 
5.3.2.4 The addition of anti-CCL3 into differentiation cultures significantly 
reduced the area of resorption after 14 days of culture 
Harvested disks from m-CSF and RANKL cultures exhibited 1.5 ± 0.4% resorption 
across the disk surface.  Through anti-CCL3 supplementation, a significant 3-fold 
reduction in the area of resorption across the disk to 0.4 ± 0.1 % (p≤0.05) 
resulted(Figure 5.7 and 5.8).  m-CSF and RANKL cultures in combination with IgG 
showed comparable levels of resorption; 0.6 ± 0.1 % and 0.7 ± 0.1 % respectively.  
m-CSF alone or in combination with anti-CCL3 or IgG did not produced resorption 
(Figure 5.8).   
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Figure 5. 5 - Neutralisation of CCL3 (anti-CCL3 8ng/mL) in m-CSF and RANKL cultures reduced osteoclast number.Human osteoclast cultures were treated 
for 14 days withanti-CCL3 and/or ± isotype control IgG1.  Anti-CCL3 caused a visual reduction in osteoclast number(red circles) to m-CSF and RANKL 
cultures.  Osteoclast number in isotype control cultures were comparable to m-CSF and RANKL cultures.  No TRAP+ve cells were found in m-CSF only 
cultures.  Scale bar 50μm.  
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Figure 5. 6 - Neutralisation of CCL3 (8ng/mL) significantly decreased osteoclast 
number.Osteoclast assays ± anti-CCL3 or IgG1 were run to day 14 where disks were 
harvested, fixed and stained.  i.)  TRAP+ve cells were comparable in m-CSF and RANKL 
cultures ± anti-CCL3. ii.)  Osteoclast count significantly decreased in the presence of anti-
CCL3 (p≤0.05).  iii.) and iv.)  TRAP+ve cell and osteoclast number were comparable in m-CSF 
and RANKL ± IgG1 cultures(n=4 donors; 4 replicate disks per donor, mean plotted). v.) and 
vi.) No TRAP+ve cells or osteoclasts were found in the absence of RANKL.  For m-CSF and 
RANKL ± anti-CCL3 n=9 donors; 4 replicate disks per donor, mean plotted.  Statistical 
analysis using a Student's t-test (* = p≤0.05).  Mean ± SEM data.  
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Figure 5. 7 - Resorption pit number was visually reduced after neutralisation of CCL3 in m-CSF and RANKL cultures.At day 14 disks were harvested from 
osteoclast assays and adherent cells were removed, stained with toluidine blue or calcein, and imaged by light or confocal microscopy.  M-CSF ± anti-CCL3 
or IgG1 showed no resorption.  M-CSF and RANKL cultures showed extensive resorption, which was shown to reduce in the presence of anti-CCL3 but not 
IgG1.Toluidine blue scale bar=50μm, confocal images 1 pixel = 0.27µm. 
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Figure 5. 8 - Neutralisation of CCL3 in m-CSF and RANKL cultures led to a significant 
reduction in area resorbed at day 14.Disks were harvested at day 14 of the osteoclast 
assay.  Adhered cells were removed and disks stained with toluidine blue prior to 
quantification of resorbed area.  i.)  Anti-CCL3 supplementation into m-CSF and RANKL 
caused a significant decrease in area resorbed % compared to m-CSF and RANKL cultures 
(p≤0.05, n=8 donors; 2 replicate disks per donor, mean  plotted).ii. and iii.) Differentiation 
cultures treated with isotype control Ab (minimum of n=3 donors; 2 replicate disks per 
donor, mean plotted) or cultures without RANKL showed no significant difference to 
matched controls.  Student's t-test performed (* = p≤0.05).  Mean ± SEM shown.  
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 5.3.2.5 Anti-CCL3 did not significantly affect the depth and volume of 
resorption pits 
Resorption pit number across the disk was significantly reduced in the presence of 
anti-CCL3 (Section 5.3.2.4) but the individual parameters of each pit were still 
unknown (i.e. area, volume and depth).  Such individual pit parameters are thought 
to be result of ‘stationary resorption’, where the osteoclast has tightly adhered to 
the bone substrate forming a sealing zone and creating a contained space in which 
degradative enzymes are released.  To assess whether stationary resorption is 
altered in the presence of anti-CCL3, confocal microscopy was used to create XY 
and XZ image stacks.  3D reconstructions of eroded bone surfaces were then made 
from these image stacks which allowed assessment of individual pit parameters. 
Average pit area (1963 ± 414 versus 1988 ± 341) and perimeter (188 ± 16 compared 
to 187 ± 9) were comparable in m-CSF and RANKL versus m-CSF, RANKL and anti-
CCL3 cultures (n=6 donors).   Pit depth (7.1 ± 0.9µm versus 6.7 ± 0.6µm)and pit 
volume (527.3 ± 90.9µm3 versus 573.9 ± 90.0µm3) in m-CSF and RANKL cultures 
with and without anti-CCL3 were also comparable.   
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Figure 5. 9 - CCL3 has no effect on resorption pit characteristics.The three-dimensional 
analysis of resorption pits from confocal imaging at x60 yielded XY images showcasing the 
presence of pits (i).XZ slices (red lines) facilitated the visualisation of pit depth (ii).  
Individual pit characteristics in m-CSF, RANKL and anti-CCL3 cultures showed no significant 
differences in pit area, perimeter, depth or volume to m-CSF and RANKL cultures (iii – vi 
respectively; n=6 donors; 2 disks per donor imaged, 10 images per disk quantified, mean 
plotted). 0.27µm = 1 pixel.  Statistical analysis using a Student's t-test was performed.  
Mean ± SEM data shown.  
iii.) 
v.) vi.) 
iv.) 
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 5.3.3 Quantifying the presence of selected indirect markers of osteoclast 
function, pain and inflammation 
Due to the postulated direct role of CCL3 in osteoclast formation from Sections 
5.3.2.3 and 5.3.2.4, secondary markers of osteoclast differentiation (TRAP5b) and 
resorption (CTX-1), were measured at day 7 and day 10 to provide additional 
evidence for a biological role of CCL3 in osteoclastogenesis.  Levels of NGF, CCL2, 
CCL5, IL-6 and sIL-6R were also quantified in supernatants harvested from across 
the OC assay time-course by ELISA to assess any relationship CCL3 may have with 
pain and inflammation markers. 
 
5.3.3.1 Soluble marker of osteoclast differentiation, TRAP5b, and 
resorptive function, CTX-1, were not significantly reduced by anti-
CCL3 
TRAP5b was significantly elevated in m-CSF and RANKL differentiation versus non-
differentiating (m-CSF only) cultures; 1.37 ± 0.28 versus 0.19 ± 0.09 U/L (p≤0.01, 
Figure 5.10).  TRAP5b was not altered by anti-CCL3 (1.43 ± 0.43 U/L) in 
differentiation cultures.  
CTX-1 increased in m-CSF and RANKL cultures compared to m-CSF only, but this was 
not significant (0ng/mL to 0.14 ± 0.06ng/mL respectively).  In the presence of anti-
CCL3, CTX-1 from m-CSF and RANKL cultures was reduced but not significantly.  
CTX-1 levels were at the lower limit detection sensitivity for the assay.  
 
5.3.3.2 Establishing the effect of anti-CCL3 on the secretion of indirect 
markers of pain and inflammation (CCL2, CCL5, IL-6 and sIL-6R) 
from human osteoclast differentiation cultures in vitro 
CCL2 was produced at high levels comparable in m-CSF alone cultures and m-CSF 
and anti-CCL3 treated cultures.  Supplementation of cultures with RANKL caused 
CCL2 levels to decrease gradually from day 0 to day 14 (41 ± 19 to 19 ± 5ng/mL).  
Comparable expression was found in m-CSF, RANKL and anti-CCL3 cultures.  CCL5 
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 was only measured in five assays as levels were consistently lower than the 
detection limit of the ELISA (Figure 5.11). 
sIL-6R from m-CSF cultures in the presence and absence of anti-CCL3 slowly 
declined across the time-course; 63 ± 28 to 28 ± 13pg/mL.   The supplementation of 
RANKL into these cultures yielded comparable levels of sIL-6R, as did the addition of 
anti-CCL3.  The secretion of IL-6 across the time-course matched that of sIL-6R.  In 
m-CSF only and m-CSF with anti-CCL3, IL-6 was comparable and gradually declined; 
144 ± 113 (day 0) to 49 ± 35pg/mL (day 14).  In cultures supplemented further with 
RANKL, a similar declining profile of secretion was reported; 73 ± 22 (day 0) to 42 ± 
24pg/mL (day 14), which again was unaffected in the presence of anti-CCL3; 52 ± 14 
(day 0) to 20 ± 18pg/mL (day 14, Figure 5.12).    
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Figure 5. 10 - CTX-1 and TRAP5b secretion at day 10 increased in the presence of RANKL 
but anti-CCL3 had no further effect on their levels.Supernatants from osteoclast 
differentiation assays were collected at day 10 and analysed by ELISA for CTX-1 and 
TRAP5b.  i.) Soluble TRAP5b significantly increased in m-CSF and RANKL cultures compared 
to m-CSF only cultures (p≤0.01), but was not affected through CCL3 neutralisation in m-CSF 
and RANKL cultures.  ii.) CTX-1 increased in m-CSF and RANKL cultures compared to m-CSF 
only but this was not significant.  Anti-CCL3 treatment caused a decrease in CTX-1 levels, as 
did IgG1, but this was not significant.  m-CSF and RANKL ± anti-CCL3; N=6 donors, 2 
replicate disks per treatment condition, mean plotted.IgG1 control; N=4 donors, 2 replicate 
disks, mean plotted.  Statistical analysis using a Student's t-test was performed (** = 
p≤0.01).  Mean ± SEM data reported.  
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Figure 5. 11 - Soluble inflammatory chemokines in anti-CCL3 treated osteoclast cultures 
were not significantly reduced compared to controls. Supernatants from across a 14-day 
osteoclast differentiation assay were collected and analysed for soluble mediators of 
inflammation via ELISA.  i.) CCL2 showed no significant difference across a 14-day time-
course in m-CSF only and m-CSF + anti-CCL3 cultures.  ii.)  CCL2 concentrations in m-CSF 
and RANKL cultures across the 14-day time-course were unaltered in the presence of anti-
CCL3 or IgG1.  .  iii.) CCL5 in m-CSF only cultures were negligible until day 10 (n=1 donor; 4 
replicate measurements per donor, mean of donor plotted ± S.E.M.).  iv.)  CCL5 in m-CSF 
and RANKL cultures ± anti-CCL3 or IgG1 increased from day 0 to day 10, but this was not 
significant.  For m-CSF ± anti-CCL3; n=4 donors, 4 replicate measurements per donor, mean 
of all donors plotted ± S.E.M.).  For m-CSF, RANKL ± anti-CCL3;n=9 donors, 4 replicate 
measurements per donor, mean of all donors plotted ± S.E.M.  Statistical analysis using a 
one-way ANOVA was performed.  Mean ± SEM reported.  N.B. no sample exists for m-CSF 
and anti-CCL3 cultures at day 1 due to analyst error.  
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Figure 5. 12 - Soluble inflammatory cytokines in anti-CCL3 treated osteoclast cultures 
were not significantly altered compared to controls.  Across the 14-day osteoclast 
differentiation assay collected supernatants were analysed for soluble inflammatory 
cytokines using ELISA.  i.) and ii.)  A biphasic response of sIL6R in m-CSF only cultures was 
ameliorated through the supplementation of RANKL.  In cultures supplemented with anti-
CCL3 or isotype control, sIL-6R was comparable to m-CSF and RANKL cultures.  iii.) and iv.)  
IL-6 concentration was shown to decrease across the time-course in m-CSF only ± anti-
CCL3.  In m-CSF and RANKL cultures alone or in combination with anti-CCL3 or IgG1, the 
profile of IL-6 was unchanged.  For m-CSF ± anti-CCL3; n=4 donors, 4 replicate 
measurements per donor, mean of all donors plotted ± S.E.M.).  For m-CSF, RANKL ± anti-
CCL3;n=9 donors, 4 replicate measurements per donor, mean of all donors plotted ± S.E.M.  
Statistical analysis using a one-way ANOVA was performed.  Means ± SEM reported.  N.B. 
no sample exists for m-CSF and anti-CCL3 cultures at day 1 due to analyst error.  
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 5.3.4 Comparing the potency of anti-CCL3 compared to OPG in the inhibition 
of osteoclast formation and function 
Data reported showed a clear role for CCL3 in driving osteoclast differentiation and 
subsequently a role in the resorption of bone-substrate. Next the comparative 
efficacy of anti-CCL3 versus an established inhibitor of osteoclastogenesis (OPG) 
was tested.  OPG or anti-CCL3 was investigated at 8ng/mL per culture well.  Cell 
counts and bone substrate resorbed were measured on day 14 whilst soluble 
markers of osteoclast differentiation (TRAP5B), bone resorption (CTX-1; measured 
on day 10), and pain (NGF, CCL2, CCL3, IL-6) and inflammation (CCL2, CCL3, CCL5, IL-
6 and sIL-6R) were quantified by ELISA across the time-course. 
 
5.3.4.1 The addition of OPG into osteoclast differentiation cultures 
significantly reduced osteoclast number and bone substrate 
resorption after 14 days 
OPG reduced the number of TRAP+ve cells (246 ± 84) and significantly decreased 
osteoclasts (21 ± 9) counted per disk compared to m-CSF and RANKL cultures (536 ± 
146 and 299 ± 84 respectively; p≤0.05).  TRAP+ve cells and osteoclast numbers were 
comparable in OPG and anti-CCL3 treated cultures (Figure 5.13 and Figure 5.14).  
OPG prevented resorption of ivory and images were comparable with those from 
m-CSF only cultures (Figure 5.15).  OPG and anti-CCL3 had equivalent potency in 
this regard (n=3, Figure 5.16).  
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Figure 5. 13 - M-CSF and RANKL cultures supplemented with OPG showed an extensive 
decrease in TRAP+ve cells and osteoclasts adhered to disks.M-CSF and RANKL cultures 
alone showed the presence of TRAP+ve cells (green circles) and osteoclasts (red circles) in 
high numbers across the disk.  Through the addition of OPG a remarkable decrease in 
TRAP+ve cells and osteoclasts were seen, along with a visual reduction in cell size.  In m-CSF 
control cultures no TRAP+ve cells or osteoclasts were seen.  Scale bar 50μm.  
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Figure 5. 14 - OPG (8ng/mL) significantly reduced osteoclast number in m-CSF and RANKL 
cultures.Osteoclast assays were supplemented with 8ng/mL OPG over a 14 day time-course 
(m-CSF and RANKL cultures; n=8 donors, 4 replicate disks per donor, m-CSF, RANKL + OPG; 
n=5, 4 replicate disks per donor; mean per donor plotted ).  At day 14 disks were harvested 
and stained.  i.) OPG reduced TRAP+ve cell count but not significantly compared to m-CSF 
and RANKL cultures.  ii.)  OPG significantly reduced osteoclast count compared to m-CSF 
and RANKL (p≤0.05).  iii. and iv.) M-CSF cultures ± OPG showed no significant increase in 
TRAP+ve cells or osteoclast count.  v. and vi.) OPG had no effect on TRAP+ve cell or osteoclast 
number compared to m-CSF and RANKL cultures + anti-CCL3.  Student's t-test was 
performed(* = p≤0.05).  Mean ± SEM data reported.  
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Figure 5. 15 - OPG (8ng/mL) substantially reduced the appearance of resorption pits in human osteoclast differentiation assays..  Osteoclast assays ± OPG 
were cultured to day 14.  At assay termination disks were harvested, adhered cells removed, and disks were stained with toluidine blue or calcein prior to 
imaging with light or confocal microscopy.  Resorption pits were only visibly present in m-CSF and RANKL cultures without OPG.  Toluidine blue scale bar= 
50μm, confocal images 1 pixel =0.27µm. 
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Figure 5. 16 - OPG (8ng/mL) significantly reduced area resorbed at day 14 when 
supplemented into osteoclast differentiation cultures.Disks from osteoclast assays were 
harvested at day 14, cells removed, and were stained with toluidine blue prior to facilitate 
the quantification of area resorbed.  i.) A significant decrease in percentage area resorbed 
was found between m-CSF and RANKL cultures and those supplemented with OPG (p≤0.05; 
n=3 donors, 2 replicate disks per donor, means plotted).  No significant difference was 
reported between anti-CCL3 and OPG supplemented differentiation cultures.  ii.) 
Resorption was absent in RANKL-deficient cultures(n=4 donors; 2 replicates per donor, 
mean plotted).  Statistical analysis using a Student's t-test (* = p≤0.05).  Mean ± SEM 
reported.  
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 5.3.4.2 OPG supplementation had no significant effect on the secreted 
soluble mediators of osteoclast differentiation (TRAP5b) and bone 
resorption (CTX-1) 
OPG had no effect on TRAP5b levels when compared to m-CSF and RANKL 
differentiation cultures; 1.42 ± 0.12 versus 1.37 ± 0.28 U/L (Figure 5.17).  CTX-1 
levels from m-CSF and RANKL cultures reduced in the presence of OPG, although 
not significantly; 0.14 ± 0.06 to 0.01 ± 0.01 ng/mL.  Again, CTX-1 levels were at the 
lower limit of detection.  
 
5.3.4.3 The addition of OPG in human osteoclast differentiation cultures 
reduced inflammation mediators (CCL2, CCL3, CCL5, sIL-6R and IL-
6) to levels comparable to m-CSF only cultures 
Although high levels of CCL2 were found its secretion was comparable from m-CSF 
alone or m-CSF and RANKL cultures in the presence of OPG (Figure 5.18, i and ii).  
CCL3 secretion from m-CSF cultures in the presence or absence of OPG yielded 
comparable concentration profiles.CCL3 in m-CSF and RANKL cultures increased 
from day 0 to day 1 (63 ± 15 to 184 ± 59pg/mL), which was absent in the additional 
presence of OPG (40 ± 3 to 40 ± 8pg/mL; Figure 5.22, iii and iv).   CCL5 was again 
found to be below the lower limit of detection in n=7 assays, where in n=1 minimal 
levels were detected in all cultures (Figure 5.18, v and vi). 
In the presence and absence of OPG, comparable declining profiles of sIL-6R 
expression were found in m-CSF alone, and m-CSF and RANKL cultures; in m-CSF 
and RANKL averaging 30 ± 15 (day 0) to 10 ± 7pg/mL (day 14; Figure 5.19, i and ii).  
Similar results were shown for IL-6 concentrations in m-CSF only and m-CSF and 
RANKL cultures in the presence or absence of OPG; in m-CSF and RANKL averaging 
73 ± 22 (day 0) to 42 ± 24pg/mL (day 14; Figure 5.19, iii and iv).   
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Figure 5. 17 - TRAP5b and CTX-1 decreased but not significantly in the presence of OPG 
(8ng/mL).Supernatants from osteoclast differentiation assays were collected at day 10 and 
were analysed by ELISA for the presence of CTX-1 and TRAP5b.  i.) Soluble TRAP5b from 
OPG treated differentiation cultures was comparable to differentiation cultures at day 10.  
ii.)  OPG supplementation of m-CSF and RANKL cultures decreased CTX-1 levels but not 
significantly.  M-CSF and RANKL;N=7 donors, mean from 2 replicate disks per donor 
plotted.  M-CSF, RANKL + OPG;N=5 donors, mean from 2 replicate disks per donor plotted.  
Statistical analysis using a Student's t-test was performed.  Mean ± SEM reported. 
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Figure 5. 18 - Soluble chemokine inflammatory marker CCL3 was reduced in OPG treated 
osteoclast cultures.Supernatants across the time-course of osteoclast assays were 
collected and analysed via ELISA. i. and ii.) CCL2 secretion was comparable within all 
treatment conditions.  iii. and iv.) CCL3 in m-CSF and RANKL assays increased at day 1 and 
thus slowly declined to day 14.  OPG treated cultures showed baseline levels from day 0 to 
14.  v. and vi.)  CCL5 increased in m-CSF and RANKL cultures but negligible levels were 
found in OPG.  No sample existed for m-CSF and OPG cultures at day 1.  M-CSF and RANKL; 
N=7 donors, 2 replicate disks per donor.  M-CSF, RANKL + OPG;N=5 donors, 2 replicate disks 
per donor.  Means of all donors plotted ± SEM reported. One-way ANOVA preformed.  
0
100
200
300
0 1 3 7 10 14DAY
C
C
L3
 C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
0
25
50
75
0 1 3 7 10 14DAY
C
C
L5
 C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
0
25
50
75
0 1 3 7 10 14DAY
C
C
L5
 C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
202 
 
  
 
 
m-CSF m-CSF and RANKL 
i.) 
0
25
50
75
100
0 1 3 7 10 14DAY
+ OPG
sI
L-
6R
 C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
 
ii.) 
0
25
50
75
100
0 1 3 7 10 14DAY
+ OPG
sI
L-
6R
 C
on
ce
nt
ra
tio
n 
(p
g/
m
L)
 
iii.)   
 
iv.)  
 
Figure 5. 19 - Soluble cytokine inflammatory markers in OPG cultures were not 
significantly different to osteoclast control cultures.Supernatants across the time-course 
of osteoclast assays were collected and analysed via ELISA.  i. and ii.) sIL-6R in m-CSF only 
and m-CSF and RANKL cultures ±  OPG were not significantly altered.  iii. and iv.) IL-6 
concentration was comparable in m-CSF only cultures ± OPG, and within m-CSF and RANKL 
± OPG. No sample existed for m-CSF and OPG cultures at day 1.  M-CSF and RANKL; N=7 
donors, 2 replicate disks per donor.  M-CSF, RANKL + OPG;N=5 donors, 2 replicate disks per 
donor.  Means of all donors plotted ± SEM reported.  One-way ANOVA preformed.  
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 5.3.5 Determining the impact of inhibiting CCL3 on bone pathology and 
inflammation in a murine model of CIA 
The inhibitory effect of anti-CCL3 on bone resorption in vitro was established in 
Section 5.3.2 and its therapeutic potential suggested in Section 5.3.4.  Next the 
effectiveness of this strategy in vivo was tested in the murine model of collagen 
induced arthritis (CIA).  Brand, Latham & Rosloniec (2007) reported the use and 
application of this model for RA, where mice were immunized with CFA and type II 
collagen on day 0 and by day 21 show the first clinical signs of arthritis (erythema 
and swelling of the meta-tarsals/tarsals/ankle joint).  In this respect, the murine 
model of inflammatory arthritis (CIA) was established and treatment ensued with 
either anti-CCL3 or a paired isotype control antibody (IgG1).  Mice received five 
treatment doses of either anti-CCL3 or isotype control by intraperitoneal injection 
on alternate days.  The same dose of each treatment was given to each mouse.  
Dose was calculated from the average murine weight and previously reported CCL3 
concentrations in murine plasma (Kasama et al. 1995). The experiment ended on 
day 29 when joints were harvested for 3D imaging (micro-CT) and histology 
(haematoxylin and TRAP staining).  
5.3.5.1 The treatment of murine CIA with anti-CCL3 had no effect on 
clinical score 
Anti-CCL3 exerted diminutive impact upon CIA-associated inflammation, by clinical 
score (5 ± 2) and paw diameter measurements (2.4 ± 0.2mm), versus mice treated 
with the isotype control Ab (6 ± 2 and 2.4 ± 0.1mm; Figure 5.20).  
 
5.3.5.2 In anti-CCL3 treated mice a significant reduction in radiological 
erosive score in hind paws and forepaws were found 
Radiological assessment of erosions in the tarsals, meta-tarsals and phalanges joints 
of the hind paw were carried out to show the in vivo effect of anti-CCL3 on the 
resorptive activity of the osteoclast.  A significant 2-fold decrease in the number of 
erosions per hind paw in anti-CCL3 treated mice compared to isotype mice was 
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 proven (p≤0.01, Figure 5.21).   Similarly, treatment with anti-CCL3 yielded a 
significant 2-fold reduction in forepaw erosions compared to isotype controls; 1.50 
± 0.44 compared to 2.91 ± 0.49 (p≤0.05, Figure 5.22).  Using micro-CT extensive 
bone degradation was seen in hind paw reconstructions, where anti-CCL3 had a 
protective effect on joint architecture; specifically in the tarsal joints (Figure 5.23).    
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Figure 5. 20 - The in vivo treatment of mice with anti-CCL3 had no significant effect on the 
progression of CIA.Anti-CCL3 or isotype control Ab was given to a murine model of CIA on 
alternate days.  The injection of anti-CCL3 had no significant impact on the clinical score of 
mice compared to isotype controls (n=6 per group).   No significant difference was noted 
between treatment groups for paw diameter. Statistical analysis using a two way ANOVA 
was performed, and means ± SEM data values were reported. 
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Figure 5. 21 - Radiological erosions in hind paws were significantly reduced in animals 
treated with anti-CCL3 compared to isotype controls.i.)Representative x-rays of hind paws 
from CIA mice treated with either anti-CCL3 or isotype control were acquired.  ii.) A 
significant reduction in the number of eroded joints was found in hind paws from mice 
treated with anti-CCL3 compared to isotype controls (p≤0.01, n=6 mice per group; left and 
right hind paw assessed). Arrows indicate radiological erosions.  Statistical analysis using a 
Student's t-test was performed(** = p≤0.01), and means ± SEM data values were reported.  
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Figure 5. 22 - Radiological erosions in forepaws were significantly reduced in animals 
treated with anti-CCL3 compared to isotype controls.i.)Representative x-rays of forepaws 
from anti-CCL3 or isotype control Ab treated CIA mice were acquired.  ii.) The number of 
eroded joints in the forepaw was significantly reduced in the presence of anti-CCL3 
compared to isotype controls (p≤0.05, n=6 mice per group; left and right forepaw 
assessed). Arrows indicate radiological erosions.  Statistical analysis using a Student's t-test 
was performed(* = p≤0.05), and means ± SEM data values were reported.  
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Figure 5. 23 - Micro-CT reconstructions illustrated the substantial protective effect of 
anti-CCL3 treatment on joint structureA reconstruction of the hind paw of an isotype 
treated mouse (n=1) and an anti-CCL3 treated mouse (n=1) shows the clear substantial 
differences in eroded bones of the tarsals.  Anti-CCL3 treated mice appear protected from 
the erosive behaviour. 
  
Isotype Ab Anti-CCL3 Ab 
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 5.3.5.3 Arthritis index was significantly reduced in the distal joints of anti-
CCL3 treated mice 
Forepaws fixed in formalin were sectioned and stained with haematoxylin and TRAP 
facilitating assessment of inflammatory infiltrate, synovial hyperplasia, pannus 
formation and bone destruction, leading to the arthritic index (A.I.; composed of 
inflammatory and degenerative score).  Inflammatory cell infiltration and synovial 
hyperplasia were comparable in shoulder joints from isotype and anti-CCL3 treated 
mice (A.I. 3.8 ± 0.6 versus 2.3 ± 0.4) and minimal cartilage/bone loss was present.  
Further analysis of the shoulder joint showed no significant difference in 
inflammatory (isotype: 2.9 ± 0.6, anti-CCL3: 1.9 ± 0.5) or degenerative score 
(isotype: 0.8 ± 0.2, anti-CCL3: 0.4 ± 0.2).  Extensive TRAP staining was seen in the 
humerus growth plate in both treatment groups, highlighting the location of 
osteoclasts (Figure 5.24, i and ii, arrows). 
The A.I. of the elbow was significantly reduced in anti-CCL3 treated mice compared 
to isotype controls; 4.9 ± 0.6 versus 2.7 ± 0.7 (Figure 5.25, p≥0.05).  The 
inflammatory score was not significantly different in the forearm and elbow joint; 
3.8 ± 0.4 versus 2.4 ± 0.6, but adipocytes had been displaced by infiltrating cells in 
both groups, along with an increase in exudate fibrin deposits in isotype treated 
mice but not anti-CCL3.  TRAP staining was localised to the epiphysis in isotype 
controls, but was negligible in anti-CCL3 mice (Figure 5.24, iii and iv, arrows).  The 
degenerative score for the elbow in anti-CCL3 animals compared to controls was 
significantly reduced; 1.1 ± 0.3 versus 0.4 ± 0.2 (Figure 5.25, p≥0.01).   
A.I. of the wrist significantly decreased in the presence of anti-CCL3; 6.8 ± 0.6 versus 
3.8 ± 0.36 (Figure 5.25, p≥0.01).  Infiltrating immune cells were visibly enhanced in 
both adipose tissue and exudate of isotype controls, along with hyperplasia and 
bone erosions.  A 1.8-fold significant decrease in inflammatory score from the wrist 
was reported after treatment with anti-CCL3; 5.3 ± 0.5 versus 2.9 ± 0.6 (Figure 5.25, 
p≥0.01).  Inflammatory cell infiltration into surrounding tissues was evident in 
isotype joints, seen by ‘creeping’ over bone surface, but infiltration into the 
exudates was minimal (Figure 5.24, v and vi, arrows).  The presence of TRAP was 
greatly increased in the radius and carpals of isotype animals, but anti-CCL3 mice 
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 appeared protected with minimal TRAP presence or bone erosions.  Degenerative 
scores for anti-CCL3 treated mice were significantly reduced from isotype controls; 
1.5 ± 0.2 versus 0.9 ± 0.2 (Figure 5.25, p≥0.05).   
 
5.3.5.4 Anti-CCL3 treatment of CIA significantly reduced histological 
osteoclast counts compared to isotype controls 
In the shoulder joint no significant change in osteoclast number was found between 
isotype groups and those treated with anti-CCL3; 34 ± 7 versus 30 ± 5 osteoclasts 
(Figure 5.26, i).  In the distal elbow joint, a significant reduction in osteoclast 
number was seen in anti-CCL3 treated mice; 18 ± 7 versus 4 ± 2 osteoclasts (p≥0.05, 
Figure 5.26).  A significant decrease in osteoclast number was also found in the 
wrist joint of anti-CCL3 treated mice compared to isotype controls; 62 ± 21 versus 
18 ± 4 osteoclasts (Figure 5.26, iii, p≥0.05).  Overall, the in vivo data reported here 
proves that the significant reduction in bone degradation was due to significantly 
reduced osteoclast formation and resorptive activity, and further supports in vitro 
data.    
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 Isotype IgG1 Ab Anti-CCL3 Ab 
i.). 
 
ii.) 
 
iii.) 
 
iv.) 
 
v.)  
 
vi.) 
 
Figure 5. 24 - Enhanced TRAP staining was visualised in isotype control treated mice 
compared to anti-CCL3 treated.CIA-induced mice were treated with 5 doses of isotype 
IgG1 Ab (n=6) or anti-CCL3 Ab(n=6) prior to being culled on day 29. i + ii.)  TRAP (red 
arrows) was evident in the humerus’ epiphysis and growth plate in IgG1 treated mice, but 
only in the growth plate of anti-CCL3.  iii. + iv.) TRAP localised in the elbow epiphysis of IgG1 
mice but was absent in anti-CCL3 mice.  v +vi.)  Radial epiphysis showed extensive 
localisation of TRAP in carpals of IgG1 controls, compared to anti-CCL3 mice.  Inflammatory 
infiltration, hyperplasia and resorption were seen in both treatment groups, but an 
extensive phenotype in the carpals of isotype mice were reported (black arrows).  Scale bar 
1mm. 
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Figure 5. 25 - Anti-CCL3 treatment of CIA significantly reduced histological erosive scores 
in the elbow and wrist joints.Fore-arm sections were assessed for an inflammatory index 
score; subsynovial inflammation, synovial exudate and synovial hyperplasia/pannus 
formation, and erosive score.  Addition of these scores resulted in the arthritis index (A.I.).  
i.) No significant difference in A.I. of isotype control mice and anti-CCL3 was seen in the 
shoulder joint.  ii.)  A.I. significantly reduced in the elbow joint after anti-CCL3 treatment 
(p≥0.05), but no change in inflammatory index resulted.  A significant decrease in erosive 
score compared to anti-CCL3was found (p≥0.05).  iii.) Anti-CCL3 significantly decreased the 
wrist A.I. (p≥0.01), which resulted from a significant reduction in inflammatory index and 
erosive score (p≥0.01 and p≥0.05).N=6 mice per group, left and right forepaw assessed. 
Statistical analysis using a Student's t-test performed.  Mean ± SEM data reported. 
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Figure 5. 26 - Osteoclast number significantly reduced in the elbow and wrist joints of 
anti-CCL3 treated mice.Following the histological analysis of fore-arm sections from mice 
treated with isotype or anti-CCL3 the presence of TRAP+ve osteoclasts was assessed per 
section.  i.) Osteoclast number was unchanged in the shoulder joint of anti-CCL3 and 
isotype control treated mice.  ii.) A significant reduction in osteoclast number in the elbow 
joints of anti-CCL3 mice compared to isotype controls resulted (p≥0.05).  iii.)  In wrists joints 
a significant decrease in osteoclast count resulted through anti-CCL3 treatment when 
compared to isotype control treated mice (p≥0.05).  N=6 mice per group, left and right 
forepaw assessed. Statistical analysis using a Student's t-test was performed, and means ± 
SEM data values were reported.  
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 5.4 Discussion 
Increased CCL3 has been linked to enhanced osteoclastogenesis and bone 
resorption in both murine and human bone marrow cultures (Tak et al. 1997, Toh et 
al. 2004, Szekanecz et al. 2010, Takano et al. 2014).  In this chapter a novel role of 
CCL3 in osteoclastogenesis was suggested from its significant early increase after 
RANKL stimulation.  Neutralisation of CCL3 caused a significant attenuation of 
osteoclast number and resorption to similar levels as OPG in CD14+ve monocultures.  
Such in vitro data therefore postulates CCL3 as a novel therapeutic target in 
diseases characterised by extensive bone destruction, such as experimental 
inflammatory arthritis (CIA).  In summary, the data presented in this chapter 
identifies a novel biomarker in destructive bone diseases with potential therapeutic 
benefits.  The contextualisation of the above results and their impact on the clinical 
aspect of bone diseases will next be discussed. 
 
5.4.1 CCL3 synergistically increased osteoclast formation in the 
presence of RANKL signalling 
This chapter reports a novel role of CCL3 in mediating a significant increase in early 
osteoclastogenesis, which was linked to osteoclast formation and bone resorption.  
Furthermore, experiments investigating the effect of neutralising CCL3 on 
osteoclastogenesis reported a clear role of CCL3 in osteoclast differentiation 
(TRAP+ve cells and osteoclast counts), rather than the resorptive potential of the 
osteoclast (individual pit area, depth and volume data). 
Although the mechanisms through which CCL3 aided osteoclast differentiation 
were not investigated, several theories could be postulated when considering the 
conclusions of previously published studies where CCL3 has been reported as 
RANKL dependent.  Data reported in this chapter concurs with the previously 
reported RANKL-mediated increase in CCL3 in both mononuclear cell assays (24 
hours post RANKL; Koch et al. 1994) and RAW264 osteoclast precursors (48 hours 
post RANKL; Ishida et al. 2006).  More recently, addition of CCL3 into CD14+ve 
monocyte cultures was reported to increase osteoclast differentiation (Dapunt et 
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 al. 2014).  Collectively, the above studies suggest a common RANKL-mediated 
increase in CCL3 levels, allowing a crossover in RANKL signalling and CCL3 
expression to be postulated (Koch et al. 1994, Ishida et al. 2006, Dapunt et al. 
2014).  Although both RANKL and CCL3 activate their own independent receptors 
(RANK - TRAFs and CCR1- GPCR respectively), the transcription and translation of 
downstream signalling proteins (NFATc1, AKT, MAPK and JNK)from each pathway 
could be intersected (Lentzsch et al. 2003, Mueller & Strange 2004, Blair et al. 2005, 
Wada et al. 2006, Heinemann et al. 2011). 
Specifically, RANK activates TRAF6 which localises to its cytoplasmic region 
activating c-Src (leading to PI3K and Akt), NF-κβ, MAP kinases (JNK) and 
extracellular signal-related kinases (ERK1/2).  Such activation results in the nuclear 
relocalisation of transcription factors (NFATc1, c-fos, P.U.1, AP.1, c-Jun) and the 
phosphorylation of STAT1 leading to the transduction of osteoclast related genes 
(DC-STAMP, Atp6v0d2, CATK, MMP9 and TRAP; Galibert et al. 1998, Blair et al. 
2005, Wada et al. 2006).  Comparatively, CCR1 activates MAPK and ERK1/2, but in a 
similar mechanism increases Akt through c-Src.  The activation and relocation of NF-
κβ, JNK, NFATc1, AP.1 to the nucleus results leading to enhanced NFATc1, MAPK, 
JNK and osteoclast related gene expression (DC-STAMP, Atp6v0d2, CATK, TRAP, 
integrins, vitronectin and calcitonin (Jimi et al. 1999, Kukita et al. 2004, Mueller& 
Strange 2004, Kim et al. 2005, Wada et al. 2006, Xing et al. 2012).  Interestingly, 
CCR1 expression was observed to be increased on marrow cells cultured in RANKL 
(Yu et al. 2004) and from studies using RAW264 cells increased CCR1 was reported  
following NFATc1 activation (Ishida et al. 2006).  Therefore, we can hypothesis that 
RANKL increased CCR1 expression on CD14+ve monocytes in our cultures, thus 
increasing cellular responsiveness to CCR1 ligands and increasing cell migration.  
The resultant and combined elevated expression of NFATc1, MAPK and JNK from 
both RANKL and CCL3 signalling would therefore offer one possible mechanism for 
the synergistic generation of osteoclast precursors. 
Furthering current knowledge, in this chapter anti-CCL3 significantly reduced 
osteoclast number but had no effect on TRAP+ve cell count or supernatant-
associated levels of TRAP5b.  RANKL-RANK signalling could therefore be dominant 
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 over CCL3-CCR1 signalling.  Alternatively, it could be thought of as independent 
from RANKL-RANK signalling, but with similar effects on rate-determining steps of 
osteoclastogenesis; pre-cursor cell migration and fusion (Takayanagi et al. 2002, 
Cassady et al. 2003, Ikeda et al. 2004, Partington et al. 2004,Sharma et al. 
2007,Dapunt et al. 2014).  In contradiction, Albuquerque et al. (2013) showed CCL3 
essential for murine TRAP expression.  However, this difference could be explained 
by the use of a global CCL3 knockout model in vivo that resulted in a reduction of T 
cell and osteoblast mediated RANKL secretion, thus decreasing TRAP+vecell counts 
(Yu et al. 2004, Castellino et al. 2006, Harvey & Kaymakcalan 2010, Dapunt et al. 
2014). 
 
5.4.2 CCL3 in precursor cell migration 
This chapter illustrates an important role of CCL3 in osteoclastogenesis.  One such 
mechanism whereby CCL3 could mediate these effects is on precursor cell 
migration.  Although not directly studied in this thesis, in 2004 Yu et al. reported 
enhanced precursor cell migration in the presence of CCL3 and RANKL.  Ishida et al. 
(2006) further commented upon the global role of CCR1 ligands on osteoclast 
precursor cell migration, where a disruption of CCR1 signalling through receptor 
antagonism or inhibition resulted in decreased osteoclast number.  In 2013 the 
mechanism behind decreased cell migration was established by Gilliland et al. 
(2013), where CCR1 signalling lead to increased F-actin polymerisation, thus 
meaning an attenuated CCR1 stimulation would result in decreased migration and 
motility.  Secondary to the effects of anti-CCL3 on cell migration, migratory 
chemokines including CCL2 were unlikely to exert cell migration (as shown in this 
chapter), where Mizutani et al. (2009)and Ishii et al. (2010) showed CCL2 and CCL5 
to have no effect on pre-cursor cell migration in the absence or presence of RANKL.   
Alongside precursor cell migration, cell fusion into multi-nucleated giant cells could 
also present itself as a rate-determining step in osteoclastogenesis.  The fusion 
proteins DC-STAMP and Atp6v0d2 (H+-ATPase V0 domain) both play critical roles in 
cell-cell fusion and are downstream signalling proteins from NFATc1 activation 
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 (Kukita et al. 2004, Lee et al. 2006, Kim et al. 2008).  Although not established 
within this chapter, a pivotal finding showed CCL3 to have no effect on DC-STAMP 
expression, but again did enhance osteoclast formation (Kukita et al. 2004).  It is 
therefore suggested that the effects of CCL3 on osteoclast differentiation were 
independent from the expression of the fusion protein DC-STAMP. 
The role of Atp6v0d2 in osteoclast formation was studied in a global knock-out 
mouse, where decreased bone resorption but increased bone formation was found 
(Lee et al. 2006).  TRAP5b levels in Atp6v0d2-/- mice remained unchanged to 
controls (Lee et al. 2006).  Comparably, TRAP5b was also unchanged in osteoclast 
cultures treated with anti-CCL3, despite a significant reduction in osteoclast 
number.  Further data provided by Lee et al. (2006) showed a 5-fold reduction in 
ADAM-8 and -12from Atp6v0d2-/-cultures, where osteoclast number could not be 
rescued by ADAM -8 and -12 supplementation (Lee et al. 2006).  Additionally, CCR1-
/- mice expressed decreased NFATc1 and Atp6v0d2, implicating CCR1 ligands (e.g. 
CCL3) in the expression and function of Atp6v0d2 (Hoshino et al. 2010).  A potential 
in vitro role of CCL3 in Atp6v0d2- mediated cell fusion could therefore be 
postulated. 
Further experimental work would be necessary to establish the role of Atp6v0d2 in 
osteoclastogenesis.  Through gene disruption and gene depletion in vivo, 
knowledge of the importance and interplay between Atp6v0d2 and CCR1 signalling 
in osteoclastogenesis could be established.  The experimental design would need to 
be carefully considered to ensure the essential expression of NFATc1, MAPK and 
JNK; i.e. NFATc1 knock-out is lethal mid-gestation (Abdul-Sater et al. 2012).  In vitro, 
the molecular and protein expression of Atp6v0d2 could be quantified through 
western blot analysis, PCR or immunohistochemical staining.  Disks would need to 
be harvested along with culture supernatants at earlier time-points (2-, 4-, 8-, 10-, 
12-, 24-, 48- hours post RANKL supplementation) to identify when CCL3 exerts its 
primary effect on osteoclastogenesis and if this effects Atp6v0d2 expression.  The 
pathways through which m-CSF, RANKL and CCL3 effect cellular responses, and the 
stages at which osteoclast differentiation could be affected, are defined in Figure 
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 5.27.  Note that CCL3/CCR5 signalling is negligible in osteoclastogenesis as 
previously reported by Doodes et al. (2009)and Lebre et al. (2011). 
 
Figure 5. 27 - A schematic of RANKL-RANK and CCL3-CCR1 signalling pathways and their 
possible paths of interaction.RANKL binds to RANK on the surface on the cell and 
causes a cascade of intracellular signals.  Initially, TNF-receptor associated factors 
(TRAFs) localise to the cytoplasmic domain of RANK which leads to c-Src, NF-κβ and 
MAP kinase activation (Galibert et al. 1998, Blair et al. 2005 and Wada et al. 2006).  
Alternatively, CCL3 signals through its G protein coupled receptor CCR1 which 
directly activates downstream signalling molecules including MAP kinases, ERK1/2 
and c-Src (Mueller & Strange 2004).     In both pathways the activation of these 
proteins leads to transcription factor relocation to the nucleus and the transduction 
of osteoclastic genes; DC-STAMP, Atp6v0d2, CATK, MMPs, TRAP, which typify 
differentiating osteoclasts.   Highlighted in red are areas of osteoclastogenesis that 
may be affected. 
 
5.4.3 CCL3 exerts negligible effects on mature osteoclast resorptive function 
Following on from studying the effects of CCL3 on osteoclastogenesis, the effect of 
CCL3 on the resorptive capability of the osteoclast was assessed.  The neutralisation 
of CCL3 significantly reduced the total area of bone resorbed over the 14 day 
differentiation period, but no significant change in individual pit characteristics (pit 
area, volume and depth) were found.  These data suggested that there was no 
effect of anti-CCL3 on resorption variables such as the motility of mature 
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 osteoclasts, their attachment to bone surfaces, or the secretion of degradative 
enzymes. 
However, CCL3 has been linked to the migration of mature osteoclasts 
differentiated in the presence of RANKL from murine RAW264 cells, where its 
presence caused a 2-fold increase in osteoclast motility after 24-hours (Yu et al. 
2004).  Neutralisation of anti-CCL3 was therefore suggested to reduce osteoclast 
motility, thus resulting in decreased resorption from active osteoclasts.  This theory 
could be examined by fluorescently tagging F-actin (FITC-phalloidin; Wilson et al. 
2009) and monitoring the osteoclasts motility rates across the disks surface. 
Secondary to osteoclast motility, an effect of anti-CCL3 on reducing osteoclast 
attachment to bone substrate may also have occurred.  Integrin αvβ3 expressed by 
the osteoclast is used for adherence to vitronectin, osteopontin and bone 
sialoprotein (Horton 1997, Duong et al. 1999).  αv expression is downstream of 
NFATc1 implicating this integrin in RANK and CCR1 signalling, where CCR1 inhibition 
has shown decreased αvβ3 (Ishida et al. 2006, Lin et al. 2013).  Subsequently, the 
neutralization of CCL3 in m-CSF and RANKL cultures could reduce αv through 
reducing NFATc1, thus reducing osteoclast attachment.  Opposing data has 
however been reported by Yu and colleagues (2004), who observed that CCL3 had 
no effect on osteoclast attachment, although they did not quantify the molecular 
expression of αvβ3 integrins.  To further define the role of CCL3 on osteoclast 
attachment the expression of αv integrins and the profile of NFATc1would need to 
be monitored at the molecular and protein level (qPCR). 
Finally, in addition to osteoclast motility and attachment, CCL3 may also have 
affected the secretion of resorptive enzymes from the osteoclast.  However, from 
data reported in this chapter the effect of CCL3 on resorptive enzyme secretion is 
thought to be minimal as there were no differences in the pit areas and depths 
between cultures with and without anti-CCL3.  The data reported here supports 
that of Yu et al. (2004) who used an in vitro model of osteoclastogenesis which 
showed CCL3 to have no effect on the ability of a mature osteoclast to form 
resorption pits.  Subsequently, the significant reduction in bone resorption reported 
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 in this chapter is thought to be a secondary effect of significantly attenuated 
osteoclast number, rather than a direct effect of CCL3 on resorption.  Supporting 
this Ishii et al. (2010) reported CCL3 to be down-regulated following the 
differentiation of mononuclear cells into osteoclasts, suggesting CCL3 signalling was 
no longer pivotal to mature osteoclast function in vitro.   
However, a postulated peripheral role of CCL3 on in vivo osteoclastogenesis can be 
suggested from the associated role of increased CCL3 in bone diseases 
characterized by enhanced bone resorption (Choi et al. 2000, Repeke et al. 2010, 
Vallet et al. 2011).  Using CCL3-/- mice CCL3 has been reported to have no effect on 
the secretion of resorptive enzymes including CATK (bone resorptive) and MMP-13 
(cartilage destructive), from the osteoclast (Albuquerque Taddei et al. 2013, Kikuta 
& Ishii 2013).  Additionally, their secretion was unaffected by Met-RANTES, a CCR1 
antagonist, thus confirming these enzymes act independently of CCR1 signalling.  In 
addition MMP-9 is also involved in joint destruction, where CCL3 has been found to 
stimulate its secretion in lung metastasis models from mononuclear cells and 
macrophages, however MMP-9 secretion from the osteoclast due to CCL3 remains 
unknown (Yang et al. 2006, Wu et al. 2008). To definitively prove the importance of 
CCL3 on the direct secretion of resorptive enzymes further experiments are needed 
where MMP presence and activity could be assessed using zymography (Leeman et 
al. 2002, Hu et al. 2010, Franco et al. 2011, Chellaiah & Ma 2013). 
 
5.4.4 CCL3 inhibition potency vs. established osteoclast inhibitor in vitro 
Data reported throughout this chapter therefore support the utilisation of anti-
CCL3 as therapeutic against enhanced bone resorption.  Prior to assessing the 
efficacy of anti-CCL3 in inhibiting osteoclast formation in vivo, the potency of 
osteoclast inhibition in the presence of anti-CCL3 compared to the known inhibitor 
OPG was assessed in vitro (Udagawa et al. 2000, Irie et al. 2007).  The importance 
of OPG was previously reported as secretion increased after peak osteoclast 
differentiation, preventing extensive osteoclastogenesis (Irie et al. 2007).  Published 
data states OPG supplementation into co-cultures of osteoblasts and bone marrow 
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 cells completely inhibited osteoclast differentiation, maturation and survival, along 
with the blockade of substrate resorption (Jimi et al. 1999). 
For the first time, data reported in this chapter shows anti-CCL3 to have the same 
potency as OPG in inhibition of osteoclast formation in human CD14+ve osteoclast 
monocultures supplemented with m-CSF and RANKL.  An increased sample number 
however would be needed to prove reproducibility of this comparison.  Of pivotal 
importance, in cultures supplemented with OPG substantially reduced levels of 
CCL3, but not CCL2, CCL5, IL-6 and sIL-6R levels were found.  Further evidence was 
therefore provided for involvement of CCL3 in the stimulation of early osteoclast 
formation by a RANKL-dependent pathway, thus providing a rationale for the use of 
anti-CCL3 as a therapeutic in destructive bone disease.   
Initial experiments using anti-CCL3 as a therapeutic in models of destructive bone 
disease (i.e. arthritis, ovariectomized mice or cancer models) would be needed for 
proof of concept (Kameda et al. 1997, Bord et al. 2003, Oursler 2003, McClung et al. 
2006, Cummings et al. 2009, Pierroz et al. 2010, Yasuda et al. 2013).  If the 
neutralisation of CCL3 results in significantly attenuated bone destruction, the 
potency of such a treatment would next be assessed against current therapeutics; 
i.e. Denosumab, where a benefit vs. cost model could be established.  In theory 
anti-CCL3 exerts several benefits over Denosumab, firstly that Denosumab is only 
functional in the presence of RANKL; if given after RANK activation, osteoclast 
differentiation and resorption still occur.  Secondly, that determining Denosumab 
doses capable of inhibiting pathologically- enhanced bone resorption without 
disrupting bone homeostatic balance is difficult.  For example, Bargman et al. 
(2012) treated mice with varying doses of OPG-Fc and found it could result in both 
osteopetrosis and osteoporosis.  Although RANK signalling still occurs after anti-
CCL3 treatment, research has shown significantly decreased motility and 
differentiation of pre- and mature osteoclasts (Yu et al. 2004).  Osteopetrosis and 
osteoporosis are unlikely to occur with anti-CCL3 due to the redundancy of the 
chemokine system.  However, this is, at the same time, a disadvantage of a therapy 
such as anti-CCL3: additional chemokines (CCL2 and CCL5) may increase and 
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 enhance osteoclastogenesis in the absence of CCL3 in vivo through indirect RANKL 
secretion (Ishii et al. 2010). 
Not only may anti-CCL3 attenuate bone destruction, it may also lead to a reduction 
in pain.  The active secretion of protons creates an acidic environment leading to 
dissolution of bone mineral.  Hyperalgesia may also arise from the acidic 
environment, as suggested by Nagae and colleagues (2006), where CFA injected 
into hind paws of mice led to an increase in acid-sensing ion channel (ASIC) and 
transient receptor potential vanilloid 1 (TRPV1) mRNA in dorsal root ganglions  
(DRGs).  Thus, through anti-CCL3 attenuating bone destruction, a reduction of 
hyper-algesia may also result.  Furthermore, the expression of TRPV1 on DRG was 
shown to be co-expressed with CCR1 (CCL3 receptor) on >85% of neurons, where 
CCL3 caused a 3-fold increase in TRPV1 sensitivity (Zhang et al. 2005).  This pivotal 
finding provides the first mechanistic evidence for increased sensitization and pain 
in the presence of CCL3.  A finding further supported by the identification of an 
endogenous self-amplification loop for CCL3 in microglial cells led to elevated CCL3 
mRNA and enhanced NFAT signalling (Kataoka et al. 2009). 
The prevalence of pain may also have resulted from the receptor, CCR1, and the 
ligand, CCL3.  CCR1 inhibition has resulted in significant reductions of pain-like 
behaviour in animal models of hyperalgesia (Lewis et al. 2014).  However, CCR1 is 
the receptor for many chemokines and therefore it could be the lack of CCL5, CCL7 
or CCL23 signalling through CCR1 that has caused the decrease in pain.  For 
example, CCL2 is linked to heightened pain perceptions in pelvic pain syndrome, 
where its neutralization has led to significant attenuation of pain-like behaviour 
(Quick et al. 2012).  Commonly, mRNA levels of CCL2 and CCL3 increase 
simultaneously as in sciatic nerve injury models, therefore suggesting an 
ambiguous, dual neuro-inflammatory role of these chemokines (Kiguchi et al. 
2013).  However, in relation to osteoclast-associated pain, the impact of CCL2 is 
thought minimal due to unchanging levels in the presence of RANKL +/- anti-CCL3 
from our in vitro cultures.  To prove the importance of CCL3 in destructive bone 
pain further in vitro osteoclast differentiation assays are needed to quantify 
alternative pain mediator secretions (bradykinin, prostaglandin E2 etc.) in order to 
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 establish possible pain pathways.  The effects of anti-CCL3 on such pathways could 
then be assessed using an in vivo model of inflammatory arthritis (e.g. CIA) with 
behavioural testing prior to and post anti-CCL3 treatment. 
 
5.4.5 CCL3 as a potential therapeutic target in vitro 
To distinguish whether our significant reduction in osteoclast number and area 
resorbed in vitro was translated in vivo, the role of CCL3 was assessed in a murine 
model of inflammatory arthritis; CIA.  Kasama et al. (1995) first reported the 
importance of CCL3 in the murine model of CIA where increasing concentrations of 
CCL3 over the induction time-course were found.  A similar increasing profile was 
recorded within in vitro experiments reported in this chapter, together implying a 
role of CCL3 in the instigation and progression of CIA directed by the osteoclast.  
Following the quantification of CCL3 in vivo, Kasama et al. (1995) immunized 
animals with a CCL3-directed antibody which led to a reduction in disease 
presentation.  The data reported in this chapter contradicts such a reduction, where 
no significant decrease in macroscopic scores of inflammation (clinical score and 
paw diameter) were reported.  Although not fully understood, such differences may 
have resulted from variations in CIA induction and time-course (i.e. CIA was 
assessed for 29 days in this chapter versus 68 days in Kasama et al. 1995). 
Following the assessment of anti-CCL3 on macroscopic pathologies associated with 
CIA, microscopic changes were assessed due to the novel findings of this thesis 
suggesting a role of CCL3 on osteoclastogenesis (see chapter 5.3.2.3).  Radiological 
data showed a significant reduction of joint erosions in both fore- and hind paws of 
anti-CCL3 treated mice compared to controls, along with a visual improvement of 
hind paw joint structure by micro-CT imaging.  Due to slow fixation methods hind 
paws were used for micro-CT analysis whilst forepaws were fixed quickly and used 
for histological analysis.  Furthermore, forepaw analysis showed a significant 
reduction in degenerative score and osteoclast number in the presence of anti-CCL3 
in the distal joints.  This data therefore led to the novel finding that CCL3 was 
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 involved in osteoclastogenesis in vivo, thus translating our data from in vitro studies 
into a more complex model of osteoclast differentiation.   
To definitiely prove the importance of CCL3 in oteoclastogenesis and in turn CIA 
severity, additional experiments would be essential.  Primarily, sample size would 
need to be increased alongside the repeition of this experiment to ensure that the 
effects seen within this chapter were not due to chance and are reproducible.  
During these additional stage 1 experiments a CCL3 concentration profile over the 
course of CIA induction would be quantified, similar to that which Kasama et al. 
(1995).  From this profile, a tailored dose range of anti-CCL3 could then be used in 
stage 2 experiments to assess the minimum effective dose and maximum tolerated 
dose concentrations (due to side effects or lethality).  In addition the Cmax and Tmax 
could be identified to understand the absorption and removal of the compound.  
Additionally, in stage 2 experiments the dosing frequency and method of drug 
delivery would need to assessed, whilst maintaining compliance with Home Office 
and Project License regulations, to distinguish optimal treatment periods.  Post 
stage 2 maximal beneficial effects of anti-CCL3 treatment in CIA development 
should therefore be known, where it may be concluded that an increased dose of 
anti-CCL3 could significantly reduce macroscopic inflammatory scores.   
Alternative routes of CCL3 inhibition may also be preferred to administering anti-
CCL3 such as ligand knock-out models or receptor antagonists/inhibitors.  
Chintalacharuvu et al. (2005) reported the importance of CCL3 in CIA by showing a 
significant reduction in inflammatory components in a CCL3-/- murine model.  Whilst 
providing data which was contrary to that found in this chapter with anti-CCL3 
treatment, differences may have resulted from complete knock-out of CCL3 versus 
its neutralisation (which may have only be partial due to dosing).  The completion 
of stage 2 experiments as outlined above are pivotal to further insight into this 
finding to establish whether macroscopic pathologies of CIA can ever be inhibited 
by anti-CCL3 treatment.  If, however a significant reduction of macroscopic 
pathologies does not result, anti-CCL3 may have altered the phenotype or density 
of infiltrating cells into the joint.  For example, from the monocyte, macrophage, T 
cell and/or neutrophil phenotype which is typified by CIA, and this could be 
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 assessed by FACS or immunohistochemistry (Tak et al. 1997, Ramos et al. 2005, Xue 
et al. 2007, Szekanecz et al. 2010, Jonker et al. 2013, Shi et al. 2015). 
The significant reduction in osteoclast number and joint erosions did however 
support previous data reported by Kondo et al. (2011) who showed CCL3-/- and 
CCR1-/- mice to have attenuated leukocyte migration, osteoclast differentiation and 
joint erosions compared to CCR5-/- and wild-type mice.  Together with data 
reported in this chapter (both in vitro and in vivo), CCR1 is supported as the main 
receptor for CCL3-induced pathology in bone resorption, and therefore again 
presents itself as a potential therapeutic target.  Initial use of a CCR1 antagonist, 
UCB35625, was shown to inhibit leukocyte chemotaxis, and could therefore 
potentially decrease osteoclast precursor cell migration (Sabroe et al. 2000).  
Following this, CCR1 antagonist, BX471, specifically inhibited signal transduction 
and osteoclastogenesis even after CCL3 stimulation (Oba et al. 2005).  The CCR1 
antagonist J-113863 which was given to mice with CIA also decreased inflammatory 
and destructive bone scores, alongside reducing leukocyte migration to joints 
(Amat et al. 2006).  Furthermore, the CCR1 inhibitor MLN3897 also led to decreased 
cell interactions attenuating cell growth and survival through inhibition of Akt 
signalling (Vallet et al. 2007).  It could thus be concluded that when combined with 
novel in vitro and in vivo data reported in this chapter, the antagonism of CCR1-
CCL3 signalling reduced mature osteoclast formation, likely due to the inhibition of 
mononuclear cell migration, fusion and interaction.  The impact of this novel 
therapeutic target will be further discussed in context with human diseases in 
Chapter 6, the General Discussion. 
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 5.5 Conclusion 
This chapter has identified and discussed a novel role of CCL3 in early osteoclast 
differentiation.  Specifically, a RANKL-dependent, significant increase in CCL3 
secretion occurred after 24-hours, exerting a significant role in early osteoclast 
differentiation in vitro.  The neutralisation of CCL3 by an anti-CCL3 antibody in vitro, 
significantly attenuated osteoclast number and area resorbed to levels seen in OPG 
treated cultures.  Individual resorption pit parameters were not significantly altered 
after CCL3 neutralisation, suggesting CCL3 has a role in osteoclast differentiation 
but not in osteoclastic resorption.  The significant decrease of CCL3 in OPG 
supplemented cultures supports a RANKL-dependent action.  In addition, the 
results reported in this chapter were contextualised in terms of pathological pain 
associated with bone destructive diseases, and a strong link between CCL3 and pain 
was postulated.  The treatment of our reported murine model of CIA with anti-CCL3 
led to significantly reduced radiological erosive scores and histological analysis 
showed significantly reduced osteoclast counts in distal joints.  In conclusion, CCL3 
neutralization was shown to be beneficial both in vitro and in vivo for the 
attenuation of osteoclastogenesis and protection of joints from osteolysis.  Taken 
together, the data reported in this chapter and that previously published, 
implicates CCL3 in the development, progression and pain associated with 
destructive bone diseases.  Further work establishing dose ranges is pivotal to 
establishing whether this therapeutic would be effective in reducing inflammatory 
pathologies in humans, and nociception. 
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6 Chapter 6:General Discussion  
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 This thesis reports novel data on the role of IL-6 trans-signalling and CCL3 in 
osteoclast-mediated bone destruction supporting their published roles in 
inflammatory disease pathology (Tamura et al. 1993, Schluger & Rom 1997, Ajuebor 
et al. 2004, Gabay 2006, Pharoah et al. 2006, Tanaka et al. 2014).  The importance 
of IL-6 trans-signalling and CCL3 is commonly reported in terms of inflammation, 
but data regarding their role in joint destruction is beginning to emerge as 
discussed in the previous chapters.  However, the methodologies of co-cultures or 
receptor knock-out models are commonly reported in published studies which 
leave ambiguity as to the initiator of osteoclastogenesis and subsequent resorption 
(i.e. indirect effects of co-cultured cells on osteoclastogenesis).  For example, co-
cultures of bone marrow cells were used by Choi et al. 2000 where CCL3 was 
reported as an osteogenic factor.  All data reported in this thesis was obtained from 
the in vitro monoculture methodology established in Chapter 3: CD14+ve monocytes 
cultured on ivory in the presence of m-CSF and RANKL.  At least 6 donors were used 
for each treatment condition, with multiple disk replicates per donor per condition.  
This robust methodology increased data integrity and validity over that previously 
reported from studies using cell co-cultures on glass (Hirayama et al. 2002, Peruzzi 
et al. 2012).  Quantification of cytokines in culture supernatants allowed direct 
association with postulated osteoclastogenesis biomarkers.   
Data presented in Chapter 3 also defined a novel computational algorithm for cell 
visualization and counting which was validated to provide high-throughput data 
analysis.  The development of this algorithm vastly reduced analysis time (10-fold i 
comparison to conventional methods), thus enabling greater replicate numbers per 
donor under each treatment condition, further increasing data validity through 
reproducibility.   The use of this algorithm could be wide-spread following further 
validation; i.e. pit number or surface area quantification, nuclei counting per cell, or 
tracking cellular migration in combination with imaging modalities (Kramer et al. 
2013).  The development of a processing algorithm for confocal images also led to 
quantitative resorption pit area and depth measurements where early changes in 
3D resorptive characteristics were detected.  This was reported as a pivotal finding 
in understanding the impact of pro-inflammatory stimuli on bone resorption.  
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 Similar methodologies have been reported by Soysa et al. (2009) and Goldberg et 
al. (2012) who have all shown differences in osteoclast nuclei number, surface area 
and ‘resorption cavity locations’ respectively, but not in the presence of 
inflammatory mediators. 
The application of the above methods in Chapters 4 and 5 yielded novel data about 
IL-6 trans-signalling and CCL3.  Stimulated IL-6 trans-signalling lead to significantly 
increased osteoclast number.  Preliminary data suggested a IL-6 trans-signalling to 
also significantly enhance individual osteoclast resorption in terms of pit depth, 
which could be inhibited through sgp130-Fc.  At the conclusion of Chapter 5, CCL3 
was shown as significantly increased in the presence of RANKL and was suggested 
to exert an early role in osteoclast fusion and differentiation, where its 
neutralization significantly reduced bone resorption both in vitro and in vivo.  Such 
data therefore supports therapeutics designed to inhibit IL-6 trans-signalling and 
CCL3. 
 
6.2 The dual importance of IL-6 trans-signalling in bone destruction 
and inflammation 
IL-6/sIL-6R is one of the main pathogenic instigators of chronic inflammation and 
plays a major role in inflammatory arthritis (Romas et al. 1996).  IL-6 is a pleiotropic 
cytokine affecting leukocytes, hepatocytes, bone cells and personal well-being, 
resulting in inflammation, increased hepcidin (anaemia), altered bone homeostasis 
and fatigue respectively (Madhok et al. 1993, Nemeth et al. 2004, Benedetti et al. 
2006,Davis et al. 2008).  IL-6 activates both inflammatory and resorptive 
pathologies and has thus been termed a 'keystone' cytokine in arthritis, 
osteoporosis, systemic lupus erythematosus, Castleman's disease, psoriasis and 
encephalomyelitis (Grossman et al. 1989, Yoshizaki et al. 1989, Eugster et al. 2001, 
Ripley et al. 2005, Hunter and Jones 2015).  In Chapter 4 evidence was provided for 
a role of IL-6 trans-signalling in direct osteoclast formation and resorption, 
postulated to be resultant of the expression and activation of gp130 on the 
osteoclasts membrane (Johnson et al. 2015).  Furthermore, an association between 
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 RANK and IL-6 has also been reported by Tsangari et al. (2004) where IL-6 inhibition 
reduced RANK on precursor cells decreasing osteoclastogenesis, postulating an 
association with the autocrine up-regulation of RANK.   
IL-6 trans-signalling is thus postulated as pivotal in bone destructive diseases such 
as the arthritides (i.e. RA, JIA psoriatic arthritis), periodontitis and MM (Urashima et 
al. 1996, Robak et al. 1998, Elkayam et al. 2000, Peake et al. 2006, Hienz., Paliwa& 
Ivanovski2015).  In chronic inflammation sIL-6R (resultant of proteolytic cleavage 
and alternative splicing primarily from neutrophils) and IL-6 are elevated in synovial 
fluid, serum and plasma resulting in leukocyte chemotaxis, infiltration, hyperplasia, 
cytokine secretion, proteolytic enzyme secretion and osteoclast differentiation 
(Srirangan & Choy 2010, Lamas et al. 2013).  In periodontitis the accumulation of 
leukocytes at periodontal lesions results from enhanced IL-6 which further 
stimulates the secretion of pro-osteoclastogenic cytokines (i.e. RANKL) from nearby 
cells (i.e. osteoblasts via PGE2 synthesis) and decreased anti-osteoclastogenic 
cytokines (i.e. OPG), which together enhance resorption (Chapter 4; Dayer & Choy 
2010, Hosokawa et al. 2014, Feng et al. 2017).  Similarly, in MM IL-6 supports 
plasma cell proliferation, differentiation, secretion of lytic enzymes and is thought 
to attenuate apoptosis leading to increased bone lesions (Lauta 2003).  The 
development of therapeutics inhibiting IL-6 trans-signalling would therefore be 
beneficial in multiple clinical diseases which present with inflammation and/or 
bone destruction. 
Unfortunately no such therapeutics are currently available to man, highlighting a 
novel area of drug development.  It is hoped that novel treatments specifically 
blocking IL-6 trans-signalling will replicate and further improve on current 
therapeutics such as tocilizumab (anti-IL-6R) which has been shown to decrease 
disease pathology (Sigaux et al. 2017).  The inhibition of IL-6 trans-signalling is 
preferable over treatment with tocilizumab due to its specific targeting of trans-
signalling and not classical (Wong et al. 2006, Axmann et al. 2009, Jones et al 2011).  
Preliminary data supporting the progression of sgp130-Fc as a has been shown in 
animal models (i.e. RA, cancer, peritonitis, bowel diseases and atherosclerosis) 
where sgp130-Fc substantially reduced chronic-inflammation (Atreya et al. 2000, 
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 Nowell et al. 2003, Becker et al. 2004, Bollrath et al. 2009, Nowell et al. 2009, 
Schuett et al. 2012).  In addition, sgp130-Fc decreases the IL-6/sIL-6R complex half-
life and aids its clearance, thereby further reducing IL-6 trans-signalling (Peters et al. 
1996,Jones et al. 2011).  Treatment with epigallocatechin-3-gallate (EGCG) has also 
been shown to increase endogneous sgp130 and thus decrease IL-6 trans-signalling 
(Ahmed et al. 2008).  However, further work assessing the reproducibility of such 
data and the validity of the findings in human diseases is needed. 
Alongside the importance of IL-6 trans-signalling in chronic inflammation and bone 
destruction, IL-6 trans-signalling is significantly elevated in cardiovascular diseases, 
a common co-morbidity of arthritis, due to decreased inhibition by endogenous 
sgp130 (Voskuyl et al. 2006, Naranjo et al. 2008, Kawashiri et al. 2011, Klimek et al. 
2014).  Support for the use of sgp130-Fc therapy in atherosclerosis has been 
reported where inflammatory monocyte infiltration and plaque formation are 
reduced (Pardali et al. 2012, Schuett et al. 2012).  The therapeutic targeting of IL-6 
trans-signalling would therefore be beneficial in the treatment of primary and 
secondary diseases of chronic inflammation, thus enhancing drug efficacy and 
ultimately the quality of patient life. 
Despite such promising data, initial experiments assessing the therapeutic potential 
of inhibiting IL-6 trans-signalling on osteoclastogenesis and resorption are still 
needed in vivo to determine the translation of in vitro data from Chapter 4.  For 
example; treatment of CIA with sgp130-Fc where skeletal changes are monitored in 
vivo by quantification of bone turnover (i.e. IVIS and radiographs across disease 
duration), in addition to post mortem whole body imaging (i.e. µCT and 
radiographs) and histology (i.e. TRAP staining) assessing cell counts (inflammatory 
and osteoclasts) and bone erosions (Schneider et al. 2005).  If the assessments of 
bone destruction are significantly reduced, evidence would be provided for dual 
functionality of sgp130-Fc in the inhibition of bone resorption and inflammation, 
exerting a significant advantage over current pharmaceuticals which globally knock-
out IL-6 signalling.  The dosing frequency and concentration of sgp130-Fc would 
require optimisation, and a comparison with alternative therapeutics (receptor and 
ligand synthetic antagonists/agonists or intracellular signalling inhibitors) would be 
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 essential to ensure maximum drug efficacy and marketability.  Furthermore, 
immunological differences and differing drug metabolism between rodent and man 
may pose difficulities and thus will require careful consideration.  A cost-benefit 
analysis of inhibiting global IL-6 (i.e. tocilizumab or sirukumab) to IL-6 trans-
signalling specifically would also be pivotal in marketing such a therapeutic, 
alongside highlighting an important area of further research. 
 
6.3 The clinical relevance of CCL3 
The neutralization of CCL3 was also postulated as a therapeutic for destructive 
bone diseases (Chapter 5 Section 5.3.5).  CCL3 is clinically elevated in arthritis, 
asthma, lymphocytic leukaemia, multiple myeloma, retinal 
inflammation/degeneration, neuropathological diseases, osteomyelitis, breast and 
lung cancer (Scheven et al. 1999, Wolf et al. 2003, Bièche et al. 2004, Pharoah et al. 
2006, Geppert et al. 2010, Tregoning et al. 2010, Jehs et al. 2011, Sivina et al. 2011, 
Bandinelli et al. 2012, Chang et al. 2013, Dapunt et al. 2014, Mittal et al. 2014, 
Tsirakis et al. 2014, Kohno et al. 2014).  Research currently shows CCL3 foremost 
effects leukocyte migration (primarily monocytes) linking it to chronic inflammation 
and osteoclastogenesis, whilst also exerting a regulatory role in haematopoietic 
stem cell proliferation which, when uncontrolled, results in leukemogenesis and 
lymphoma (Baba & Mukaida 2014, Takahashi et al. 2015). 
The implications of CCL3 neutralization have already been reported in leukocyte 
associated diseases including Wallerian degeneration, psoriasis and multiple 
myeloma, where anti-CCL3 reduced myelin breakdown and clearance by 
macrophages, regulated FOXP3 Tregs and decreased osteoclastogenesis and 
adhesion of myeloma-stromal cells respectively (Oba et al. 2005, Perrin et al. 2005, 
Bolzoni et al. 2013, Chen et al. 2013).  The development of a therapeutic capable of 
inhibiting CCL3 would also be advantageous in the treatment of CCL3-induced fever 
where the common cyclooxygenase inhibitor ibuprofen is ineffective (Minano et al. 
1990, Melo Soares et al. 2006).  Furthermore, CCL3 has also been reported as 
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 significant in the pathogenesis of asthma through eosinophil recruitment, thus its 
inhibition could additionally aid asthmatic patients (Phillips et al. 2003). 
In addition to an inflammatory role, CCL3 is also emerging as an important mediator 
in destructive bone diseases, where its elevated presence at osteolytic sites has 
been reported, alongside its effect on in vivo bone resorption through global knock-
out models (Takano et al. 2014).  The global knock out of CCL3 resulted in a 
significant reduction in arthritic score and an attenuation in osteoclast 
differentiation and joint erosions in CIA and AIA mice respectivley (Chintalacharuvu 
et al. 2005, Kondo et al. 2011).  In conjunction with the exerted role of CCL3 in 
osteoclastogenesis, a dual pathogenic mechanism of the inhibition of osteoblast 
function has been reported.  CCL3 significantly decreased bone mineralisation and 
osteocalcin release in MM stromal cell cultures due to increased ERK signalling and 
down-regulation of osterix (Vallet et al. 2011).  The data reported by Vallet et al. 
(2011) highlighting CCL3 as a pathogenic instigator of bone destruction supported 
and furthered the findings of Hoshino et al. (2010) where CCR1-/- mice presented 
with elevated osteoblast transcription factors (Runx2 and Atf4) and bone proteins 
(osteopontin and osteonectin), but reduced osteoclast size and number. 
Furthermore osteoclasts from CCR1-/- mice to exhibited attenuated RANK 
expression, thus reducing RANKL-RANK interaction (Hoshino et al. 2010).  From the 
data reported in Chapter 5 (Section 5.3.2.1) CCL3 was postulated as RANKL-
dependent and was shown to exert a similar efficacy on osteoclastogenesis 
inhibition as the RANKL decoy receptor, OPG (Chapter 5 Section 5.3.4).  Such data 
therefore supported the work of Hoshino et al. (2010) and the in vivo therapeutic 
use of anti-CCL3 in animal models.  The therapeutic use of anti-CCL3 over OPG 
would be advantageous, firstly as homeostatic bone turnover would not be altered 
by anti-CCL3 (i.e. basal RANKL-induced osteoclastogenesis unaffected), and 
secondly due to the redundancy of the chemokine system where non-pathological 
chemotaxis from co-stimulating chemokines would still prevail.  Additional benefits 
of neutralizing CCL3 may also arise after further testing assessing dosage and 
frequency of anti-CCL3 treatment where reduced leukocyte migration may present 
as 'anti-inflammatory' effects in addition to anti-resorptive.   
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 The therapeutic potential of inhibiting CCL3 could therefore exert a major 
advantage in bone destructive diseases.  Of additional interest is a novel chemokine 
receptor termed GPR15/BOB which was located on PBMCs from RA patients 
(Cartwright et al. 2014).  Although the ligands of this receptor are not yet identified 
it has a known similarity to CCR5, an additional CCL3 receptor.  GPR15/BOB could 
therefore be used in the pathogenesis of RA through CCL3 signalling, and could 
present itself as a novel therapeutic target.  However, extensive research must be 
carried out prior to this being confirmed. 
A positive correlation between CCL3 and mental health diseases (Alzheimer’s 
disease, schizophrenia and depressive disorders) has also been reported 
(Merendino et al. 2004, Simon et al. 2008, Geppert et al. 2010, Marksteiner et al. 
2011, Reale et al. 2011).  Ascoli and colleagues (2016) reported increased CCL3 
mRNA in bipolar patients that causes shift in macrophages expression, favouring 
M1 macrophages (CCL3 and IL-6 secreting), and subsequently affecting neuronal 
development (disputed by Nakatani et al. 2006, Teixeira et al. 2008, Brietzke et al. 
2009).  The presentation of mental health disorders (i.e. anxiety) has also been 
linked to RA (Watad et al. 2017).  It has been postulated that both social (i.e. the 
patients mental attitude to coping with RA) and biological (i.e. increased CCL3) 
factors impact patient quality of life.  Thus an additional subset of diseases which 
could benefit from the development of a novel anti-CCL3 therapeutic is presented. 
 
 
6.4 IL-6 trans-signalling and CCL3 as novel therapeutic targets 
The relevance of both IL-6 trans-signalling and CCL3 in destructive and 
inflammatory bone disease has therefore been discussed, alongside some common 
and novel therapeutics currently used.  Although current therapies (both 
conventional and biological DMARDs) alleviate arthritic symptoms for the majority 
of patients, there still remain patients who are unresponsive and thus the need for 
novel therapeutics development exists (Kim et al. 2015).  In addition, evidence is 
emerging questioning the long term therapeutic use of biological DMARDs such as 
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 tocilizumab due to their associated adverse effects of significantly elevating serum 
total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein 
cholesterol and apolipoproteins 1-and 2 in RA (Kawashiri et al. 2011). 
The clinical relevance of developing an inhibitor to both IL-6 trans-signalling and 
CCL3 is clear from the above discussions.  However, the effectiveness of these 
treatments alone on in vivo osteoclastogenesis and bone destruction has yet to be 
established.  On reflection of in vitro data in Chapters 4 and 5, inhibition of IL-6 
trans-signalling by sgp130-Fc was postulated to significantly reduce resorptive 
activity, and anti-CCL3 to significantly attenuate osteoclast differentiation, with a 
consideration that increased dose may reduce inflammation.  However, due to the 
redundancy of the chemokine system a significant reduction on inflammation may 
never result.  Thus it could be hypothesised that anti-CCL3 could be given 
therapeutically to attenuate osteoclast fusion and differentiation, in tandem with 
an IL-6 trans-signalling inhibitor to decrease mature osteoclast resorptive activity, 
thus reducing bone destruction via two mechanisms.  As both mediators also exert 
comparable stimuli for cell motility, monocyte migration would consequentially 
decrease (Clahsen & Schaper 2008).  Moreover, secondary effects of inhibiting IL-6 
trans-signalling would be beneficial in decreasing associated inflammation (Scheller 
et al. 2011).   The efficacy and tolerance between two drugs and their interaction 
pathways would however need to be assessed in order to distinguish any 
synergistic relationship.  Safety testing assessing the production of ADAs would also 
be pivotal in determining the fate of such therapeutics to avoid immunogenicity 
complications (such tests would also need to be completed for each independently 
if they were to be developed). 
Alongside the inhibition of inflammation and pathology, a reduction in pain 
perception may also occur, as increased concentrations of both have been linked to 
hyperalgesia in knee replacement patients (Tomankova et al. 2014).  IL-6 trans-
signalling sensitizes nociceptors and TRPV1 channels on DRG leading to increased 
neuronal cell communication (Murphy et al. 1999, Obreja et al. 2002, De Jongh et 
al. 2003, Miguel, Kraychete & Nascimento. 2014).  CCR1 (receptor to CCL3) is co-
expressed with TRPV1 on DRG where CCL3 stimulation causes a 3-fold increase in 
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 sensitivity and maintains neuronal viability potentiating hyperalgesia and 
nociception (Brenneman et al. 1999, Zhang et al. 2005).  The further 
characterization of the combined and independent effects of CCL3 and IL-6/sIl-6R 
complex on nociception would need to be established first in vitro; i.e. through the 
treatment of cerebral cortical cells and cortical astrocytes (feeder cells) with IL-
6/sIL-6R, sgp130-Fc, CCL3 and/or anti-CCL3.  The quantification of neuronal survival 
and activation would then ensue.  If successful, such treatments may also be test in 
behavioural animal models prior to their additional use as potential analgesics. 
 
6.5 Novel biomarkers of destructive bone diseases 
Current biomarkers fail to detect the early progression of arthritic diseases thus 
highlighting the need for novel markers.  Recent research has postulated the use of 
calprotectin as a biomarker of RA, where a significant correlation to disease activity 
(CRP and auto-antibodies) and ultrasound score were reported (Soliman et al. 
2016).  Although valuable in the prognosis of RA, the use of calprotectin as a 
biomarker still focuses upon the inflammatory side of the arthritides (inflammatory 
marker correlations and soft tissue ultrasound), and not on the dual importance of 
bone destruction.  The need for a novel biomarker of destructive bone diseases is 
therefore still fundamental for the early classification of disease. 
Research supporting the use of CCL3 as a biomarker was previously reported by 
Takahashi et al. (2015), in a model of diffuse large B cell lymphoma, where the 
secretion of CCL3 from malignant B cells was indicative of B cell receptor activation 
and lymphoma diagnosis.  Although not in a model of destructive bone disease, the 
use of CCL3 as a biomarker was shown to predict disease progression.  From data 
reported in Chapters 4 and 5 showing IL-6 trans-signalling and CCL3 as important 
early mediators in osteoclast differentiation (i.e. increased precursor cell migration, 
proliferation and TRAP+ve cell fusion), it is postulated that IL-6/sIL-6R complex and 
CCL3 could be used as novel biomarkers of destructive bone diseases. 
Assessment of endogenous IL-6/sIL-6R and CCL3 concentrations could be 
performed alongside common tests for the diagnosis of arthritis (i.e. complete 
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 blood count, urine, blood biochemistry, rheumatoid factor), where serum or joint 
aspirates could be collected from patients and analyzed by automated ELISA (i.e. 
Randox Evidence Biochip Array).  A comparison of results against a 'normal range' 
could determine the likeliness of destructive or inflammatory disease phenotype 
(Richie & Francis 2003).  For example; a patient presenting with increased IL-6/sIL-
6R and CCL3 is likely to suffer from an aggressive destructive bone phenotype 
(correlation with osteoclastogenesis and resorption), opposed to a patient with 
increased TNF-α and rheumatoid factor, who is likely to have an inflammatory 
disease phenotype with minimal bone destruction.  A schematic of this is presented 
in Figure 6.1.  Further work defining pathogenic ranges would be needed, but the 
following have already been published and could be used for guidance: >20.3 
ng/mL CCL3 in synovial fluid indicative of destructive bone phenotypes, >55.2pg/mL 
CCL3 in plasma, >5pg/mL IL-6 or >41ng/mL sIL-6R in serum (Robak et al. 1998, 
Pharoah et al. 2006,Takahashi et al. 2015, Palma et al. 2016). 
Through the identification of novel biomarkers, the prediction of early disease 
phenotype could have a significant impact on the following: specific therapeutics 
patients receive, early commencement of treatments, prevention of severe 
pathology (both inflammatory and destructive), maintaining joint functionality, 
decreasing hyperalgesia, reducing side effects of 'blanket drugs' (i.e. nausea after 
methotrexate), reducing cost to NHS (i.e. multiple  drug treatments), and finally, 
increasing the patient’s quality of life. 
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Patient 
presenting 
with joint 
pain 
Blood sample taken 
  
      
    
                                       
Biomarker 
testing ↑CRP   ↑ TNF-α   ↑IL-1   ↑IL-8   ↑IL-6   
  
↑CCL3   ↑RANKL 
    
 
    
 
          
 
        
Postulated 
disease 
phenotype 
Inflammatory Disease 
  
  
Destructive Disease 
  
 
    
 
←  Early action and hypothetical treatment   →   
  Drugs: 
Infliximab, Etanercept, Anakinra, Tocilizumab, sgp130-
Fc, analgesics 
    
Denosumab, Tocilizumab, 
neutralising Ab to 
osteoclastogenic factors (i.e. Anti-
CCL3), analgesics 
      
      
Benefits: 
Increased mobility, decreased inflammation, 
decreased stiffness and pain 
  
  
Decreased bone destruction, 
maintained joint architecture, 
decreased pain, increased mobility 
    
      
  Figure 6. 1 - A flow diagram illustrating the theory behind the early diagnosis of inflammatory and destructive bone diseases, in addition to the 
postulated specific therapeutics which could be developed to prevent disease progression.  
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 6.6 Conclusion 
In conclusion, results reported in this thesis present novel data from imaging and 
analysis methodologies for the identification of specific pro-inflammatory 
mediators involved in enhanced osteoclast activity.  Specifically, both IL-6 trans-
signalling and CCL3 are reported as important early mediators of osteoclast 
differentiation with clear effects on bone resorption.  Further experimental work 
using both in vivo animal models and arthritic patient samples will be necessary to 
fully elucidate the mechanisms and importance of IL-6 trans-signalling and CCL3 in 
destructive bone diseases.  IL-6 trans-signalling and CCL3 could become novel 
therapeutic targets and/or biomarkers of disease activity. 
 
 
240 
 
  
 
 
 
 
 
7 Chapter 7: References 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
241 
 
 Abdul-sater Z. et al. (2012) Two Heterozygous Mutations in NFATC1 in a Patient 
with Tricuspid Atresia. PLOS One 7: 1–12. 
Abe Y. et al. (2015) Inhibitory effect of bisphosphonate on osteoclast function 
contributes to improved skeletal pain in ovariectomized mice. J Bone Miner 
Metab 33: 125–134. 
Ahmed S. et al. (2008) Epigallocatechin-3-gallate inhibits IL-6 synthesis and 
suppresses transsignaling by enhancing soluble gp130 production. PNAS 105: 
14692-14697. 
Ajuebor M.N., Kunkel S.L. & Hogaboam C.M. (2004) The role of CCL3 / macrophage 
inflammatory protein-1 a in experimental colitis. European Journal of 
Pharmacology, 497: 343–349. 
Albuquerque De S.R. et al.(2013) The effect of CCL3 and CCR1 in bone remodeling 
induced by mechanical loading during orthodontic tooth movement in mice. 
Bone 52: 259–267.  
Amat M. et al. (2006) Pharmacological blockade of CCR1 ameliorates murine 
arthritis and alters cytokine networks in vivo. British Journal of Pharmacology 
149: 666–675. 
Anandarajah A.P. et al. (2008) The effect of etanercept on osteoclast precursor 
frequency and enhancing bone marrow oedema in patients with psoriatic 
arthritis. Ann Rheum Dis 67: 296–301. 
Anderson L.C. & Rao R.D. (2001) Intereukin-6 and nerve growth factor levels in 
peripheral nerve and crainstem after trigeminal nerve injury in the rat.  
Archives of Oral Biology 46: 633-640. 
Andratsch M. et al. (2009) A Key Role for gp130 Expressed on Peripheral Sensory 
Nerves in Pathological Pain. The Journal of Neuroscience 29: 13473–13483. 
Andrews N.A. (2008) Denosumab and the Treatment of Rheumatoid Arthritis : In an 
Occupied Field , Where Will a RANKL Inhibitor Fit In? International Bone & 
Mineral Society 5: 351–356. 
Antonov A.S. et al. (2011) αVβ3 Integrin Regulates Macrophage Inflammatory 
Responses via PI3 Kinase/Akt-Dependent NF-κB Activation. J Cell Physiol. 226: 
469–476. 
Atreya R. et al. (2000) Blockade of interleukin 6 trans signalling suppresses T-cell 
resistance against apoptosis in chronic intestinal inflammation: Evidence in 
Chron disease and experimental colitis in vivo.  Nature Medicine 6: 583 - 588. 
Axmann R. et al. (2009) Inhibition of Interleukin-6 Receptor Directly Blocks 
Osteoclast Formation In Vitro and In Vivo. Arthritis & Rheumatism 60: 2747–
2756. 
Azuma Y. et al. (2000) Tumour Necrosis Factor-α Induces Differentiation of Bone 
242 
 
 Resorption by Osteoclasts.  J. Biol. Chem. 275: 4858-4864. 
Baba T. & Mukaida N.(2014) Role of macrophage inflammatory protein ( MIP ) -1 α / 
CCL3 in leukemogenesis. Molecular and Cellular Oncology1: e29899-1 - 
e29899-5. 
Bandinelli F. et al. (2012) CCL2 , CCL3 and CCL5 chemokines in systemic sclerosis : 
the correlation with SSc clinical features and the effect of prostaglandin E1 
treatment. Clinical and Experimental Rheumatology 30: s44-49. 
Bargman R. et al. (2012) High- and low-dose OPG–Fc cause osteopetrosis-like 
changes in infant mice. Pediatric Research 72: 495–501. 
Becker C. et al. (2004) TGF-β suprresses tumour progression in colon cancer by 
inhibition of IL-6 trans-signalling.  Immunity, 21: 491-501. 
Bendele A. et al. (1999) Animal Models of Arthritis : Relevance to Human Disease *. 
Toxicologic Pathology 27: 134–142. 
Benedetti F.D. et al. (2006) Impaired skeletal development in interleukin-6 
transgenic mice. Arthritis & Rhuematism 54: 3551-3563. 
Berg van den Wim B (2009) Lessons from animal models of arthritis over the past 
decade. Arthritis Research & Therapy 11: 250. 
BertoliniD.R. et al. (1986) Stimulation of bone resorption and inhibition of bone 
formation in vitro by human tumour necrosis factors. Nature 319: 516-518. 
Besson J.M. (1999) The neurobiology of pain.  The Lancet 353: 1610-1615. 
Bharadwaj U. et al. (2011) Mesothelin overexpression promotes autocrine IL-6 / sIL-
6R trans-signaling to stimulate pancreatic cancer cell proliferation. 
Carcinogenesis 32: 1013–1024. 
Bièche I. et al. (2004) Molecular profiling of inflammatory breast cancer: 
Identification of a poor-prognosis gene expression signature.  Clinical Cancer 
Research 10: 6789-6795. 
Blair H.C., Robinson L.J. & Zaidi M. (2005) Osteoclast signalling pathways. 
Biochemical and Biophysical Research Communications 328: 728–738. 
Bollrath J. et al. (2009) gp130-mediated STAT3 activation in enterocytes regulates 
cell survival and cell-cycle progression during colitis-associated tumorigenesis.  
Cancer Cell 15: 91-102. 
Bolzoni M. et al. (2013) Immunomodulatory drugs lenalidomide and pomalidomide 
inhibit multiple myeloma-induced osteoclast formation and the RANKL / OPG 
ratio in the myeloma microenvironment targeting the expression of adhesion 
molecules. Experimental Hematology 41: 387–397. 
Bonetta L. et al. (2005) Flow cytometry smaller and better.  Nature Methods 2: 785-
795. 
243 
 
 Bord S. et al. (2003) The effects of estrogen on osteoprotegerin , RANKL , and 
estrogen receptor expression in human osteoblasts. Bone32: 136–141. 
Boyce B.F., Schwarz E.M.& Xing, L. (2006). Osteoclast precursors: cytokine-
stimulated immunomodulators of inflammatory bone diesase. Curr Opin 
Rheumatol 18:427-432. 
Boyle W.J., Simonet W.S. & Lacey D.L. (2003) Osteoclast differentiation and 
activation.  Nature 423: 337-342. 
Bozec A. et al. (2008) Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor 
signalling and hypoxia.Nature Letters 454: 221–226. 
Brackertz D., Mitchell G.F. & Mackay I.R. (1977) Antigen-induced arthritis in 
mice.Arthritis & Rheumatism 20: 841-850. 
Brand D.D., Latham K.A. & Rosloniec E.F. (2007). Collagen-induced arthritis. Nature 
Protocols 2: 1269–1275. 
Braun J. et al. (1999) Low secretion of tumor necrosis factor-α, but no other th1 or 
th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity 
in reactive arthritis.  Arthritis & Rhuematism 42: 2039-2044. 
Brenneman D.E. et al. (1999) VIP and D -ala-peptide T-amide release chemokines 
which prevent HIV-1 GP120-induced neuronal death. Brain Research 838:27–
36. 
Brietzke E. et al. (2009) Brain , Behavior , and Immunity Abnormalities in serum 
chemokine levels in euthymic patients with Bipolar Disorder. Brain, Behavior 
and Immunity23:1079–1082.  
Briscoe, J. et al., 1996. JAKs, STATs and signal transduction in response to the 
interferons and other cytokines. Phil. Trans. R. Soc. Lond., 351, pp.167–171. 
Bune, A.J., Hayman, A.R. & Evans, M.J., 2001. Mice lacking tartrate-resistant acid 
phosphatase ( Acp 5 ) have disordered macrophage in ¯ ammatory responses 
and reduced clearance of the pathogen , Staphylococcus aureus. Immunology, 
(Acp 5). 
Caetano-lopes J., Canhão H. & Fonseca J.E. (2007) Osteoblasts and bone formation. 
Acta Reumatólogica Portuguesa 32:103-110. 
Campos S.B. et al.(2009) Cytokine-induced F-actin reorganization in endothelial cells 
involves RhoA activation. Am J Physiol Renal Physiol296: F487–F495. 
Cartwright A. et al. (2014) Cytokine Orphan receptor GPR15 / BOB is up-regulated in 
rheumatoid arthritis. Cytokine 67: 53–59. 
Cassidy A.I. et al. (2003) Regulation of the murine TRACP gene promoter.  Journal of 
Bone and Mineral Research 18: 1901- 1904. 
Castellino F. et al. (2006) Chemokines enhance immunity by guiding naive CD8+ T 
244 
 
 cells to CD4+ T cell-dendritic cell interaction. Nature 440: 890-895. 
Chailurkit L. et al. (2001) Biochemical Markers of Bone Turnover and Response of 
Bone Mineral Density to Intervention in Early Postmenopausal Women : An 
Experience in a Clinical Laboratory. Clinical Chemistry 47:1083–1088. 
Chang D.H. et al. (2013) The Effect of Lung Cancer on Cytokine Expression in 
Peripheral Blood Mononuclear Cells. PLOS One 8: e64456. 
Chellaiah M.A. & Ma T. (2013). Membrane Localization of Membrane Type 1 Matrix 
Metalloproteinase by CD44 Regulates the Activation of Pro-Matrix 
Metalloproteinase 9 in Osteoclasts. BioMed Research International 2013: 1-13. 
Chen Q. et al. (2001) Testosterne inhibits osteoclast formation stimulated by 
parathyroid hormone through androgen receptor.  FEBS Letters 491: 91-93. 
Cheng J. et al.(2011) Interleukin-4 Inhibits RANKL-Induced NFATc1 Expression Via 
STAT6: A Novel Mechanism Mediating its Blockade of Osteoclastogenesis. J 
Cell Biochem 112: 3385-3392. 
Chenu C. et al. (1988) Transforming growth factor 13 inhibits formation of 
osteoclast-like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. 
85: 5683–5687. 
Cheung W., Simmons C.A. & You L. (2012) Osteocyte apoptosis regulates osteoclast 
precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 
expression. Bone 50: 104–110.  
Chintalacharuvu S.R. et al. (2005) An essential role for CCL3 in the development of 
collagen antibody-induced arthritis. Immunology Letters 100: 202–204. 
Choi S.J. et al. (2000) Macrophage inflammatory protein 1-alpha is a potential 
osteoclast stimulatory factor in multiple myeloma.  Blood. 96: 671-675.  
Choi S.J. et al.(2001) Antisense inhibition of macrophage inflammatory protein 1- α 
blocks bone destruction in a model of myeloma bone disease.J. Clin. 
Invest.108: 833–1841. 
Choy E.H.S. et al. (2002) Therapeutic Benefit of Blocking Interleukin-6 Activity With 
an Anti – Interleukin-6 Receptor Monoclonal Antibody in Rheumatoid Arthritis. 
Arthritis & Rheumatism 46: 3143–3150. 
Chubb S.A.P. (2012) Measurement of C-terminal telopeptide of type I collagen ( CTX 
) in serum. Clinical Biochemistry 45: 928–935.  
Ciancanelli M.J. et al. (2015) Life-threatening influenza and impaired interferon 
amplifcation in humna IRF7 deficiency.  Science 348: 448-453. 
Clahsen T. & Schaper F. (2008) Interleukin-6 acts in the fashion of a classicla 
chemokine on monocyte cells by inducing integrin activation, cell adhesion, 
actin polymerization, chemotaxis, and transmigration.  J Leukoc. Biol. 84: 1-9. 
245 
 
 Cook M.J. (1965) The anatomy of the laboratory mouse. Academic Press, M.R.C. 
Laboratory Animals Centre, Elsevier. 
Copp D.H. et al. (1962) Evidence for Calcitonin- A new hormone from the 
parathyroid that lowers blood calcium. The Endocrine Society 70: 638- 649. 
Coppieters K. et al. (2006) Formatted Anti – Tumor Necrosis Factor-α VHH Proteins 
Derived From Camelids Show Superior Potency and Targeting to Inflamed 
Joints in a Murine Model of Collagen-Induced Arthritis. Arthritis & Rheumatism 
54: 1856–1866. 
Coxon F.P. (2012) Chapter 25 - Fluorescence Imaging of Osteoclasts Using Confocal 
Microscopy. Bone Research Protocols, Methods in Molecular Biology 816. 
Cromartie W.J. et al. (1977) Arthritis in rats after systemic injection of streptococcal 
cells or cell walls. The Journal of Experimental Medicine 146: 1585–1602. 
Crook, T. & Warwick, D., 2011. Avoiding fusion in wrist arthritis. The Journal of Bone 
and Joint Surgery, pp.4–8. 
Cummings S.R. et al. (2009) Denosumab for prevention of fractures in 
postmenopausal women with osteoporosis.  N Engl Med 361:756-65. 
Cunha, F. et al., 2007. The pattern of immune cell infiltration in 
chromoblastomycosis : involvement of macrophage inflammatory protein-1 
alpha / CCL3 and fungi persistence . Rev. Inst. Med. trop., (October 2015). 
Danks L. et al. (2002) Synovial macrophage-osteoclast differentiation in 
inflammatory arthritis. Ann Rheum Dis 61: 916–921. 
Dapunt U. et al. (2014) The Macrophage Inflammatory Proteins MIP1α (CCL3) and 
MIP2α (CXCL2) in Implant-Associated Osteomyelitis : Linking Inflammation to 
Bone Degradation.Mediators of Inflammation 2014; 1-10. 
Davis M.C. et al. (2008) chronic stress and regulation of cellular markers of 
inflammation in rheumatoid arthritis: Implications for fatigue.  Brain Behav 
Immun. 22:24-32. 
Davies J. et al. (1989) the osteoclast functional antigen, implicated in the regulation 
of bone resorption, is biochemically related to the vitronectin receptor.  The 
Journal of Cell Biology 109: 1817-1826. 
Dawson J.K. et al. (2001) Fibrosing alveolitis in patients with rheumatoid arthritis as 
assessed by high resolution computed tomography, chest radiography and 
pulmonary function tests.  Thorax 56: 622-627. 
De Jongh R.F. et al. (2003) The role of Interleukin-6 in nociception and pain.  
Anesthesia & Analgesia 96:1096-1103. 
Dinser R. (2008) Animal models for arthritis. Best Practice & Research Clinical 
Rheumatology 22: 253–267. 
246 
 
 Døhn U.M. et al. (2006) Are bone erosions detected by magnetic resonance imaging 
and ultrasonography true erosions? A comparison with computed tomography 
in rheumatoid arthritis metacarpophalangeal joints.  Arthritis Research & 
Therapy 8: 1-9. 
Doodes P.D. et al. (2009) CCR5 Is Involved in Resolution of Inflammation in 
Proteoglycan-Induced Arthritis. Arthritis & Rheumatism 60: 2945–2953. 
Doyle F.H., Banks L.M. & Pennock J.M. (1980) Radiological observations on bone 
resorption in Paget's disease.  Arthritis and Rheumatism 23: 1205-1214. 
Ducy P. et al.(1997) Osf2 / Cbfa1 : A Transcriptional Activator of Osteoblast 
Differentiation. Cell 89: 747–754. 
Dumonde D.C. & Glynn L.E. (1961) The production of arthritis in rabbits by an 
immunological reaction to fibrin.  British Journal of Experimental Pathology 43: 
373-383 
Duong L.T. & Rodan G.A. (1999) The role of integrins in osteoclast function. Journal 
of Bone Mineral Metabolism.  17: 1-6. 
Duong L.T. et al. (2000) Integrins and signaling in osteoclast function.  Matrix 
Biology 19: 97-105. 
Durand M. et al. (2013) Monocytes from patients with osteoarthritis display 
increased osteoclastogenesis and bone resorption.  Arthritis & Rheumatism 65: 
148-158. 
Eder J. (1997) Tumour necrosis factor-α and interleukin 1 signalling : do MAPKK 
kinases connect it all? Trends in Pharmacological Sciences 18: 319–322. 
Elder C.J. & Bishop N.J. (2014) Rickets. Lancet383: 1665–1676. 
Elkayam O. et al. (2000) Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients 
iwth psoriatic arthritis.  Rheumatol Int 19: 101-105. 
Enzerink A. et al. (2009) Clustering of fibroblasts induces proinflammatory 
chemokine secretion promoting leukocyte migration. Molecular Immunology 
46: 1787–1795. 
Fan J. et al. (2011) Chemokine Transcripts as Targets of the RNA-Binding Protein 
HuR in Human Airway Epithelium. The Journal of Immunology, 186: 2482-2494. 
Feng W. et al. (2017) combination of IL-6 and sIL-6R differentially regaulte varying 
levels of RANKL-induced osteoclastogenesis through NF-κβ ERK and JNK 
signalling pathways.  Nature Scientific Reports 7: 41411. 
Filgueira L. (2004) Fluorescence-based staining for tartrate-resistant acidic 
phosphotase (TRAP) in osteoclasts combined with other fluorescent dyes and 
protocols.  Jounral of Histochemistry & Cytochemistry 52: 411-414. 
Finnegan A. et al. (1999) Proteoglycan (Aggrecan)-Induced Arthritis in BALB/c Mice 
247 
 
 Is a Th1-Type Disease Regulated by Th2 Cytokines. The Journal of Immunology 
163: 5383-5390. 
Firestein G.S. et al. (1994) Synovial interleukin-1 receptor antagonist and 
interleukin- 1 balance in rheumatoid arthritis.  Arhtritis & Rheumatism 37: 644-
652. 
Fleischmann R.M. et al. (2006) Safety of extended treatment with anakinra in 
patients with rheumatoid arthritis. Ann Rheum Dis 65: 1006–1012. 
Franco G.C.N. et al. (2012) Inhibition of matrix metalloproteinase-9 activity by 
Doxycycline ameliorates RANK ligand-induced osteoclast differentiation in 
vitro and in vivo. Exp Cell Res 317: 1454–1464. 
Gabay C. (2006) Interleukin-6 nd chronic inflammation.  Arthritis Research & 
Therapy 8: S3. 
Gado K. et al.(2000) Role of interleukin-6 in the pathogenesis of multiple myeloma. 
Cell Biology International 24: 195–209. 
Galibert L. et al. (1998) The Involvement of Multiple Tumor Necrosis Factor 
Receptor (TNFR) -associated Factors in the Signaling Mechanisms of Receptor 
Activator of NF-κB, a Member of the TNFR Superfamily*. The Journal of 
Biological Chemistry 273: 34120–34127. 
Galicia J.C. et al. (2004) Polymorphisms in the IL-6 receptor (IL-6R) gene: strong 
evidence that serum levels of soluble IL-6R area genetically influenced.  Genes 
and Immunity 5: 513-516. 
Gao Y. et al. (1998) Expression of IL-6 receptor and sgp130 in mouse bone marrow 
cells during osteoclast differentiation.  Bone 22: 487-493. 
Garbers C. et al. (2001) Species specificity of ADAM10 and ADAM17 proteins in 
interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 
receptor shedding.  the Journal of Biological Chemistry 286: 14804-14811. 
Gay C.V. & Mueller W.J. (1973) Carbonic anhydrase and osteoclasts: Localization by 
labeled inhibitor autoradiography. Science 183: 432-434. 
Geppert A.M. et al. (2010) CCL3 correlates with the number of mood disturbances 
and personality changes in patients with Alzheimer's disease.  Psychiatry 
Research 176: 261-264. 
Gengenbacher M. et al. (2007) Infliximab inhibits bone resorption by circulating 
osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing 
spondylitis. Ann Rheum Dis 67: 620-624. 
Genovese M.C. et al. (2008). Interleukin-6 Receptor Inhibition With Tocilizumab 
Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to 
Disease-Modifying Antirheumatic Drugs. Arthritis & Rheumatism 58: 2968–
2980. 
248 
 
 Gilliland C.T. et al. (2013) The chemokine receptor CCR1 is constitutively active , 
which leads to G protein-independent, β-arrestin-mediated internalization*. 
The Journal of Biological Chemistry 288: 32194-32210. 
Goldberg S.R. et al. (2012) A 3D scanning confocal imaging method measures pit 
volume and captures the role of Rac in osteoclast function. Bone 51: 145–152. 
 Goldring S.R. & Gravallese E.M.(2000). Pathogenesis of bone erosions in 
rheumatoid arthritis. Current Opinion in Rheumatology 12:195-199. 
Gravestein L.A. &Borst J.(1998). Tumor necrosis factor receptor family members in 
the immune system. Immunology 10: 423-434. 
Grevers L.C. et al. (2011) S100A8 Enhances Osteoclastic Bone Resorption In Vitro 
Through Activation of Toll-like Receptor 4. Arthritis & Rheumatism 63: 1365–
1375. 
Grigoriadis A.E. et al. (1994) c-Fos: a key regulaotr of osteoclast-macrophage 
lineage determination and bone remodelling.  Science 266: 443-448. 
Grivennikov S. et al.(2009). IL-6 and STAT3 are required for survival of intestinal 
epithelial cells and development of colitis associated cancer. Cancer Cell 15: 
103–113. 
Grossman R.M. et al. (1989) Interleukin 6 is expressed in high levels in psoriatic skin 
and stimulates proliferation of cultured human keratinocytes.  Proc. Natl. 
Acad. Sci. 86: 6367-6371. 
Halleen J.M. et al. (1999) Intracellular fragmentation of bone resorption products 
by reactive oxygen species generated by osteolcastic tartrate-resistant acid 
phosphatase.  The Jounral of Biological Chemistry 274: 22907-22910. 
Halleen J.M. et al. (2000) Tartrate-Resistant Acid Phosphatase 5b : A Novel Serum 
Marker of Bone Resorption*. Journal of Bone and Mineral Research 15: 1337–
1345. 
Han X. et al. (2000) CD47, a Ligand for the Macrophage Fusion Receptor, 
Participates in Macrophage Multinucleation *. The Journal of Biological 
Chemistry 275: 37984–37992. 
Han J-H. et al. (2001) Macrophage inflammatory protein-1α is an osteoclastogenic 
factor in myeloma that is dependent of receptor activator of nuclear factor κβ 
ligand.  Blood 97: 3349-3353. 
Hargreaves K.M. et al. (1988) Bradykinin is increased during acute and chronic 
inflammation: therapeutic implications.  Clin Pharmacol Ther 44:613-621. 
Harvey B.P. & Kaymakcalan Z. (2010) RANKL expression in human T-lymphocytes 
requires cooperative signaling through the T-cell receptor and adhesion 
molecule CD2. Journal of Translational Medicine 8: O4.  
Hashizume M., Hayakawa N. & Mihara M.(2008) IL-6 trans-signalling directly 
249 
 
 induces RANKL on fibroblast-like synovial cells and is involved in RANKL 
induction by TNF-α and IL-17. Rheumatology 47: 1635–1640. 
Hashizume M. & Mihara M. (2009). Desirable effect of combination therapy with 
high molecular weight hyaluronate and NSAIDs on MMP production. 
Osteoarthritis and Cartilage17: 1513–1518.  
Hashizume M. & Mihara M. (2011) The Roles of Interleukin-6 in the Pathogenesis of 
Rheumatoid Arthritis. Arthritis 2011: 1-8. 
Heinemann C. et al. (2011) Development of an osteoblast / osteoclast co-culture 
derived by human bone marrow stromal cells and human monocytes for 
biomaterials testing. European Cells and Materials 21: 80-93. 
Heinrich P.C. et al. (1998) Interleukin-6-type cytokine signalling through the gp130 / 
Jak / STAT pathway. Biochem. J. 334: 297–314. 
Hee Jeon et al. (2012) Quantification of temporal changes in 3D osteoclastic 
resorption pit using confocal laser scanning microscopy.  Tissue Engineering 
and Regenerative Medicine 9: 29-35.  
Helfrich M.H. & Ralston S.H. (2012) Bone Research Protocols. Springer Protocols 
(Methods in Molecular Biology) 816: 1-643. 
Heymann D. et al. (1998) Oncostatin m stimulates macrophage-polykaryon 
formation in long-term human bone-marrow cultures. Cytokine 10: 98–109. 
Hienz S.A., Paliwal S. & Ivanovski S. (2015) Mechanisms of bone reosrption in 
periodontitis.  Journal of Immunology Research 2015: 615486. 
Hill P.A. et al. (1998) The Cellular Actions of Interleukin-11 on Bone Resorption in 
Vitro. Endocrinology 139: 1564–1572. 
Hirano T., Ishihara K. & Hibi M.(2000) Roles of STAT3 in mediating the cell growth , 
di  erentiation and survival signals relayed through the IL-6 family of cytokine 
receptors. Oncogene 19: 2548–2556. 
Hirayama T. et al. (2002) Osteoclast formation and activity in the pathogenesis of 
osteoporosis in rheumatoid arthritis. Rheumatology 41: 1232–1239. 
Hitchon C.A. & El-gabalawy H.S.(2011) The Synovium in Rheumatoid Arthritis. The 
Open Rheumatology Journal 5: 107–114. 
Hodge J.M. et al. (2011) M-CSF potently augments RANKL-induced resorption 
activation in mature human osteoclasts.  PLOS one 6: e21462. 
Holmdahl R. et al. (1992) Arthritis induced in rats with adjuvant oil is a genetically 
restricted, dependent autoimmune disease. Immunology 76: 197–202. 
Hopkins S.J.& Meager A. (1988) Cytokines in synovial fluid : The presence of tumour 
necrosis factor and interferon. Clin. exp. Immunol. 73: 88–92. 
250 
 
 HortonM. A. (1997) The αvβ3 Integrin “Vitronectin Receptor.” Int. J. Biochem. Cell 
Biol.29: 721-725. 
Horwood N.J. et al. (2001) IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast 
Formation In Vitro. The Journal of Immunology 166: 4915-4921. 
Hoshino A. et al. (2010) Deficiency of Chemokine Receptor CCR1 Causes Osteopenia 
Due to Impaired Functions of Osteoclasts and Osteoblasts*.The Journal of 
Biological Chemistry 285; 28826–28837. 
Hosokawa Y. et al. (2014) IL-6 trans-signalling enahnces CCL20 production from IL-
1β-stimulated human periodontal ligament cells.  Inflammation 37: 381-386. 
Houssiau F.A. et al. (1988) Interleukin-6 in synovial fluid and serum of patients with 
rheuamtoid arthritis and other inflammatory arthritides.  Arthritis and 
Rheumatism 31: 784-788. 
Hu X. & Beeton C. (2010) Detection of Functional Matrix Metalloproteinases by 
Zymography. Journal of Visualized Experiments 45: e2445. 
Hu Y. et al. (2008) IFN- γ and STAT1 Arrest Monocyte Migration and Modulate 
RAC/CDC42 Pathways. The Journal of Immunology 180: 8057-8065.   
Huang H. et al. (2006) Induction of c-fos and NFATc1 during RANKL-stimulated 
osteoclast differentiation is mediatred by the p38 signaling pathway. 
Biochemical and Biophysical Research Communications 351: 99-105. 
Hunter C.A. & Jones S.A. (2015) IL-6 as a keystone cytokine in health and 
disease.Nature Immunology 16: 448-457. 
Hussein H. et al. (2016) Cathepsin K inhibition renders equine bone marrow 
nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation in 
vitro.  Comparative Immunology, Microbiology and Infectious Diseases 45: 40-
47. 
Ichikawa S. et al. (2016) Radiographic quantifications of joint space narrowing 
progression by computer-based approach using temporal subtraction in 
rheumatoid wrist. British Journal of Radiology 89: 20150403. 
Ikeda F. et al. (2004) Critical roles of c-Jun signaling in regulation of NFAT family and 
RANKL-regulated osteoclast differentiation. J. Clin. Invest.114: 475–484. 
Irie A. et al. (2007) Heparin enhances osteoclastic bone resorption by inhibiting 
osteoprotegerin activity. Bone 41: 165–174. 
Ishii T. et al. (2010) Control of Osteoclast Precursor Migration : A Novel Point of 
Control for Osteoclastogenesis and Bone Homeostasis. IBMS BoneKey 7: 279–
286. 
Ishida N. et al. (2006) CCR1 acts downsteram of NFAT2 in osteoclastogenesis and 
enhances cell migration.  Journal of Bone and Mineral Research 21: 48-57. 
251 
 
 Ishimi Y. et al. (1990) IL-6 is produced by osteoblasts and induces bone resorption. 
The Journal of Immunology 145: 3297-3303. 
Islam R. et al. (2014) Pin1 Regulates Osteoclast Fusion Through Suppression of the 
Master Regulator of Cell Fusion DC-STAMP. Journal of Celluar Physiology 229: 
2166–2174. 
Iwamoto T. et al. (2008) Molecular aspects of rheumatoid arthritis: chemokines in 
the joints of patients. FEBS Journal 275: 448-4455. 
Issekutz A.C. et al. (1994) The role of tumour necrosis factor-alpha and IL-1 in 
polymorphonuclear leucocyte and T lymphocyte recruitment to joint 
inflammation in adjuvant arthritis. Clin Exp Immunol 97: 26–32. 
James I.E. et al. (1999) Development and Characterization of a Human In Vitro 
Resorption Assay : Demonstration of Utility Using Novel Antiresorptive Agents. 
Journal of Bone and Mineral Research 14: 1562–1569. 
Jehs T. et al. (2011). Astrocytoma cells upregulate expression of pro-inflammatory 
cytokines after co-culture with activated peripheral blood mononuclear cells. 
Acta Pathologica, Microbiologica et Immunologica Scandinavica 119: 551–561. 
Jeon O.H. et al. (2012) Quantification of temporal changes in 3D osteoclastic 
resorption pit using confocal laser scanning microscopy.  Tissue Engineering 
and Regenerative Medicine 9: 29-35. 
Jilka R.L. (2003) Biology of the Basic Multicellular Unit and the pathophysiology of 
Osteoporosis.  Med Pediatr Oncol 41: 182-185. 
Jimi E. et al. (1999) Interleukin 1 Induces Multinucleation and Bone-Resorbing 
Activity of Osteoclasts in the Absence of Osteoblasts / Stromal Cells. 
Experimental Cell Research 247: 84–93. 
Jimi E. et al. (1999) Osteoclast differentiation factor acts as a multifunctional 
regulator in murine osteoclast differentiation and function.  The Journal of 
Immunology 163:434-442. 
Jobke B. et al. (2014) Bisphosphonate-osteoclasts : Changes in osteoclast 
morphology and function induced by antiresorptive nitrogen-containing 
bisphosphonate treatment in osteoporosis patients. Bone 59: 37–43. 
Johnson R.W. et al. (2014) The primary function of gp130 Signaling in osteoblasts is 
to maintain bone formation and strengthrather than promote osteoclast 
formaiton. Journal of Bone and Mineral Research 29: 1492–1505. 
Johnson R.W. et al. (2015) Glycoprotein 130 (gp130)/interleukin-6 (IL-6) signalling in 
osteoclasts promotes bone formation in periosteal and trabecular bone.  Bone 
81: 343-351. 
Jones S.J., Arora M. & Boyde A. (1995) The Rate of Osteoclastic Destruction of 
Calcified Tissues Is Inversely Proportional to Mineral Density.  Calcified Tissue 
252 
 
 International 56: 554-558. 
Jones S.A., Scheller J. & Rose-John S. (2011) Therapeutic strategies for the clinical 
blockade of IL-6 / gp130 signaling. J. Clin. Invest. 121: 3375-3383. 
Jongh De R.F. et al.(2003) The Role of Interleukin-6 in Nociception and Pain. 
Anesthesia & Analgesics 96: 1096–1103. 
Jonker M. et al. (2013) Comparative analysis of inflammatory infiltrates in collagen- 
induced arthritis , kidney graft rejection and delayed-type hypersensitivity in 
non-human primates. Inflamm. Res. 62: 181–194. 
Joosten L.A.B. et al. (2009) Inflammatory arthritis in caspase-1 gene deficient mice: 
Contribution of proteinase 3 for caspase-1-independent production of 
bioactive IL-1β.  Arthritis & Rhuematology 60: 3651-3662. 
Jostock T. et al. (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 
receptor transsignaling responses.  Eur. J. Biochem. 268: 160-167. 
Jougasaki M. et al. (2010) Statins suppress interleukin-6-induced monocyte chemo-
attractant protein-1 by inhibiting Janus kinase / signal transducers and 
activators of transcription pathways in human vascular endothelial cells. British 
Journal of Pharmacology 159: 1294–1303. 
Kaji H. et al. (1996) Prostaglandin E2 stimulates osteoclast-like cell formation and 
bone-resorbing activty via osteoblasts: role of cAMP-dependent protein 
kinase.  Jounral of Bone and Mineral Research 11: 62-71. 
Kameda T. et al. (1997) Estrogen inhibits bone resorption by directly inducing 
apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186: 489-495. 
Kamolmatyakull, S., Chen, W. & Lil, Y., 2001. Interferon-γ down-regulates gene 
expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J 
Dent Res. 80: 351-355. 
Kanazawa I. (2015) Osteocalcin as a hormone regulating glucose metabolism. World 
J. Diabetes 6: 1345–1354. 
Kannan K., Ortmann R.A. & Kimpel D. (2005) Animal models of rheumatoid arthritis 
and their relevance to human disease. Pathophysiology 12: 167–181. 
Kasama T. et al. (1995) Interleukin-10 Expression and Chemokine Regulation During 
the Evolution of Murine Type 11 Collagen-induced Arthritis. J. Clin. Invest. 95: 
2868-2876. 
Kataoka A. et al. (2009) Activation of P2X7 receptors induces CCL3 production in 
microglial cells through transcription facto NFAT. Journal of Neurochemistry 
108: 115–125. 
Kawashiri S. et al. (2011) Effects of the anti-interleukin-6 receptor antibody, 
tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.  
Rheumatol Int. 31: 451-456. 
253 
 
 Keller J. et al. (2012) Divergent resorbability and effects on osteoclast formation of 
commonly used bone substitutes in a human in vitro-assay.  PLOS One 7: 
e46757. 
Kempeni J.(1999) Preliminary results of early clinical trials with the fully human anti-
TNF monoclonal antibody D2E7. Ann Rheum Dis 58: I70–72. 
Keophiphath M. et al. (2010) CCL5 promotes macrophage recruitment and survival 
in human adipose tissue.  Arterioscler Thromb Vasc Biol 30: 39-45. 
Keul R. et al. (1998) A possible role for soluble IL-6 receptor in the pathogenesis of 
systemic onset juvenile chronic arthritis.  Cytokine 10: 729-734. 
Kiguchi N. et al. (2013) Cytokine Epigenetic upregulation of CCL2 and CCL3 via 
histone modifications in infiltrating macrophages after peripheral nerve injury. 
Cytokine64: 666–672. 
Kikuta J. et al. (2013) Sphingosine-1-phosphate-mediated osteoclast precursor 
monocyte migration is a critical point of control in antibone-resorptive action 
of active vitamin D. PNAS 110: 7009–7013. 
Kikuta J. & Ishii M.(2013) Osteoclast migration, differentiation and function: novel 
therapeutic targets for rheumatic diseases. Rheumatology 52: 226–234. 
Kim L.H. et al. (2003) Identification of Novel SNPs in the Interleukin 6 Receptor 
Gene ( IL6R ). Wiley-Liss 601: 1–6. 
Kim M.S., Day C.J. & Morrison N.A. (2005) MCP-1 Is Induced by Receptor Activator 
of Nuclear Factor-κB Ligand, Promotes Human Osteoclast Fusion, and Rescues 
Granulocyte Macrophage Colony-stimulating Factor Suppression of Osteoclast 
Formation *. The Journal of Biological Chemistry, 280: 16163–16169. 
Kim K. et al. (2008) NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 
and the dendritic cell-specific transmembrane protein (DC-STAMP).  Molecular 
Endocrinology 22: 176-185. 
Kim T. et al. (2010) ATP6v0d2 deficiency increases bone mass , but does not 
influence ovariectomy-induced bone loss. Biochemical and Biophysical 
Research Communications 403; 73–78. 
Kim G.W. et al. (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: Past, 
present, and future. Archives of Pharmacal Research 38: 575–584. 
Kinne R.W., Stuhlmuller B.& Burmester G. R.(2007) Cells of the synovium in 
rheumatoid arthritis: Macrophages. Arthritis Research & Therapy 9: 1–16. 
Kishimoto T. et al. (1995) Interleukin-6 Family of Cytokines and gp130. The Journal 
of The American Society of Hematology 86: 1243–1254. 
Kitaura H. et al. (2002) Effect of IL-12 on TNF- α -Mediated Osteoclast Formation in 
Bone Marrow Cells: Apoptosis Mediated by Fas/Fas Ligand Interaction. The 
Journal of Immunology 169: 4732-4738. 
254 
 
 Kitaura H. et al. (2014) Effect of Cytokines on Osteoclast Formation and Bone 
Resorption during Mechanical Force Loading of the Periodontal Membrane. 
The Scientific World Journal 2014: 617032. 
Klein D.C. & Raisz L.G. (1970) Prostaglandins: Stimulation of Bone Resorption in 
Tissue Culture. Endocrinology 86: 1436–1440. 
Klimek E. et al. (2014) Blood Monocyte Subsets and Selected Cardiovascular Risk 
Markers in Rheumatoid Arthritis of Short Duration in relation to Disease 
Activity. BioMed Research International 2014: 736853. 
Klouche M. et al. (1999) Novel Path to Activation of Vascular Smooth Muscle Cells: 
Up-Regulation of gp130 Creates an Autocrine Activation Loop by IL-6 and Its 
Soluble Receptor. The Journal of Immunology 163: 4583-4589. 
Knowles H.J. et al. (2012) Chondroclasts are mature osteoclasts which are capable 
of cartilage matrix resorption.  Journal of the European Society of Pathology 
461: 205–210. 
Kobayashi K. et al. (2000) Tumor Necrosis Factor-α Stimulates Osteoclast 
Differentiation by a Mechanism Independent of the ODF/RANKL – RANK 
Interaction. J. Exp. Med 191: 275-285. 
Kobayashi Y. et al. (2006) Prostaglandin E2 enhances osteoclastic differentiation of 
precursor cells through protein kinase A- dependent phosphorylation of TAK1.  
The Journal of Biological Chemistry 280: 11395-11403. 
Koch A.E. et al. (1994) Macrophage Inflammatory Protein-1α.J. Clin. Invest. 93: 921–
928. 
Koch A.E. (2005) Chemokines and their receptors in rheumatoid arthritis.  Arthritis 
& Rheumatism 52: 710-721. 
Kohno H. et al. (2014) CCL3 production by microglial cells modulates disease 
severity in murine models of retinal degeneration. J Immunol. 192: 3816–3827. 
Kojima H. et al. (2013) IL-6-STAT3 signaling and premature senescence. JAK-STAT 2: 
e25763. 
Kokkonen H. et al. (2010) Up-Regulation of Cytokines and Chemokines Predates the 
Onset of Rheumatoid Arthritis.  Arthritis & Rheumatism 62: 383-3941. 
Komano Y. et al. (2006) Identification of a human peripheral blod monocyte subset 
that differentiates into osteoclasts.  Arthritis Research & Therapy 8: R152. 
Kotake S. et al. (1996) Interleukin-6 and soluble interleukin-6 receptors in the 
synovial fluids from rheumatoid arthritis patients are responsible for 
osteoclast-like cell formaiton.  Journal of Bone and Mineral Research 11: 88-
95.   
Kondo T. et al. (2011). Essentials roles of CCL3-CCR1 axis in the pathogenesis of 
antigen-induced arthritis.  (Cytokine Poster Session 2 : Chemokines and their 
255 
 
 Receptors). Cytokine 56: 80. 
Kramer N. et al. (2013) In vitro cell migration and invasion assays.  Mutation 
Research 752: 10-24. 
Kudo O. et al. (2003) Interleukin-6 and interleukin-11 support human osteoclast 
formation by a RANKL-independent mechanism. Bone 32: 1–7. 
Kukita T. et al. (2004) RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis. 
J. Exp. Med200: 941-946. 
Kuno K. & Matsushima K. (1994) The IL-1 receptor signalling pathway. Journal of 
Leukocyte Biology 56: 542-547. 
Kusano K. et al. (1998) Regulation of Matrix Metalloproteinases (MMP-2, -3, -9, and 
-13) by Interleukin-1 and Interleukin-6 in Mouse Calvaria: Association of MMP 
Induction with Bone Resorption. Endocrinology 139: 1338–1345. 
Kyrtsonis M.C. et al. (1996) Soluble interleukin-6 receptor (sIL-6R), a new prognostic 
factor in multiple myeloma.  British Journal of Haematology 93: 398-400. 
Lacey D.L. et al. (1998) Osteoprotegerin Ligand is a cytokine that regulates 
osteoclast differentiation and activation.  Cell 93: 165-176. 
Lader C.S. & Flanagan A.M. (1998) Prostaglandin E2, interleukin 1α and tumor 
necrosis factor-α increase human osteoclast formation and bone resorption in 
vitro.  Endocrinology 139: 3157-3164. 
Lamas J.R. et al. (2013) Alternative splicing and poteolytic rupture contribute to the 
generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis.  Cytokine 
61: 720-723. 
Lambiase A. et al. (1997) Immundeficiency and other clinical immunology. J Clin 
Immunol 100: 408-414. 
Lauta V.M. (2003) A review of the cytokine network in multiple myeloma.  Cancer 
97: 2440-2452. 
Lebre M.C. et al. (2011) Why CCR2 and CCR5 blockade failed and why CCR1 
blockade might still be effective in the treatment of rheumatoid arthritis.  PLOS 
one 6: e21772. 
Lee S. et al. (2003) Interleukin-7 Is a Direct Inhibitor of in Vitro Osteoclastogenesis. 
Endocrinology 144: 3524–3531. 
Lee S.H. et al. (2006) v-ATPase V 0 subunit d2 – deficient mice exhibit impaired 
osteoclast fusion and increased bone formation. Nature Medicine 12: 1403–
1409. 
Lee S.K. & Lorenzo J. (2006) Cytokines regulating osteoclast formation and function. 
CurrentOpinion in Rheumatology 18: 411–418. 
256 
 
 Leeman M.F., McKay J.A. & Murray G.I., (2002) Matrix metalloproteinase 13 activity 
is associated with poor prognosis in colorectal cancer.J Clin Pathol 55: 758–
762. 
Lehenkari P. et al. (1998) carbonic anhydrase II plays a major role in osteoclast 
differentiation and bone resorption by effecting the steady state intracellular 
pH and Ca2+.  Experimental Cell Research 242: 128-137. 
Lent van P.L.E.M. et al. (1995) Major Role for Interleukin 1 but Not for Tumor 
Necrosis Factor in Early Cartilage Damage in Immune Complex Arthritis in 
Mice. The Journal of Rheumatology 22: 2250-2258. 
Lentzsch S. et al. (2003) Macrophage inflammatory protein 1-alpha (MIP-1α) 
triggers migration and signaling cascades mediating survival and proliferation 
in multiple myeloma ( MM ) cells.Blood 101: 3568–3573. 
Leszczyński M. (2010) Image Preprocessing for Illumination Invariant Face 
Verification. Journal of Telecommunications and Information Technology 4: 
19–25. 
Lewis N.D. et al. (2014) CCR1 Plays a Critical Role in Modulating Pain through 
Hematopoietic and Non-Hematopoietic Cells. PLOS One 9: e105883. 
Li Y-P. & Chen W. (1999) characterization of mouse cathepsin K gene, the gene 
promoter, and the gene expression.  Jounral of Bone and  Mineral Research 14: 
487-499. 
Lin T-H. et al. (2013) CCL2 increases αvβ3 integrin expression and subsequently 
promotes prostate cancer migration. Biochimica et Biophysica Acta 1830: 
4917–4927. 
Lind M. et al. (1995) IL-4 and IL-13, but not IL-10, are chemotactic factors for human 
osteoblasts. Cytokine 7: 78–82. 
Liu C-C. & Howard G.A. (1991) Bone-cell changes in estrogen-induced bone-mass 
increase in mice: dissociation of osteoclasts from bone surfaces.  The 
Anatomical Record 229: 240-250. 
Loeser J.D. & Melzack R. (1999) Pain: an overview.  Lancet 353: 1607-09. 
Lorenzo J.A., Sousa S.L. & Leahy C.L. (1990) Inhibitory factor (LIF) inhibits basal bone 
resorption in fetal rat long bone cultures. Cytokine 2: 266–271. 
Lubberts E. et al. (2004) Treatment With a Neutralizing Anti-Murine Interleukin-17 
Antibody After the Onset of Collagen-Induced Arthritis Reduces Joint 
Inflammation, Cartilage Destruction, and Bone Erosion. Arthritis & 
Rheumatism 50: 650–659. 
Luchin, A. et al., 2000. The Microphthalmia Transcription Factor Regulates 
Expression of the Tartrate-Resistant Acid Phosphatase Gene During Terminal 
Differentiation of Osteoclasts. Journal of Bone and Mineral Research, 15(3), 
257 
 
 pp.451–460. 
Lutter A-H. et al. (2010) A novel resorption assay for osteoclast functionality based 
on an osteoblast-derived native extracellular matrix.  Journal of Cellular 
Biochemistry 109: 1025-1032. 
Madhok R. et al. (1993) Serum interleukin 6 levels in rheumatoid arthritis: 
correlations with clinical and laboratory indices of disease activity.  Annals of 
Rheumatic Diseases 52: 232-234. 
Maina A.M. & Kraus H. (2012) successful treatment of osteitis fibrosa cystica from 
primary hyperparathyroidism.  Case reports in Orthopedics 2012: 145760. 
Mantovani A., Kaplanski G. & Farnarier C. (2003) IL-6 : a regulator of the transition 
from neutrophil to monocyte recruitment during inflammation. TRENDS in 
Immunology 24: 25–29. 
Marenzana M. et al. (2013) Effect of sclerostin-neutralising antibody on 
periarticular and systemic bone in a murine model of rheumatoid arthritis : a 
microCT study. Arthritis Research & Therapy 15: R125. 
Marinou I. et al. (2007) Association of interleukin-6 and interleukin-10 genotypes 
with radiographic damage in rheumatoid arthritis is dependent on 
autoantibody status. Arthritis & Rheumatism 56: 2549-2556. 
Marksteiner J. et al. (2011) Five out of 16 plasma signalling proteins are enhanced in 
plasma of patients with mild cognitive impairment and Alzheimer's disease.  
Neurobiol. Aging 32: 539-540.  
Maslinski W. et al. (2003) Unbalanced levels of bone resorption promoting factors 
in bone marrow from patients with rheumatoid arthritis in comparison to 
osteoarthritis.  Arthritis Res Ther 5 (suppl 3): S23. 
Massey H.M. & Flanagan A.M. (1999) Humna osteoclasts derive from CD14-positive 
monocytes.  British Journal of Haematology 106: 167-170. 
Matsuno H. et al. (2002) the role of TNF-α in the pathogenesis of inflammation and 
joint destruction in rheumatoid arthritis (RA): a study using human RA/SCID 
mouse chimera. Rheumatology 41: 329-337. 
McClung M.R. et al. (2006) Denosumab in postmenopausal women with low bone 
mineral density.  N Engl J Med 354: 821-831. 
McInnes I.B. & Schett G. (2007) Cytokines in the pathogenesis of rheumatoid 
arthritis. Nature Reviews Immunology 7: 429–442. 
McGonagle D. et al. (1999) The relationship between synovitis and bone changes in 
early untreated rheumatoid arthritis.  Arthritis & Rheumatism 42: 1706-1711. 
McQueen F.M. (2000) Magnetic resonance imaging in early inflammatory arthritis: 
what is its role? Rhuematology 39: 700-706. 
258 
 
 Mediero A., Perez-aso M. & Cronstein B.N. (2014) Activation of EPAC1 / 2 is 
essential for osteoclast formation by modulating NF  B nuclear translocation 
and actin cytoskeleton rearrangements. The FASEB Journal 28: 1–13. 
Melo Soares D. et al. (2006) CCL3/macrophage inflammatory protein-1α induces 
fever and increases prostaglandin E2 in cerebospinal fluid of rats: Effect of 
antipyretic drugs.  Brain Research 1109: 83-92. 
Merendino R.A. et al. (2004) Involvement of fractalkine and macrophage 
inflammatory protein-1 alpha in moderate- severe depression. Mediators of 
Inflammation 13: 205–208. 
Michael H. et al. (2005) Estrogen and testosterone use different cellular pathways 
to inhibit osteoclastogenesis and bone resorption.  Jounral of Bone and 
Mineral Research 20: 2224-2232. 
Miguel de M., Kraychete D.C. & Nascimento R.J.M. (2014) Chronic pain: cytokines, 
lymphocytes and chemokines.  Inflammation & Allergy - Drug Targets 13: 339-
349. 
Mihara M. et al. (2012)  IL-6/IL-6 receptor system and its role in physiological and 
pathological conditions.  Clinical Science 122: 143-159. 
Minano F.J. et al. (1990) Macrophage inflammatory protein-1: unique action on the 
hypothalamus to evoke fever.  Brain Research Bulletin 24: 849-852. 
Mittal A.K. et al. (2014) Chronic Lymphocytic Leukemia Cells in a Lymph Node 
Microenvironment Depict Molecular Signature Associated with an Aggressive 
Disease. Molecular Medicine 20: 290–301. 
Miyamoto K. et al. (2009) MCP-1 expressed by osteoclasts stimulates 
osteoclastogenesis in an autocrine/paracrine manner.  Biochemical and 
Biophysical Communications 383: 373-377. 
Miyamoto T. (2011) Regulators of Osteoclast Differentiation and Cell-Cell Fusion. 
Keio J Med 60: 101–105. 
Mizutani K. et al. (2009) The Chemokine CCL2 Increases Prostate Tumor Growth and 
Bone Metastasis through Macrophage Recruitment. Neoplasia 11: 1235–1242. 
Motyckova G. et al. (2001)  Linking osteopetrosis and pycnodysostosis: Regulation 
of cathepsin K expression by the microphthalmia transcription factor family.  
PNAS 98: 5798-5803. 
Mueller A. & Strange P.G. (2004)  CCL3 acting via the chemokine receptor CCR5, 
leads to independent activation of Janus kinase 2 (JAK 2) and Gi proteins.  FEBS 
Letters 570: 126-132. 
Müller-Newen G. et al. (1998) Soluble IL-6 Receptor Potentiates the Antagonistic 
Activity of Soluble gp130 on IL-6 Responses. The Journal of Immunology 161: 
6347-6355. 
259 
 
 Muller L.O., Humphries P. & Rosendahl K., 2015. The joints in juvenile idiopathic 
arthritis. Insights Imaging: 275–284. 
Murphy P.G. et al.(1999) Endogenous interleukin-6 contributes to hypersensitivity 
to cutaneous stimuli and changes in neuropeptides associated with chronic 
nerve constriction in mice. European Journal of Neuroscience 11: 2243–2253. 
Nagae M. et al. (2006) Osteoclasts play a part in pain due to the inflammation 
adjacent to bone. Bone 39: 1107–1115. 
Nakashima K. et al. (2002) The Novel Zinc Finger-Containing Transcription Factor 
Osterix Is Required for Osteoblast Differentiation and Bone Formation. Cell 
108: 17–29. 
Nakatani N. et al. (2006) Genome-wide expression analysis detects eight genes with 
robust alterations specific to bipolar I disorder : relevance to neuronal network 
perturbation. Human Molecular Genetics15: 1949–1962. 
Nandakumar K.S., Svensson L. & Holmdahl R.(2003) Collagen Type II-Specific 
Monoclonal Antibody- Induced Arthritis in Mice. American Journal of 
Pathology 163: 1827–1837. 
Naranjo A. et al. (2008) Cardiovascular disease in patients with rheumatoid 
arthritis : results from the QUEST-RA study. Arthritis Research & Therapy 10: 
R30. 
Narni-mancinelliE. et al. (2007) Memory CD8  T cells mediate antibacterial 
immunity via CCL3 activation of TNF / ROI+ phagocytes. JEM204: 2075-2087. 
Neer R.M. et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone 
mineral density in postmenopausal woman with osteoporosis.  N Engl J Med 
344: 1434- 1441. 
Nemeth E. et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the 
synthesis of the iron regulatory hornome hepcidin.  Journal of Clinical 
Investigration 113: 1271-1276. 
Nemunaitis J.(1993) Macrophage function activating cytokines : potential clinical 
application. Clinical Reviews in Oncology/Hematology 14: 153–171. 
Nevius E. et al. (2015) Oxysterols and EB12 promote osteoclast precursor migration 
to bone surfaces and regulate bone mass homeostasis.  J Exp. Med. 212: 1931-
1946.  
Nicholson G.C. et al. (2000) Induction of osteoclasts from CD14-positive human 
peripheral blood mononuclear cells by receptor activator of  nuclear factor κβ 
ligand (RANKL).  Clinical Science 99: 133-140. 
Nijweide P. et al. (1982) Bone formation and calcification by osteoblast-like cells.  
The Journal of Cell Biology 93: 318-323. 
Nogueira-barbosa M.H. et al. (2010) Magnetic resonance imaging in the evaluation 
260 
 
 of periosteal reactions *. Radiol Bras.43: 266–271. 
Nowell M.A. et al. (2003) Soluble IL-6 Receptor Governs IL-6 Activity in Experimental 
Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130. The 
Journal of Immunology 171: 3202-3209. 
Nowell M.A. et al. (2009) Therapeutic targetting of IL-6 trans-signaling counteracts 
STAT3 control of experimental inflammatory arthritis.The Journal of 
Immunology 182: 613-622. 
Oba Y. et al. (2015) MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast 
formaiton and increase adhesion of myeloma cells to marrow stromal cells.  
Experimental Hematology 33: 272-278. 
Obreja O. et al. (2002) Interleukin-6 in combination with its soluble IL-6 receptor 
sensitises rat skin nociceptors to heat , in vivo. Pain 96: 57–62. 
Obreja O. et al.(2005) Fast modulation of heat-activated ionic current by 
proinflammatory interleukin 6 in rat sensory neurons. Brain 128: 1634–1641. 
O'Brien C.A. et al. (1999) STAT3 activation in stromal/osteoblastic cells is required 
for induction of the receptor activator of NF-κβ ligand and stimulation of 
osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-
Dihydroxyvitamin D3 or parathyroid hormone.  Journal of Biological Chemistry 
274: 19301-19308. 
Oddie G.W. et al. (2000) Structure, function and regulaiton of Tartrate-resistant acid 
phosphatase.  Bone 27: 575-584. 
Oh J.W., Revel M.& Chebath(1996) A soluble interleukin 6 receptor isolated from 
conditioned medium of human breast cancer cells is encoded by a 
differentially spliced mRNA. Cytokine 8: 401–409. 
Oikawa T. et al. (2012) Tks5-dependent formation of circumferential podosomes/ 
invadopodia mediates cell-cell fusion.  J. Cell Biol. 197: 553-568. 
Oreffo R.O.C. et al. (1999) expression of estrogen receptor-alpha in cells of the 
osteoclast-lineage.  Histochem Cell Biol 111: 125-133. 
Oursler M.J. (2003) Direct and indirect effects of estrogen on osteoclasts. J 
Musculoskel Neuron Interact 3: 363–366. 
Palma B.D. et al. (2016) Osteolytic lesions, cytogenetic features and bone marrow 
levels of cytokines and chemokines in multiple myeloma patients: Role of 
chemokine (C-C motif) ligand 20.  Leukemia 30: 409-416. 
Palmqvist P. et al. (2002) IL-6, Leukemia Inhibitory Factor, and Oncostatin M 
Stimulate Bone Resorption and Regulate the Expression of Receptor Activator 
of NF- κB Ligand, Osteoprotegerin, and Receptor Activator of NF- κB in Mouse 
Calvariae. The Journal of Immunology 169: 3353-3362. 
Palmqvist P. et al. (2006). Inhibition of Hormone and Cytokine-stimulated 
261 
 
 Osteoclastogenesis and Bone Resorption by Interleukin-4 and Interleukin-13 Is 
Associated with Increased Osteoprotegerin and Decreased RANKL and RANK in 
a STAT6-dependent Pathway*. The Journal of Biological Chemistry 281: 2414–
2429. 
Pardali E. & Waltenberger J. (2012) Monocyte function and trafficking in 
cardiovascular disease. Thrombosis and Haemostasis 108: 804–811. 
Park S-J. et al. (2004) IL-6 regulates in vivo dendritic cell differentiation through 
STAT3 activation.  Journal of Immunology 173: 3844-3854. 
Partington G.A. et al. (2004) Mitf – PU . 1 interactions with the tartrate-resistant 
acid phosphatase gene promoter during osteoclast differentiation. Bone 34: 
237–245. 
Patel D.D. et al. (2001) CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. 
Clinical Immunology 98: 39-45.  
Pathak J.L. et al. (2015) CXCL8 and CCL20 Enhance Osteoclastogenesis via 
Modulation of Cytokine Production by Human Primary Osteoblasts. PLOS One 
10: e0131041. 
Peake N.J. et al. (2006)  Interleukin-6 signalling in juvenile idiopathic arthritis is 
limited by proteolytically cleaved soluble inter-leukin-6 receptor.  
Rheumatology 45: 1485-1489. 
Pearse R.N. et al. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin 
cytokine axis to trigger bone destruction and promote tumour progression.  
PNAS 98: 11581-11586. 
Perrin F.E. et al. (2005) Involvement of monocyte chemoattractant prtein-1, 
macrophage inflammatory protein-1α and interleukin-1β in Wallerian 
degeneration.  Brain 128: 854-866. 
Peruzzi B. et al. (2012) c-Src and IL-6 inhibit osteoblast differentiation and integrate 
IGFBP5 signalling.   Nature Communications 3: 630. 
Peters M. et al. (1996) the function of the soluble interleukin 6 (IL-6) receptor in 
vivo: sensitization of human soluble IL-6 receptor transgenic mice towards lL-6 
and prolongation of the plasma half-life of IL-6.  J. Exp. Med.  183: 1399-1406. 
Pettit A.R. et al. (2001) TRANCE/RANKL knock-out mice are protected from bone 
erosion in a serum transfer model of arthritis.  American Journal of Pathology 
159: 1689-1699. 
Pharoah D.S. et al. (2006) Expression of the inflammatory chemokines CCL5, CCL3 
and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 
production by an atypical subset of CD8+ T cells. Arthritis Research & Therapy 
8: R50. 
Phillips R.M. et al. (2003) Variations in eosinophil chemokine responses: An 
262 
 
 investigation of CCR1 and CCR3 function, expression in atopy, and 
identification of a functional CCR1 promoter.  Journal of Immunology 170: 
6190-6201.  
Pierroz D.D. et al. (2010) Are Osteoclasts Needed for the Bone Anabolic Response to 
Parathyroid Hormone? The Journal of Biological Chemistry 285: 28164–28173. 
Piper K., Boyde A. & Jones S.J. (1992) The relationship between the number of 
nuclei of an osteoclast and its resorptive capability in vitro.  Anatomy and 
Embryology 186: 291-299. 
Podgorski I. et al. (2009) Bone Marrow-Derived Cathepsin K Cleaves SPARC in Bone 
Metastasis. The American Journal of Pathology 175: 1255–1269. 
Polil V. et al. (1994) Interleukin-6 deficient mice are protected from bone loss 
caused by estrogen depletion. The EMBO Journal 13: 1189-1196. 
Poole K.E.S. &Reeve J. (2005) Parathyroid hormone — a bone anabolic and 
catabolic agent Kenneth ES Poole and Jonathan Reeve. Current Opinion in 
Rheumatology 5: 612–617. 
Quick M.L. et al.(2012) CCL2 and CCL3 are essential mediators of pelvic pain in 
experimental autoimmune prostatitis. Am J Physiol - Regulatory, Integrative 
and Comparative Physiology 303: R580-R589. 
Quinn J.M.W. et al. (1998) A combination of osteoclast differentiation factor and 
macrophage-colony stimulating factor is sufficient for both human and mouse 
osteoclast formation.  Endocrinology 139: 4424-4427. 
Quinones M. et al. (2006) CC chemokine receptor (CCR)-2 prevents arthritis 
development following infection by Mycobacterium avium.  J Mol Med 84: 
503-512. 
Raisz L.G. (1999) Physiology and Pathophysiology of Bone Remodeling. Clinical 
Chemistry 45: 1353–1358. 
Raisz L.G. (2005) Pathogenesis of osteoporosis : concepts, conflicts, and prospects. 
J. Clin. Invest 115: 3318-3325. 
Ralston S.H., Langston A.L. & Reid I.R. (2008) Pathogenesis and management of 
Paget ’ s disease of bone. The Lancet 372: 155–163. 
Ramos C.D.L. et al. (2005) MIP-1α [CCL3] acting on the CCR1 receptor mediates 
neutrophil migration in immune inflammation via sequential release of TNFα 
and LTB4. Journal of Leukocyte Biology78: 167–177. 
Rana R.S., Wu J.S. & Eisenberg R.L.(2009) Periosteal Reaction. AJR 193: 259–272. 
Ravi A.K. et al. (2014) Increased levels of soluble interleukin-6 receptor and CCL3 in 
COPD sputum. Respiratory Research 15: 103. 
Raza K. et al. (2005) Early rheumatoid arthritis is characterized by a distinct and 
263 
 
 transient synovial fluid cytokine profile of T cell and stromal cell origin. 
Arthritis Research & Therapy 7: R784- 795. 
Reale M. et al. (2011) Dysregulation of chemo-cytokine production in schizophrenic 
patients versus healthy controls. BMC Neuroscience 12: 13. 
Reddy S. V et al. (1995) Characterization of the 5 ’ -Flanking Region of the Human 
Tartrate-Resistant Acid Phosphatase (TRAP) Gene. Bone 16: 587–593. 
Reid I.R. et al. (1990) Leukemia Inhibitory Factor : A Novel Bone-Active Cytokine. 
Endocrinology 126: 1416–1420. 
Ren M. et al. (2010) Polymerization of MIP-1 chemokine (CCL3 and CCL4) and 
clearance of MIP-1 by insulin-degrading enzyme.  The EMBO Journal 29: 3952-
3966. 
Ren K. & Dubner R. (2010) Interactions between the immune and nervous systems 
in pain.  Nat Med. 16: 1267-1276. 
Repeke C.E. et al. (2010) Non-inflammatory destructive periodontal disease: a 
clinical, microbiological, immunological and genetic investigation. J Appl Oral 
Sci, 20: 113–121. 
Repeke C.E. et al. (2010) Evidences of the cooperative role of the cytokines CCL3, 
CCL4 and CCL5 and its recepotrs CCR1+ and CCR5+ in RANKL+ cell migration 
throughout experimental periodontitis in mice.  Bone 46: 112-1130. 
Richie A.M. & Francis M.L. (2003) Diagnostic Approach to Polyarticular Joint Pain. 
Am Fam Physician 68: 1151–1160. 
Richter F. et  al. (2010) Tumour necrosis factor causes persistent sensitization of 
joint nociceptors to mechanical stimuli in rats.  Arthritis & Rheumatism 62: 
3806-3814. 
Riggs B.L., Khosla S. & Melton L.J. (2002) Sex Steroids and the Construction and 
Conservation of the Adult Skeleton. Endocrine Reviews 23: 279–302. 
Ripley B.J.M. et al. (2005) Raised levels of interleukin 6 in systemic lupus 
erythematosus correlate with anaemia.  Annuals of Rheumatic Diseases 64: 
849-853. 
Robak T. et al. (1998) Serum levels of interleukin-6 type cytokines and soluble 
interleukin-6 receptor in patients with rheumatoid arthritis. Mediators of 
Inflammation 7: 347–353. 
Rocha F.A.C., Andrade L.E.C. & Jancar S. (1996) Immune complex induced arthritis in 
rats: role of lipid mediators on cell infiltration. Mediators of Inflammation 5: 
104–109. 
Rodan G.A. (1998) Bone homeostasis. Proc. Natl. Acad. Sci. 95: 13361–13362. 
Rogers J., Shepstone L. & Dieppe P. (1997) Bone formers : osteophyte and 
264 
 
 enthesophyte formation are positively associated. Annals of Rheumatic 
Diseases 56: 85–90. 
Romas E. et al. (1996) The role of gp130-mediated signals in osteoclast 
development: regulation of interleukin 11 production by osteoblasts and 
distribution of its receptor in bone marrow cultures.  J. Exp. Med. 183: 2581-
2591. 
Rood J.A. et al. (1997) Genomic organization and chromosome localization of the 
human cathepsin K gene (CTSK).  Genomics 41: 169-176. 
Roodman G.D. et al. (1992) Interleukin 6: A potential autocrine/paracrine factor in 
Paget's disease of bone.  J. Clin. Invest. 89: 46-52. 
Roodman G.D. (1999) Cell biology of the osteoclast.  Experimental Hematology 27: 
1229-1241. 
Rose-John, S.(2012) IL-6 Trans-Signaling via the Soluble IL-6 Receptor : Importance 
for the Pro-Inflammatory Activities of IL-6. International Journal of Biological 
Sciences 8: 1237-1247. 
Ross F.P. (2006) M-CSF, c-Fms, and Signaling in Osteoclasts and their 
Precursors.Ann. N.Y. Acad. Sci 1068: 110–116. 
Sabroe I. et al. (2000) A Small Molecule Antagonist of Chemokine Receptors CCR1 
and CCR3. The Journal of Biological Chemistry 275: 25985–25992. 
Sago K. et al. (1999) The integrin αvβ5 is expressed on avian osteoclast precursors 
and regulated by retinoic acid.  Journal of Bone and Mineral Research 14: 32-
38.  
Sanecka A. et al. (2011) DC-STAMP knock-down deregulates cytokine production 
and T-cell stimulatory capacity of LPS- matured dendritic cells. BMC 
Immunology 12: 57. 
Sarma U. & Flanagan A.M. (1996) Macrophage colony-stimulating factor induces 
substantial osteoclast generation and bone resorption in human bone marrow 
cultures.  Blood 88: 2531-2540. 
Scheller J. et al. (2011) The pro- and anti-in fl ammatory properties of the cytokine 
interleukin-6. Biochemica et Biophysica Acta 1813: 878–888. 
Schett G. (2007) Cells of the synovium in rheumatoid arthritis Osteoclasts. Arthritis 
Research & Therapy 9: 203. 
Schett G. (2007) Erosive arthritis. Arthritis Research & Therapy 9: S2. 
Schett G. (2007) Joint remodelling in inflammatory disease.  Ann Rheum Dis 66: 
(Suppl III). 
Schett G. (2007)  How does joint remodelling work? Cell Adhesion & Migration 1: 
102-103. 
265 
 
 Schett G. & Teitelbaum S.L.(2009) Osteoclasts and Arthritis. Journal of Bone and 
Mineral Research 24: 1142–1146. 
Scheven B.A.A. et al. (1999) Macrophage-Inflammatory Protein-1α Regulates 
Preosteoclast Differentiation in Vitro. Biochemical and Biophysical Research 
Communications 778: 773–778. 
Schimmer R.C. et al. (1998) Streptococcal Cell Wall-Induced Arthritis: Requirements 
for IL-4, IL-10, IFN- γ, and Monocyte Chemoattractant Protein-1. The Journal of 
Immunology 16-: 1466-1471. 
Schluger N.W. & Rom W.N. (1997) Early responses to infection: chemokines as 
mediators of inflammation.  Current Opinion in Immunology 9: 504-508. 
Schneider A. et al. (2005) Bone turnover mediates preferential localization of 
prostate cancer in the skeleton.  Endocrinology 146: 1727-1736. 
Schuett H. et al. (2012) Transsignaling of Interleukin-6 Crucially Contributes to 
Atherosclerosis in Mice. Aterioscler Thromb Vasc Biol 32: 281-290. 
Schumacher N. et al. (2015) Shedding of endogenous interleukin-6 receptor (IL-6R) 
is governed by a disintegrin and metalloproteinase (ADAM) proteases while a 
full length IL-6R isoform localizes to circulating microvesicles.  The Journal of 
Biological Chemistry 290: 26059-26071. 
Seeuws S. et al. (2010) A multiparameter approach to monitor disease activity in 
collagen-induced arthritis. Arthritis Research & Therapy 12:R160. 
Sharma S.M. et al. (2007) MITF and PU.1 Recruit p38 MAPK and NFATc1 to Target 
Genes during Osteoclast Differentiation*. The Journal of Biological Chemistry 
282: 15921–15929. 
Shi M. et al. (2015) The protective effects of chronic intermittent hypobaric hypoxia 
pretreatment against collagen-induced arthritis in rats. Journal of 
Inflammation 12:23. 
Shidara K. et al. (2008) Serum Levels of TRAP5b , a New Bone Resorption Marker 
Unaffected by Renal Dysfunction, as a Useful Marker of Cortical Bone Loss in 
Hemodialysis Patients. Calcif Tissue Int 82: 278–287. 
Sigaux J. et al. (2017) Immunogenicity of tocilizumab in patients with rheumatoid 
arthritis.  Joint Bone Spine 84: 39-45. 
Simon N.M. et al. (2008) A Detailed Examination of Cytokine Abnormalities in Major 
Depressive Disorder. Euro Neuropsychopharmacol. 18: 230–233. 
Simpson A. & Horton M.A. (1989) Expression of the vitronectin recepotr during 
embryonic development; an immunohistological study of the ontogeny of the 
osteoclast in the rabbit.  Br. J. Exp. Path. 70: 257-265. 
Sims N.A. & Romas E. (2015) Is RANKL inhibition both anti-resorptive and anabolic 
in rheumatoid arthritis ? Arthritis Research & Therapy 17:328. 
266 
 
 Sivina M. et al. (2011) CCL3 (MIP-1α) plasma levels and the risk for disease 
progression in chronic lymphocytic leukemia. Blood 117: 1662–1670. 
Sleiman I. et al. (2004) Osteitis fibrosa cystica, coeliac disease and Turner syndrome: 
A case report. Digestive and Liver Disease 36: 486–488. 
Soliman A.F. et al. (2016) Potential role of calprotectin as a monitoring biomarker 
for clinical and sonographic activity and treatment outcome in recent-onset 
rheumatoid arthritis.  Egyptian Rheumatology & Rehabilitation 43: 143-149. 
Song H-P. et al. (2015) Phenotypic characterization of type II collagen-induced 
arthritis in Wistar rats. Experimental and Therapeutic Medicine 10: 1483–1488. 
Soysa N. S. et al. (2009) Three-dimensional characterization of osteoclast bone-
resorbing activity in the resorption lacunae.  J Med Dent Sci. 56: 107-112. 
Soysa N.S. et al. (2012) Osteoclast formation and differentiation: An overview. J 
Med Dent Sci. 59: 65-74. 
Sreeja R. et al. (2009) A scanning electron microscopic study of the patterns of 
external root resorption under different conditions.  J Appl Oral Sci. 17: 481-
486. 
Srirangan S. & Choy E.H. (2010) The role of Interleukin 6 in the pathophysiology of 
rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 2: 247–
256. 
Stark Z. & Savarirayan R. (2009) Osteopetrosis. Orphanet Journal of Rare Diseases 
4:5. 
Strassle B.W. et al. (2010) Inhibition of osteoclasts prevents cartilage loss and pain 
in a rat model of degenerative joint disease. Osteoarthritis and Cartilage 18: 
1319–1328. 
Sundaram K. et al. (2007) RANK ligand signaling modulates the matrix 
metalloproteinase-9 gene expression during osteoclast differentiation. 
Experimental Cell Research313: 168-178. 
Susa et al. M. (2004) Human primary osteoclasts: in vitro generation and 
applications as pharmacological and clinical assay.  Journal of Translational 
Medicine 2:6. 
Suzuki M. et al. (2010) Cytokine IL-6 and IL-1 synergistically enhanced the 
production of MMPs from synovial cells by up-regulating IL-6 production and 
IL-1 receptor I expression. Cytokine 51: 178–183. 
Szekanecz Z. et al. (2010) Chemokines and chemokine receptors in arthritis. Front 
Biosci 2: 153-167. 
Tak P.P. et al. (1997) Analysis of the synovial cell infiltrate in relation to local disease 
activity. Arthritis & Rheumatism 40: 217–225. 
267 
 
 Takahashi N. et al. (1988) Osteoclast-like cell formation and its regulation by 
osteotropic hormones in mouse bone marrow cultures.  Endocrinology 122: 
1373-1382. 
Takahashi K. et al. (2015) CCL3 and CCL4 are biomarkers for B cell receptor pathway 
activation and prognostic serum markers in diffuse large B cell 
lymphoma.British Journal of Haematology 171: 726–735. 
Takano T. et al. (2014) Mesenchymal stem cells markedly suppress inflammatory 
bone destruction in rats with adjuvant-induced arthritis. Laboratory 
Investigation 94: 286–296. 
Takayanagi H. et al. (2000) T-cell-mediated regulation of osteoclastogenesis by 
signalling cross-talk between RANKL and IFN-γ. Letter to Nature408: 600-605. 
Takayanagi H. et al. (2002) Induction and activation of the transcription factor 
NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of 
osteoclasts.  Developmental Cell 3: 889-901. 
Tamura T. et al. (1993) Soluble interleukin-6 receptor triggers osteoclast formation 
by interleukin 6. Proc. Natl. Acad. Sci.90: 11924–11928. 
Tanaka K. et al. (2013) Anti-interleukin-6 receptor antibody prevents systemic bone 
mass loss via reducing the number of osteoclast precursors in bone marrow in 
a collagen-induced arthritis model. Clinical and Experimental Immunology 175: 
172–180. 
Taouli B. et al. (2002) Imaging of the hand and wrist in RA.  Amm Rheum Dis 61: 
687-869. 
Teitelbaum S.L., Tondrovi M.M.  & Ross F.P. (1997) Osteoclasts, macrophages, and 
the molecular mechanisms of bone resorption.  J Leukoc Biol. 61: 381-388. 
Teixeira A.L. et al. (2008) Increased serum lefels of CCL11/eotaxin in schizophrenia.  
Progress in Neuro-Psychopharmacology & Biological Psychiatry 32: 710-714. 
Tenhumberg S. et al. (2008) Structure-guided optimization of the interleukin-6 
trans-signaling antagonist sgp130.  Journal of Biological Chemistry 282: 27200-
27207. 
Teramachi J. et al. (2014) Increased IL ‐ 6 Expression in Osteoclasts Is Necessary But 
Not Suf fi cient for the Development of Paget ’ s Disease of Bone. Journal of 
Bone and Mineral Research 29: 1456–1465. 
Toh K. et al.(2004) Possible involvement of MIP-1 a in the recruitment of osteoclast 
progenitors to the distal tibia in rats with adjuvant-induced arthritis. 
Laboratory Investigation 84: 1092–1102. 
Toma C.D. et al. (2007) Fusion of the wrist in rheumatoid arthritis. The Journal of 
Bone and Joint Surgery 89: 1620–1626. 
Tomankova T. et al. (2014) Comparison of periprosthetic tissues in knee and hip 
268 
 
 joints : differential expression of CCL3 and DC-STAMP in total knee and hip 
arthroplasty and similar cytokine pro fi les in primary knee and hip 
osteoarthritis. Osteoarthritis and Cartilage 22: 1851–1860. 
Toraldo G. et al. (2003) IL-7 induces bone loss in vivo by induction of receptor 
activator of nuclear factor κβ ligand and tumor necrosis factor α from T cells. 
PNAS 100: 125–130. 
Tregoning J.S. et al. (2010) The Chemokine MIP1 a / CCL3 Determines Pathology in 
Primary RSV Infection by Regulating the Balance of T Cell Populations in the 
Murine Lung. PLOS One 5: e9381. 
Trentham D.E., Townes A.S. & Kang A.H. (1978) Autoimmunity to type II collagen: 
an experimental model of arthritis*. The Journal of Experimental Medicine 
146: 857- 868. 
Trifilo M.J. et al. (2003) CC Chemokine Ligand 3 (CCL3) Regulates CD8+-T-Cell 
Effector Function and Migration following Viral Infection. Journal of Virology 
77: 4004–4014. 
Tsangari H. et al. (2004) Increased expression of IL-6 and RANK mRNA in human 
trabecular bone from fragility fracture of the  femoral neck.  Bone 35: 334-342. 
Tsirakis G. et al. (2014) Increased serum levels of MIP-1alpha correlate with bone 
disease and angiogenic cytokines in patients with multiple myeloma. Med 
Oncol 31: 778. 
Tzur et al. (2011)  Optimizing Optical Flow Cytometry for Cell Volume-Based Sorting 
and Analysis. PLOS One 6: e16053. 
Udagawa N. et al. (1996) Interleukin-6 and Soluble Interleukin-6 Receptors in the 
Synovial Fluids from Rheumatoid Arthritis Patients Are Responsible for 
Osteoclast-like Cell Formation. Journal of Bone and Mineral Research 11:1. 
Udagawa N. et al. (2000) Osteoprotegerin Produced by Osteoblasts Is an Important 
Regulator in Osteoclast Development and Function*. Endocrinology 141: 
3478–3484. 
Uderhardt S. et al. (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac 
joints. Ann Rheum Dis 69: 592–597. 
Urashima M. et al. (1996) Interleukin-6 promotes multiple myeloma cell growth via 
phosphoryltion of retinoblastoma protein.  Blood 88: 2219-2227. 
Vallet S. et al. (2007) MLN3897 , a novel CCR1 inhibitor , impairs osteoclastogenesis 
and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 
110: 3744–3752. 
Vallet S. et al. (2011) A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone 
Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function. 
Leukemia 25: 1174–1181. 
269 
 
 Vangsness C.T. et al. (2011) Human knee synovial fluid cytokines correlated with 
grade of knee osteoarthritis.  Bulletin of the NYU Hospital for Joint Diseases 69: 
122-127. 
Ved N. & Haller J.O. (2002) Periosteal reaction with normal-appearing underlying 
bone : a child abuse mimicker. Emergency Radiology 9: 278–282. 
Vergunst C.E. et al. (2008) Modulation of CCR2 in Rheumatoid Arthritis. Arthritis & 
Rheumatism 58: 1931–1939. 
Voskuyl A.E. (2006) The heart and cardiovascular manifestations in rheumatoid 
arthritis. Rheumatology 45: iv4-iv7. 
Wada T. et al. (2006) RANKL – RANK signaling in osteoclastogenesis and bone 
disease. TRENDS in Molecular Medicine 12: 17-25. 
Warshawsky H. et al. (1980) Direct in vivo demonstration by radioautography of 
specific binding sites for calcitonin in skeletal and renal tissues of the rat.  
Journal of Cell Biology 85: 682-694. 
Watad A. et al. (2017) Anxiety disorder among rheumatoid arthritis patients: 
Insights from real-life data.  Journal of Affective Disorders 213: 30-34. 
Weissenbach M. et al. (2004) Interleukin-6 is a direct mediator of T cell migration.  
Eur. J. Immunol. 34: 2895-2906. 
Weitzmann M.N. et al. (2000) Interleukin-7 stimulates osteoclast formation by up-
regulating the T-cell production of soluble osteoclastogenic cytokines.  Blood 
96: 1873-1878. 
Whitehead K.A., Langer R. & Anderson D.G.(2009) Knocking down barriers: 
advances in siRNA delivery. Nature Reviews8:129-138. 
Wilson S.R. et al. (2009) Cathepsin K Activity-dependent Regulation of Osteoclast 
Actin Ring Formation and Bone Resorption*. The Journal of Biological 
Chemistry 284: 2584–2592. 
Wintges K. et al. (2013) Imparied bone formation and increased osteoclastogenesis 
in mice lacking chemokine (C-C motif) ligand 5.  Journal of Bone and Mineral 
Research 28: 2070-2080. 
Witwicka H. et al. (2015) Studies of OC-STAMP in Osteoclast Fusion : A New 
Knockout Mouse Model , Rescue of Cell Fusion , and Transmembrane 
Topology. PLOS One 10: e0128275. 
Wolf M. et al. (2003) Cathepsin D Specifically Cleaves the Chemokines Macrophage 
Inflammatory Protein-1α, Macrophage Inflammatory Protein-1β, and SLC That 
Are Expressed in Human Breast Cancer. American Journal of Pathology, 162: 
1183–1190. 
Wolpe S.D. et al. (1988) Macrophages secrete a novel heparin-binding protein with 
inflammatory and neutrophil chemokinetic properties. J. Exp. Med. 167: 570-
270 
 
 581. 
Wong P.K.K. et al. (2006) Interleukin-6 Modulates Production of T Lymphocyte – 
Derived Cytokines in Antigen-Induced Arthritis and Drives Inflammation-
Induced Osteoclastogenesis. Arthritis & Rheumatism 54: 158–168. 
Wu Y. et al. (2005) Synovial Fibroblasts Promote Osteoclast Formation by RANKL in 
a Novel Model of Spontaneous Erosive Arthritis. Arthritis & Rheumatism 52: 
3257–3268. 
Wu Y. et al. (2008) CCL3-CCR5 Axis Regulates Intratumoral Accumulation of 
Leukocytes and Fibroblasts and Promotes Angiogenesis in Murine Lung 
Metastasis Process. The Journal of Immunology 181: 6384-6393. 
Xing L., Xiu Y. & Boyce B.F. (2012) Osteoclast fusion and regulation by RANKL-
dependent and independent factors. World J. Orthop. 18: 212–222. 
Xue M. et al. (2007) A critical role for CCL2 and CCL3 chemokines in the regulation 
of polymorphonuclear neutrophils recruitment during corneal infection in 
mice. Immunology and Cell Biology 85: 525–531. 
Yagi M. et al. (2005) DC-STAMP is essential for cell – cell fusion in osteoclasts and 
foreign body giant cells. JEM202: 345–351. 
Yanaba K. et al. (2004) role of C-C chemokine receptors 1 and 5 and 
CCL3/macrophage inflammatory protein-1α in the cutaneous Arthus reaction: 
possible attenuation of their inhibitory effect by compensatory chemokine 
production.  Eur.  J. Immunol. 34: 3553-3561. 
Yang S. et al. (1996) Functions of the M-CSF receptor on osteoclasts.  Bone 18: 355-
360. 
Yang X. et al. (2006) Essential contribution of a chemokine, CCL3, and its receptor, 
CCR1, to hepatocellular carcinoma progression. Int. J. Cancer 118: 1869–1876. 
Yang S. et al. (2013) Quantification of bone changes in a collagen- induced arthritis 
mouse model by reconstructed three dimensional micro-CT. Biological 
Procedures Online 15:8. 
Yano S. et al. (2005) Functional Expression of β-Chemokine Receptors in 
Osteoblasts: Role of Regulated upon Activation, Normal T Cell Expressed and 
Secreted (RANTES) in Osteoblasts and Regulation of Its Secretion by 
Osteoblasts and Osteoclasts. Endocrinology 146: 2324–2335. 
Yasuda H. (2013) RANKL , a necessary chance for clinical application to osteoporosis 
and cancer-related bone diseases. World J. Orthop. 18: 207–217. 
Yoneda T. et al. (2011) Involvement of acidic microenvironment in the 
pathophysiology of cancer-associated bone pain.  Bone 48: 100-105. 
Yoshitake F. et al. (2008) Interleukin-6 Directly Inhibits Osteoclast Differentiation by 
Suppressing Receptor Activator of NF-κB Signaling Pathways. The Journal of 
271 
 
 Biological Chemistry 283: 11535–11540. 
Yoshizaki K. et al. (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal 
transduction with a humanized anti-IL-6 receptor antibody. Springer Seminars 
in Immunopatholgy 20: 247–259. 
Yu X. et al. (2004) CCR1 Chemokines Promote the Chemotactic Recruitment, RANKL 
Development, and Motility of Osteoclasts and Are Induced by Inflammatory 
Cytokines in Osteoblasts. Journal of Bone and Mineral Research 19: 2065–
2077. 
Zhang N. et al. (2005) A proinflammatory chemokine, CCL3, sensitizes the heat- and 
capsaicin-gated ion channel TRPV1. PNAS  102: 4536-4541. 
Zhang X., Huang J. & McNaughton P.A.(2005) NGF rapidly increases membrane 
expression of TRPV1 heat-gated ion channels. The EMBO Journal 24: 4211–
4223. 
Zhang W. et al. (2009) NAD(P)H oxidase-dependent regulation of CCL2 production 
during retinal inflammation.  Invest. Opthalmol. Vis. Sci. 50: 3033-3040.  
Zheng M.H. et al. (1994) Carbonic anhydrase II gene transcript in cultured 
osteoclasts from neonatal rats: effect of calcitonin.  Cell Tissue Res. 276: 7-13. 
Zucchetto A. et al. (2009) Cell Adhesion Molecule-1 Are Interchained by Sequential 
Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. Cancer Res. 69: 
4001–4009. 
 
  
272 
 
  
 
 
 
 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
  
273 
 
 Appendix 1 – MATLAB code for automated counting algorithm 
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 Appendix 2- Quantification of Pit Depths 
 
 
 
Appendix 2 –Flow diagram for the calculation of depth and volume of pits from 
the analysis of 3-D confocal stacks.  Data collected at x60 was loaded into 
metamorph and the average intensity of a pit was defined. Through the application 
of an inclusive threshold and a median filter, both background noise and data slices 
below the base of the pit were removed.  A binary image was then produced which 
could be summed to allow the removal of background signal and facilitate the 
creation of an intensity profile for each pit. 
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